<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006423.pub2" GROUP_ID="ENDOC" ID="957806080413033013" MERGED_FROM="" MODIFIED="2013-07-23 14:53:03 +0100" MODIFIED_BY="Bernd Richter" REVIEW_NO="" REVMAN_SUB_VERSION="5.2.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2013-07-23 14:53:03 +0100" MODIFIED_BY="Bernd Richter">
<TITLE MODIFIED="2009-04-07 11:03:51 +0200" MODIFIED_BY="[Empty name]">Glucagon-like peptide analogues for type 2 diabetes mellitus</TITLE>
<CONTACT MODIFIED="2013-07-23 14:53:03 +0100" MODIFIED_BY="Bernd Richter"><PERSON ID="89657079368766714838110823094050" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Deepson</FIRST_NAME><MIDDLE_INITIALS>S.</MIDDLE_INITIALS><LAST_NAME>Shyangdan</LAST_NAME><POSITION>Research Fellow</POSITION><EMAIL_1>D.S.Shyangdan@warwick.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Warwick Evidence</DEPARTMENT><ORGANISATION>Health Sciences Research Institute, Warwick Medical School, University of Warwick</ORGANISATION><ADDRESS_1>Gibbet Hill Campus</ADDRESS_1><CITY>Coventry</CITY><ZIP>CV4 7AL</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-07-23 14:53:03 +0100" MODIFIED_BY="Bernd Richter"><PERSON ID="89657079368766714838110823094050" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Deepson</FIRST_NAME><MIDDLE_INITIALS>S.</MIDDLE_INITIALS><LAST_NAME>Shyangdan</LAST_NAME><POSITION>Research Fellow</POSITION><EMAIL_1>D.S.Shyangdan@warwick.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Warwick Evidence</DEPARTMENT><ORGANISATION>Health Sciences Research Institute, Warwick Medical School, University of Warwick</ORGANISATION><ADDRESS_1>Gibbet Hill Campus</ADDRESS_1><CITY>Coventry</CITY><ZIP>CV4 7AL</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="18481" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Pamela</FIRST_NAME><LAST_NAME>Royle</LAST_NAME><POSITION>Senior Research Fellow</POSITION><EMAIL_1>pamelaleeroyle@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Warwick Evidence</DEPARTMENT><ORGANISATION>Health Sciences Research Institute, Warwick Medical School, University of Warwick</ORGANISATION><ADDRESS_1>Gibbet Hill Campus</ADDRESS_1><CITY>Coventry</CITY><ZIP>CV4 7AL</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="19622" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Christine</FIRST_NAME><LAST_NAME>Clar</LAST_NAME><EMAIL_1>clar@cc-archie.de</EMAIL_1><ADDRESS><DEPARTMENT>Researcher in Systematic Reviews</DEPARTMENT><ORGANISATION>Cochrane Metabolic and Endocrine Disorders Group</ORGANISATION><ADDRESS_1>Hasenheide 67</ADDRESS_1><CITY>Berlin</CITY><ZIP>10967</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49 30 69040459</PHONE_1><PHONE_2>+49 3061286521</PHONE_2><FAX_1>+49 3061202026</FAX_1></ADDRESS></PERSON><PERSON ID="FFBC648082E26AA200DA2AF39FDE5B99" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Pawana</FIRST_NAME><LAST_NAME>Sharma</LAST_NAME><POSITION>Research Fellow</POSITION><EMAIL_1>p.sharma@abdn.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Health Services Research Unit</DEPARTMENT><ORGANISATION>University of Aberdeen</ORGANISATION><ADDRESS_1>Foresterhill</ADDRESS_1><CITY>Aberdeen</CITY><ZIP>AB25 2ZD</ZIP><REGION>Grampian</REGION><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="19661" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Norman</FIRST_NAME><LAST_NAME>Waugh</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>n.r.waugh@warwick.ac.uk</EMAIL_1><EMAIL_2>n.r.waugh@abdn.ac.uk</EMAIL_2><URL>http://www.abdn.ac.uk/public_health/staff/nwaugh.shtml</URL><ADDRESS><DEPARTMENT>Warwick Evidence</DEPARTMENT><ORGANISATION>Health Sciences Research Institute, Warwick Medical School, University of Warwick</ORGANISATION><ADDRESS_1>Gibbet Hill Campus</ADDRESS_1><CITY>Coventry</CITY><ZIP>CV4 7AL</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="D8BF301282E26AA20078D4E640A553B2" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Ailsa</FIRST_NAME><LAST_NAME>Snaith</LAST_NAME><POSITION>Systematic Reviewer</POSITION><EMAIL_1>chris@snaith550.fsnet.co.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Public Health</DEPARTMENT><ORGANISATION>University of Aberdeen, School of Medicine</ORGANISATION><CITY>Aberdeen</CITY><ZIP>Ab 25 2ZD</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2011-10-05 10:18:37 +0200" MODIFIED_BY="Gudrun Paletta">
<UP_TO_DATE>
<DATE DAY="1" MONTH="3" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="3" YEAR="2011"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="3" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="10" YEAR="2011"/>
<LAST_CITATION_ISSUE ISSUE="10" YEAR="2011"/>
</DATES>
<WHATS_NEW MODIFIED="2013-07-23 15:18:06 +0200" MODIFIED_BY="Gudrun Paletta">
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2013-07-23 15:18:06 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="6" YEAR="2013"/>
<DESCRIPTION>
<P>Feedback arrived at 8 June 3013</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-07-23 15:16:38 +0200" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-07-23 15:16:38 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="5" MONTH="10" YEAR="2011"/>
<DESCRIPTION>
<P>This review version is identical with the previously published one. The only correction that is being made is in the authors contact details.<BR/>
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2011-06-30 17:02:31 +0200" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2011-06-30 17:02:31 +0200" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2010-01-18 19:02:31 +0100" MODIFIED_BY="[Empty name]">
<NAME>University of Aberdeen, Department of Public Health</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2011-06-30 17:02:31 +0200" MODIFIED_BY="[Empty name]">
<NAME>University of Warwick, Warwick Evidence</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-09-01 15:37:42 +0200" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2011-09-01 15:30:10 +0200" MODIFIED_BY="Bernd Richter">
<TITLE MODIFIED="2011-06-29 10:30:03 +0200" MODIFIED_BY="[Empty name]">Glucagon-like peptide analogues for type 2 diabetes</TITLE>
<SUMMARY_BODY MODIFIED="2011-09-01 15:30:10 +0200" MODIFIED_BY="Bernd Richter">
<P>Glucagon-like peptide analogues or agonists are a new kind of drug in the treatment of type 2 diabetes that are given by injection under the skin. They regulate glucose levels by stimulating glucose-dependent insulin secretion and biosynthesis, and by suppressing glucagon secretion, delaying gastric emptying and promoting satiety.  Various glucagon-like peptide-1 agonists are in use or in the licensing process, including exenatide, liraglutide, albiglutide, taspoglutide, lixisenatide and LY2189265.</P>
<P>Seventeen randomised controlled trials of mostly moderate to high quality randomised approximately 6899 people with type 2 diabetes mellitus. Studies were mostly of short duration, usually 26 weeks. The longest duration study was 30 weeks. Of the seventeen studies, one compared albiglutide with placebo, two compared exenatide 10 µg twice daily against exenatide 2 mg once weekly, one compared exenatide 2 mg once weekly against insulin glargine, one compared exenatide 2 mg once weekly against pioglitazone and sitagliptin, five compared liraglutide with placebo, two compared liraglutide with sulphonylurea, one each compared exenatide twice daily with liraglutide, liraglutide with sitagliptin, liraglutide with rosiglitazone and liraglutide with insulin glargine, two compared taspoglutide with placebo and one each compared lixisenatide with placebo and LY2189265 with placebo. In people already treated with oral anti-diabetes drugs, addition of glucagon-like peptide analogues improved blood sugar control in comparison to placebo, rosiglitazone, pioglitazone or sitagliptin, but not always in comparison to insulin (for exenatide) or glimepiride (a sulphonylurea). Glucagon-like peptide analogous caused more weight loss than any of the comparison treatments. However, more nausea and other gastrointestinal effects such as diarrhoea or vomiting were seen, though these tended to wear off and were not seen in all participants. There was slightly more hypoglycaemia with glucagon-like analogous than with placebo, but generally less than with other anti-diabetic treatments. The incidence of hypoglycaemia occurred more frequently in participants taking concomitant sulphonylurea. The studies were not long enough to assess long-term side effects. None of the studies investigated mortality or morbidity.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-08-31 14:20:48 +0200" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2011-08-30 11:53:32 +0200" MODIFIED_BY="Bernd Richter">
<P>Glucagon-like peptide analogues are a new class of drugs used in the treatment of type 2 diabetes that mimic the endogenous hormone glucagon-like peptide 1 (GLP-1). GLP-1 is an incretin, a gastrointestinal hormone that is released into the circulation in response to ingested nutrients. GLP-1 regulates glucose levels by stimulating glucose-dependent insulin secretion and biosynthesis, and by suppressing glucagon secretion, delayed gastric emptying and promoting satiety.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2011-08-31 14:20:20 +0200" MODIFIED_BY="[Empty name]">
<P>To assess the effects of glucagon-like peptide analogues in patients with type 2 diabetes mellitus.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2011-08-30 12:17:59 +0200" MODIFIED_BY="Bernd Richter">
<P>Studies were obtained from electronic searches of <I>The Cochrane Library </I>(last search issue 1, 2011), MEDLINE (last search March 2011), EMBASE (last search March 2011), Web of Science (last search March 2011) and databases of ongoing trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2011-06-29 16:40:33 +0200" MODIFIED_BY="[Empty name]">
<P>Studies were included if they were randomised controlled trials of a minimum duration of eight weeks comparing a GLP-1 analogue with placebo, insulin, an oral anti-diabetic agent, or another GLP-1 analogue in people with type 2 diabetes.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-08-30 10:48:31 +0200" MODIFIED_BY="Bernd Richter">
<P>Data extraction and quality assessment of studies were done by one reviewer and checked by a second. Data were analysed by type of GLP-1 agonist and comparison treatment. Where appropriate, data were summarised in a meta-analysis (mean differences and risk ratios summarised using a random-effects model).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2011-08-31 14:20:48 +0200" MODIFIED_BY="[Empty name]">
<P>Seventeen randomised controlled trials including relevant analyses for 6899 participants were included in the analysis. Studies were mostly of short duration, usually 26 weeks.</P>
<P>In comparison with placebo, all GLP-1 agonists reduced glycosylated haemoglobin A1c (HbA1c) levels by about 1%. Exenatide 2 mg once weekly and liraglutide 1.8 mg reduced it by 0.20% and 0.24% respectively more than insulin glargine. Exenatide 2 mg once weekly reduced HbA1c more than exenatide 10 &#956;g twice daily, sitagliptin and pioglitazone. Liraglutide 1.8 mg reduced HbA1c by 0.33% more than exenatide 10 &#956;g twice daily. Liraglutide led to similar improvements in HbA1c compared to sulphonylureas but reduced it more than sitagliptin and rosiglitazone.</P>
<P>Both exenatide and liraglutide led to greater weight loss than most active comparators, including in participants not experiencing nausea. Hypoglycaemia occurred more frequently in participants taking concomitant sulphonylurea. GLP-1 agonists caused gastrointestinal adverse effects, mainly nausea. These adverse events were strongest at the beginning and then subsided. Beta-cell function was improved with GLP-1 agonists but the effect did not persist after cessation of treatment.</P>
<P>None of the studies was long enough to assess long-term positive or negative effects.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2011-06-30 17:06:07 +0200" MODIFIED_BY="[Empty name]">
<P>GLP-1 agonists are effective in improving glycaemic control.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-09-01 15:37:42 +0200" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2011-08-31 15:49:02 +0200" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2011-08-31 15:49:02 +0200" MODIFIED_BY="[Empty name]">
<P>Type 2 diabetes is characterised by hyperglycaemia, associated with insulin resistance and hyperinsulinaemia, but later by progressively impaired insulin secretion in response to glucose load (ingestion of nutrients, i.e. a meal).</P>
<P>A consequence of this is chronic hyperglycaemia (i.e. elevated levels of plasma glucose) with disturbances of carbohydrate, fat and protein metabolism. Long-term complications of diabetes mellitus include retinopathy, nephropathy and neuropathy. The risk of cardiovascular disease is increased. For a detailed overview of diabetes mellitus, please see under 'Additional information' in the information on the Metabolic and Endocrine Disorders Group in <I>The Cochrane Library</I> (see 'Cochrane Review Groups (CRGs)'). For an explanation of methodological terms, see the main glossary in <I>The Cochrane Library</I>.</P>
<P>Maintenance of tight glucose control is important in preventing complications of diabetes. Traditional treatments for type 2 diabetes aim to control blood glucose and reduce the development of diabetes-associated secondary complications (<LINK REF="REF-Turner-1996" TYPE="REFERENCE">Turner 1996</LINK>). However, there is usually a progressive deterioration in blood glucose control in type 2 diabetes necessitating changes in treatment. People with type 2 diabetes are initially advised on lifestyle changes (weight loss, more exercise and diet) and offered ongoing patient education. If the lifestyle changes fail to control blood glucose, metformin (especially in overweight people) or sulphonylureas (if metformin is contraindicated or not tolerated, or if the person is not overweight) are considered (<LINK REF="REF-NICE-CG87-2009" TYPE="REFERENCE">NICE CG87 2009</LINK>). When monotherapy with these drugs no longer provides adequate glycaemic control, combination therapy is an option (metformin plus sulphonylurea), but it may only be a matter of time before treatment must be intensified (for example by using insulin therapy or pioglitazone) to control glucose levels adequately. The UKPDS (United Kingdom Prospective Diabetes Study) study has shown that the deterioration in glycaemic control may be attributed to the loss of pancreatic insulin-secreting beta-islet cell function (<LINK REF="REF-Turner-1996" TYPE="REFERENCE">Turner 1996</LINK>). In addition some of the oral hypoglycaemic agents lead to weight gain and hypoglycaemia, which in turn affects person's compliance and glycaemic control. A glycosylated haemoglobin A1c (HbA1c) level of more than 7% has been taken to indicate inadequate glycaemic control (<LINK REF="REF-Nathan-2009" TYPE="REFERENCE">Nathan 2009</LINK>) though targets should be individualised.</P>
</CONDITION>
<INTERVENTION MODIFIED="2011-08-30 11:53:57 +0200" MODIFIED_BY="Bernd Richter">
<P>Glucagon-like peptide analogues or agonists are a new group of drugs that mimic the action of an endogenous hormone called glucagon-like peptide 1 (GLP-1). GLP-1 is an incretin, a gastrointestinal hormone that is released into the circulation in response to ingested nutrients. GLP-1 regulates glucose levels by stimulating glucose-dependent insulin secretion and biosynthesis, and by suppressing glucagon secretion, delaying gastric emptying and promoting satiety (<LINK REF="REF-Baggio-2004" TYPE="REFERENCE">Baggio 2004</LINK>; <LINK REF="REF-Nauck-1993" TYPE="REFERENCE">Nauck 1993</LINK>).  GLP-1 lowers glucagon secretion in type 2 diabetes in a glucose-dependent manner thus preventing interference in the normal glucagon counter-regulatory response to hypoglycaemia (<LINK REF="REF-Nauck-2002" TYPE="REFERENCE">Nauck 2002</LINK>).</P>
<P>Circulating GLP-1 undergoes destruction by an enzyme, dipeptidyl-peptidase IV (DPP-IV), resulting in a half-life of 1 to 2 minutes. The natural form is therefore not suitable as a treatment.</P>
<SUBSECTION>
<HEADING LEVEL="3">Adverse effects of the intervention</HEADING>
<P>Weight gain is a major side effect of some traditional type 2 diabetes therapies such as the sulphonylureas and the glitazones. However, the GLP-1 analogues have been shown to produce weight loss in people with type 2 diabetes (<LINK REF="REF-Amori-2007" TYPE="REFERENCE">Amori 2007</LINK>; <LINK REF="REF-Barnett-2009" TYPE="REFERENCE">Barnett 2009</LINK>; <LINK REF="REF-Monami-2009" TYPE="REFERENCE">Monami 2009</LINK>; <LINK REF="REF-NICE-CG87-2009" TYPE="REFERENCE">NICE CG87 2009</LINK>; <LINK REF="REF-Norris-2009" TYPE="REFERENCE">Norris 2009</LINK>).</P>
<P>As regards adverse effects, nausea is common but wears off with time. No serious adverse effects have yet been proven, but there has been concern about exenatide and liraglutide causing pancreatitis. The manufacturers argue that there is no evidence to explain the pathogenesis of pancreatitis with exenatide and also reports that pancreatitis is common in type 2 diabetes, and therefore is not related to the drug. Studies on rats and mice with doses exceeding the recommended human dose showed histological changes of chronic pancreatitis, but the animals appeared healthy with no behavioural changes suggestive of pain. In addition, the animals were taking food normally and growth was also normal (<LINK REF="REF-Butler-2010" TYPE="REFERENCE">Butler 2010</LINK>). The FDA reports that after marketing of exenatide, there have been some cases of acute pancreatitis but that the incidence was low (<LINK REF="REF-FDA-2009" TYPE="REFERENCE">FDA 2009</LINK>). The main concern is about the prolonged use of the drug, as there is evidence of chronic low-grade pancreatitis in rodents and chronic pancreatitis is one of the important causes of pancreatic adenocarcinoma. In the liraglutide development program, it was found that there were more cases of pancreatitis with liraglutide compared with other oral comparators (<LINK REF="REF-EMEA-2009" TYPE="REFERENCE">EMEA 2009</LINK>), but the absolute risk was low. There are no long term data available to substantiate this. Recently, FDA has issued a warning to remind all the doctors that liraglutide may cause pancreatitis and thyroid carcinoma (<LINK REF="REF-Journal-Watch-2011" TYPE="REFERENCE">Journal Watch 2011</LINK>).</P>
<P>In addition, there have been reports of thyroid carcinoma in rodents. A two year carcinogenicity study was performed on rats and mice with liraglutide and it was observed that there was proliferation of C-cells of the thyroid. The changes were dose-dependent and ranged from mild or moderate hyperplasia to malignancy. Liraglutide induced carcinogenic changes by a non-genotoxic, specific GLP-1 receptor mechanism to which rodents are specifically sensitive, whereas monkeys and humans are less sensitive (<LINK REF="REF-EMEA-2009" TYPE="REFERENCE">EMEA 2009</LINK>). Although humans are not sensitive, the chances of carcinogenic changes with liraglutide cannot be discounted due to lack of evidence. Similarly, a two year carcinogenicity study on rats and mice with exenatide reported incidence of benign thyroid C-cell adenomas among rats whereas no such cases were found in mice (<LINK REF="REF-FDA-2009" TYPE="REFERENCE">FDA 2009</LINK>). The exposure to the drug ranged from 5 to 130 times the recommended maximum human exposure dose.</P>
</SUBSECTION>
</INTERVENTION>
<THEORY MODIFIED="2011-08-30 15:28:02 +0200" MODIFIED_BY="Bernd Richter">
<P>There are currently at least six GLP-1 analogues. Exenatide (Byetta, Lilly/Amylin) and liraglutide (NN2211, Novo Nordisk) have reached the market. Albiglutide (GlaxoSmithKline), taspoglutide (Ipsen and Roche), lixisenatide (Sanofi-Aventis) and LY2189265 (Lilly) have been the subject of trials.</P>
<P>Some current glucose lowering treatments cause hypoglycaemia owing to the glucose-independent effect of the drugs. In contrast, the action of the GLP-1 analogues is glucose-dependent, i.e. the higher the plasma glucose level, the greater the effect of GLP-1 on insulin secretion with the greatest effect in hyperglycaemic conditions, and little or no effect when the blood glucose concentration is less than 3.61 mmol/L (65 mg/dL). This should reduce the occurrence of hypoglycaemia.</P>
<P>Much interest has been raised by the possibility that the GLP-1 analogues might reduce the loss of beta-cell mass. Studies in rodents have shown that GLP-1 increases pancreatic islet beta-cell mass by enhancing beta-cell proliferation (<LINK REF="REF-Xu-1999" TYPE="REFERENCE">Xu 1999</LINK>), increasing the differentiation of new beta-cells from progenitor cells in the pancreatic duct epithelium (<LINK REF="REF-Abraham-2002" TYPE="REFERENCE">Abraham 2002</LINK>) and reducing beta-cell apoptosis (<LINK REF="REF-Farilla-2003" TYPE="REFERENCE">Farilla 2003</LINK>; <LINK REF="REF-Li-2003" TYPE="REFERENCE">Li 2003</LINK>). If this applied in humans, use of GLP-1 analogues may hold the potential to maintain or enhance beta-cell mass in type 2 diabetes, and prevent progression of the disease.</P>
<SUBSECTION>
<HEADING LEVEL="3">Current evidence for effectiveness of glucagon-like peptide analogues in type 2 diabetes</HEADING>
<P>Recent evidence has been summarised in reviews by Shyangdan and colleagues (<LINK REF="REF-Shyangdan-2010" TYPE="REFERENCE">Shyangdan 2010</LINK>), Monami and colleagues (<LINK REF="REF-Monami-2009" TYPE="REFERENCE">Monami 2009</LINK>), Barnett (<LINK REF="REF-Barnett-2009" TYPE="REFERENCE">Barnett 2009</LINK>), Amori (<LINK REF="REF-Amori-2007" TYPE="REFERENCE">Amori 2007</LINK>), Norris and colleagues (<LINK REF="REF-Norris-2009" TYPE="REFERENCE">Norris 2009</LINK>) and in HTA reports for NICE (<LINK REF="REF-Shyangdan-2011" TYPE="REFERENCE">Shyangdan 2011</LINK>; <LINK REF="REF-Waugh-2010" TYPE="REFERENCE">Waugh 2010</LINK>). This Cochrane review is partly based on, and partly an update of, the review by Shyangdan and colleagues (<LINK REF="REF-Shyangdan-2010" TYPE="REFERENCE">Shyangdan 2010</LINK>). That review concluded that GLP-1 agonists are effective in improving glycaemic control when used as third line agents. In contrast to insulin, glitazones and sulphonylureas, GLP-1 agonists cause weight reduction and the occurrence of hypoglycaemia is less. The risk of hypoglycaemia increased when GLP-1 agonists were combined with a sulphonylurea but not when given with metformin. GLP-1 agonists caused gastrointestinal adverse events mainly nausea but this decreased over time.</P>
<P>There have been several other good quality reviews, but these have tended to include all trials. However not all trials are relevant to clinical practice. Some were designed to identify the optimum dosage. Others investigated GLP-1 analogues against placebo in people on no other glucose lowering drug, whereas in practice, older cheaper drugs with long safety records, such as metformin, should be used first. In the UK, the NICE guideline recommends that the GLP-1 analogues should be used in triple therapy (<LINK REF="REF-NICE-CG87-2009" TYPE="REFERENCE">NICE CG87 2009</LINK>; <LINK REF="REF-NICE-TA203-2010" TYPE="REFERENCE">NICE TA203 2010</LINK>). In the USA, it appears that they are more frequently used in dual therapy.</P>
<P>A long-acting-release (LAR) formulation of exenatide has been developed that undergoes slow degradation over a period of weeks and can therefore be administered as a single injection per week. Liraglutide is given only once daily. Newer GLP-1 analogues include albiglutide, taspoglutide, lixisenatide and LY2189265.</P>
</SUBSECTION>
</THEORY>
<IMPORTANCE MODIFIED="2011-08-30 11:48:29 +0200" MODIFIED_BY="Bernd Richter">
<P>Conventional treatments used to control hyperglycaemia in type 2 diabetes are unsatisfactory due to weight gain, risk of hypoglycaemia or a decrease in efficacy with disease progression (<LINK REF="REF-Pratley-2008" TYPE="REFERENCE">Pratley 2008</LINK>). Their glucose-dependent mechanism of action suggests that the GLP-1 analogues should not cause hypoglycaemia. In addition it appears that these agents cause weight loss rather than weight gain. Since most people with type 2 diabetes are overweight or obese, this is potentially very important. At present, when people with type 2 diabetes have poor control on a combination of oral agents, the next step is to start a third oral hypoglycaemic agents such as a gliptin or pioglitazone, or a GLP-1 agonist or insulin (<LINK REF="REF-NICE-CG87-2009" TYPE="REFERENCE">NICE CG87 2009</LINK>)). The guideline states that GLP-1 agonists should be continued if it leads to reduction of 1% in HbA1c level and 3% in weight by six months. GLP-1 agonists cause gastrointestinal adverse events, mainly nausea, leading to discontinuation of the drug in some people. However, there is some evidence that the newer GLP-1 analogues used once weekly or once every two weeks reduce this adverse event.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2011-08-30 11:49:03 +0200" MODIFIED_BY="Bernd Richter">
<P>To assess the effects of glucagon-like peptide analogues in patients with type 2 diabetes mellitus.</P>
</OBJECTIVES>
<METHODS MODIFIED="2011-09-01 15:31:42 +0200" MODIFIED_BY="Bernd Richter">
<SELECTION_CRITERIA MODIFIED="2011-08-30 13:40:55 +0200" MODIFIED_BY="Bernd Richter">
<CRIT_STUDIES MODIFIED="2011-08-30 11:49:54 +0200" MODIFIED_BY="Bernd Richter">
<P>Randomised controlled clinical trials.</P>
<P>Only articles published in full were included, except that meeting abstracts were considered if they contained data on secondary outcomes from a study already published in full, or if there was a published protocol (so that information on the design and quality are available).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2011-06-24 10:25:56 +0200" MODIFIED_BY="[Empty name]">
<P>Adults (over 18 years of age) with type 2 diabetes.</P>
<P>To be consistent with changes in classification and diagnostic criteria of type 2 diabetes mellitus through the years, the diagnosis should have been established using the standard criteria valid at the time of the beginning of the trial (<LINK REF="REF-ADA-1997" TYPE="REFERENCE">ADA 1997</LINK>; <LINK REF="REF-ADA-1999" TYPE="REFERENCE">ADA 1999</LINK>; <LINK REF="REF-WHO-1998" TYPE="REFERENCE">WHO 1998</LINK>). Ideally, diagnostic criteria should have been described. If necessary, authors' definition of diabetes mellitus were used.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2011-08-30 13:40:55 +0200" MODIFIED_BY="Bernd Richter">
<P>Trials with a minimum duration of eight weeks of any glucagon-like peptide 1 (GLP-1) analogue (exenatide 10 &#956;g twice daily compared against exenatide 2 mg once weekly, exenatide 2 mg once weekly, liraglutide, albiglutide, taspoglutide, lixisenatide and newer GLP-1 analogues) in combination with metformin or sulphonylurea or both were considered. Studies were also considered if they included additional oral antihyperglycaemic agents, such as thiazolidinediones (TZD). Trials comparing exenatide 10 &#956;g twice daily against placebo or other oral hypoglycaemic agents were not considered. Exenatide 10 &#956;g twice daily is not considered in this review, apart from in comparison with the long-acting form, having been reviewed elsewhere (<LINK REF="REF-Shyangdan-2010" TYPE="REFERENCE">Shyangdan 2010</LINK>) and because it is expected to be replaced by the long-acting, once weekly form.</P>
<P>Since GLP-1 agonists are not licensed for use as first line therapy in treatment-naive patients, the inclusion criteria are based on the comparisons which are considered to be relevant to clinical practice as suggested by the NICE guideline (<LINK REF="REF-NICE-CG66-2008" TYPE="REFERENCE">NICE CG66 2008</LINK>) and by the ADA/EASD joint statement (<LINK REF="REF-Nathan-2009" TYPE="REFERENCE">Nathan 2009</LINK>).</P>
<P>Therefore, the following comparisons were <U>excluded</U>:</P>
<OL>
<LI>GLP-1 used as a monotherapy, whether compared with placebo or another drug.</LI>
<LI>Use of GLP-1 in patients naive to treatment, i.e. patients need to have been diagnosed with type 2 diabetes for at least a year and to have been on at least one oral hypoglycaemic drug for six months; where trials did not give sufficient detail, we accepted them if the mean duration of diabetes exceeded two years.</LI>
<LI>Trials of a GLP-1 agonists on patients having failed only on a sulphonylurea or a glitazone without having been tried on metformin; in practice, some trials included people who have failed on either metformin or a sulphonylurea, and did not necessarily give results separately. We accepted any such trials if 70% of patients or more had been on metformin.</LI>
<LI>Trials or arms using non-standard doses. So most of the data from dose-ranging studies were not relevant.</LI>
</OL>
<SUBSECTION>
<HEADING LEVEL="4">Dosages</HEADING>
<P>The standard exenatide regimen is to start with 5 µg twice daily and to increase after a month or so to 10 µg twice daily.</P>
<P>The dose of liraglutide is less clear, with some trials suggesting starting with 0.6 mg, and then increasing in stages to 1.2 mg or 1.8 mg. There are some trials in Japanes patients where liraglutide has been used in the dose of 0.9 mg (<LINK REF="REF-Kaku-2010" TYPE="REFERENCE">Kaku 2010</LINK>). Otherwise, trials or arms with less than 1.2 mg daily (final dose) were excluded.</P>
<P>For newer GLP-1 agonists, we only included dosages that are likely to be used in routine care - i.e. those with maximal effects while minimising adverse events.</P>
<P>The following comparisons were included:</P>
<P>
<B>1. GLP-1 agonist as a third line agent</B>. There are two questions of interest to clinicians in this situation. The first is whether the GLP-1 analogues are effective in improving glycaemic control, without causing adverse effects. The second is whether GLP-1 analogues are as good as, or better than other options. Since dual therapy is usually metformin and a sulphonylurea, the other options are insulin, a glitazone or a gliptin.        </P>
<P>So comparisons are:</P>
<P>1a. Dual therapy + GLP-1 versus dual therapy + placebo</P>
<P>1b. Dual therapy + GLP-1 versus same dual therapy + another antihyperglycaemic agent</P>
<P>
<B>2. GLP-1 agonist as a second line agent</B>
</P>
<P>The questions are similar to those for third line use:</P>
<P>2a. Monotherapy + GLP-1 versus same monotherapy + placebo</P>
<P>2b. Monotherapy + GLP-1 versus same monotherapy + any antihyperglycaemic agent</P>
<P>
<B>3. GLP-1 agonist versus other GLP-1 agonist</B>
</P>
<P>The general principles of inclusion apply here. So, trials were only included if they compared different GLP-1 analogues as third line or second line agents.</P>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2011-08-30 11:58:26 +0200" MODIFIED_BY="Bernd Richter">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2011-08-30 11:58:26 +0200" MODIFIED_BY="Bernd Richter">
<UL>
<LI>glycaemic control as measured by glycated haemoglobin (HbA1c);</LI>
<LI>hypoglycaemia: graded as mild (symptoms easily controlled by individual), moderate (normal activities interrupted but assistance not required), severe (individual requiring assistance, and associated with blood glucose level less than 50 mg/dL (4 mmol/L) or with prompt recovery after oral carbohydrate or glucagons or intravenous glucose), serious (life threatening or required subject to be admitted to hospital);</LI>
<LI>weight gain or loss/change in body mass index.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2011-08-30 11:28:19 +0200" MODIFIED_BY="Bernd Richter">
<UL>
<LI>health-related quality of life (using a validated instrument);</LI>
<LI>adverse effects (for example congestive heart failure, oedema, pancreatitis, other gastrointestinal effects);</LI>
<LI>mortality (all-cause mortality; diabetes-related mortality (death from myocardial infarction, stroke, peripheral vascular disease, renal disease, hyper- or hypoglycaemia or sudden death);</LI>
<LI>morbidity (both  specific to diabetes such as retinopathy or nephropathy, and cardiovascular  morbidity, for example angina pectoris, myocardial infarction, heart failure, stroke, peripheral vascular disease);</LI>
<LI>blood pressure;</LI>
<LI>fasting blood glucose and post-prandial glucose;</LI>
<LI>plasma lipids (triglycerides, total cholesterol, HDL and LDL-cholesterol);</LI>
<LI>beta-cell function.</LI>
</UL>
<P>
<B>
<I>Covariates, effect modifiers and confounders</I>
</B>
</P>
<UL>
<LI>age;</LI>
<LI>ethnicity;</LI>
<LI>body mass index;</LI>
<LI>HbA1c at baseline;</LI>
<LI>diabetes duration.</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-08-30 12:19:38 +0200" MODIFIED_BY="Bernd Richter">
<P>See: Cochrane Metabolic and Endocrine Disorders Group methods.</P>
<ELECTRONIC_SEARCHES MODIFIED="2011-08-30 12:17:54 +0200" MODIFIED_BY="Bernd Richter">
<P>We used the following sources for the identification of trials:</P>
<UL>
<LI>
<I>The Cochrane Library</I> (issue 1, 2011);</LI>
<LI>MEDLINE (1996 to March 2011);</LI>
<LI>EMBASE (1998 to March 2011);</LI>
<LI>Web of Science (1980 to March 2011).</LI>
</UL>
<P>We also searched databases of ongoing trials:</P>
<UL>
<LI>Current Controlled Trials (www.controlled-trials.com) and ClinicalTrials.gov</LI>
</UL>
<P>See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for details on all search strategies.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2011-08-30 12:19:38 +0200" MODIFIED_BY="Bernd Richter">
<UL>
<LI>American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) web sites were searched for recent meeting abstracts</LI>
<LI>The web sites of the FDA (Food and Drug Administration) and EMEA were searched for information on efficacy and safety</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="4">Reference lists</HEADING>
<P>We also looked for additional studies by searching the reference lists of included trials and (systematic) reviews, meta-analyses and health technology assessment reports identified.</P>
<P>Studies published in any language were to be included.</P>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-09-01 15:31:42 +0200" MODIFIED_BY="Bernd Richter">
<STUDY_SELECTION MODIFIED="2011-09-01 15:31:42 +0200" MODIFIED_BY="[Empty name]">
<P>To determine the studies to be assessed further, three authors (PR, DS, PS) independently scanned the abstract, titles or both sections of every record retrieved. All potentially relevant articles were investigated as full text.  Few differences in opinion existed which were resolved by a third party (NW). There was no article needing the author's clarification for selection. An adapted PRISMA (preferred reporting in systematic review and meta-analysis (<LINK REF="REF-Moher-2009" TYPE="REFERENCE">Moher 2009</LINK>)) flow-chart of study selection is attached (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2011-08-30 10:46:03 +0200" MODIFIED_BY="Bernd Richter">
<P>Two of the three authors (CC, DS, PS) independently extracted data using a standard data extraction form that was tested, piloted and modified for the current review. Data extraction was checked by a second author (CC, PR, DS). Relevant data on study population, intervention, study design and outcomes were pulled out from included studies. See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> for details. Few discrepancies were discussed and resolved between two authors. There was no such disagreements needing a third reviewer.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2011-08-30 12:21:08 +0200" MODIFIED_BY="Bernd Richter">
<P>One of the three authors (CC, DS, PS) assessed risk of bias of each trial, the assessment was checked by another author (CC, PR, DS). Any disagreements were resolved by consensus between the authors. There was no requirement of a third party to resolve the problems.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2011-08-30 12:23:14 +0200" MODIFIED_BY="Bernd Richter">
<P>Dichotomous data were expressed as relative risks with 95% confidence intervals (CI) and continuous data were expressed as mean differences with 95% CIs. Outcomes published in different scales were expressed as standardised mean differences (SMD).</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2011-08-30 12:22:59 +0200" MODIFIED_BY="Bernd Richter">
<P>We planned to take into account the level at which randomisation occurred, such as cross-over trials, cluster-randomised trials and multiple observations for the same outcome.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2011-08-30 12:24:01 +0200" MODIFIED_BY="Bernd Richter">
<P>Numbers of patients screened, randomised and analysed as intention-to-treat or per-protocol were recorded, as were descriptions of withdrawals or losses to follow-up and reasons for withdrawals. Each study was assessed for risk of bias for the issues of incomplete outcome data or missing data by investigating drop-outs, losses to follow-up and withdrawn study participants and issues of last-observation-carried-forward (LOCF) and was compared to specification of primary outcome parameters and power calculation.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2011-08-30 12:26:12 +0200" MODIFIED_BY="Bernd Richter">
<P>We identified heterogeneity by visual inspection of the forest plots and by using a standard Chi<SUP>2 </SUP>test with a significance level of &#945; = 0.1, in view of the low power of this test. We specifically examined heterogeneity employing the I<SUP>2</SUP> statistic which quantifies inconsistency across studies to assess the impact of heterogeneity on the meta-analysis (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>; <LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>), where an I<SUP>2</SUP> statistic of 75% and more indicates a considerable level of inconsistency (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>When heterogeneity was found, we planned to determine potential reasons for it by examining individual study and subgroup characteristics.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2010-01-17 11:49:50 +0100" MODIFIED_BY="[Empty name]">
<P>Studies were checked for outcome reporting bias.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2011-08-30 12:26:38 +0200" MODIFIED_BY="Bernd Richter">
<P>Data were summarised statistically if they were available, sufficiently similar and of sufficient quality. Data were summarised using a random-effects model. Analyses were done separately for the different drugs and the different comparisons as outlined above.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2009-12-23 20:28:42 +0100" MODIFIED_BY="[Empty name]">
<P>Results for hypoglycaemia were analysed in separate subgroups for studies including and not including sulphonylurea therapy.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2011-08-30 12:27:33 +0200" MODIFIED_BY="Bernd Richter">
<P>Due to the limited number of studies in each comparison, sensitivity analyses were not carried out. Relevant sensitivity analyses would have especially included analysis by risk of bias.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-09-01 15:37:42 +0200" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2011-09-01 15:37:42 +0200" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2011-09-01 15:37:42 +0200" MODIFIED_BY="[Empty name]">
<P>Seventeen randomised controlled trials fulfilled the inclusion criteria and were included in the review. Four hundred and eighty six records were screened for eligibility. A total of 449 papers were excluded on the basis of title and abstract. Thirty seven full-text articles were assessed for eligibility, out of which 20 articles, details are shown in <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>, were excluded. Of the 17 studies included, four examined exenatide, eight liraglutide (one trial examined exenatide against liraglutide), two taspoglutide and one each examined lixisenatide, albiglutide and LY2189265. Of the exenatide trials, two trials compared exenatide twice daily against once weekly exenatide, one compared once weekly exenatide against insulin glargine and one compared once weekly exenatide against sitagliptin and pioglitazone. The most important studies with liraglutide were against active comparators. The active comparators were exenatide, rosiglitazone, glargine, sitagliptin and glimepiride. Albiglutide and taspoglutide were compared to placebo. Some of the trials also included other comparison groups, as outlined below. For an overview of comparisons please see <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2011-08-30 12:48:37 +0200" MODIFIED_BY="Bernd Richter">
<P>Characteristics of included studies are shown under <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. Studies were prefixed with the first or first few letters of the drug so that trials appear in the right order in the 'Characteristics of included studies' table.</P>
<SUBSECTION>
<HEADING LEVEL="4">Albiglutide</HEADING>
<P>
<I>Design</I>: The trial by <LINK REF="STD-A-_x002d_-Rosenstock-2009" TYPE="STUDY">A - Rosenstock 2009</LINK> assessing the effects of albiglutide was a multi-centre and multi-national double-blind placebo controlled trial. The primary aim of the study was to study the safety, efficacy and tolerability of incremental doses of albiglutide compared to exenatide or placebo, all in combination with background antihyperglycaemic therapy. The group receiving exenatide was open label and was excluded in the present review as all participants also received metformin, whereas only a proportion of the patients in the other groups did. Study duration was 16 weeks.</P>
<P>
<I>Participants</I>: The study included 361 participants with type 2 diabetes with a mean diabetes duration of 4.9 years. Participants had a mean age of between 51 and 56 years. Baseline glycosylated haemoglobin A1c (HbA1c) was between 7.9% and 8.0%, and baseline body mass index (BMI) between 31.2 kg/m<SUP>2</SUP>and 33 kg/m<SUP>2</SUP>. About a quarter to a third of participants were drug-naive, while the remainder were receiving metformin monotherapy. Participants were excluded if they had used any other oral antidiabetic agent before the beginning of the study.</P>
<P>
<I>Interventions</I>: The trial compared 10 intervention groups. Eight different doses of the drug (4 mg or 15 mg or 30 mg weekly, 15 mg or 30 mg or 50 mg biweekly, and 50 mg or 100 mg monthly) were compared against placebo or exenatide. Only the groups using 30 mg once a week and 30 mg once every two weeks were included in the review for comparison because the trial was partly a dose ranging study and some doses are not relevant to clinical practice. Excluded doses were less effective, caused more adverse effects, or caused more fasting plasma glucose (FPG) fluctuation. Metformin was continued at pre-study doses.</P>
<P>
<I>Outcomes</I>: The primary outcome of the study was HbA1c and FPG changes at the end of the study while the secondary outcomes included fasting fructosamine, C-peptide, glucagon, insulin, and lipid levels, beta-cell function and assessment of adverse events. Occurrence and duration of nausea and vomiting, immunogenicity, level of anti-albiglutide antibodies and pharmacokinetics of albiglutide were assessed. Most of these outcomes were also assessed during the 11 week washout period.</P>
<P> </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Exenatide</HEADING>
<P>Out of the seventeen trials included, five (one trial (<LINK REF="STD-L-_x002d_-LEAD-6-Buse-2009" TYPE="STUDY">L - LEAD 6 Buse 2009</LINK>) compared exenatide and liraglutide and therefore it will be considered under liraglutide) examined the safety and efficacy of exenatide.</P>
<P>
<I>Design</I>: Three trials were open label (<LINK REF="STD-E-_x002d_-Blevins-2011" TYPE="STUDY">E - Blevins 2011</LINK>; <LINK REF="STD-E-_x002d_-Diamant-2010" TYPE="STUDY">E - Diamant 2010</LINK>; <LINK REF="STD-E-_x002d_-Drucker-2008" TYPE="STUDY">E - Drucker 2008</LINK>) while one was double-blind (<LINK REF="STD-E-_x002d_-Bergenstal-2010" TYPE="STUDY">E - Bergenstal 2010</LINK>). Trial duration ranged from 24 to 30 weeks. All the trials were conducted in multiple settings. Two of them were multinational (<LINK REF="STD-E-_x002d_-Bergenstal-2010" TYPE="STUDY">E - Bergenstal 2010</LINK>; <LINK REF="STD-E-_x002d_-Diamant-2010" TYPE="STUDY">E - Diamant 2010</LINK>). A study by <LINK REF="STD-E-_x002d_-Drucker-2008" TYPE="STUDY">E - Drucker 2008</LINK> was carried out in USA and Canada whereas the study by <LINK REF="STD-E-_x002d_-Blevins-2011" TYPE="STUDY">E - Blevins 2011</LINK> was conducted in the USA only.</P>
<P>
<I>Participants</I>: The trials included a total of 1525 randomised patients. Trial participants had a mean age of between 52 and 58 years. Between 40% and 52% of participants in trials were female. Ethnicity was reported in all the studies and the proportion of Caucasian participants ranged between 30% and 85%. All studies included participants with type 2 diabetes with a mean diabetes duration of between 5 years and 8 years, with most taking oral anti diabetic agents (OADs). Baseline HbA1c was between 8.3% to 8.6% and baseline BMI was between 32 kg/m<SUP>2</SUP>and 35 kg/m<SUP>2</SUP>. Three trials (<LINK REF="STD-E-_x002d_-Blevins-2011" TYPE="STUDY">E - Blevins 2011</LINK>; <LINK REF="STD-E-_x002d_-Diamant-2010" TYPE="STUDY">E - Diamant 2010</LINK>; <LINK REF="STD-E-_x002d_-Drucker-2008" TYPE="STUDY">E - Drucker 2008</LINK>) gave detailed information on previous treatments. Participants were taking metformin, sulphonylureas or thiazolidinediones either on its own or in combination. The studies by <LINK REF="STD-E-_x002d_-Blevins-2011" TYPE="STUDY">E - Blevins 2011</LINK> and <LINK REF="STD-E-_x002d_-Drucker-2008" TYPE="STUDY">E - Drucker 2008</LINK> also included between 14% and 21% of participants on diet and exercise only.</P>
<P>
<I>Interventions</I>: Two trials (<LINK REF="STD-E-_x002d_-Blevins-2011" TYPE="STUDY">E - Blevins 2011</LINK>; <LINK REF="STD-E-_x002d_-Drucker-2008" TYPE="STUDY">E - Drucker 2008</LINK>) compared long acting exenatide i.e. 2 mg once weekly against twice daily exenatide i.e. 10 µg. Twice daily exenatide regimen would start with 5 µg twice a day, increasing to 10 µg twice a day after a few weeks. The study by <LINK REF="STD-E-_x002d_-Bergenstal-2010" TYPE="STUDY">E - Bergenstal 2010</LINK> compared long acting exenatide against sitagliptin 100 mg once daily and pioglitazone 45 mg once daily while the study by <LINK REF="STD-E-_x002d_-Diamant-2010" TYPE="STUDY">E - Diamant 2010</LINK> compared long acting exenatide against insulin glargine.</P>
<P>
<I>Outcomes</I>: In all the trials, the primary outcome measure was change in HbA1c value from baseline to end of study. Secondary outcome measures included changes in FPG, postprandial glucose (PPG), body weight, hypoglycaemia, blood pressure, lipid profile, beta-cell function, adverse events, and immunogenicity of exenatide. Quality of life was reported by two trials (<LINK REF="STD-E-_x002d_-Blevins-2011" TYPE="STUDY">E - Blevins 2011</LINK>; <LINK REF="STD-E-_x002d_-Diamant-2010" TYPE="STUDY">E - Diamant 2010</LINK>) and none of the trials reported diabetes-related morbidity (most of them did not last long enough for a meaningful assessment of this outcome).</P>
<P> </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Liraglutide</HEADING>
<P>Eight trials assessed the safety and efficacy of liraglutide.</P>
<P>
<I>Design</I>: Two trials (<LINK REF="STD-L-_x002d_-LEAD-6-Buse-2009" TYPE="STUDY">L - LEAD 6 Buse 2009</LINK>; <LINK REF="STD-L-_x002d_-Pratley-2010" TYPE="STUDY">L - Pratley 2010</LINK>) were open label and five trials were double blind (<LINK REF="STD-L-_x002d_-Kaku-2010" TYPE="STUDY">L - Kaku 2010</LINK>; <LINK REF="STD-L-_x002d_-LEAD-1-Marre-2009" TYPE="STUDY">L - LEAD 1 Marre 2009</LINK>; <LINK REF="STD-L-_x002d_-LEAD-2-Nauck-2009" TYPE="STUDY">L - LEAD 2 Nauck 2009</LINK>; <LINK REF="STD-L-_x002d_-LEAD-4-Zinman-2009" TYPE="STUDY">L - LEAD 4 Zinman 2009</LINK>; <LINK REF="STD-L-_x002d_-Yang-2010" TYPE="STUDY">L - Yang 2010</LINK>). One trial (<LINK REF="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009" TYPE="STUDY">L - LEAD 5 Russell-J 2009</LINK>) included two double blind groups and one open label group. Trial duration was 26 weeks for all trials except one, <LINK REF="STD-L-_x002d_-Yang-2010" TYPE="STUDY">L - Yang 2010</LINK>, which was 16 weeks long. All trials were multi-centre and multi-national trials except <LINK REF="STD-L-_x002d_-Kaku-2010" TYPE="STUDY">L - Kaku 2010</LINK> which was carried out in multiple settings in Japan only. The study by <LINK REF="STD-L-_x002d_-Yang-2010" TYPE="STUDY">L - Yang 2010</LINK> included participants from three Asian countries namely China, South Korea and India.</P>
<P>
<I>Participants</I>: The trials included a total of 5086 randomised participants (excluding liraglutide 0.6 mg dose from all other trials except <LINK REF="STD-L-_x002d_-Kaku-2010" TYPE="STUDY">L - Kaku 2010</LINK>). Liraglutide doses of 0.6 mg and 0.9 mg are standard in Japan and hence <LINK REF="STD-L-_x002d_-Kaku-2010" TYPE="STUDY">L - Kaku 2010</LINK> was included in this review. Trial participants had a mean age of between 52.7 years and 61.3 years. Between 33% and 55% of participants in trials were female. Ethnicity was not reported in three of the eight trials (<LINK REF="STD-L-_x002d_-LEAD-1-Marre-2009" TYPE="STUDY">L - LEAD 1 Marre 2009</LINK>; <LINK REF="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009" TYPE="STUDY">L - LEAD 5 Russell-J 2009</LINK>; <LINK REF="STD-L-_x002d_-Yang-2010" TYPE="STUDY">L - Yang 2010</LINK>) and the proportion of Caucasian participants ranged between 81% and 93%. In the study by <LINK REF="STD-L-_x002d_-Kaku-2010" TYPE="STUDY">L - Kaku 2010</LINK>, all the participants were Japanese. All studies included participants with type 2 diabetes with a mean diabetes duration of between 6.0 years and 11.6 years, with all taking oral antidiabetic medication. Only one trial (<LINK REF="STD-L-_x002d_-LEAD-1-Marre-2009" TYPE="STUDY">L - LEAD 1 Marre 2009</LINK>) did not clearly report on pre-study medication, but it can be assumed that the participants were tried on metformin because most of them were from Europe and Asia where metformin is used as a first line medication. Baseline HbA1c values were between 8.1% and 8.6% and baseline BMI was between 29.4 kg/m<SUP>2</SUP> and 33.9 kg/m<SUP>2</SUP>. Background antihyperglycaemic medication included sulphonylureas in four trials (<LINK REF="STD-L-_x002d_-Kaku-2010" TYPE="STUDY">L - Kaku 2010</LINK>; <LINK REF="STD-L-_x002d_-LEAD-1-Marre-2009" TYPE="STUDY">L - LEAD 1 Marre 2009</LINK>; <LINK REF="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009" TYPE="STUDY">L - LEAD 5 Russell-J 2009</LINK>; <LINK REF="STD-L-_x002d_-LEAD-6-Buse-2009" TYPE="STUDY">L - LEAD 6 Buse 2009</LINK>), and thiazolidinediones in one trial (<LINK REF="STD-L-_x002d_-LEAD-4-Zinman-2009" TYPE="STUDY">L - LEAD 4 Zinman 2009</LINK>).  </P>
<P>
<I>Interventions</I>: Two trials (<LINK REF="STD-L-_x002d_-LEAD-1-Marre-2009" TYPE="STUDY">L - LEAD 1 Marre 2009</LINK>, <LINK REF="STD-L-_x002d_-LEAD-2-Nauck-2009" TYPE="STUDY">L - LEAD 2 Nauck 2009</LINK>) compared five intervention groups, five trials (<LINK REF="STD-L-_x002d_-Kaku-2010" TYPE="STUDY">L - Kaku 2010</LINK>; <LINK REF="STD-L-_x002d_-LEAD-4-Zinman-2009" TYPE="STUDY">L - LEAD 4 Zinman 2009</LINK>; <LINK REF="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009" TYPE="STUDY">L - LEAD 5 Russell-J 2009</LINK>; <LINK REF="STD-L-_x002d_-Pratley-2010" TYPE="STUDY">L - Pratley 2010</LINK>; <LINK REF="STD-L-_x002d_-Yang-2010" TYPE="STUDY">L - Yang 2010</LINK>) compared three different intervention groups, and <LINK REF="STD-L-_x002d_-LEAD-6-Buse-2009" TYPE="STUDY">L - LEAD 6 Buse 2009</LINK> compared two intervention groups. Liraglutide was dosed at 0.6, 0.9, 1.2 or 1.8 mg/day, however, in this review we only consider 1.2 and 1.8 mg/day except <LINK REF="STD-L-_x002d_-Kaku-2010" TYPE="STUDY">L - Kaku 2010</LINK>. The study by <LINK REF="STD-L-_x002d_-Kaku-2010" TYPE="STUDY">L - Kaku 2010</LINK> compared 0.6 or 0.9 mg/day of liraglutide against placebo, with all participants receiving concomitant glimepiride therapy. <LINK REF="STD-L-_x002d_-LEAD-1-Marre-2009" TYPE="STUDY">L - LEAD 1 Marre 2009</LINK> compared 1.2 or 1.8 mg/day of liraglutide against placebo or rosiglitazone (4 mg/day), with all groups receiving concomitant glimepiride therapy. <LINK REF="STD-L-_x002d_-LEAD-2-Nauck-2009" TYPE="STUDY">L - LEAD 2 Nauck 2009</LINK> compared 1.2 or 1.8 mg/day of liraglutide against placebo or glimepiride 4 mg/day, with all groups receiving concomitant therapy with metformin. <LINK REF="STD-L-_x002d_-LEAD-4-Zinman-2009" TYPE="STUDY">L - LEAD 4 Zinman 2009</LINK> compared 1.2 or 1.8 mg/day of liraglutide against placebo, with all groups receiving concomitant therapy with metformin and rosiglitazone. <LINK REF="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009" TYPE="STUDY">L - LEAD 5 Russell-J 2009</LINK> compared 1.8 mg/day of liraglutide versus insulin glargine or placebo, with all groups receiving concomitant therapy with metformin and glimepiride. <LINK REF="STD-L-_x002d_-LEAD-6-Buse-2009" TYPE="STUDY">L - LEAD 6 Buse 2009</LINK> compared 1.8 mg/day of liraglutide against 10 µg BID exenatide, with all groups remaining on their existing sulphonylurea and/or metformin therapy. <LINK REF="STD-L-_x002d_-Pratley-2010" TYPE="STUDY">L - Pratley 2010</LINK> compared 1.2 or 1.8 mg/day of liraglutide against sitagliptin 100 mg/day, with all groups continuing their existing metformin therapy. <LINK REF="STD-L-_x002d_-Yang-2010" TYPE="STUDY">L - Yang 2010</LINK> compared 1.2 or 1.8 mg/day against glimepiride 4 mg/day, with all participants receiving metformin 2000 mg/day. Most trials included a run-in period used for drug titration.</P>
<P>
<I>Outcomes</I>: In all the trials the primary outcome measure was change in HbA1c value from baseline to end of study. Secondary outcome measures included changes in FPG, postprandial glucose (PPG), hypoglycaemia, body weight, adverse events, blood pressure, lipid profile, beta-cell function and liraglutide immunogenicity. Only one study (<LINK REF="STD-L-_x002d_-LEAD-6-Buse-2009" TYPE="STUDY">L - LEAD 6 Buse 2009</LINK>) reported health-related quality of life and none reported about diabetes-related mortality.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Lixisenatide </HEADING>
<P>One trial assessed the safety and efficacy of lixisenatide.</P>
<P>
<I>Design:</I> The trial by <LINK REF="STD-Lixi-_x002d_-Ratner-2010" TYPE="STUDY">Lixi - Ratner 2010</LINK> assessing the effects of lixisenatide was a double-blind, multi-national, parallel-group, placebo controlled trial. Trial duration was 13 weeks.</P>
<P>
<I>Participants:</I> The trial included a total of 542 randomised participants with type 2 diabetes with a mean duration of diabetes between 6.0 years and 7.2 years. Trial participants had a mean age of between 55.4 years and 56.8 years. Between 40.4% and 63% of participants in the trial were female. The total proportion of Caucasian participants were between 64.8% and 86.8%. All the participants were taking metformin. Baseline HbA1c values were between 7.46% and 7.61% and baseline BMI was between 30.7 kg/m<SUP>2</SUP> and 32.8 kg/m<SUP>2</SUP>.</P>
<P>
<I>Interventions:</I> The trial compared nine intervention groups. Lixisenatide was dosed at 5 &#956;g, 10 &#956;g, 20 &#956;g, 30 &#956;g once or twice daily and compared against placebo twice daily, with all participants receiving stable dose of metformin. All groups also received diet and lifestyle counselling according to the American Diabetes Association guidelines. It also included an initial 2-week screening phase followed by a 2-week, single blind, placebo run in period.</P>
<P>
<I>Outcomes:</I> The primary outcome measure was change in HbA1c from baseline to end of study. Secondary outcome measures included the proportion of participants achieving HbA1c level of less than 7% or less than 6.5%, changes in body weight, FPG, 2-hour post-prandial glucose, hypoglycaemia, blood pressure, heart rate, electrocardiogram (ECG) and anti-lixisenatide antibodies. Quality of life and diabetes related morbidity were not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">LY2189265</HEADING>
<P>One trial assessed the safety and efficacy of LY2189265.</P>
<P>
<I>Design:</I> The trial by <LINK REF="STD-LY2189265-_x002d_Umpierrez-2011" TYPE="STUDY">LY2189265 -Umpierrez 2011</LINK> assessing the effects of LY2189265 was a double-blind, placebo-controlled randomised trial. It was carried out in multiple settings in US and Puerto Rico. Trial duration was 16 weeks.</P>
<P>
<I>Participants:</I> The trial included a total of 262 participants with type 2 diabetes, of which 46% to 56% were female. Mean duration of diabetes was between 7.5 years and 9.0 years. Trial participants had a mean age of between 54 years and 59 years. Between 55% and 61% of participants were Caucasians. Majority of the participants (72.7% to 73.8%) were taking metformin and sulphonylurea in combination. Mean HbA1c was between 8.05% and 8.43% and baseline BMI was between 33.7 kg/m<SUP>2 </SUP>and 34.2 kg/m<SUP>2</SUP>.</P>
<P>
<I>Interventions: </I>The trial compared four intervention groups. LY2189265 (LY) was dosed at 0.5, 1.0 and 2.0 mg. First group (also referred as LY 0.5/1.0 mg) received once weekly subcutaneous injection of LY 0.5 mg in the first four weeks followed by 1.0 mg once weekly injection in the next 12 weeks. Second group (also referred as LY 1.0/1.0 mg) received once weekly subcutaneous injection of LY 1.0 mg for 16 weeks. Third group (also referred as LY 1.0/2.0 mg) received once weekly injection of LY 1.0 mg in the first four weeks followed by once weekly injection of LY 2.0 mg in the next 12 weeks. Placebo was given as weekly injection. All the participants continued their baseline oral antihyperglycaemic drugs.</P>
<P>
<I>Outcomes:</I> The primary outcome measure was change in HbA1c from baseline to end of study. Secondary outcome measures included change in FPG, blood glucose response following a solid mixed-meal test, change in body weight, beta-cell function, treatment emergent adverse events, and hypoglycaemia.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Taspoglutide</HEADING>
<P>Two trials (<LINK REF="STD-T-_x002d_-Nauck-2009" TYPE="STUDY">T - Nauck 2009</LINK>; <LINK REF="STD-T_x002d_-Ratner-2010" TYPE="STUDY">T- Ratner 2010</LINK>) assessed the safety and efficacy of taspoglutide.</P>
<P>
<I>Design: </I>Both trials (<LINK REF="STD-T-_x002d_-Nauck-2009" TYPE="STUDY">T - Nauck 2009</LINK>; <LINK REF="STD-T_x002d_-Ratner-2010" TYPE="STUDY">T- Ratner 2010</LINK>) assessing the effects of taspoglutide were double blind multi-centre and multi-national placebo controlled. </P>
<P>
<I>Participants</I>: The trials included a total of 439 participants with type 2 diabetes with a mean diabetes duration of between five years and eight years. Participants had a mean age of between 53 years and 60 years and between 36% and 64% were female. Ethnicity was not reported. Baseline HbA1c was between 7.8% and 8.0%, baseline BMI was between 31.5 kg/m<SUP>2 </SUP>and 33.3 kg/m<SUP>2</SUP>. All participants had been on metformin monotherapy.</P>
<P>
<I>Interventions</I>: <LINK REF="STD-T-_x002d_-Nauck-2009" TYPE="STUDY">T - Nauck 2009</LINK> compared six intervention groups. Five different doses of taspoglutide (5 mg or 10 mg or 20 mg once weekly or 10 mg or 20 mg once every two weeks) were compared against placebo. In this review, we only consider 10 mg and 20 mg once weekly and 20 mg once every two weeks as the other doses are unlikely to be relevant to clinical practice. The prestudy drugs were continued at the same dose throughout the study period. The trial by <LINK REF="STD-T_x002d_-Ratner-2010" TYPE="STUDY">T- Ratner 2010</LINK> compared four intervention groups. Three different doses of taspoglutide i.e. 20, 30 and 40 mg once weekly were used in the study. Taspoglutide 20 mg was injected once every week in the first 4 weeks and then continued in the same dose for the next four weeks (20/20 mg group) or titrated to 30 mg (20/30 mg group) or to 40 mg (20/40 mg group). All the participants continued metformin in their prestudy dose. The prestudy diet and exercise plan was followed throughout the study. Some participants also received medications for cardiovascular risk factors.</P>
<P>
<I>Outcomes</I>: The primary outcome measure in <LINK REF="STD-T-_x002d_-Nauck-2009" TYPE="STUDY">T - Nauck 2009</LINK> was change in HbA1c from baseline to end of study while <LINK REF="STD-T_x002d_-Ratner-2010" TYPE="STUDY">T- Ratner 2010</LINK> explored gastrointestinal tolerability. It was assessed by comparing the number of participants who withdrew from study because of gastrointestinal adverse events Secondary outcome measures in <LINK REF="STD-T-_x002d_-Nauck-2009" TYPE="STUDY">T - Nauck 2009</LINK> included changes in FPG, postprandial glucose, body weight, hypoglycaemia, adverse events, lipid profile, and beta-cell function. <LINK REF="STD-T_x002d_-Ratner-2010" TYPE="STUDY">T- Ratner 2010</LINK> explored changes in FPG, HbA1c, body weight and pharmacokinetic parameters. Quality of life and diabetes-related  morbidity were not reported.</P>
<P> </P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2010-02-10 12:27:39 +0100" MODIFIED_BY="[Empty name]">
<P>Studies were excluded because they were not primary trials, because they did not compare clinically relevant interventions, or because patients did not fulfil the inclusion criteria (mainly because of previous medication).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2011-08-30 10:43:07 +0200" MODIFIED_BY="Bernd Richter">
<P>Details of risk of bias assessment of the trials are shown in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> section, in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<ALLOCATION MODIFIED="2011-06-24 10:32:35 +0200" MODIFIED_BY="[Empty name]">
<P>Out of the seventeen trials, randomisation was adequate in nine, while for the remaining eight (<LINK REF="STD-A-_x002d_-Rosenstock-2009" TYPE="STUDY">A - Rosenstock 2009</LINK>; <LINK REF="STD-E-_x002d_-Drucker-2008" TYPE="STUDY">E - Drucker 2008</LINK>; <LINK REF="STD-L-_x002d_-Kaku-2010" TYPE="STUDY">L - Kaku 2010</LINK>; <LINK REF="STD-L-_x002d_-LEAD-1-Marre-2009" TYPE="STUDY">L - LEAD 1 Marre 2009</LINK>; <LINK REF="STD-L-_x002d_-LEAD-6-Buse-2009" TYPE="STUDY">L - LEAD 6 Buse 2009</LINK>; <LINK REF="STD-L-_x002d_-Yang-2010" TYPE="STUDY">L - Yang 2010</LINK>; <LINK REF="STD-LY2189265-_x002d_Umpierrez-2011" TYPE="STUDY">LY2189265 -Umpierrez 2011</LINK>; <LINK REF="STD-T_x002d_-Ratner-2010" TYPE="STUDY">T- Ratner 2010</LINK>) the randomisation procedure was not reported or unclear. Ten trials had adequate allocation concealment, while the rest of the trials (<LINK REF="STD-A-_x002d_-Rosenstock-2009" TYPE="STUDY">A - Rosenstock 2009</LINK>; <LINK REF="STD-E-_x002d_-Drucker-2008" TYPE="STUDY">E - Drucker 2008</LINK>; <LINK REF="STD-L-_x002d_-Kaku-2010" TYPE="STUDY">L - Kaku 2010</LINK>; <LINK REF="STD-L-_x002d_-LEAD-1-Marre-2009" TYPE="STUDY">L - LEAD 1 Marre 2009</LINK>; <LINK REF="STD-L-_x002d_-Yang-2010" TYPE="STUDY">L - Yang 2010</LINK>; <LINK REF="STD-LY2189265-_x002d_Umpierrez-2011" TYPE="STUDY">LY2189265 -Umpierrez 2011</LINK>; <LINK REF="STD-T_x002d_-Ratner-2010" TYPE="STUDY">T- Ratner 2010</LINK>) did not report on allocation concealment.</P>
</ALLOCATION>
<BLINDING MODIFIED="2011-06-24 10:33:33 +0200" MODIFIED_BY="[Empty name]">
<P>Eleven trials were double blind (<LINK REF="STD-A-_x002d_-Rosenstock-2009" TYPE="STUDY">A - Rosenstock 2009</LINK>; <LINK REF="STD-E-_x002d_-Bergenstal-2010" TYPE="STUDY">E - Bergenstal 2010</LINK>; <LINK REF="STD-L-_x002d_-Kaku-2010" TYPE="STUDY">L - Kaku 2010</LINK>; <LINK REF="STD-L-_x002d_-LEAD-1-Marre-2009" TYPE="STUDY">L - LEAD 1 Marre 2009</LINK>; <LINK REF="STD-L-_x002d_-LEAD-2-Nauck-2009" TYPE="STUDY">L - LEAD 2 Nauck 2009</LINK>; <LINK REF="STD-L-_x002d_-LEAD-4-Zinman-2009" TYPE="STUDY">L - LEAD 4 Zinman 2009</LINK>; <LINK REF="STD-L-_x002d_-Yang-2010" TYPE="STUDY">L - Yang 2010</LINK>; <LINK REF="STD-Lixi-_x002d_-Ratner-2010" TYPE="STUDY">Lixi - Ratner 2010</LINK>; <LINK REF="STD-LY2189265-_x002d_Umpierrez-2011" TYPE="STUDY">LY2189265 -Umpierrez 2011</LINK>; <LINK REF="STD-T-_x002d_-Nauck-2009" TYPE="STUDY">T - Nauck 2009</LINK>; <LINK REF="STD-T_x002d_-Ratner-2010" TYPE="STUDY">T- Ratner 2010</LINK>) while five trials (<LINK REF="STD-E-_x002d_-Blevins-2011" TYPE="STUDY">E - Blevins 2011</LINK>; <LINK REF="STD-E-_x002d_-Diamant-2010" TYPE="STUDY">E - Diamant 2010</LINK>; <LINK REF="STD-E-_x002d_-Drucker-2008" TYPE="STUDY">E - Drucker 2008</LINK>; <LINK REF="STD-L-_x002d_-LEAD-6-Buse-2009" TYPE="STUDY">L - LEAD 6 Buse 2009</LINK>; <LINK REF="STD-L-_x002d_-Pratley-2010" TYPE="STUDY">L - Pratley 2010</LINK>) were open label. <LINK REF="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009" TYPE="STUDY">L - LEAD 5 Russell-J 2009</LINK> was a three-armed placebo controlled blinded study, with liraglutide and liraglutide placebo, and the glargine arm open label.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2011-06-24 11:16:26 +0200" MODIFIED_BY="[Empty name]">
<P>All the trials except three (<LINK REF="STD-L-_x002d_-Kaku-2010" TYPE="STUDY">L - Kaku 2010</LINK>; <LINK REF="STD-L-_x002d_-Pratley-2010" TYPE="STUDY">L - Pratley 2010</LINK>; <LINK REF="STD-L-_x002d_-Yang-2010" TYPE="STUDY">L - Yang 2010</LINK>) used intention-to-treat analysis. All the trials reported on rates and reasons for withdrawal. Rates of withdrawal ranged between 1% and 42% (often with more withdrawals in the GLP-1 agonist groups).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2011-06-24 10:34:07 +0200" MODIFIED_BY="[Empty name]">
<P>All the pre-specified (both primary and secondary) outcomes were reported in all the trials. Ethnicity was not reported in five trials (<LINK REF="STD-L-_x002d_-LEAD-1-Marre-2009" TYPE="STUDY">L - LEAD 1 Marre 2009</LINK>; <LINK REF="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009" TYPE="STUDY">L - LEAD 5 Russell-J 2009</LINK>; <LINK REF="STD-L-_x002d_-Yang-2010" TYPE="STUDY">L - Yang 2010</LINK>; <LINK REF="STD-T-_x002d_-Nauck-2009" TYPE="STUDY">T - Nauck 2009</LINK>; <LINK REF="STD-T_x002d_-Ratner-2010" TYPE="STUDY">T- Ratner 2010</LINK>) but other baseline characteristics were reported in the remaining trials.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2011-06-17 09:54:21 +0200" MODIFIED_BY="[Empty name]">
<P>A description about the power calculation was unclear in the trial by <LINK REF="STD-L-_x002d_-Kaku-2010" TYPE="STUDY">L - Kaku 2010</LINK>. However, all the remaining trials had carried out a power calculation. Baseline groups were comparable in all trials.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-09-01 14:50:53 +0200" MODIFIED_BY="[Empty name]">
<P>An overview of the results for all comparisons is shown in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="3">Albiglutide</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Albiglutide versus placebo</HEADING>
<P>Results for albiglutide are shown in <LINK TAG="ANALYSES_AND_DATA" TYPE="SECTION">Data and analyses</LINK>, 1.1 to 1.12.</P>
<SUBSECTION>
<HEADING LEVEL="5">HbA1c</HEADING>
<P>
<LINK REF="STD-A-_x002d_-Rosenstock-2009" TYPE="STUDY">A - Rosenstock 2009</LINK> found a significant difference (P &lt; 0.05) for HbA1c values between albiglutide and placebo at the end of the study. HbA1c levels decreased by 0.87% (SD 0.65) and 0.79% (SD 0.98) in the participants receiving albiglutide 30 mg weekly and 30 mg every two weeks respectively, whereas the level of HbA1c only decreased by 0.17% (SD 1.01) in the placebo group. The end values of HbA1c were 7.1%, 7.2% and 7.7% for albiglutide 30 mg weekly, albiglutide 30 mg every two weeks and placebo respectively. Similarly, there was a significant difference in the proportion of participants reaching target HbA1c of less than 7% between the albiglutide and placebo groups (52% for albiglutide 30 mg weekly, 50% for 30 mg every two weeks and 20% for placebo). Greater reductions in HbA1c levels were seen in participants with baseline HbA1c values of 8.5% or more but details were not given.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Hypoglycaemia</HEADING>
<P>A definition of hypoglycaemia was not given in the study. No significant difference was found for the incidence of hypoglycaemia among groups. None of the participants in the albiglutide 30 mg weekly group reported hypoglycaemia. Only one patient (3.1%) in the albiglutide 30 mg every two weeks and two patients (3.9%) in the placebo group reported hypoglycaemia during the study period.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Weight change</HEADING>
<P>Weight decreased in both albiglutide and placebo groups. At the end of the study, there was a reduction of 1.4 kg (SD 2.4) in the 30 mg weekly group, of 1.6 kg (SD 2.5) in the 30 mg every two weeks group and of 0.7 kg (SD 2.9) in the placebo group. There were no significant differences in weight reduction between the study groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>The incidence of adverse events was similar across all groups and ranged between 66.7% and 84.4%. The majority of the adverse events were nausea, vomiting and diarrhoea and the incidence of the first two was more in the participants receiving albiglutide 30 mg once every week while the incidence of diarrhoea was comparatively more in the 30 mg biweekly group. Similarly, the number of participants with a positive immunogenicity test was also higher in albiglutide 30 mg once every week group compared with other groups (6.4% in albiglutide 30 mg weekly versus 3.1% in albiglutide 30 mg every two weeks and 2% with placebo). None of the participants on albiglutide therapy suffered from pancreatitis or any cardiac disorders, however the incidence of skin reactions to the drug was more in the albiglutide group compared to placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Blood pressure</HEADING>
<P>Both albiglutide and placebo groups showed a decrease in systolic and diastolic blood pressure. However, the reduction of blood pressure in the albiglutide groups when compared to placebo group was not significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Fasting plasma glucose</HEADING>
<P>Significant reductions (P &lt; 0.05) in fasting plasma glucose were observed in the albiglutide groups compared to placebo. Reduction of 1.44% (SD 2.03) and 1.58% (SD 2.06) were observed with albiglutide 30 mg weekly and 30 mg every two weeks while the reduction was 0.10% (SD 2.90) in the placebo group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Lipid profiles</HEADING>
<P>No significant changes were seen in the lipid profiles of the participants treated with either albiglutide or placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Beta-cell function</HEADING>
<P>A significant improvement in beta-cell function (HOMA-B ratio) was seen in the participants treated with 30 mg albiglutide weekly (1.4) compared to placebo (1.0) whereas the difference to placebo was not significant with 30 mg albiglutide every two weeks (1.2).</P>
<P> </P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Exenatide</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Exenatide versus thiazolidinedione (pioglitazone)</HEADING>
<P>Results for exenatide versus thiazolidinedione are shown in <LINK TAG="ANALYSES_AND_DATA" TYPE="SECTION">Data and analyses</LINK>, 2.1 to 2.10. Only one study (<LINK REF="STD-E-_x002d_-Bergenstal-2010" TYPE="STUDY">E - Bergenstal 2010</LINK>) compared once weekly exenatide (2 mg) against pioglitazone 45 mg daily.</P>
<SUBSECTION>
<HEADING LEVEL="5">HbA1c</HEADING>
<P>
<LINK REF="STD-E-_x002d_-Bergenstal-2010" TYPE="STUDY">E - Bergenstal 2010</LINK> found a slightly greater reduction in HbA1c with once weekly exenatide than with pioglitazone 45 mg once daily (-1.5% versus -1.2%, P = 0.02).</P>
<P>The proportion of participants achieving target HbA1c level of less 7% was not different between the two treatment groups (60% versus 52%, P = 0.15).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Hypoglycaemia</HEADING>
<P>In the trial, minor hypoglycaemia was defined as any episode where a participant experienced symptoms consistent with hypoglycaemia and a blood glucose level of less than 3 mmol/L. Major hyperglycaemia was defined as any episode resulting in loss of consciousness, seizure or coma that resolved after administration with glucagon or glucose, or any episode with blood glucose level of less than 3.0 mmol/L and a severe impairment that required third-party assistance to resolve the episode. Incidences of minor hypoglycaemia were similar between the groups, two participants in the exenatide group and one in the pioglitazone group. There were no cases of major hypoglycaemia.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Weight change</HEADING>
<P>Participants taking exenatide once weekly lost weight while those taking pioglitazone gained weight (-2.3 kg versus + 2.8 kg, P &lt; 0.00001).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Quality of life</HEADING>
<P>In <LINK REF="STD-E-_x002d_-Bergenstal-2010" TYPE="STUDY">E - Bergenstal 2010</LINK>, it was found that all the five parameters of weight-related quality of life and IWQOL total score significantly improved with exenatide (IWQOL total score 5.15, 95% CI 3.11 to 7.19) and not with pioglitazone (1.20, 95% CI -0.87 to 3.28). The treatment difference between exenatide and pioglitazone was significant (3.94, 95% CI 1.28 to 6.61, P = 0.0038). The improvement in IWQOL total score with exenatide was consistent with differences in body weight changes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>Withdrawals due to adverse events were increased with once weekly exenatide than pioglitazone (6.9% versus 3.6%). The most commonly reported adverse events with exenatide were nausea and diarrhoea. Withdrawals from the trial were mostly because of these events. Incidences of other adverse events such as headache, urinary tract infection and injection-site pruritus were similar between the groups. Pioglitazone caused more serious adverse events than exenatide (6% versus 3%). Two other serious events (one in exenatide and other in pioglitazone) led to withdrawals. About half of the participants had low levels of anti-exenatide antibodies (48%) but in 40% they were not detectable, and there was no relation to glycaemic control and safety.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Blood pressure</HEADING>
<P>Reduction in systolic and diastolic blood pressure was not significantly different between the two groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Fasting plasma glucose</HEADING>
<P>
<LINK REF="STD-E-_x002d_-Bergenstal-2010" TYPE="STUDY">E - Bergenstal 2010</LINK> found that the reduction in fasting plasma glucose level between once weekly exenatide and pioglitazone was not different (-1.8 mmol/L versus -1.5 mmol/L, P = 0.33).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Post-prandial glucose</HEADING>
<P>Both exenatide 2 mg once weekly and pioglitazone 45 mg daily led to reduction in post-prandial glucose levels but the difference was not significant between the two groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Lipid profiles</HEADING>
<P>It was found that only pioglitazone led to a significant reduction in triglycerides level. Exenatide 2 mg once weekly led to reduction in total cholesterol and LDL levels. In contrast, pioglitazone led to an increment in these levels. All these changes were not significant. It was also found that all the drugs led to improvement in HDL levels.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Exenatide versus DPP-4 inhibitors (sitagliptin)</HEADING>
<P>Results for exenatide versus DPP-4 inhibitors are shown in <LINK TAG="ANALYSES_AND_DATA" TYPE="SECTION">Data and analyses</LINK>, 3.1 to 3.10. Only one study (<LINK REF="STD-E-_x002d_-Bergenstal-2010" TYPE="STUDY">E - Bergenstal 2010</LINK>) compared once weekly exenatide (2 mg) against sitagliptin 100 mg daily.</P>
<SUBSECTION>
<HEADING LEVEL="5">HbA1c</HEADING>
<P>
<LINK REF="STD-E-_x002d_-Bergenstal-2010" TYPE="STUDY">E - Bergenstal 2010</LINK> found a significantly greater reduction in HbA1c with once weekly exenatide than with sitagliptin 100 mg daily (-1.5% versus -0.9%, P &lt; 0.00001). Similarly, the proportion of participants achieving an HbA1c level of less than 7% was significantly higher with once weekly exenatide than with sitagliptin 100 mg daily (60% versus 35%, P &lt; 0.0001).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Hypoglycaemia</HEADING>
<P>Please see above for definition of hypoglycaemia. The incidence of minor hypoglycaemia was slightly more in the sitagliptin group than the exenatide group (n = 5 versus n = 2). There were no cases of major hypoglycaemia.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Weight change</HEADING>
<P>In <LINK REF="STD-E-_x002d_-Bergenstal-2010" TYPE="STUDY">E - Bergenstal 2010</LINK>, once weekly exenatide led to a significantly greater weight loss than sitagliptin 100 mg daily (-2.3 versus -0.8 kg, P = 0.0009).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Quality of life</HEADING>
<P>In <LINK REF="STD-E-_x002d_-Bergenstal-2010" TYPE="STUDY">E - Bergenstal 2010</LINK>, all five parameters of weight-related quality of life and IWQOL total score significantly improved with exenatide (IWQOL total score 5.15, 95% CI 3.11 to 7.19) and sitagliptin (4.56, 95% CI 2.56 to 6.57). The improvement in IWQOL total score with exenatide was consistent with differences in body weight changes.</P>
<P>In <LINK REF="STD-E-_x002d_-Bergenstal-2010" TYPE="STUDY">E - Bergenstal 2010</LINK>, overall treatment satisfaction was comparatively higher with exenatide than with sitagliptin (3.96 versus 2.35). The treatment difference between the two was 1.61 (95% CI 0.07 to 3.16, P = 0.0406).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>More withdrawals due to adverse events were seen with once weekly exenatide than sitagliptin (6.9% versus 3%). The most commonly reported adverse events with exenatide and sitagliptin were nausea and diarrhoea, while vomiting was more common with exenatide only. Withdrawals from the trial were mostly because of these events. Incidences of other adverse events such as headache, urinary tract infection and injection-site pruritus were similar between the groups. Incidences of serious adverse events were similar in the exenatide and sitagliptin groups (3% versus 3%). All these events resolved except one in the sitagliptin group, that was fatal. About half (48%) of participants had low levels of anti-exenatide antibodies (48%) while in 40% they were not detectable, with no relation to glycaemic control and safety.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Blood pressure</HEADING>
<P>At the end of the study, exenatide 2 mg once weekly was found to cause significantly greater reduction in systolic blood pressure than with sitagliptin (treatment difference of -4 mm Hg, 95% CI -6 to -1, P = 0.0055). Reductions in diastolic blood pressure were not different between the groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Fasting plasma glucose</HEADING>
<P>
<LINK REF="STD-E-_x002d_-Bergenstal-2010" TYPE="STUDY">E - Bergenstal 2010</LINK> found a significant difference in favour of once weekly exenatide compared with sitagliptin 100 mg daily (-0.90 mmol/L, 95% CI -1.50 to -0.30, P = 0.0038).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Post-prandial glucose</HEADING>
<P>Exenatide 2 mg once weekly caused significantly greater reductions in post-prandial glucose levels at all measurements of the six-point self-monitored blood glucose profile than with sitagliptin 100 mg daily (P &lt; 0.05).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Lipid profiles</HEADING>
<P>Exenatide 2 mg once weekly led to reductions in total cholesterol and LDL levels. In contrast, sitagliptin led to an increment. All these changes were not significant. All the drugs led to improvement in HDL levels.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Exenatide versus insulin (glargine)</HEADING>
<P>Results for exenatide versus insulin glargine are shown in <LINK TAG="ANALYSES_AND_DATA" TYPE="SECTION">Data and analyses</LINK>, 4.1 to 4.10. The trial by <LINK REF="STD-E-_x002d_-Diamant-2010" TYPE="STUDY">E - Diamant 2010</LINK> compared once weekly exenatide against insulin glargine.</P>
<SUBSECTION>
<HEADING LEVEL="5">HbA1c</HEADING>
<P>Once weekly exenatide led to a slightly greater reduction in HbA1c than with insulin glargine (-1.5% versus -1.3%). The treatment difference between the two group was -0.20% (95% CI -0.35 to -0.05, P = 0.03).</P>
<P>Similarly, the proportion of participants achieving a target HbA1c levels of less than 7% was slightly higher in the once weekly exenatide group than in the insulin glargine group (60% versus 48%, P = 0.03).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Hypoglycaemia</HEADING>
<P>In the study, minor hypoglycaemia was defined as participants experiencing signs or symptoms of hypoglycaemia, with concurrent blood glucose level of less than 3.0 mmol/L that was either self-treated or resolved independently. Any episode causing loss of consciousness or seizure that resolved after treatment with glucose or any episode with documented blood glucose level of less than 3.0 mmol/L requiring third party assistance was termed as major hypoglycaemia. The number of participants that experienced minor hypoglycaemia was greater in the group taking insulin glargine than those taking exenatide (26% versus 8%). Similarly the number of participants experiencing symptoms of hypoglycaemia but not confirmed by blood glucose measurement was also higher in the group taking insulin glargine (31% versus 13%). Hypoglycaemia occurred most frequently in those taking concomitant sulphonylurea. Major hypoglycaemia occurred in three patients (2 in insulin glargine group and 1 in exenatide group). All three cases were treated with oral carbohydrate administration and did not lead to study discontinuation.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Weight change</HEADING>
<P>Participants taking once weekly exenatide lost significant amounts of weight while those taking insulin glargine gained weight (-2.6 kg versus +1.4 kg). The treatment difference was -4.0 kg (95% CI -4.55 to -3.45, P &lt; 0.00001).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Quality of Life</HEADING>
<P>It was reported in the trial that a significant improvement for one of the IWQOL-Lite domains (self esteem) and one EQ-5D dimensions resulted with once weekly exenatide compared with insulin glargine (no data given). All other domains were similar between the two groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>The most frequently reported adverse events with exenatide were nausea, diarrhoea, nasopharyngitis, injection-site reaction and headache while nasopharyngitis and headache were most common with insulin glargine. Gastrointestinal adverse events were mild to moderate in intensity.</P>
<P>Withdrawals due to adverse events were greater in the exenatide group than in the insulin glargine group (4.7% vs. 0.9%). The incidence of serious adverse events was not different between the groups (5% in exenatide group vs. 4% in insulin glargine group). No deaths occurred during the study period. There was one case of oedematous pancreatitis in the exenatide group. It resolved a day after onset and the participant fully recovered. It was found that 68% of participants tested positive for anti-exenatide antibodies however, these had no effect on treatment response and safety.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Fasting plasma glucose</HEADING>
<P>The reduction in fasting plasma glucose was slightly greater with insulin glargine than with exenatide (-2.8 mmol/L versus -2.1 mmol/L). The treatment difference between the two groups was 0.70 (95% CI 0.14 to 1.26, P = 0.01).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Post-prandial glucose and glucose profiles</HEADING>
<P>Both treatments reduced post-prandial glucose at all eight time points. Participants taking once weekly exenatide had significantly lower glucose concentrations after dinner than insulin glargine (P = 0.004) while those on insulin glargine had lower glucose concentrations at 0300 h (P = 0.022) and before breakfast (P &lt; 0.0001). Once weekly exenatide led to greater reduction in post-prandial glucose excursions compared to insulin glargine after morning (P = 0.001) and evening (P = 0.033) meals.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Liraglutide</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Liraglutide versus placebo</HEADING>
<P>Results for liraglutide 0.6 mg versus placebo are shown in <LINK TAG="ANALYSES_AND_DATA" TYPE="SECTION">Data and analyses</LINK>, 5.1 to 5.9. Results for liraglutide 0.9 mg verus placebo are shown in <LINK TAG="ANALYSES_AND_DATA" TYPE="SECTION">Data and analyses</LINK>, 6.1 to 6.9. Results for liraglutide 1.2 mg versus placebo are shown in <LINK TAG="ANALYSES_AND_DATA" TYPE="SECTION">Data and analyses</LINK>, 7.1 to 7.13. Results for liraglutide 1.8 mg versus placebo are shown in <LINK TAG="ANALYSES_AND_DATA" TYPE="SECTION">Data and analyses</LINK>, 8.1 to 8.13. <LINK TAG="ANALYSES_AND_DATA" TYPE="SECTION">Data and analyses</LINK>, 9.1 to 9.4 show comparisons of 1.2 mg with 1.8 mg liraglutide.</P>
<SUBSECTION>
<HEADING LEVEL="5">HbA1c</HEADING>
<P>One trial reported change in HbA1c level for 0.6 or 0.9 mg liraglutide versus placebo (<LINK REF="STD-L-_x002d_-Kaku-2010" TYPE="STUDY">L - Kaku 2010</LINK>). The reduction in HbA1c level at end of the study was significantly greater with 0.9 mg liraglutide than with 0.6 mg liraglutide (-1.56% versus -1.46%) or placebo (-1.56% versus -0.4%). Similarly, the proportion of participants achieving a target HbA1c level of less than 7% was significantly greater with 0.9 mg liraglutide than with 0.6 mg liraglutide (71.3% versus 46.5%, P &lt; 0.05) or placebo (71.3% versus 14.8%, P &lt; 0.0001). Three trials reported HbA1c for 1.2 mg liraglutide versus placebo (<LINK REF="STD-L-_x002d_-LEAD-1-Marre-2009" TYPE="STUDY">L - LEAD 1 Marre 2009</LINK>; <LINK REF="STD-L-_x002d_-LEAD-2-Nauck-2009" TYPE="STUDY">L - LEAD 2 Nauck 2009</LINK>; <LINK REF="STD-L-_x002d_-LEAD-4-Zinman-2009" TYPE="STUDY">L - LEAD 4 Zinman 2009</LINK>). HbA1c was significantly reduced with 1.2 mg liraglutide compared to placebo. The overall mean difference was -1.15 (95% CI -1.33 to -0.96, P &lt; 0.00001), with no significant heterogeneity of the results. Reductions in HbA1c ranged from -1.0% to -1.5% in the 1.2 mg liraglutide groups, while HbA1c changes ranged from +0.23% to -0.5% in the placebo groups.</P>
<P>The reduction of HbA1c with 1.8 mg liraglutide was similar to that of 1.2 mg liraglutide. Overall, the four studies examining this comparison (<LINK REF="STD-L-_x002d_-LEAD-1-Marre-2009" TYPE="STUDY">L - LEAD 1 Marre 2009</LINK>; <LINK REF="STD-L-_x002d_-LEAD-2-Nauck-2009" TYPE="STUDY">L - LEAD 2 Nauck 2009</LINK>; <LINK REF="STD-L-_x002d_-LEAD-4-Zinman-2009" TYPE="STUDY">L - LEAD 4 Zinman 2009</LINK>; <LINK REF="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009" TYPE="STUDY">L - LEAD 5 Russell-J 2009</LINK>) found a difference of -1.15 (95% CI -1.31 to -0.99, P &lt; 0.00001) between 1.8 mg liraglutide and placebo. There was no substantial heterogeneity. As with 1.2 mg liraglutide, reductions in HbA1c with 1.8 mg liraglutide ranged from -1.0% to -1.5%. There was no significant difference between 1.2 mg and 1.8 mg liraglutide in reducing HbA1c (see <LINK REF="CMP-009.01" TYPE="ANALYSIS">Analysis 9.1</LINK>).</P>
<P>The proportion of participants achieving an HbA1c level of 7% or less was also higher with 1.2 mg liraglutide compared with placebo, with 35% to 57.5% reaching the target in the liraglutide groups, and 8% to 28% in the placebo groups. The overall risk ratio for liraglutide 1.2 mg versus placebo was 2.91 (95% CI 1.74 to 4.87, P &lt; 0.0001). There was significant heterogeneity (which disappeared when excluding <LINK REF="STD-L-_x002d_-LEAD-4-Zinman-2009" TYPE="STUDY">L - LEAD 4 Zinman 2009</LINK>).</P>
<P>After treatment with 1.8 mg liraglutide, 42% to 54% reached an HbA1c value of 7% or less. The overall risk ratio for liraglutide 1.8 mg compared with placebo was 3.25 (95% CI 1.97 to 5.36, P &lt; 0.00001), with significant heterogeneity (which disappeared when excluding <LINK REF="STD-L-_x002d_-LEAD-4-Zinman-2009" TYPE="STUDY">L - LEAD 4 Zinman 2009</LINK>). There was no significant difference between 1.2 and 1.8 mg liraglutide (see <LINK REF="CMP-009.02" TYPE="ANALYSIS">Analysis 9.2</LINK>).</P>
<P>Both <LINK REF="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009" TYPE="STUDY">L - LEAD 5 Russell-J 2009</LINK> and <LINK REF="STD-L-_x002d_-LEAD-2-Nauck-2009" TYPE="STUDY">L - LEAD 2 Nauck 2009</LINK> reported the lowest HbA1c values with liraglutide at week 12, with a slight increase towards the end of the studies. However, in the <LINK REF="STD-L-_x002d_-LEAD-4-Zinman-2009" TYPE="STUDY">L - LEAD 4 Zinman 2009</LINK> study, HbA1c remained steady until the end of the study after the lowest level was observed at week 12. In <LINK REF="STD-L-_x002d_-LEAD-1-Marre-2009" TYPE="STUDY">L - LEAD 1 Marre 2009</LINK>, the largest decrease in HbA1c with liraglutide was seen in participants previously on monotherapy compared with those on previous combination therapy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Hypoglycaemia</HEADING>
<P>In the study by <LINK REF="STD-L-_x002d_-Kaku-2010" TYPE="STUDY">L - Kaku 2010</LINK>, minor hypoglycaemia was defined as an episode that could be self-treated while those requiring third-party assistance was considered as major. It was reported that the rate of minor hypoglycaemic episodes (events/patient/year) was higher in the liraglutide groups (2.17 in the 0.6 mg group, 1.96 in the 0.9 mg group) than in the placebo group (1.01). All three trials of 1.2 mg liraglutide reported hypoglycaemia. <LINK REF="STD-L-_x002d_-LEAD-1-Marre-2009" TYPE="STUDY">L - LEAD 1 Marre 2009</LINK> and <LINK REF="STD-L-_x002d_-LEAD-4-Zinman-2009" TYPE="STUDY">L - LEAD 4 Zinman 2009</LINK> defined minor hypoglycaemia as an episode that could be self-treated while those needing third party assistance or medical interventions were categorised as major. In <LINK REF="STD-L-_x002d_-LEAD-1-Marre-2009" TYPE="STUDY">L - LEAD 1 Marre 2009</LINK>, the proportion of participants with minor hypoglycaemia was significantly higher (P = 0.048) with liraglutide 1.2 mg compared with placebo whereas in <LINK REF="STD-L-_x002d_-LEAD-4-Zinman-2009" TYPE="STUDY">L - LEAD 4 Zinman 2009</LINK> and <LINK REF="STD-L-_x002d_-LEAD-2-Nauck-2009" TYPE="STUDY">L - LEAD 2 Nauck 2009</LINK> no significant difference was seen. Overall, there was no significant difference in minor hypoglycaemia between 1.2 mg liraglutide and placebo (risk ratio 1.54, 95% CI 0.54 to 4.42, P = 0.42), with no significant heterogeneity. Rates of hypoglycaemia were between 0.8% and 9.2% in the liraglutide groups and between 2.6% and 5.1% in the placebo groups.</P>
<P>There were no reports of major hypoglycaemic episodes in participants on either liraglutide 1.2 mg or placebo in any of the studies.</P>
<P>Of the four studies reporting hypoglycaemia with 1.8 mg liraglutide, <LINK REF="STD-L-_x002d_-LEAD-1-Marre-2009" TYPE="STUDY">L - LEAD 1 Marre 2009</LINK> found that the incidence of minor hypoglycaemia was higher with liraglutide 1.8 mg compared with placebo (P = 0.0065). Similarly, <LINK REF="STD-L-_x002d_-LEAD-4-Zinman-2009" TYPE="STUDY">L - LEAD 4 Zinman 2009</LINK> found that the rate of minor hypoglycaemia was significantly higher with liraglutide 1.8 mg compared with placebo (P = 0.0004). In <LINK REF="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009" TYPE="STUDY">L - LEAD 5 Russell-J 2009</LINK>, hypoglycaemia was categorised as major (third party assistance), minor (FPG less than 3.1 mmol/L) and symptoms only. The rate of hypoglycaemia reported was 0.06, 1.2 and 1.0 events/patient-year (major, minor and symptoms only) in the 1.8 mg liraglutide group and 0, 1.0 and 0.5 events/patient-year in the placebo group. The proportion of participants with hypoglycaemia was higher with 1.8 mg liraglutide compared to placebo (27.4% versus 16.7%). There was no significant difference in minor hypoglycaemia between 1.8 mg liraglutide and placebo in <LINK REF="STD-L-_x002d_-LEAD-2-Nauck-2009" TYPE="STUDY">L - LEAD 2 Nauck 2009</LINK>. In the other trials, the rate of hypoglycaemia was about between 2.5% and 8% with 1.8 mg liraglutide. Overall, there was significantly more hypoglycaemia with 1.8 mg liraglutide, risk ratio 1.66 (95% CI 1.15 to 2.40, P = 0.007), with no significant heterogeneity.</P>
<P>In two of the trials, no cases of major hypoglycaemia were seen (<LINK REF="STD-L-_x002d_-LEAD-2-Nauck-2009" TYPE="STUDY">L - LEAD 2 Nauck 2009</LINK>; <LINK REF="STD-L-_x002d_-LEAD-4-Zinman-2009" TYPE="STUDY">L - LEAD 4 Zinman 2009</LINK>). In <LINK REF="STD-L-_x002d_-LEAD-1-Marre-2009" TYPE="STUDY">L - LEAD 1 Marre 2009</LINK>, one major hypoglycaemic episode was reported in a participant on liraglutide 1.8 mg and glimepiride; this was considered to be related to glimepiride and not the study drug and accordingly the dose of glimepiride was reduced. In <LINK REF="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009" TYPE="STUDY">L - LEAD 5 Russell-J 2009</LINK>, five patients had major hypoglycaemic events in the 1.8 mg liraglutide group with only one requiring some medical assistance.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Weight change</HEADING>
<P>In <LINK REF="STD-L-_x002d_-Kaku-2010" TYPE="STUDY">L - Kaku 2010</LINK>, there was no change in mean body weight with both 0.6 and 0.9 mg dose of liraglutide while a reduction of 1.12 kg in weight was seen with placebo. Two of the three trials showed significantly more weight loss with 1.2 mg liraglutide than with placebo (<LINK REF="STD-L-_x002d_-LEAD-2-Nauck-2009" TYPE="STUDY">L - LEAD 2 Nauck 2009</LINK>; <LINK REF="STD-L-_x002d_-LEAD-4-Zinman-2009" TYPE="STUDY">L - LEAD 4 Zinman 2009</LINK>), while one showed no significant difference (<LINK REF="STD-L-_x002d_-LEAD-1-Marre-2009" TYPE="STUDY">L - LEAD 1 Marre 2009</LINK>). No significant weight changes in either the 1.2 mg liraglutide group of the placebo group were seen in the study using only sulphonylurea as concomitant antihyperglycaemic therapy (+0.3 kg SD 3.02 with 1.2 mg liraglutide, -0.1 kg SD 2.88 with placebo)(<LINK REF="STD-L-_x002d_-LEAD-1-Marre-2009" TYPE="STUDY">L - LEAD 1 Marre 2009</LINK>). In the other two studies (<LINK REF="STD-L-_x002d_-LEAD-2-Nauck-2009" TYPE="STUDY">L - LEAD 2 Nauck 2009</LINK>; <LINK REF="STD-L-_x002d_-LEAD-4-Zinman-2009" TYPE="STUDY">L - LEAD 4 Zinman 2009</LINK>) the weight loss in the 1.2 mg liraglutide groups was between 1.1 and 1.6 kg greater than in the placebo groups (P &lt; 0.00001 for the combined effect in the two studies). Weight loss in the 1.2 mg liraglutide groups was between 1.0 and 2.6 kg, weight change in the placebo groups ranged between -1.5 and +0.6 kg.</P>
<P>In three of the four studies, the weight reduction with 1.8 mg liraglutide was significantly greater than with placebo (<LINK REF="STD-L-_x002d_-LEAD-2-Nauck-2009" TYPE="STUDY">L - LEAD 2 Nauck 2009</LINK>; <LINK REF="STD-L-_x002d_-LEAD-4-Zinman-2009" TYPE="STUDY">L - LEAD 4 Zinman 2009</LINK>; <LINK REF="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009" TYPE="STUDY">L - LEAD 5 Russell-J 2009</LINK>). There was no difference between the groups in <LINK REF="STD-L-_x002d_-LEAD-1-Marre-2009" TYPE="STUDY">L - LEAD 1 Marre 2009</LINK>. Overall, the mean difference for 1.8 mg liraglutide versus placebo was -1.33 (95% CI -2.38 to -0.27, P = 0.01) with significant heterogeneity (P &lt; 0.0001) (probably due to different co-interventions having different effects on weight). Weight loss in the 1.8 mg liraglutide groups was between -0.2 and -2.8 kg. Overall, weight loss with 1.8 mg liraglutide was 0.48 kg (95% CI 0.08 to 0.88) greater than with 1.2 mg liraglutide (P = 0.02), see <LINK REF="CMP-009.03" TYPE="ANALYSIS">Analysis 9.3</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>In <LINK REF="STD-L-_x002d_-Kaku-2010" TYPE="STUDY">L - Kaku 2010</LINK>, the total numbers of adverse events were similar across all groups (76.1% in 0.6 mg group, 78.4% in 0.9 mg group and 75% in placebo). It was reported that the most common adverse events in the trial were nasopharyngitis, diarrhoea and constipation. The proportions of participants complaining of gastrointestinal adverse events in the first four weeks were higher in the liraglutide groups than the placebo group. The numbers of participants withdrawing from the study were similar across the groups (n = 3 in 0.6 mg group, n = 2 in 0.9 mg group and n = 2 in placebo group). Treatment-related serious adverse events were seen in eight participants (3 in 0.6 mg group, 2 in 0.9 mg group and 3 in placebo group) but no deaths occurred in the trial.</P>
<P>In all four trials (<LINK REF="STD-L-_x002d_-LEAD-1-Marre-2009" TYPE="STUDY">L - LEAD 1 Marre 2009</LINK>; <LINK REF="STD-L-_x002d_-LEAD-2-Nauck-2009" TYPE="STUDY">L - LEAD 2 Nauck 2009</LINK>; <LINK REF="STD-L-_x002d_-LEAD-4-Zinman-2009" TYPE="STUDY">L - LEAD 4 Zinman 2009</LINK>; <LINK REF="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009" TYPE="STUDY">L - LEAD 5 Russell-J 2009</LINK>), the most frequently reported adverse events with liraglutide were gastrointestinal events. Nausea occurred in between 10.5% and 29% of participants in the 1.2 mg liraglutide groups and in between 14% and 40% in the 1.8 mg liraglutide groups; vomiting in between 4.5% and 7% with 1.2 mg and between 5% and 17% with 1.8 mg liraglutide; and diarrhoea in around 8% with 1.2 mg and between 10% and 15% with 1.8 mg liraglutide. The corresponding rates in the placebo groups were between around 2% to 4% nausea, 1% to 3.5% vomiting, and 4% to 5.3% diarrhoea. Withdrawals due to adverse events were between 5% and 10% with 1.2 mg liraglutide, between 4% and 15% with 1.8 mg liraglutide and between 1% and 5% in the placebo groups.</P>
<P>Most of the withdrawals were due to gastrointestinal events and occurred during the first four to eight weeks of the studies. Serious adverse events occurred in around 4% of participants with 1.2 mg liraglutide, between 4% and 6% of participants on 1.8 mg liraglutide, and between 3% and 7% of participants on placebo. Only one trial reported a case of pancreatitis, in <LINK REF="STD-L-_x002d_-LEAD-2-Nauck-2009" TYPE="STUDY">L - LEAD 2 Nauck 2009</LINK>, one of the participants on 1.2 mg liraglutide withdrew from the study because of acute pancreatitis. There were two deaths reported in the study considered unrelated to the study drug. There were no deaths in <LINK REF="STD-L-_x002d_-LEAD-1-Marre-2009" TYPE="STUDY">L - LEAD 1 Marre 2009</LINK> or <LINK REF="STD-L-_x002d_-LEAD-4-Zinman-2009" TYPE="STUDY">L - LEAD 4 Zinman 2009</LINK>.</P>
<P>None of the studies found any significant differences between treatment groups for physical examination findings, laboratory analyses, ECG, ophthalmology and other adverse events. Between 10% and 13% of participants were positive for anti-liraglutide antibodies (no difference reported between 1.2 and 1.8 mg), however, this had no effect on the HbA1c response or on adverse events.  </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Blood pressure</HEADING>
<P>The Japanese study (<LINK REF="STD-L-_x002d_-Kaku-2010" TYPE="STUDY">L - Kaku 2010</LINK>) reported that neither systolic and diastolic blood pressure changed in any group (no data given). Only one trial (<LINK REF="STD-L-_x002d_-LEAD-4-Zinman-2009" TYPE="STUDY">L - LEAD 4 Zinman 2009</LINK>) reported significantly more reduction in systolic blood pressure with 1.2 or 1.8 mg liraglutide compared to placebo weighted mean difference to placebo between -4.5 and -5.6 mm Hg), whereas there was no significant difference between either 1.2 or 1.8 mg liraglutide and placebo in systolic blood pressure in <LINK REF="STD-L-_x002d_-LEAD-2-Nauck-2009" TYPE="STUDY">L - LEAD 2 Nauck 2009</LINK>, and a significant difference between 1.8 mg liraglutide and placebo in <LINK REF="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009" TYPE="STUDY">L - LEAD 5 Russell-J 2009</LINK>. Overall, there was no significant difference in systolic blood pressure for 1.2 mg liraglutide versus placebo (mean difference -3.26 mm Hg (95% CI -7.71 to 1.20, P = 0.15, significant heterogeneity, possibly due to different co-interventions)), but the results for 1.8 mg liraglutide versus placebo were marginally significant (-2.42 mm Hg, 95% CI -4.90 to 0.05, P = 0.05, no significant heterogeneity). In <LINK REF="STD-L-_x002d_-LEAD-1-Marre-2009" TYPE="STUDY">L - LEAD 1 Marre 2009</LINK>, there was a reduction in both systolic and diastolic blood pressure with 1.2 and 1.8 mg liraglutide and with placebo but the difference between the groups was not significant (not enough details given to include the data in the statistical summary). There was no reduction in diastolic blood pressure in any of the groups.</P>
<P>There was no significant difference in systolic blood pressure between 1.2 and 1.8 mg liraglutide, see <LINK REF="CMP-009.04" TYPE="ANALYSIS">Analysis 9.4</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Fasting plasma glucose</HEADING>
<P>In <LINK REF="STD-L-_x002d_-Kaku-2010" TYPE="STUDY">L - Kaku 2010</LINK>, both 0.6 mg (-2.3 mmol/L) and 0.9 mg (-2.28 mmol/L) liraglutide significantly reduced fasting plasma glucose levels compared with placebo (-0.64 mmol/L). Fasting plasma glucose was significantly reduced with liraglutide 1.2 mg or 1.8 mg compared to placebo. The overall mean difference was -2.13 (95% CI -2.59 to -1.68, P &lt; 0.0001, no significant heterogeneity) for 1.2 mg liraglutide versus placebo, and -2.21 (95% CI -2.49 to -1.93, P &lt; 0.00001, no significant heterogeneity) for 1.8 mg liraglutide versus placebo. Changes in fasting plasma glucose ranged between -1.6 and -2.2 mmol/L with 1.2 mg liraglutide, between -1.55 and -2.4 mmol/L with 1.8 mg liraglutide and between -0.4 and +1.01 mmol/L with placebo.</P>
<P>All studies reported that fasting plasma glucose values decreased within two weeks of commencing liraglutide and remained relatively stable thereafter.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Post-prandial glucose</HEADING>
<P>
<LINK REF="STD-L-_x002d_-Kaku-2010" TYPE="STUDY">L - Kaku 2010</LINK> found that both doses of liraglutide (0.6 mg and 0.9 mg) led to significant improvement in the self-monitored 7-point plasma glucose profiles compared to placebo (P &lt; 0.0001). In <LINK REF="STD-L-_x002d_-LEAD-1-Marre-2009" TYPE="STUDY">L - LEAD 1 Marre 2009</LINK>, <LINK REF="STD-L-_x002d_-LEAD-2-Nauck-2009" TYPE="STUDY">L - LEAD 2 Nauck 2009</LINK>, <LINK REF="STD-L-_x002d_-LEAD-4-Zinman-2009" TYPE="STUDY">L - LEAD 4 Zinman 2009</LINK> post-prandial glucose values were significantly reduced with 1.2 mg liraglutide versus placebo (reductions by 2.3 to 2.6 mmol/L with liraglutide compared to reductions of 0.4 to 0.8 mmol/L with placebo). Similarly, reductions in post-prandial glucose values with 1.8 mg liraglutide were significantly larger than with placebo (reductions by 1.8 to 2.7 mmol/L with liraglutide compared to reductions of 0.30 to 0.8 mmol/L with placebo). In <LINK REF="STD-L-_x002d_-LEAD-4-Zinman-2009" TYPE="STUDY">L - LEAD 4 Zinman 2009</LINK>, the post-prandial increment (post-meal minus pre-meal value) was significantly reduced over breakfast in both liraglutide (1.2 and 1.8 mg) groups, but not at the other meals. <LINK REF="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009" TYPE="STUDY">L - LEAD 5 Russell-J 2009</LINK> reported that significantly more participants on 1.8 mg liraglutide achieved the ADA target for post-prandial glucose (&#8804; 10 mmol/L) participants on placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Lipid profiles</HEADING>
<P>In <LINK REF="STD-L-_x002d_-Kaku-2010" TYPE="STUDY">L - Kaku 2010</LINK>, it was reported that no significant changes occurred in any of the parameters of the lipid profile with any treatment. No data were reported.</P>
<P>Details of effects on lipid profiles were also reported by <LINK REF="STD-L-_x002d_-LEAD-4-Zinman-2009" TYPE="STUDY">L - LEAD 4 Zinman 2009</LINK>. For both liraglutide groups, there was a decrease in free fatty acids (-0.03 mmol/L SE 0.02 to -0.05 mmol/L SE 0.02), whereas levels were increased with placebo (+0.02 mmol/L SE 0.02, P &lt; 0.05). There was significantly more reduction in triglycerides and LDL cholesterol with 1.2 mg liraglutide than with placebo (triglycerides: -0.38 mmol/L SE 0.10 versus -0.13 mmol/L SE 0.11 with placebo, P &lt; 0.05; LDL cholesterol: -0.28 mmol/L SE 0.07 versus -0.10 mmol/L SE 0.07 with placebo, P &lt; 0.05). No significant difference to placebo was seen in the 1.8 mg liraglutide group (reduction in triglycerides: -0.32 mmol/L SE 0.10; LDL cholesterol: -0.23 mmol/L SE 0.07).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Beta-cell function</HEADING>
<P>
<LINK REF="STD-L-_x002d_-LEAD-1-Marre-2009" TYPE="STUDY">L - LEAD 1 Marre 2009</LINK>, <LINK REF="STD-L-_x002d_-LEAD-2-Nauck-2009" TYPE="STUDY">L - LEAD 2 Nauck 2009</LINK>, <LINK REF="STD-L-_x002d_-LEAD-4-Zinman-2009" TYPE="STUDY">L - LEAD 4 Zinman 2009</LINK> all reported HOMA-B and proinsulin-to-insulin ratio for 1.2 and 1.8 mg liraglutide versus placebo. All studies showed a significant improvement in HOMA-B with 1.2 mg liraglutide compared to placebo (improvement between +23% and +28% compared to between -4% and +6% with placebo). In <LINK REF="STD-L-_x002d_-LEAD-1-Marre-2009" TYPE="STUDY">L - LEAD 1 Marre 2009</LINK>, HOMA-B improvement with 1.8 mg liraglutide was only marginal compared to placebo (P = 0.051), but the difference was significant in the other two studies. The improvement in HOMA-B all three studies was between +27% and +35%.</P>
<P>All three studies showed a significant improvement in proinsulin-to-insulin ratio both with 1.2 and 1.8 mg liraglutide compared to placebo. Changes were between -0.03 and -0.12 with 1.2 mg liraglutide, between -0.09 and -0.12 with 1.8 mg liraglutide, and between +0.02 and +0.1 with placebo. There was a significant improvement in proinsulin-to-C-peptide ratio with 1.2 and 1.8 mg liraglutide in <LINK REF="STD-L-_x002d_-LEAD-4-Zinman-2009" TYPE="STUDY">L - LEAD 4 Zinman 2009</LINK>, and with 1.8 mg liraglutide in <LINK REF="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009" TYPE="STUDY">L - LEAD 5 Russell-J 2009</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Liraglutide versus insulin (glargine)</HEADING>
<P>Results for liraglutide 1.8 mg versus insulin glargine are shown in <LINK TAG="ANALYSES_AND_DATA" TYPE="SECTION">Data and analyses</LINK>, 10.1 to 10.9. This comparison was only carried out by <LINK REF="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009" TYPE="STUDY">L - LEAD 5 Russell-J 2009</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="5">HbA1c</HEADING>
<P>HbA1c was significantly more reduced with 1.8 mg liraglutide than with insulin glargine (mean difference -0.24%, 95% CI -0.39 to -0.08, P = 0.0015 according to the original analysis). HbA1c was reduced by 1.33% with liraglutide and by 1.09% with insulin glargine.</P>
<P>Similarly, the proportion of participants achieving the target HbA1c level of less than 7% was higher with liraglutide compared with insulin glargine (53.1% versus 45.8%, P = 0.0139).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Hypoglycaemia</HEADING>
<P>The proportion of participants with minor hypoglycaemia was similar with liraglutide and insulin glargine. Minor hypoglycaemia was seen in 27% of patients in the liraglutide group and 29% in the glargine group. Five patients had major hypoglycaemic events in the liraglutide group with only one requiring medical assistance. There were no reports of major hypoglycaemic episodes in the glargine group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Weight change</HEADING>
<P>There was significant weight reduction in the liraglutide group (-1.8 kg SE 0.33) while weight increased the insulin glargine group (+1.6 kg SE 0.33). The mean treatment difference was -3.43 kg (95% CI -4.00 to -2.86, P &lt; 0.0001, according to the original analysis).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>The most frequently reported adverse events were nausea, vomiting and diarrhoea, which were more frequent with liraglutide than with insulin glargine (see above). The incidence of gastrointestinal events in the glargine group was similar to that in the placebo group (or even somewhat lower). No other adverse events were seen with glargine (for liraglutide results see above).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Blood pressure</HEADING>
<P>There was a significant reduction of systolic blood pressure with liraglutide (-4.0 mm Hg) whereas an increase was seen with insulin glargine (+0.54 mm Hg) (treatment difference -2.53 mm Hg (95% CI -6.82 to -2.20, P = 0.0001, according to the original analysis). There was no significant effect on diastolic blood pressure in any of the comparison groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Fasting plasma glucose</HEADING>
<P>There was no significant difference in fasting plasma glucose between liraglutide and insulin glargine. Fasting plasma glucose was reduced by 1.55 mmol/L in the liraglutide group and by 1.79 mmol/L in the glargine group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Post-prandial glucose</HEADING>
<P>There was no significant difference in post-prandial glucose between liraglutide and insulin glargine. Post-prandial glucose was reduced by 1.8 mmol/L in the liraglutide group and by 1.6 mmol/L in the glargine group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Beta-cell function</HEADING>
<P>The proinsulin-to-insulin ratio was significantly improved with liraglutide compared to insulin glargine (treatment difference -0.00366, 95% CI -0.0057 to -0.00136, P = 0.0019).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Liraglutide versus thiazolidinedione (rosiglitazone)</HEADING>
<P>Results for liraglutide 1.2 mg versus rosiglitazone are shown in <LINK TAG="ANALYSES_AND_DATA" TYPE="SECTION">Data and analyses</LINK>, 11.1 to 11.11. Results for liraglutide 1.8 mg versus rosiglitazone are shown in <LINK TAG="ANALYSES_AND_DATA" TYPE="SECTION">Data and analyses</LINK>, 12.1 to 12.11. Only one RCT compared liraglutide and rosiglitazone, <LINK REF="STD-L-_x002d_-LEAD-1-Marre-2009" TYPE="STUDY">L - LEAD 1 Marre 2009</LINK> (1.2 and 1.8 mg liraglutide). The dose of rosiglitazone was 4 mg.</P>
<SUBSECTION>
<HEADING LEVEL="5">HbA1c</HEADING>
<P>In <LINK REF="STD-L-_x002d_-LEAD-1-Marre-2009" TYPE="STUDY">L - LEAD 1 Marre 2009</LINK>, both liraglutide and rosiglitazone reduced HbA1c levels, but the reduction was significantly greater with liraglutide (P &lt; 0.0001). HbA1c reduction was by 1.08% to 1.13% with liraglutide and by 0.44% with rosiglitazone.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">HbA1c equal to or less than 7%</HEADING>
<P>The proportion of participants achieving ADA HbA1c target levels was significantly greater with liraglutide compared with rosiglitazone (P &#8804; 0.0003). Between 35% and 42% reached an HbA1c level of less than 7% with liraglutide, while only 22% on rosiglitazone did (<LINK REF="STD-L-_x002d_-LEAD-1-Marre-2009" TYPE="STUDY">L - LEAD 1 Marre 2009</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Hypoglycaemia</HEADING>
<P>The incidence of minor hypoglycaemia was significantly higher with liraglutide (8.1% to 9.2%, 0.51 events/patient-year) than with rosiglitazone (4.3%, 0.12 events/patient-year) (P = 0.048).There was one report of major hypoglycaemia in a participant on 1.8 mg liraglutide and glimepiride. This was considered to be related to glimepiride and its dose was reduced.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Weight change</HEADING>
<P>There was a significant difference in weight change in favour of both liraglutide groups compared to rosiglitazone (P &lt; 0.0001). Participants on liraglutide had weight changes of between -0.2 to +0.3 kg, while weight increased by 2.1 kg in the rosiglitazone group (<LINK REF="STD-L-_x002d_-LEAD-1-Marre-2009" TYPE="STUDY">L - LEAD 1 Marre 2009</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>The most frequently reported adverse event was gastrointestinal disorders that included nausea, vomiting and diarrhoea, which was more frequent with liraglutide than with rosiglitazone (see above). No other adverse events were seen with rosiglitazone (for liraglutide results see above) (<LINK REF="STD-L-_x002d_-LEAD-1-Marre-2009" TYPE="STUDY">L - LEAD 1 Marre 2009</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Fasting plasma glucose</HEADING>
<P>The participants on liraglutide had significantly greater reductions in fasting plasma glucose levels compared to those on rosiglitazone (-1.6 mmol/L for liraglutide versus -0.88 mmol/L for rosiglitazone, P &#8804; 0.006). Similarly, at the end of study the proportions of participants achieving ADA target fasting plasma glucose values of between 5.0 mmol/L and 7.2 mmol/L were greater with both doses of liraglutide compared with rosiglitazone (37% to 38% with liraglutide versus 26% with rosiglitazone, P &#8804; 0.01).  </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Post-prandial glucose</HEADING>
<P>The reduction in mean post-prandial glucose values was significantly greater with both doses of liraglutide compared to rosiglitazone (-2.5 to -2.7 mmol/L with liraglutide versus -1.8 mmol/L with rosiglitazone, P &lt; 0.05).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Beta-cell function</HEADING>
<P>The improvement in mean HOMA-B was significantly greater with both doses of liraglutide compared with rosiglitazone (P &lt; 0.05). Similarly, the reduction in the proinsulin-to-insulin ratio was also greater with liraglutide compared to rosiglitazone (P &#8804; 0.02).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Liraglutide versus DPP-4 inhibitors (sitagliptin)</HEADING>
<P>Results for liraglutide 1.2 mg versus sitagliptin are shown in <LINK TAG="ANALYSES_AND_DATA" TYPE="SECTION">Data and analyses</LINK>, 13.1 to 13.11. Results for liraglutide 1.8 mg versus sitagliptin are shown in <LINK TAG="ANALYSES_AND_DATA" TYPE="SECTION">Data and analyses</LINK>, 14.1 to 14.11. The comparison between liraglutide and sitagliptin was carried out by <LINK REF="STD-L-_x002d_-Pratley-2010" TYPE="STUDY">L - Pratley 2010</LINK>. The dose of sitagliptin was 100 mg daily.</P>
<SUBSECTION>
<HEADING LEVEL="5">HbA1c</HEADING>
<P>In <LINK REF="STD-L-_x002d_-Pratley-2010" TYPE="STUDY">L - Pratley 2010</LINK>, the reduction in HbA1c with 1.8 mg liraglutide was higher than with 1.2 mg liraglutide (-1.5% versus -1.24%) or sitagliptin 100 mg (-1.5% versus -0.9%). The treatment difference between liraglutide 1.8 mg versus sitagliptin was -0.6% (95% CI -0.78 to -0.42, P &lt; 0.00001) while the difference between liraglutide 1.2 mg versus sitagliptin was -0.34% (95% CI -0.53 to -0.15, P = 0.0006).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">HbA1c equal to or less than 7%</HEADING>
<P>
<LINK REF="STD-L-_x002d_-Pratley-2010" TYPE="STUDY">L - Pratley 2010</LINK> found that the proportion of participants achieving this target was significantly higher with liraglutide than with sitagliptin. Fifty six percent of participants taking liraglutide 1.2 mg, 44% taking liraglutide 1.8 mg and 22% on sitagliptin achieved this target HbA1c level.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Hypoglycaemia</HEADING>
<P>In <LINK REF="STD-L-_x002d_-Pratley-2010" TYPE="STUDY">L - Pratley 2010</LINK>, the proportion of participants experiencing minor hypoglycaemia was similar in all groups(i.e. 5%). It reported that one participant on 1.2 mg liraglutide had a major hypoglycaemic episode, but none on the 1.8 mg dose or on sitagliptin.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Weight change</HEADING>
<P>The weight change with liraglutide was significantly greater compared to sitagliptin (P &lt; 0.00001). The mean weight loss with liraglutide was between -2.86 and -3.38 kg, while only a reduction of 0.96 kg occurred with sitagliptin (<LINK REF="STD-L-_x002d_-Pratley-2010" TYPE="STUDY">L - Pratley 2010</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>In <LINK REF="STD-L-_x002d_-Pratley-2010" TYPE="STUDY">L - Pratley 2010</LINK>, the most frequently reported treatment-emergent adverse events were gastrointestinal related symptoms, that were more frequent with liraglutide than with sitagliptin. Out of all gastrointestinal symptoms, nausea was the most common however, it was transient in nature.The incidence of infections was not different between liraglutide and sitagliptin. The occurrence of serious adverse events were similar between the groups and were thought not to be related to the study drug. Two deaths occurred (one with pancreatic carcinoma taking 1.8 mg liraglutide and one with fatal cardiac arrest taking sitagliptin), both regarded not to be related to the study drug. There were no cases of pancreatitis. No report on anti-liraglutide antibodies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Blood pressure</HEADING>
<P>The effect on systolic blood pressure was not different amongst the groups. The treatment difference between liraglutide 1.2 mg and sitagliptin was 0.39 mm Hg (95% CI -2.08 to 2.86, P = 0.76) while the difference between liraglutide 1.8 mg and sitagliptin was 0.22 mm Hg (95% CI -2.25 to 2.69, P = 0.86). The effect on diastolic blood pressure was significantly greater with sitagliptin compared with liraglutide 1.8 mg (-1.78 versus +0.07 mm Hg) but not compared with liraglutide 1.2 mg (-1.78 versus -0.71 mm Hg).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Fasting plasma glucose</HEADING>
<P>Reduction in fasting plasma glucose was significantly greater with liraglutide than with sitagliptin. The mean treatment difference between liraglutide 1.2 mg and sitagliptin was -1.04 mmol/L (95% CI -1.46 to -0.62, P &lt; 0.00001) and the difference between liraglutide 1.8 mg versus sitagliptin was -1.31 mmol/L (95% CI -1.73 to -0.89, P &lt; 0.00001).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Postprandial glucose</HEADING>
<P>It was reported that post-prandial glucose recorded during the study was highly variable, suggesting that most glucose values were not post-prandial. The authors also added that meal patterns i.e. content and time of day were different across different countries.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Beta cell function</HEADING>
<P>In <LINK REF="STD-L-_x002d_-Pratley-2010" TYPE="STUDY">L - Pratley 2010</LINK>, both doses of liraglutide led to significant improvements in HOMA of &#946;-cell function compared with sitagliptin. Similarly liraglutide also led to significant improvements in C-peptide concentration, and proinsulin-to-insulin ratio compared to sitagliptin. The improvement in HOMA index for insulin concentration was not significantly different between the group. Liraglutide 1.8 mg and sitagliptin led to improvement in fasting insulin level but the difference between the two groups was not significant.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Liraglutide versus sulphonylurea (glimepiride)</HEADING>
<P>Results for liraglutide 1.2 and 1.8 mg versus sulphonylurea are shown in <LINK TAG="ANALYSES_AND_DATA" TYPE="SECTION">Data and analyses</LINK>, 16.1 to 16.13 and 17.1 to 17.13 respectively. This comparison was carried out by <LINK REF="STD-L-_x002d_-LEAD-2-Nauck-2009" TYPE="STUDY">L - LEAD 2 Nauck 2009</LINK> (versus 1.2 and 1.8 mg liraglutide) and <LINK REF="STD-L-_x002d_-Yang-2010" TYPE="STUDY">L - Yang 2010</LINK> (versus 1.2 and 1.8 mg liraglutide). The dose of glimepiride was 4 mg daily.</P>
<SUBSECTION>
<HEADING LEVEL="5">HbA1c</HEADING>
<P>There was no significant difference between 1.2 or 1.8 mg liraglutide and glimepiride. Reductions in HbA1c level with liraglutide ranged between -0.97% and -1.45% and between -0.98% and -1.39% with glimepiride.</P>
<P>There was also no significant difference between liraglutide and glimepiride in the proportion of participants reaching an HbA1c of 7% or less (range 35% to 45% with liraglutide and 36% to 44% with glimepiride).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Hypoglycaemia</HEADING>
<P>The incidence of hypoglycaemia was significantly lower with liraglutide compared with glimepiride (0% to 2% with liraglutide versus 17% to 19% with glimepiride. The mean treatment difference between liraglutide 1.2 mg and glimepiride was 0.06 (95% CI 0.00 to 1.72, P = 0.10 with significant heterogeneity, I<SUP>2</SUP> statistic = 82%). This may have been because none of the participants in the study by <LINK REF="STD-L-_x002d_-Yang-2010" TYPE="STUDY">L - Yang 2010</LINK> taking liraglutide 1.2 mg had minor hypoglycaemia. The mean treatment difference between liraglutide 1.8 mg and glimepiride was 0.13, 95% CI 0.07 to 0.25, P &lt; 0.00001. No cases of major hypoglycaemia were reported with either treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Weight change</HEADING>
<P>Participants of the liraglutide groups lost between 2.3 and 2.8 kg, while participants in the glimepiride group gained between 0.08 and 1 kg. It was reported that nausea was not responsible for weight loss in these participants.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>The most frequently reported adverse event was gastrointestinal disorders that included nausea, vomiting and diarrhoea, which was more frequent with liraglutide than with rosiglitazone (40% to 44% with liraglutide and 17% with glimepiride reported in <LINK REF="STD-L-_x002d_-LEAD-2-Nauck-2009" TYPE="STUDY">L - LEAD 2 Nauck 2009</LINK> whereas no data given by <LINK REF="STD-L-_x002d_-Yang-2010" TYPE="STUDY">L - Yang 2010</LINK>). It was also reported that the gastrointestinal adverse events with liraglutide was transient and occurred more frequently in the first four weeks and the incidence decreased overtime. The occurrence of serious adverse events were similar between the groups and they were considered not related to the treatment drugs. Withdrawals due to adverse events ranged between 9.4% and 12.9% with liraglutide and 1.3% to 3% with glimepiride.</P>
<P>In <LINK REF="STD-L-_x002d_-Yang-2010" TYPE="STUDY">L - Yang 2010</LINK>, anti-liraglutide antibodies did not have any effect on safety or HbA1c response.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Blood pressure</HEADING>
<P>There was a significant difference in favour of both 1.2 and 1.8 mg liraglutide compared to glimepiride in terms of change in systolic blood pressure. In <LINK REF="STD-L-_x002d_-LEAD-2-Nauck-2009" TYPE="STUDY">L - LEAD 2 Nauck 2009</LINK>, systolic blood pressure was reduced by between 2.3 and 2.8 mm Hg in the liraglutide groups and increased by 0.4 mm Hg in the glimepiride group (P = 0.01). Similarly, in <LINK REF="STD-L-_x002d_-Yang-2010" TYPE="STUDY">L - Yang 2010</LINK>, the systolic blood pressure decreased by more than 3 mm Hg in the liraglutide groups while only decreased by 0.91 mm Hg in the glimepiride group. In <LINK REF="STD-L-_x002d_-LEAD-2-Nauck-2009" TYPE="STUDY">L - LEAD 2 Nauck 2009</LINK>, diastolic blood pressure did not change from baseline in any of the intervention groups while in <LINK REF="STD-L-_x002d_-Yang-2010" TYPE="STUDY">L - Yang 2010</LINK> it slightly decreased in all treatment groups</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Fasting plasma glucose</HEADING>
<P>There was no significant difference in decrease in fasting plasma glucose from baseline between liraglutide and glimepiride groups (-1.6 to -2.12 mmol/L with liraglutide and -1.3 to -2.18 mmol/L with glimepiride).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Post-prandial glucose</HEADING>
<P>There was a reduction in post-prandial glucose level with all treatment groups (-2.3 to -3.51 mmol/L with liraglutide, -2.5 to -2.6 mmol/L with glimepiride) but the difference was significant only between liraglutide 1.8 mg and glimepiride (-3.51 versus -2.6 mmol/L, P &lt; 0.0001).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Beta-cell function</HEADING>
<P>
<LINK REF="STD-L-_x002d_-LEAD-2-Nauck-2009" TYPE="STUDY">L - LEAD 2 Nauck 2009</LINK> reported that there was a significant improvement in mean HOMA-B value with all treatment groups and the difference was not significant between the treatment groups (+ 23% to + 28% with liraglutide, + 25% with glimepiride). Similar reductions in the proinsulin-to-insulin ratio were observed with liraglutide or glimepiride.</P>
<P>
<LINK REF="STD-L-_x002d_-Yang-2010" TYPE="STUDY">L - Yang 2010</LINK> also reported improvements in mean HOMA-B value with all treatment groups but the difference between the groups was not significant. Similarly all treatment groups led to reduction in the proinsulin-to-insulin ratio but the difference between the groups was not significant.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Lixisenatide</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Lixisenatide versus placebo</HEADING>
<P>Results for lixisenatide versus placebo are shown in <LINK TAG="ANALYSES_AND_DATA" TYPE="SECTION">Data and analyses</LINK>, 15.1 to 15.8. The comparison was carried out by only one study (<LINK REF="STD-Lixi-_x002d_-Ratner-2010" TYPE="STUDY">Lixi - Ratner 2010</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">HbA1c</HEADING>
<P>A dose-dependent reduction in HbA1c level was observed with both once daily and twice daily regimen. Reductions in HbA1c level ranged between 0.47% and 0.87% with lixisenatide compared to reduction of 0.18% with placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">HbA1c equal to or less than 7%</HEADING>
<P>The proportion of participants achieving the target HbA1c level of 7% or less were significantly (P &lt; 0.05) higher with both once daily (47% to 69%) and twice daily (51% to 77%) lixisenatide compared with placebo (32%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Hypoglycaemia</HEADING>
<P>There was no dose-dependent relationship with symptomatic hypoglycaemic episodes. The occurrence of hypoglycaemic episode ranged between 1 and 3 events per group. There were no cases of severe hypoglycaemia.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Weight change</HEADING>
<P>There was a dose dependent reduction in weight with both once daily and twice daily regimen of lixisenatide. Reduction in weight with the once daily lixisenatide ranged between -1.94 and -3.47 kg while the reduction with twice daily lixisenatide ranged between -2.10 and -3.89 kg. Participants in the placebo group lost 1.94 kg at end of the study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>Withdrawals due to treatment-related adverse events ranged from 1.8% to 11.1% in the once daily lixisenatide group and from 0% to 14.8% in the twice daily group. Only 1.8% of participants taking placebo withdrew from the study. The incidence of adverse events was dose-dependent. Most frequently reported adverse events were gastrointestinal, mainly nausea. It was mild to moderate in intensity and occurred in most cases during the first five weeks of the study. None of the participants had pancreatitis. Eight participants in the lixisenatide group and three in the placebo group experience serious adverse events. One participant taking lixisenatide 30 µg once daily experienced few seconds of loss of consciousness thus withdrew from the study. Another patient taking lixisenatide 10 µg once daily discontinued from the study after experiencing 30 minutes of pruritis all over the body 10 min after the injection during 3rd week of treatment and a second episode of swollen lips/tongue and difficulty in breathing within 10 min of injection. The participant improved after taking oral antihistamine. There were two more cases of urticaria with lixisenatide and three with placebo. The changes in laboratory tests and ECG were not clinically significant (data not given). At the end of study, the proportions of participants with anti-lixisenatide antibody ranged from 43.1% in the 10 µg once daily group to 71.2% in the 20 µg twice daily group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Blood pressure</HEADING>
<P>Changes in systolic blood pressure ranged from -2 to -9 mm Hg in the lixisenatide group while it fell by -3 mm Hg in the placebo group. The reduction in diastolic blood pressure with lixisenatide group ranged from -2 to -4 mm Hg while it reduced by -2 mm Hg in the placebo group. In most cases, changes in blood pressure were seen as early as week one.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Fasting plasma glucose</HEADING>
<P>A dose dependent reduction in fasting plasma glucose was observed with both once daily and twice daily regimen of lixisenatide. The reduction with the once daily regimen ranged from -0.62 to -1.02 mmol/L and ranged from -0.19 to -1.42 mmol/L with the twice daily regimen. Placebo led to reduction of 0.21 mmol/L.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Post-prandial glucose</HEADING>
<P>Similarly a dose-dependent reductions in daily averaged seven-point self monitored blood glucose and 2 hour post-prandial plasma glucose concentration occurred with both once daily and twice daily lixisenatide.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">LY2189265</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">LY2189265 versus placebo </HEADING>
<P>Results for LY2189265 versus placebo are shown in <LINK TAG="ANALYSES_AND_DATA" TYPE="SECTION">Data and analyses</LINK>, 19.1 to 19.9. The comparison between LY2189265 versus placebo was reported by <LINK REF="STD-LY2189265-_x002d_Umpierrez-2011" TYPE="STUDY">LY2189265 -Umpierrez 2011</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="5">HbA1c</HEADING>
<P>The reduction in HbA1c level with LY2189265 was significantly higher compared to the reduction with placebo at all time points. HbA1c decreased by 1.38% in the 0.5/1.0 group, by 1.32% in the 1.0/1.0 group and by 1.59% in the 1.0/2.0 group (no data given for placebo). There was no significant difference between the LY groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">HbA1c equal to or less than 7%</HEADING>
<P>The proportions of participants achieving the target HbA1c level across all treatment groups ranged from 49% to 54%.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Hypoglycaemia</HEADING>
<P>The incidence of hypoglycaemia was significantly higher in all the LY groups compared to the placebo group. The numbers of participants experiencing hypoglycaemic episodes with all LY groups were significantly (P &lt; 0.05) higher at 8 weeks compared to placebo but the incidence decreased over time. The difference at end of the study between all LY groups and placebo was not significant (P &#8805; 0.17). There were no cases of severe hypoglycaemia.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Weight change</HEADING>
<P>There was a significant weight reduction in all the LY groups compared to placebo group. Reduction in weight with LY ranged from -1.44 to -2.55 kg with the highest reduction occurring in the LY 1.0/2.0 group. With placebo, weight decreased only by 0.12 kg. Weight reduction was independent of nausea.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>The most commonly reported treatment-related adverse events were gastrointestinal and these events occurred more frequently in the highest LY dose. The occurrence of nausea, diarrhoea and abdominal distension was higher than other adverse events. The proportions of participants experiencing adverse events possibly related to the study drug were 30.8% to 41.5% for the LY groups and 22.7% for placebo. Participants discontinuing the study drug because of adverse events was comparatively greater in the LY groups compared to placebo (6.1% to 6.2% versus 1.5%).</P>
<P>Seven participants experienced serious adverse events (1 in placebo group, 3 in LY 0.5/1.0 group, 2 in LY 1.0/1.0 and 1 in LY 1.0/2.0) and the investigators considered three (hallucination, cryptogenic organising pneumonia and pancreatitis) to be related to the study drug. Two participants had pancreatitis, both in the LY 0.5/1.0 group. First case of pancreatitis was reported at week 16 and the second after week 11. There were no deaths during the study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Blood pressure</HEADING>
<P>There was reduction in both systolic (-3.5 mm Hg) and diastolic (-2.3 mm Hg) blood pressure with placebo. All LY groups had dose-dependent reductions in systolic blood pressure, ranging from -0.6 to -3.0 mm Hg, There was no reduction in diastolic blood pressure in any LY group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Fasting plasma glucose</HEADING>
<P>It was observed that the reduction in fasting plasma glucose level was significantly greater in the LY groups than in the placebo group. Reduction with LY ranged from -2.05 to -2.65 mmol/L while it fell by 0.49 mmol/L in the placebo group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Beta<I>-</I>cell function</HEADING>
<P>There was a significant improvement in HOMA2-%B in all the LY groups compared to placebo group. The improvement ranged from 32.9% to 45.6% in the LY groups while it increased by 1% in the placebo group. There was no significant change in any LY group for HOMA2-%S or HOMA2-%IR.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Taspoglutide</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Taspoglutide versus placebo</HEADING>
<P>Results for taspoglutide are shown in <LINK TAG="ANALYSES_AND_DATA" TYPE="SECTION">Data and analyses</LINK>, 18.1 to 18.16. The comparison of taspoglutide against placebo was carried out by two trials <LINK REF="STD-T-_x002d_-Nauck-2009" TYPE="STUDY">T - Nauck 2009</LINK> and <LINK REF="STD-T_x002d_-Ratner-2010" TYPE="STUDY">T- Ratner 2010</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="5">HbA1c</HEADING>
<P>
<LINK REF="STD-T-_x002d_-Nauck-2009" TYPE="STUDY">T - Nauck 2009</LINK> found a significant reduction in the level of HbA1c in participants on taspoglutide compared to placebo (P &lt; 0.0001). The reduction was similar in all taspoglutide groups (10 mg weekly -1.2%; 20 mg weekly -1.2% and 20 mg every two weeks -1.0%). The reduction in HbA1c was comparatively larger in participants with higher baseline HbA1c levels (equal to or greater than 8.0%). Similarly <LINK REF="STD-T_x002d_-Ratner-2010" TYPE="STUDY">T- Ratner 2010</LINK> also found a significant reduction in HbA1c level taking taspoglutide compared to placebo. The titration of the taspoglutide dose to higher dose did not lead to increased reduction in HbA1c levels (-1.2% in 20/20 once weekly group; -0.9% in 20/30 once weekly group and -1.2% in 20/40 once weekly group).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">HbA1c equal to or less than 7%</HEADING>
<P>
<LINK REF="STD-T-_x002d_-Nauck-2009" TYPE="STUDY">T - Nauck 2009</LINK> found a significant difference in the proportion of participants achieving target HbA1c level of less than 7% between intervention groups, with 79%, 81%, and 63% of participants achieving this target with 10 mg weekly, 20 mg weekly and 20 mg every two weeks taspoglutide, respectively, and 17% with placebo (P &lt; 0.0001 versus placebo). Similarly, the proportion of participants achieving the target HbA1c level was higher with taspoglutide than with placebo (72% in the 20/20 mg once weekly group, 53% in the 20/30 mg once weekly group, 70% in the 20/40 mg once weekly group and 19% in the placebo group).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Hypoglycaemia</HEADING>
<P>In <LINK REF="STD-T-_x002d_-Nauck-2009" TYPE="STUDY">T - Nauck 2009</LINK>, no definition of hypoglycaemia was given.  Also no data were reported for the separate comparison groups however it was reported that 6 patients had 7 hypoglycaemic events, 2 of which were asymptomatic. In addition, it was also reported that there were no cases of severe hypoglycaemia in the taspoglutide group.</P>
<P>No definition of hypoglycaemia was given in <LINK REF="STD-T_x002d_-Ratner-2010" TYPE="STUDY">T- Ratner 2010</LINK>. Incidence of hypoglycaemia was comparatively similarly between all the treatment groups. There were no cases of severe hypoglycaemia during the study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Weight change</HEADING>
<P>The weight reduction was comparatively greater in the taspoglutide groups compared with the placebo group. The reduction was significant in the 10 mg once weekly taspoglutide group (-2.1 kg, P = 0.02 versus placebo) and the 20 mg every two weekly taspoglutide group (-1.9 kg, P = 0.01 versus placebo) compared to placebo group (-0.8 kg). However there was no significant difference between the 20 mg once weekly taspoglutide group compared against placebo group. The mean difference was -1.07 kg (95% CI -2.93 to 0.79, P = 0.26) with significant heterogeneity (I<SUP>2 </SUP>statistic<SUP> </SUP>= 88%). The titration of 20 mg weekly dose to 30 mg once weekly led to significant weight reduction compared to placebo (-3 versus -2 kg, P = 0.03) but not when the dose was titrated to 40 mg weekly (-2.7 versus -2 kg, P = 0.17) (<LINK REF="STD-T_x002d_-Ratner-2010" TYPE="STUDY">T- Ratner 2010</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>In <LINK REF="STD-T-_x002d_-Nauck-2009" TYPE="STUDY">T - Nauck 2009</LINK>, the most commonly reported adverse events were gastrointestinal (nausea, vomiting and diarrhoea) which occurred more frequently in the taspoglutide groups than with placebo. In the taspoglutide groups, nausea occurred in 24% of patients on 10 mg weekly, in 52% on 20 mg weekly, and in 41% on 20 mg every two weeks (versus in 6% on placebo). Vomiting occurred in 4% of patients on 10 mg taspoglutide weekly, in 22% on 20 mg weekly, and in 24% on 20 mg every two weeks (versus in 4% on placebo). Diarrhoea occurred in 10% of patients on 10 mg taspoglutide weekly, in 10% on 20 mg weekly, and in 18% on 20 mg every two weeks (versus in 8% on placebo). Nausea was commoner at the beginning of treatment and decreased over the course of the study. Similarly, in <LINK REF="STD-T_x002d_-Ratner-2010" TYPE="STUDY">T- Ratner 2010</LINK>, the most frequently reported adverse events were gastrointestinal events, mainly nausea, diarrhoea and dyspepsia. The occurrence of these events was higher in the participants taking taspoglutide than those on placebo. The overall incidence did not change with titration to higher dose. It was also reported that nausea was mild to moderate in intensity and occurred more frequently in the first few weeks. The occurrence of nausea and vomiting reduced over time, with the greatest reduction seen in participants who remained on the 20 mg taspoglutide throughout the study. Injection site reactions were higher with taspoglutide than with placebo.</P>
<P>In <LINK REF="STD-T-_x002d_-Nauck-2009" TYPE="STUDY">T - Nauck 2009</LINK>, six patients experienced serious adverse events and that led to discontinuation in two of them in the placebo group however, the investigators considered this not to be related to the study drug. There were reports of mild to moderate injection site reactions which did not lead to any discontinuation. There were no significant differences in headache and no clinically relevant abnormalities in ECG, vital signs, and laboratory parameters.</P>
<P>In <LINK REF="STD-T_x002d_-Ratner-2010" TYPE="STUDY">T- Ratner 2010</LINK>, two serious adverse events were reported however both of them were considered not to be related to the study drug.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Fasting plasma glucose</HEADING>
<P>In <LINK REF="STD-T-_x002d_-Nauck-2009" TYPE="STUDY">T - Nauck 2009</LINK>, fasting plasma glucose was significantly reduced in all considered taspoglutide groups compared to placebo (P = 0.02 to P &lt; 0.0001). The reduction in the 10 mg weekly and the 20 mg once weekly groups was -2.5 mmol/L, -1.4 mmol/L in the 20 mg every two weeks group, and -0.78 mmol/L in the placebo group. Fasting plasma glucose fluctuated more in once every two week regimens than in the weekly regimens.</P>
<P>Fasting plasma glucose significantly reduced in all the taspoglutide groups compared to placebo. The reduction in the 20/20 mg, 20/30 mg and 20/40 taspoglutide group was -2.3 mmol/L, -1.6 mmol/L and -2.2 mmol/L respectively while the reduction in the placebo group was -2.2 mmol/L.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Post-prandial glucose</HEADING>
<P>The mean percent decrease from baseline in plasma glucose 120 min after a mixed meal was larger in the once weekly taspoglutide groups (-22% with 10 mg weekly, -18% with 20 mg weekly) compared to 20 mg once every two weeks (-5.5%) and placebo (-10.5%). Similarly, the percentage change from baseline in glucose AUC (area under the curve over 240 min) was comparatively larger in the once weekly taspoglutide groups (-27.5% with 10 mg weekly and -22.2% with 20 mg weekly) compared to 20 mg once every two weeks (-9.2%) and placebo (-7.2%).</P>
<P>The median percentage change in plasma insulin levels at 120 min was +44.4% with 20 mg once weekly taspoglutide group, +28.5% with 10 mg once weekly, -13% with 20 mg every two weeks and -15.3% with placebo. This outcome was not reported in <LINK REF="STD-T_x002d_-Ratner-2010" TYPE="STUDY">T- Ratner 2010</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Lipid profiles</HEADING>
<P>There was a decline in triglyceride levels with taspoglutide that appeared to be dose-related and there was also some decrease in total cholesterol levels. None of the other lipid parameters showed any consistent changes. Lipid profile was not reported in <LINK REF="STD-T_x002d_-Ratner-2010" TYPE="STUDY">T- Ratner 2010</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Beta-cell function</HEADING>
<P>There were statistically significant decreases in the fasting proinsulin-to-insulin molar ratio in the once weekly taspoglutide groups (-0.12 with 10 mg once weekly, -0.17 with 20 mg once weekly, P &lt; 0.01) compared to placebo. Changes with 20 mg taspoglutide every two weeks (-0.055) and placebo (+0.002) were non-significant. This outcome was not reported by <LINK REF="STD-T_x002d_-Ratner-2010" TYPE="STUDY">T- Ratner 2010</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">GLP-1 agonist versus GLP-1 agonist</HEADING>
<P>Results for different GLP-1 agonists or different GLP-1 formulations compared with each other are shown in <LINK TAG="ANALYSES_AND_DATA" TYPE="SECTION">Data and analyses</LINK>, 20.1 to 20.16. <LINK REF="STD-L-_x002d_-LEAD-6-Buse-2009" TYPE="STUDY">L - LEAD 6 Buse 2009</LINK> compared 1.8 mg once daily liraglutide with 10 µg exenatide twice daily, <LINK REF="STD-E-_x002d_-Blevins-2011" TYPE="STUDY">E - Blevins 2011</LINK> and <LINK REF="STD-E-_x002d_-Drucker-2008" TYPE="STUDY">E - Drucker 2008</LINK> compared 10 µg exenatide BID with 2 mg exenatide once weekly.</P>
<SUBSECTION>
<HEADING LEVEL="5">HbA1c</HEADING>
<P>In the direct comparison of exenatide with liraglutide (<LINK REF="STD-L-_x002d_-LEAD-6-Buse-2009" TYPE="STUDY">L - LEAD 6 Buse 2009</LINK>), HbA1c was significantly more reduced with liraglutide (-1.22% versus -0.79%, mean difference 0.33 (95% CI 0.11 to 0.55, P &lt; 0.0001). Similarly, the proportion of participants that reached the target HbA1c level of 7% or less was significantly higher with liraglutide (54%) than with exenatide (43%).</P>
<P>When comparing 10 µg exenatide twice daily with 2 mg exenatide once weekly(<LINK REF="STD-E-_x002d_-Blevins-2011" TYPE="STUDY">E - Blevins 2011</LINK>, <LINK REF="STD-E-_x002d_-Drucker-2008" TYPE="STUDY">E - Drucker 2008</LINK>), HbA1c was significantly more reduced with the weekly regimen. The mean treatment difference was 0.55% (95% CI 0.26 to 0.84, P = 0.0002) with slight heterogeneity of 55%. Similarly, the proportion of participants achieving a target HbA1c level of 7% or less was higher with once weekly exenatide. The mean difference was 0.65 (95% CI 0.42 to 1.01, P = 0.06) with significant heterogeneity (I<SUP>2 </SUP>statistic = 84%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Hypoglycaemia</HEADING>
<P>The proportion of participants who had minor hypoglycaemia was significantly higher with the exenatide group than with liraglutide (34% versus 26%, P = 0.0131). Participants on metformin as background therapy had fewer episodes of minor hypoglycaemia in both the liraglutide (6%) and the exenatide (11%) group compared to the participants taking sulphonylurea with or without metformin (33% for liraglutide versus 42% for exenatide). Two participants in the exenatide group receiving sulphonylurea as concomitant medication reported major hypoglycaemic episodes but no major episodes were reported in the liraglutide group.</P>
<P>There was no significant difference in hypoglycaemia between participants on exenatide twice daily or exenatide once a week. It was reported by <LINK REF="STD-E-_x002d_-Drucker-2008" TYPE="STUDY">E - Drucker 2008</LINK> that participants on sulphonylurea background therapy had more episodes of minor hypoglycaemia compared to the participants without sulphonylurea background therapy (with SU: 14.5% with exenatide once weekly, 15.4% with exenatide twice a day; without SU: 0% with exenatide once weekly, 1.1% with exenatide twice a day). Similarly, <LINK REF="STD-E-_x002d_-Blevins-2011" TYPE="STUDY">E - Blevins 2011</LINK> found that the participants taking concomitant sulphonylureas therapy experienced hypoglycaemia (four in the twice daily group while five in the once weekly group). No major hypoglycaemic episodes were reported in both studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Weight change</HEADING>
<P>There was no significant difference in weight loss between liraglutide and exenatide. Weight loss with exenatide was -2.87 kg (SE 0.33) and weight loss with liraglutide was -3.24 kg (SE 0.33). The proportion of participants who lost weight was similar between the groups (78% with liraglutide versus 76% with exenatide).</P>
<P>Similarly, there was no significant difference in weight loss between 10 µg exenatide BID and 2 mg exenatide QW. Weight loss ranged from -1.4 to -3.7 kg in the once weekly group and -2.3 to -3.6 kg in the twice daily group. In <LINK REF="STD-E-_x002d_-Drucker-2008" TYPE="STUDY">E - Drucker 2008</LINK>, more than 75% of the participants lost weight in both groups (76% with exenatide once weekly versus 79% with exenatide twice daily). Weight decreased in participants who reported no episodes of nausea throughout the study (70%) .In <LINK REF="STD-E-_x002d_-Blevins-2011" TYPE="STUDY">E - Blevins 2011</LINK>, 77% of participants in the exenatide once weekly group and 63% in the twice daily group lost weight.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Treatment satisfaction / Quality of life</HEADING>
<P>Overall satisfaction was significantly higher with liraglutide than with exenatide (Diabetes Treatment satisfaction Questionnaire, 15.18 SE 0.58 with liraglutide, 13.30 SE 0.58 with exenatide, P = 0.0004).</P>
<P>There was no significant difference in treatment satisfaction between exenatide once a week compared with exenatide twice daily (Diabetes Treatment Satisfaction Questionnaire); there was also no significant difference in weight-related quality of life (IWQOL-Lite).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>The overall rate of adverse events was slightly higher with exenatide than with liraglutide (79% versus 75%), but there were more serious and severe adverse events with liraglutide (serious: 5.1% versus 2.6%; severe: 7.2% versus 4.7%), only one of these (severe hypoglycaemia with exenatide) was considered treatment-related.  There were slightly more withdrawals due to adverse events with exenatide than with liraglutide (13% versus 10%). The most commonly reported adverse event was nausea followed by diarrhoea and vomiting. The rate of gastrointestinal events was similar between exenatide and liraglutide groups. However, nausea was reported to be less persistent with liraglutide. There were no reports of acute pancreatitis in either group.  One episode of mild chronic pancreatitis was reported in the liraglutide group but the investigators confirmed it not to be related to the study drug.</P>
<P>When comparing exenatide 10 µg twice daily with exenatide 2 mg once weekly, there was slightly more nausea (34.5% to 35% versus 14% to 26.4%) and vomiting (8.9% to 18.6% versus 4.7% to 10.8%) with the twice daily regimen. Nausea was predominantly mild in intensity and there were no cases of severe nausea with exenatide once a week. Participants with nausea lost somewhat more weight, but weight also decreased in participants with no nausea. Injection site pruritus occurred in 5.4% to 17.6% of the once weekly group and 1.4% to 2.4% of the twice daily group, however injection site bruising was somewhat more frequent with twice daily exenatide compared with once weekly exenatide (10.3% versus 4.7%). The proportion of participants with serious adverse events was low in both groups (2% to 5.4% for once weekly and 3.4% to 4% for twice daily) and none were considered to be related to the study drug. Withdrawal because of adverse events was similar between the groups (5% to 6.1% for once weekly versus 5% to 5.4% for twice daily exenatide).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Blood pressure</HEADING>
<P>Systolic and diastolic blood pressure decreased with both exenatide and liraglutide but there was no significant difference between the treatment groups. There was a reduction of 2 mm Hg SD 17.93 in systolic blood pressure with exenatide and of 2.51 mm Hg SD 17.55 with liraglutide.</P>
<P>Similarly, a reduction in systolic and diastolic blood pressure with both exenatide 10 µg BID and exenatide 2 mg QW was not significantly different between the groups. The reduction in systolic blood pressure ranged from 2.9 to 4.7 mm Hg with exenatide once weekly and 1.2 to 3.4 mm Hg with exenatide twice daily.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Fasting plasma glucose</HEADING>
<P>Fasting plasma glucose was significantly more reduced with liraglutide than with exenatide (-1.61 mmol/L versus -0.60 mmol/L), with a mean difference between the groups of 1.01 mmol/L (95% CI 0.46 to 1.56, P &lt; 0.0001).</P>
<P>Fasting plasma glucose was significantly was also significantly lower with 2 mg exenatide once weekly than with 10 µg exenatide BID (-1.9 to -2.3 mmol/L versus -0.7 to -1.4 mmol/L), with a mean difference between the groups of 1.18 mmol/L (95% CI 1.02 to 1.33, P &lt; 0.00001).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Post-prandial glucose</HEADING>
<P>Exenatide reduced the post-prandial plasma glucose increment (as obtained from self-monitored 7-point plasma glucose measurements) more than did liraglutide after breakfast and dinner (treatment difference breakfast: 1.33 mmol/L, 95% CI 0.80 to 1.86, P &lt; 0.0001; dinner: 1.01 mmol/L, 95% CI 0.44 to 1.57, P = 0.0005); treatment difference after lunch was not significant.</P>
<P>Both exenatide once a week and exenatide twice daily led to significant improvements in 7-point self-monitored blood glucose profiles. A meal tolerance test was carried out in 51 participants and 2 h post-prandial values were significantly more reduced with exenatide twice a day than with exenatide once weekly (-6.9 mmol/L SE 0.5 versus -5.3 mmol/L, P = 0.0124).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Lipid profiles</HEADING>
<P>There were significantly greater reductions in triglycerides and free fatty acids with liraglutide than with exenatide (triglycerides: -0.41 mmol/L SE 0.1 versus -0.23 mmol/L SE 0.1, P = 0.0485; free fatty acids: -0.17 mmol/L SE 0.02 versus -0.10 mmol/L SE 0.02, P = 0.0014), and increases in VLDL cholesterol were significantly smaller with liraglutide (+0.20 mmol/L SE 0.04 versus +0.27 mmol/L SE 0.04, P = 0.0277). There were no significant differences in any other lipid parameters.</P>
<P>When comparing exenatide twice a day and exenatide once weekly, there were significantly greater reductions from baseline in total and LDL-cholesterol with the once a week regimen (The mean difference between the two groups for total cholesterol was 0.31 mmol/L (95% CI 0.10 to 0.51, P = 0.003) with heterogeneity of 61% and the mean difference for LDL cholesterol was 0.20 mmol/L (95% CI 0.09 to 0.30) with no heterogeneity. There were no significant differences in any other lipid parameters.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Beta-cell function</HEADING>
<P>HOMA-B improved significantly more with liraglutide than with exenatide (+32.1% versus +2.7% (both different from exenatide studies), P &lt; 0.0001). There were no significant changes in proinsulin-insulin ratio with either treatment and no difference between the groups in this parameter.</P>
<P>Beta-cell function was not reported for exenatide twice daily versus once weekly.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-08-31 14:34:10 +0200" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2011-08-31 14:34:10 +0200" MODIFIED_BY="[Empty name]">
<P>For overview of results please see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>. Seventeen randomised controlled trials of mostly low risk of bias including relevant analyses for 6899 participants were included in the analysis. Of these, one compared albiglutide with placebo, two compared exenatide twice daily against once weekly exenatide, one compared once weekly exenatide against insulin glargine, one compared exenatide once weekly against sitagliptin and pioglitazone, five compared liraglutide with placebo, two compared liraglutide with glimepiride (sulphonylurea), and one each compared exenatide with liraglutide, liraglutide with sitagliptin, liraglutide with rosiglitazone and liraglutide with insulin glargine, two compared taspoglutide with placebo and one each compared lixisenatide with placebo and LY2189265 with placebo. In comparison with placebo, all glucagon-like peptide-1 (GLP-1) agonists significantly reduced glycosylated haemoglobin A1c (HbA1c) (treatment difference between 0.47% and 1.56%) and increased the proportion of participants reaching an HbA1c of 7% or less. Results for mild hypoglycaemia were variable, with more patients on exenatide and concomitant sulphonylurea and more participants on 1.8 mg liraglutide experiencing mild hypoglycaemia than patients on placebo. There were no differences in severe hypoglycaemia. Patients using GLP-1 agonists lost significantly more weight than patients in the placebo groups. GLP-1 agonists caused gastrointestinal adverse effects, mainly nausea, as well as vomiting and diarrhoea; however, studies generally reported that these effects were strongest at the beginning and then subsided, and that weight loss also occurred in patients not experiencing nausea. Fasting blood glucose was reduced significantly more with GLP-1 agonists. Where reported, GLP-1 agonists reduced post-prandial glucose and glucose variability. No significant difference in blood pressure was seen in comparison with placebo and some improvement in lipid parameters was seen, but this outcome was reported infrequently and results were inconsistent. Beta-cell function was improved with GLP-1 agonists (HOMA-B, proinsulin-to-insulin ratio).</P>
<P>Only one study assessed albiglutide but overall, the effects of this agent on HbA1c and weight appeared to be slightly less than that of the other agents. Lixisenatide was found to be superior against placebo in terms of HbA1c, weight, weight, blood pressure and FPG. One study that assessed efficacy of LY2189265 and found that it was superior to placebo with respect to HbA1c, weight, systolic blood pressure (SBP), fasting plasma glucose (FPG) and beta-cell function. Taspoglutide was found to be superior than placebo in terms of HbA1c, weight (with some doses), FPG, post-prandial glucose (PPG), beta-cell function and some improvement in triglyceride levels.</P>
<P>Both once weekly exenatide and liraglutide were superior to insulin glargine on most outcomes. There was slightly greater reduction in HbA1c level with exenatide than with glargine (-1.5% versus -1.3%) while there was a small but statistically significantly larger reduction in HbA1c with liraglutide (0.24%). The incidence of hypoglycaemia was less with once weekly exenatide than with insulin glargine (18% less). No significant difference was seen in hypoglycaemia between liraglutide and exenatide. Long acting exenatide was superior to insulin glargine in terms of the proportion of participants achieving HbA1c level &lt; 7%, weight and health-related quality of life. It was also superior to sitagliptin and pioglitazone in terms of HbA1c, weight, FPG, health-related quality of life, PPG and improvement in some parameters of lipid profile. Exenatide 2 mg weekly was superior to exenatide 10 µg twice daily with respect to HbA1c, proportion of participants reaching the target HbA1c level of 7% or less, fasting plasma glucose, frequency of gastrointestinal adverse events and improvement of some lipid parameters; however, post-prandial glucose was significantly more reduced with the twice daily regimen.</P>
<P>Liraglutide was superior to glimepiride in terms of hypoglycaemia, weight reduction and systolic blood pressure. Liraglutide was superior to rosiglitazone 4 mg with respect to HbA1c, weight reduction, fasting and post-prandial plasma glucose values and beta-cell function; there was slightly more minor hypoglycaemia with liraglutide (4%). Liraglutide was superior to sitagliptin in terms of HbA1c, weight, FPG and beta-cell function. In a head-to-head comparison of exenatide and liraglutide, liraglutide was superior to exenatide with respect to HbA1c, hypoglycaemia, patient satisfaction, less persistent nausea, systolic blood pressure, improvement of some lipid parameters, and improvement in beta-cell function. None of the studies was long enough to assess long-term positive or negative effects.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2011-08-30 15:14:53 +0200" MODIFIED_BY="Bernd Richter">
<P>Most of the studies evaluated exenatide or liraglutide. So far, few studies on other GLP-1 agonists have been published, although a number are in progress (see <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>). There were only three head-to-head comparisons of different GLP-1 agonists (one study compared liraglutide versus exenatide twice daily and other two compared exenatide twice daily vs exenatide once weekly), so no firm conclusions could be made on the relative effectiveness of the different agents. Once weekly exenatide was better than twice daily exenatide with respect to most outcomes especially HbA1c, FPG and frequency of gastrointestinal adverse events. The improvement in HbA1c with once weekly exenatide was 0.4%. In a head to head comparison of twice daily exenatide and liraglutide, liraglutide was superior to exenatide. This trial was sponsored by the manufacturer of liraglutide however, the findings appear plausible given the pharmacodynamics of the two drugs, with liraglutide having a more prolonged action with less 'peak and trough effect'. These findings suggest that the once weekly exenatide may be better than liraglutide. Hence, in future GLP-1 analogues may be given once weekly or once every two weeks.</P>
<P>In our meta-analysis, we found that there was no significant difference between the 1.2 mg and the 1.8 mg liraglutide in terms of HbA1c and systolic blood pressure. However, weight reduction with the 1.8 mg liraglutide was slightly greater than the 1.2 mg liraglutide.</P>
<P>Only one exenatide trial and one liraglutide trial carried out comparisons with insulin glargine, the most commonly used basal insulin in the UK. In addition, the liraglutide trial used the 1.8 mg dose. Therefore there is a lack of trials comparing GLP-1 agonists against insulin glargine. There are also no trials comparing GLP-1 agonists against NPH insulin, the more cost-effective insulin in type 2 diabetes (<LINK REF="REF-Waugh-2010" TYPE="REFERENCE">Waugh 2010</LINK>).</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2011-08-30 15:17:24 +0200" MODIFIED_BY="Bernd Richter">
<P>Studies were mainly of good to high quality. However, four studies had small comparison groups (fewer than 50 participants) (<LINK REF="STD-A-_x002d_-Rosenstock-2009" TYPE="STUDY">A - Rosenstock 2009</LINK>; <LINK REF="STD-Lixi-_x002d_-Ratner-2010" TYPE="STUDY">Lixi - Ratner 2010</LINK>; <LINK REF="STD-T-_x002d_-Nauck-2009" TYPE="STUDY">T - Nauck 2009</LINK>; <LINK REF="STD-T_x002d_-Ratner-2010" TYPE="STUDY">T- Ratner 2010</LINK>); six studies had a duration of between eight and 16 weeks (<LINK REF="STD-A-_x002d_-Rosenstock-2009" TYPE="STUDY">A - Rosenstock 2009</LINK>; <LINK REF="STD-L-_x002d_-Yang-2010" TYPE="STUDY">L - Yang 2010</LINK>; <LINK REF="STD-Lixi-_x002d_-Ratner-2010" TYPE="STUDY">Lixi - Ratner 2010</LINK>; <LINK REF="STD-LY2189265-_x002d_Umpierrez-2011" TYPE="STUDY">LY2189265 -Umpierrez 2011</LINK>; <LINK REF="STD-T-_x002d_-Nauck-2009" TYPE="STUDY">T - Nauck 2009</LINK>; <LINK REF="STD-T_x002d_-Ratner-2010" TYPE="STUDY">T- Ratner 2010</LINK>), and the remaining trials were between 24 to 30 weeks long - so there is insufficient evidence regarding long-term outcomes. The studies were not long enough to entirely remove concerns about pancreatitis and renal failure with exenatide (<LINK REF="REF-FDA-2008" TYPE="REFERENCE">FDA 2008</LINK>; <LINK REF="REF-FDA-2009-_x0028_kidney-function_x0029_" TYPE="REFERENCE">FDA 2009 (kidney function)</LINK>; <LINK REF="REF-FDA-2009-_x0028_safety-update_x0029_" TYPE="REFERENCE">FDA 2009 (safety update)</LINK> or pancreatitis and thyroid carcinoma with liraglutide (<LINK REF="REF-EMEA-2009" TYPE="REFERENCE">EMEA 2009</LINK>). The FDA has recently issued a reminder to physicians that there is a potential risk of thyroid carcinoma and pancreatitis with liraglutide (<LINK REF="REF-Journal-Watch-2011" TYPE="REFERENCE">Journal Watch 2011</LINK>). It is however difficult to prove if exenatide and liraglutide are responsible for pancreatitis because the incidence of it is increased in type 2 diabetes (<LINK REF="REF-Butler-2010" TYPE="REFERENCE">Butler 2010</LINK>; <LINK REF="REF-Girman-2010" TYPE="REFERENCE">Girman 2010</LINK>). One study followed up a cohort of patients taking exenatide and other hyperglycaemic drugs and concluded that there was no association of exenatide use and risk of acute pancreatitis (<LINK REF="REF-Dore-2011" TYPE="REFERENCE">Dore 2011</LINK>).</P>
<P>All the studies included in this review had industry connections.</P>
<P>In some studies there were some uncertainties or inequalities regarding previous or concomitant anti-diabetic treatment. Patients in <LINK REF="STD-L-_x002d_-LEAD-1-Marre-2009" TYPE="STUDY">L - LEAD 1 Marre 2009</LINK> were assumed to have been on previous metformin therapy, but this was not reported by the study. In <LINK REF="STD-A-_x002d_-Rosenstock-2009" TYPE="STUDY">A - Rosenstock 2009</LINK>, all patients in a concomitant exenatide group were on metformin, whereas only a proportion of patients in the other groups were, so this group could not be included in the analysis.</P>
<P>A range of studies had substantial losses to follow-up (10% and more but less than 20%), with more withdrawals often occurring in the GLP-1 groups (mainly due to adverse events).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2011-06-23 18:28:50 +0200" MODIFIED_BY="[Empty name]">
<P>Due to the limited number of studies in each categories no sensitivity or subgroup analyses were carried out and while some outcomes showed some heterogeneity in the overall results, some sources of heterogeneity could either not be identified or could only be speculated on.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2011-08-30 15:19:22 +0200" MODIFIED_BY="Bernd Richter">
<P>Other published reviews included slightly different studies:</P>
<P>The review by <LINK REF="REF-Shyangdan-2010" TYPE="REFERENCE">Shyangdan 2010</LINK> included a search up to July 2010 and included 28 studies. It however included all the exenatide studies (including twice daily dosage). This Cochrane review is an update of that review and excludes all the studies comparing the twice daily exenatide against placebo or other oral hypoglycaemic agents, but not the ones against other GLP-1 agonists.</P>
<P>The review by <LINK REF="REF-Norris-2009" TYPE="REFERENCE">Norris 2009</LINK> included a search up to 2008, and included eight trials, including two excluded by the current review as less than 70% of patients had been on previous metformin therapy. The authors concluded that exenatide 10 µg twice daily reduced HbA1c to a similar extent as insulin or oral anti-diabetic agents and that there was a beneficial effect on weight loss. Hypogycaemia with exenatide occurred mainly in participants also taking a sulphonylurea.</P>
<P>The review by <LINK REF="REF-Amori-2007" TYPE="REFERENCE">Amori 2007</LINK> included data up to 2007 only, including seven studies on exenatide and two on liraglutide. The review included comparisons that are not clinically relevant (such as monotherapy versus placebo and 0.6 mg liraglutide). The authors found a moderate effect of GLP-1 analogues on HbA1c (-1%), a beneficial effect on weight and post-prandial glucose, but increased gastrointestinal adverse events. In placebo-controlled trials, increased hypoglycaemia with exenatide was seen mainly in trials using concomitant sulphonylurea.</P>
<P>Twenty-one RCTs were included in the review by <LINK REF="REF-Monami-2009" TYPE="REFERENCE">Monami 2009</LINK>, including six unpublished studies. The search included studies up to 2008. Again, the authors found that GLP-1 agonists reduced HbA1c by around 1%, and also reduced post-prandial glucose and weight. There was no evidence of increased cardiovascular risk, but gastrointestinal adverse effects were common. Increased hypoglycaemia with exenatide versus placebo was only seen in trials using concomitant sulphonylurea.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2011-08-30 15:29:39 +0200" MODIFIED_BY="Bernd Richter">
<IMPLICATIONS_PRACTICE MODIFIED="2011-08-30 15:22:22 +0200" MODIFIED_BY="Bernd Richter">
<P>The evidence to date shows that the glucagon-like peptide 1 (GLP-1) analogues can provide a useful improvement in glucose control when added to dual treatment with oral drugs, and that at least in the short term, they can be an alternative to starting insulin. How long this effect would last, is not known. If we assume that the disease will steadily progress, as shown in <LINK REF="REF-UKPDS-16" TYPE="REFERENCE">UKPDS 16</LINK>, then some of the benefit will be lost since the beta-cells will no longer be there to release insulin. Other benefits such as delayed gastric emptying may continue, which may help control post-prandial hyperglycaemia.</P>
<P>The glucose-dependent nature of the insulin release means that hypoglycaemia should be less of a problem, but the differences in the trials were not marked. Hypoglycaemia was seen mainly when GLP-1 analogues were used in combination with sulphonylureas.</P>
<P>Weight loss is a useful feature in the trials, though perhaps seen less in routine care (<LINK REF="REF-Loh-and-Clement-2007" TYPE="REFERENCE">Loh and Clement 2007</LINK>) .</P>
<P>The drawbacks are the need for injections, once a day with liraglutide and twice daily with exenatide, the high rate of side-effects, especially nausea, and the cost. However, newer GLP-1 agonists can be given once weekly or once every two weeks.</P>
<P>Injecting of a foreign peptide could lead to antibody formation, but studies measuring antibody formation noted that although antibodies were detected, these did not appear to reduce efficacy or have any safety effects.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2011-08-30 15:29:39 +0200" MODIFIED_BY="Bernd Richter">
<P>More high quality trials are needed that:</P>
<UL>
<LI>compare one GLP-1 agonist against other GLP-1 agonists, with the emphasis on long-acting agents;</LI>
</UL>
<UL>
<LI>measure health-related quality of life and treatment satisfaction;</LI>
<LI>measure long-term outcomes (longer than one year follow-up) in terms of diabetes-related morbidity and mortality and adverse events, and to indicate duration of efficacy in a progressive disease;</LI>
<LI>examine diverse populations, including adolescents and older adults;</LI>
<LI>use active controls.</LI>
</UL>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2011-06-30 14:37:37 +0200" MODIFIED_BY="[Empty name]">
<P>None.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2011-06-30 14:37:36 +0200" MODIFIED_BY="[Empty name]">
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2011-06-30 15:23:50 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>DEEPSON SHYANGDAN: </B>Data extraction, quality assessment of studies, data summary and analysis, writing of main text</P>
<P>
<B>PAMELA ROYLE:</B> Searching for studies, study selection, checking of data, data extraction, quality assessment of studies, writing of main text</P>
<P>
<B>CHRISTINE CLAR: </B>Data extraction, quality assessment of studies, data summary and analysis, writing of main text</P>
<P>
<B>PAWANA SHARMA:</B> Data extraction, quality assessment of studies, writing of protocol</P>
<P>
<B>NORMAN WAUGH: </B>Study selection, general supervision of the review, writing of main text</P>
<P>
<B>AILSA SNAITH:</B> Author of first version of the review (exenatide and liraglutide only) and of protocol</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2011-08-30 15:29:49 +0200" MODIFIED_BY="Bernd Richter">
<UL>
<LI>Authors have changed since publication of the protocol.</LI>
<LI>Contact person has changed since publication of the protocol.</LI>
<LI>Studies with a minimum duration of eight weeks were included.</LI>
<LI>Outcome costs was deleted and blood pressure introduced.</LI>
<LI>Number of glucagon-like peptide 1 (GLP-1) agonists increased from two to six. Exenatide twice daily rendered obsolete by once weekly form so review focusses on latter.</LI>
</UL>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-08-30 15:25:57 +0200" MODIFIED_BY="Bernd Richter">
<STUDIES MODIFIED="2011-08-30 15:25:57 +0200" MODIFIED_BY="Bernd Richter">
<INCLUDED_STUDIES MODIFIED="2011-08-30 15:25:57 +0200" MODIFIED_BY="Bernd Richter">
<STUDY DATA_SOURCE="PUB" ID="STD-A-_x002d_-Rosenstock-2009" MODIFIED="2011-06-21 10:15:17 +0200" MODIFIED_BY="[Empty name]" NAME="A - Rosenstock 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-06-21 10:15:17 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosenstock J, Reusch J, Bush M, Yang F, Stewart M</AU>
<TI>Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2009</YR>
<VL>32</VL>
<NO>10</NO>
<PG>1880-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-E-_x002d_-Bergenstal-2010" MODIFIED="2011-06-21 11:35:28 +0200" MODIFIED_BY="[Empty name]" NAME="E - Bergenstal 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-06-21 11:35:28 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bergenstal RM, Wysham C, MacConell L, Malloy J, Walsh B, Yan P, et al</AU>
<TI>Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial</TI>
<SO>Lancet</SO>
<YR>Aug 2010</YR>
<VL>376</VL>
<PG>431-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-E-_x002d_-Blevins-2011" MODIFIED="2011-08-30 15:25:57 +0200" MODIFIED_BY="Bernd Richter" NAME="E - Blevins 2011" YEAR="2011">
<REFERENCE MODIFIED="2011-08-30 15:25:57 +0200" MODIFIED_BY="Bernd Richter" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blevins T, Pullman J, Malloy J, Yan P, Taylor K, Schulteis C, et al</AU>
<TI>DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes</TI>
<SO>The Journal of Clinical Endocrinology and Metabolism</SO>
<YR>2011</YR>
<VL>96</VL>
<NO>5</NO>
<PG>1301-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-E-_x002d_-Diamant-2010" MODIFIED="2011-06-21 10:18:08 +0200" MODIFIED_BY="[Empty name]" NAME="E - Diamant 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-06-21 10:18:08 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Diamant M, Van GL, Stranks S, Northrup J, Cao D, Taylor K, et al</AU>
<TI>Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial</TI>
<SO>Lancet</SO>
<YR>2010</YR>
<VL>375</VL>
<PG>2234-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-E-_x002d_-Drucker-2008" MODIFIED="2011-06-21 10:18:46 +0200" MODIFIED_BY="[Empty name]" NAME="E - Drucker 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-06-21 10:18:24 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Best JH, Boye KS, Rubin RR, Cao D, Kim TH, Peyrot M</AU>
<TI>Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily</TI>
<SO>Diabetic Medicine</SO>
<YR>2009</YR>
<VL>26</VL>
<NO>7</NO>
<PG>722-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-10-09 11:34:35 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Best JH, Rubin RR, Zhuang D, Velez F, Kim T, Peyrot M</AU>
<TI>Higher diabetes treatment satisfaction associated with improved glucose control for both exenatide once weekly and twice daily</TI>
<SO>Diabetes</SO>
<YR>2008</YR>
<VL>57</VL>
<PG>A520</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-06-21 10:18:46 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, et al</AU>
<TI>Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.[see comment]</TI>
<SO>Lancet</SO>
<YR>2008</YR>
<VL>372</VL>
<NO>9645</NO>
<PG>1240-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lixi-_x002d_-Ratner-2010" MODIFIED="2011-06-21 10:42:59 +0200" MODIFIED_BY="[Empty name]" NAME="Lixi - Ratner 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-06-21 10:42:59 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ratner RE, Rosenstock J, Boka G; DRI6012 Study Investigators</AU>
<TI>Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial</TI>
<SO>Diabetic Medicine</SO>
<YR>2010</YR>
<VL>27</VL>
<NO>9</NO>
<PG>1024-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-L-_x002d_-Kaku-2010" MODIFIED="2011-06-21 10:19:35 +0200" MODIFIED_BY="[Empty name]" NAME="L - Kaku 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-06-21 10:19:35 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaku K, Rasmussen MF, Clauson P, Seino Y</AU>
<TI>Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes</TI>
<SO>Diabetes Obesity and Metabolism</SO>
<YR>2010</YR>
<VL>12</VL>
<PG>341-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-L-_x002d_-LEAD-1-Marre-2009" MODIFIED="2011-06-21 10:21:04 +0200" MODIFIED_BY="[Empty name]" NAME="L - LEAD 1 Marre 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-06-21 10:21:04 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marre M, Shaw J, Brändle M, Bebakar WMW, Kamaruddin NA, Strand J, et al</AU>
<TI>Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU)</TI>
<SO>Diabetic Medicine</SO>
<YR>2009</YR>
<VL>26</VL>
<PG>268-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-L-_x002d_-LEAD-2-Nauck-2009" MODIFIED="2009-11-15 11:10:07 +0100" MODIFIED_BY="[Empty name]" NAME="L - LEAD 2 Nauck 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-11-15 11:10:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, et al</AU>
<TI>Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study</TI>
<SO>Diabetes Care</SO>
<YR>2009</YR>
<VL>32</VL>
<NO>1</NO>
<PG>84-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-09-17 14:36:09 +0200" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-L-_x002d_-LEAD-4-Zinman-2009" MODIFIED="2011-06-21 10:21:32 +0200" MODIFIED_BY="[Empty name]" NAME="L - LEAD 4 Zinman 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-06-21 10:21:32 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, et al</AU>
<TI>Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD)</TI>
<SO>Diabetes Care</SO>
<YR>2009</YR>
<VL>32</VL>
<NO>7</NO>
<PG>1224-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009" MODIFIED="2011-06-21 10:21:48 +0200" MODIFIED_BY="[Empty name]" NAME="L - LEAD 5 Russell-J 2009" YEAR="2008">
<REFERENCE MODIFIED="2011-06-21 10:21:48 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, et al</AU>
<TI>Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial</TI>
<SO>Diabetologia</SO>
<YR>2009</YR>
<VL>52</VL>
<PG>2046-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-L-_x002d_-LEAD-6-Buse-2009" MODIFIED="2011-06-28 15:51:14 +0200" MODIFIED_BY="[Empty name]" NAME="L - LEAD 6 Buse 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-06-28 15:51:14 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Buse J, Sesti G, Schmidt WE, Montanya E, Chang CT, Xu Y, et al</AU>
<TI>Switching from twice-daily exenatide to once-daily liraglutide improves glycemic control in T2D on oral agents</TI>
<SO>American Diabetes Association</SO>
<YR>2009</YR>
<PG>591-P</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-15 11:10:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al</AU>
<TI>Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).[see comment]</TI>
<SO>Lancet</SO>
<YR>2009</YR>
<VL>374</VL>
<NO>9683</NO>
<PG>39-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-L-_x002d_-Pratley-2010" MODIFIED="2011-06-21 10:22:54 +0200" MODIFIED_BY="[Empty name]" NAME="L - Pratley 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-06-21 10:22:54 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, et al</AU>
<TI>Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial</TI>
<SO>Lancet</SO>
<YR>2010</YR>
<VL>375</VL>
<PG>1447-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-LY2189265-_x002d_Umpierrez-2011" MODIFIED="2011-06-21 11:36:47 +0200" MODIFIED_BY="[Empty name]" NAME="LY2189265 -Umpierrez 2011" YEAR="2011">
<REFERENCE MODIFIED="2011-06-21 11:36:47 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Umpierrez GE, Blevins T, Rosenstock J, Cheng C, Anderson JH, Bastyr EJ 3rd; EGO Study Group.</AU>
<TI>The effects of LY2189265, a long-acting glucagon-like peptide-1 analog, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study</TI>
<SO>Diabetes, Obesity and Metabolism</SO>
<YR>Jan 2011</YR>
<VL>13</VL>
<PG>418-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-L-_x002d_-Yang-2010" MODIFIED="2011-06-21 11:36:35 +0200" MODIFIED_BY="[Empty name]" NAME="L - Yang 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-06-21 11:36:35 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang W, Chen L, Ji Q, Liu X, Ma J, Tandon N, et al</AU>
<TI>Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial</TI>
<SO>Diabetes, Obesity and Metabolism</SO>
<YR>Jan 2011</YR>
<VL>13</VL>
<NO>1</NO>
<PG>81-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-T-_x002d_-Nauck-2009" MODIFIED="2011-06-21 10:35:28 +0200" MODIFIED_BY="[Empty name]" NAME="T - Nauck 2009" YEAR="">
<REFERENCE MODIFIED="2011-06-21 10:35:28 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nauck MA, Ratner RE, Kapitza C, Berria R, Boldrin M, Balena R</AU>
<TI>Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study</TI>
<SO>Diabetes Care</SO>
<YR>2009</YR>
<VL>32</VL>
<NO>7</NO>
<PG>1237-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-T_x002d_-Ratner-2010" MODIFIED="2011-06-21 10:36:03 +0200" MODIFIED_BY="[Empty name]" NAME="T- Ratner 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-06-21 10:36:03 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ratner R, Nauck M, Kapitza C, Asnaghi V, Boldrin M, Balena R</AU>
<TI>Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study</TI>
<SO>Diabetic Medicine</SO>
<YR>2010</YR>
<VL>27</VL>
<PG>556-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2011-06-21 10:59:40 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Astrup-2009" MODIFIED="2011-06-21 10:36:41 +0200" MODIFIED_BY="[Empty name]" NAME="Astrup 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-06-21 10:36:41 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Astrup A, Rossner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, et al; NN8022-1807 Study Group</AU>
<TI>Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study</TI>
<SO>Lancet</SO>
<YR>2009 Nov 7</YR>
<VL>374</VL>
<PG>1606-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barnett-2007" MODIFIED="2011-06-21 10:37:21 +0200" MODIFIED_BY="[Empty name]" NAME="Barnett 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-06-21 10:37:02 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, et al</AU>
<TI>Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial</TI>
<SO>Clinical Therapeutics</SO>
<YR>2007</YR>
<VL>29</VL>
<PG>2333-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-06-21 10:37:21 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Secnik K, Hayes C, Matza L, Kim S, Oglesby A, Yurgin N, et al</AU>
<TI>Improved treatment satisfaction in patients with type-2 diabetes treated with exenatide or insulin glargine</TI>
<SO>Value in Health</SO>
<YR>2005</YR>
<VL>8</VL>
<PG>A155-A156</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-06 10:50:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trautmann M, Burger J, Johns D, Brodows R, Okerson T, Roberts A, et al</AU>
<TI>Less hypoglycemia with exenatide versus insulin glargine, despite similar Hba(1c) improvement, in patients with T2dm adjunctively treated with metformin</TI>
<SO>Diabetes</SO>
<YR>2007</YR>
<VL>56</VL>
<PG>A45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-06 10:51:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trautmann M, Burger J, Johns D, Brodows R, Okerson T, Roberts A, et al</AU>
<TI>Relationship between hypoglycaemia, background oral antidiabetic agent, and glycaemic control in patients treated with exenatide or insulin glargine</TI>
<SO>Diabetologia</SO>
<YR>2007</YR>
<VL>50</VL>
<PG>S338</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blonde-2006" MODIFIED="2011-06-21 10:39:15 +0200" MODIFIED_BY="[Empty name]" NAME="Blonde 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-06-21 10:39:15 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, et al</AU>
<TI>Interim analysis of the effects of exenatide treatment on A1C,weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes</TI>
<SO>Diabetes, Obesity and Metabolism</SO>
<YR>2006</YR>
<VL>8</VL>
<PG>436-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bode-2010" MODIFIED="2011-06-21 10:39:39 +0200" MODIFIED_BY="[Empty name]" NAME="Bode 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-06-21 10:39:39 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bode BW, Testa MA, Magwire M, Hale PM, Hammer M, Blonde L, et al; LEAD-3 Study Group</AU>
<TI>Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes</TI>
<SO>Diabetes Obesity and Metabolism</SO>
<YR>2010 Jul</YR>
<VL>12</VL>
<NO>7</NO>
<PG>604-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brixner-2009" MODIFIED="2011-06-21 10:40:11 +0200" MODIFIED_BY="[Empty name]" NAME="Brixner 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-06-21 10:40:11 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brixner DI, McAdam-Marx C, Ye X, Boye KS, Nielsen LL, Wintle M, et al</AU>
<TI>Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting</TI>
<SO>Diabetes Obesity and Metabolism</SO>
<YR>2009 Dec</YR>
<VL>11</VL>
<NO>12</NO>
<PG>1122-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buse-2004" MODIFIED="2011-06-21 10:45:03 +0200" MODIFIED_BY="[Empty name]" NAME="Buse 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-06-21 10:45:03 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD</AU>
<TI>Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2004</YR>
<VL>27</VL>
<NO>11</NO>
<PG>2628-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feingloss-2005" MODIFIED="2011-06-21 10:45:45 +0200" MODIFIED_BY="[Empty name]" NAME="Feingloss 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-06-21 10:45:45 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O; Liraglutide Dose-Response Study Group</AU>
<TI>Effects of liraglutide (NN2211), a long-acting GLP-1analogue, on glycaemic control and bodyweight in subjects with type 2 diabetes</TI>
<SO>Diabetic Medicine</SO>
<YR>2005</YR>
<VL>22</VL>
<PG>1016-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gallwitz-2010" MODIFIED="2011-06-21 10:46:42 +0200" MODIFIED_BY="[Empty name]" NAME="Gallwitz 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-06-21 10:46:42 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallwitz B, Vaag A, Falahati A, Madsbad S</AU>
<TI>Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time</TI>
<SO>International Journal of Clinical Practice</SO>
<YR>2010 Jan</YR>
<VL>64</VL>
<NO>2</NO>
<PG>267-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garber-2009-_x0028_LEAD-3_x0029_" MODIFIED="2009-11-15 11:14:27 +0100" MODIFIED_BY="[Empty name]" NAME="Garber 2009 (LEAD 3)" YEAR="2009">
<REFERENCE MODIFIED="2009-11-15 11:14:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, et al</AU>
<TI>Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.[see comment]</TI>
<SO>Lancet</SO>
<YR>2009</YR>
<VL>373</VL>
<NO>9662</NO>
<PG>473-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kapitza-2009" MODIFIED="2011-06-21 10:51:55 +0200" MODIFIED_BY="[Empty name]" NAME="Kapitza 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-06-21 10:51:55 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kapitza C, Heise T, Birman P, Jallet K, Ramis J, Balena R</AU>
<TI>Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes</TI>
<SO>Diabetic Medicine</SO>
<YR>2009 Nov</YR>
<VL>26</VL>
<NO>11</NO>
<PG>1156-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2007" MODIFIED="2009-11-06 10:55:33 +0100" MODIFIED_BY="[Empty name]" NAME="Kim 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-11-06 10:55:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, et al</AU>
<TI>Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2007</YR>
<VL>30</VL>
<PG>1487-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Madsbad-2004" MODIFIED="2011-06-21 10:53:01 +0200" MODIFIED_BY="[Empty name]" NAME="Madsbad 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-06-21 10:53:01 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR; NN2211-1310 International study group</AU>
<TI>Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211)</TI>
<SO>Diabetes Care</SO>
<YR>2004</YR>
<VL>27</VL>
<PG>1335-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malloy-2009" MODIFIED="2011-06-21 10:53:35 +0200" MODIFIED_BY="[Empty name]" NAME="Malloy 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-06-21 10:53:35 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malloy J, Capparelli E, Gottschalk M, Guan X, Kothare P, Fineman M</AU>
<TI>Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study</TI>
<SO>Clinical Therapeutics</SO>
<YR>2009 Apr</YR>
<VL>31</VL>
<NO>4</NO>
<PG>806-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moretto-2008" MODIFIED="2011-06-21 10:54:08 +0200" MODIFIED_BY="[Empty name]" NAME="Moretto 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-06-21 10:54:08 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, et al</AU>
<TI>Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study</TI>
<SO>Clinical Therapeutics</SO>
<YR>2008</YR>
<VL>30</VL>
<PG>1448-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nauck-2009" MODIFIED="2011-06-21 10:54:23 +0200" MODIFIED_BY="[Empty name]" NAME="Nauck 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-06-21 10:54:23 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harder H, Nielsen L, Thi TDT, Astrup A</AU>
<TI>The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2004</YR>
<VL>27</VL>
<PG>1915-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-15 11:21:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nauck M, Marre M.</AU>
<TI>Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits</TI>
<SO>Postgraduate Medicine</SO>
<YR>2009</YR>
<VL>121</VL>
<NO>3</NO>
<PG>5-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Okerson-2010" MODIFIED="2011-06-21 10:57:25 +0200" MODIFIED_BY="[Empty name]" NAME="Okerson 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-06-21 10:57:25 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Okerson T, Yan P, Stonehouse A, Brodows R</AU>
<TI>Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes</TI>
<SO>American Journal of Hypertension</SO>
<YR>2010 Mar</YR>
<VL>23</VL>
<NO>3</NO>
<PG>334-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Riddle-2006" MODIFIED="2011-06-21 10:57:48 +0200" MODIFIED_BY="[Empty name]" NAME="Riddle 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-06-21 10:57:48 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riddle MC, Henry RR, Poon TH, Zhang B, Mac MS, John HH, et al</AU>
<TI>Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin</TI>
<SO>Diabetes/Metabolism Research and Reviews</SO>
<YR>2006</YR>
<VL>22</VL>
<PG>483-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seino-2008" MODIFIED="2011-06-21 10:57:59 +0200" MODIFIED_BY="[Empty name]" NAME="Seino 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-06-21 10:57:59 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Seino Y, Rasmussen MF, Zdravkovic M, Kaku K</AU>
<TI>Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes</TI>
<SO>Diabetes Research and Clinical Practice</SO>
<YR>2008</YR>
<VL>81</VL>
<NO>2</NO>
<PG>161-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trescoli_x002d_Serrano-2005" MODIFIED="2009-11-06 11:02:46 +0100" MODIFIED_BY="[Empty name]" NAME="Trescoli-Serrano 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-11-06 11:02:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trescoli-Serrano C, Rivas M, Fajardo-Montanana C, Del Pino I, Garcia-Zarco M, Martorrell-Barraquet A, et al</AU>
<TI>Clinical site experience comparing insulin glargine with exenatide treatment in type 2 diabetic patients</TI>
<SO>Diabetologia</SO>
<YR>2005</YR>
<VL>48</VL>
<PG>A3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vilsboll-2007" MODIFIED="2011-06-21 10:59:40 +0200" MODIFIED_BY="[Empty name]" NAME="Vilsboll 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-06-21 10:58:24 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Courreges JP, Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, et al</AU>
<TI>Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes</TI>
<SO>Diabetic Medicine</SO>
<YR>2008</YR>
<VL>25</VL>
<NO>9</NO>
<PG>1129-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-06-21 10:59:01 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horowitz M</AU>
<TI>Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide</TI>
<SO>Diabetes, Obesity and Metabolism</SO>
<YR>2008</YR>
<VL>10</VL>
<PG>593-02</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-10-09 13:23:25 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Valentine WJ, Hammer M, Palmer AJ, Ray JA</AU>
<TI>Projecting the long-term clinical benefits of treatment with the GLP-1 analogue liraglutide in subjects with type 2 diabetes</TI>
<SO>Diabetes</SO>
<YR>2007</YR>
<VL>56</VL>
<PG>A568</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-06-21 10:59:19 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vilsboll T, Brock B, Perrild H, Levin K, Lervang HH, Kolendorf K, et al</AU>
<TI>Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus</TI>
<SO>Diabetic Medicine</SO>
<YR>2008</YR>
<VL>25</VL>
<NO>2</NO>
<PG>152-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-06-21 10:59:40 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courreges JP, et al</AU>
<TI>Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2007</YR>
<VL>30</VL>
<PG>1608-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2010-01-15 11:02:13 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2011-08-30 09:24:05 +0200" MODIFIED_BY="Bernd Richter">
<STUDY DATA_SOURCE="PUB" ID="STD-Albiglutide-NCT00838903" MODIFIED="2011-06-24 15:45:57 +0200" MODIFIED_BY="[Empty name]" NAME="Albiglutide NCT00838903" YEAR="8903">
<REFERENCE MODIFIED="2011-06-24 15:45:57 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00838903</AU>
<TI>Efficacy and safety of albiglutide in treatment of type 2 diabetes</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00838903</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Albiglutide-NCT00838916" MODIFIED="2011-06-24 16:02:34 +0200" MODIFIED_BY="[Empty name]" NAME="Albiglutide NCT00838916" YEAR="8916">
<REFERENCE MODIFIED="2011-06-24 16:02:34 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00838916</AU>
<TI>A study to determine the safety and efficacy of albiglutide in patients with type 2 diabetes</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00838916</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Albiglutide-NCT00849017" MODIFIED="2011-06-24 16:09:48 +0200" MODIFIED_BY="[Empty name]" NAME="Albiglutide NCT00849017" YEAR="9017">
<REFERENCE MODIFIED="2011-06-24 16:09:44 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00849017</AU>
<TI>Safety and efficacy study of albiglutide in type 2 diabetes</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00849017</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Albiglutide-NCT00849056" MODIFIED="2011-06-24 15:55:53 +0200" MODIFIED_BY="[Empty name]" NAME="Albiglutide NCT00849056" YEAR="9056">
<REFERENCE MODIFIED="2011-06-24 15:55:47 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00849056</AU>
<TI>Safety and efficacy of albiglutide in type 2 diabetes</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00849056</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Albiglutide-NCT01098461" MODIFIED="2011-06-24 16:16:08 +0200" MODIFIED_BY="[Empty name]" NAME="Albiglutide NCT01098461" YEAR="8461">
<REFERENCE MODIFIED="2011-06-24 16:16:07 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01098461</AU>
<TI>Dose ranging study of albiglutide in Japanese subjects</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT01098461</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Albiglutide-NCT01128894" MODIFIED="2011-06-21 11:28:28 +0200" MODIFIED_BY="[Empty name]" NAME="Albiglutide NCT01128894" YEAR="8894">
<REFERENCE MODIFIED="2011-06-21 11:28:28 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01128894</AU>
<TI>A study to determine the efficacy and safety of albiglutide as compared with liraglutide.</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT01128894</SO>
<YR>accessed 17 June 2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Exenatide-QW-NCT00641056" MODIFIED="2011-06-24 14:29:34 +0200" MODIFIED_BY="[Empty name]" NAME="Exenatide QW NCT00641056" YEAR="1056">
<REFERENCE MODIFIED="2011-06-24 14:29:28 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00641056</AU>
<TI>Efficacy of exenatide once weekly and once-daily insulin glargine in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylurea (DURATION - 3)</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00641056</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Exenatide-QW-NCT00917267" MODIFIED="2011-06-24 15:20:26 +0200" MODIFIED_BY="[Empty name]" NAME="Exenatide QW NCT00917267" YEAR="7267">
<REFERENCE MODIFIED="2011-06-24 15:20:22 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00917267</AU>
<TI>A study to examine the effects of exenatide once-weekly injection on glucose control and safety in Asian subjects</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00917267</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Exenatide-QW-NCT00935532" MODIFIED="2011-06-24 15:31:29 +0200" MODIFIED_BY="[Empty name]" NAME="Exenatide QW NCT00935532" YEAR="5532">
<REFERENCE MODIFIED="2011-06-24 15:31:29 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00935532</AU>
<TI>Study to evaluate the efficacy and safety of exenatide once-weekly injection compared to once-daily insulin in type 2 diabetes mellitus</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00935532</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Exenatide-QW-NCT01003184" MODIFIED="2011-06-24 14:50:57 +0200" MODIFIED_BY="[Empty name]" NAME="Exenatide QW NCT01003184" YEAR="3184">
<REFERENCE MODIFIED="2011-06-24 14:50:48 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01003184</AU>
<TI>Efficacy of once-weekly exenatide versus once or twice daily insulin detemir in patients with type 2 diabetes</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT01003184</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Exenatide-QW-NCT01029886" MODIFIED="2011-06-21 11:30:43 +0200" MODIFIED_BY="[Empty name]" NAME="Exenatide QW NCT01029886" YEAR="9886">
<REFERENCE MODIFIED="2011-06-21 11:30:43 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01029886</AU>
<TI>Safety and efficacy of exenatide once weekly versus liraglutide in subjects with type 2 diabetes</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT01029886</SO>
<YR>accessed 17 June 2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Exenatide-QW-NCT01144338" MODIFIED="2011-06-24 15:03:09 +0200" MODIFIED_BY="[Empty name]" NAME="Exenatide QW NCT01144338" YEAR="4338">
<REFERENCE MODIFIED="2011-06-24 15:03:00 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01144338</AU>
<TI>Exenatide study of cardiovascular event lowering trial (EXSCEL): a trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT01144338</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liraglutide-NCT00856986" MODIFIED="2011-06-21 11:06:27 +0200" MODIFIED_BY="[Empty name]" NAME="Liraglutide NCT00856986" YEAR="2009">
<REFERENCE MODIFIED="2011-06-21 11:06:27 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00856986</AU>
<TI>The effect of insulin detemir in combination with liraglutide and metformin compared to liraglutide and metformin in subjects with type 2 diabetes</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00856986</SO>
<YR>accessed 17 June 2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liraglutide-NCT01117350" MODIFIED="2011-06-21 11:30:55 +0200" MODIFIED_BY="[Empty name]" NAME="Liraglutide NCT01117350" YEAR="7350">
<REFERENCE MODIFIED="2011-06-21 11:30:55 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01117350</AU>
<TI>Efficacy assessment of insulin glargine versus liraglutide after oral agent failure (EAGLE)</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT01117350</SO>
<YR>accessed 17 June 2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liraglutide-NCT01296412" MODIFIED="2011-06-21 11:31:04 +0200" MODIFIED_BY="[Empty name]" NAME="Liraglutide NCT01296412" YEAR="6412">
<REFERENCE MODIFIED="2011-06-21 11:31:04 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01296412</AU>
<TI>Comparison of two treatment regimens (sitagliptin versus liraglutide) on participants who failed to achieve good glucose control on metformin alone (MK-0431-403)</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT01296412</SO>
<YR>accessed 17 June 2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liraglutide-NCT01336023" MODIFIED="2011-06-21 11:31:16 +0200" MODIFIED_BY="[Empty name]" NAME="Liraglutide NCT01336023" YEAR="6023">
<REFERENCE MODIFIED="2011-06-21 11:31:16 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01336023</AU>
<TI>Dual action of liraglutide and insulin degludec in type 2 diabetes: a trial comparing the efficacy and safety of insulin degludec/liraglutide, insulin degludec and liraglutide in subjects with type 2 diabetes (DUAL&#8482; I)</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT01336023</SO>
<YR>accessed 17 June 2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lixisenatide-NCT00707031" MODIFIED="2011-06-21 11:31:23 +0200" MODIFIED_BY="[Empty name]" NAME="Lixisenatide NCT00707031" YEAR="7031">
<REFERENCE MODIFIED="2011-06-21 11:31:23 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00707031</AU>
<TI>GLP-1 agonist AVE0010 versus exenatide in patients with type 2 diabetes for glycemic control and safety evaluation, on top of metformin (GETGOAL-X)</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00707031</SO>
<YR>accessed 17 June 2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lixisenatide-NCT00713830" MODIFIED="2011-06-21 11:31:29 +0200" MODIFIED_BY="[Empty name]" NAME="Lixisenatide NCT00713830" YEAR="3830">
<REFERENCE MODIFIED="2011-06-21 11:31:29 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00713830</AU>
<TI>GLP-1 agonist AVE0010 in patients with type 2 diabetes for glycemic control and safety evaluation, on top of sulfonylurea (GETGOAL-S)</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00713830</SO>
<YR>accessed 17 June 2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lixisenatide-NCT00763815" MODIFIED="2011-06-21 11:31:36 +0200" MODIFIED_BY="[Empty name]" NAME="Lixisenatide NCT00763815" YEAR="3815">
<REFERENCE MODIFIED="2011-06-21 11:31:36 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00763815</AU>
<TI>GLP-1 agonist AVE0010 in patients with type 2 diabetes for glycemic control and safety evaluation, on top of pioglitazone (GETGOAL-P)</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00763815</SO>
<YR>accessed 17 June 2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lixisenatide-NCT00975286" MODIFIED="2011-08-30 09:24:05 +0200" MODIFIED_BY="Bernd Richter" NAME="Lixisenatide NCT00975286" YEAR="">
<REFERENCE MODIFIED="2011-06-21 11:29:33 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00975286</AU>
<TI>24-week treatment with lixisenatide in type 2 diabetes insufficiently controlled with metformin and insulin glargine</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00975286</SO>
<YR>accessed 17 June 2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lixisenatide-NCT00976937" MODIFIED="2011-06-21 11:08:59 +0200" MODIFIED_BY="[Empty name]" NAME="Lixisenatide NCT00976937" YEAR="">
<REFERENCE MODIFIED="2011-06-21 11:08:59 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00976937</AU>
<TI>24-week study comparing lixisenatide to sitagliptin as add-on to metformin in obese type 2 diabetic patients younger than 50</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00976937</SO>
<YR>accessed 17 June 2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Semaglutide-NCT00696657" MODIFIED="2011-06-21 11:31:59 +0200" MODIFIED_BY="[Empty name]" NAME="Semaglutide NCT00696657" YEAR="6657">
<REFERENCE MODIFIED="2011-06-21 11:31:59 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00696657</AU>
<TI>A randomised controlled clinical trial in type 2 diabetes comparing semaglutide to placebo and liraglutide</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00696657</SO>
<YR>accessed 17 June 2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taspoglutide-NCT00717457" MODIFIED="2011-06-21 11:10:36 +0200" MODIFIED_BY="[Empty name]" NAME="Taspoglutide NCT00717457" YEAR="2009">
<REFERENCE MODIFIED="2011-06-21 11:10:36 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00717457</AU>
<TI>A study of taspoglutide versus exenatide for the treatment of patients with type 2 diabetes mellitus inadequately controlled with metformin, thiazolidinedione or a combination of both</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00717457</SO>
<YR>accessed 17 June 2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taspoglutide-NCT00744367" MODIFIED="2011-06-21 11:11:22 +0200" MODIFIED_BY="[Empty name]" NAME="Taspoglutide NCT00744367" YEAR="2008">
<REFERENCE MODIFIED="2011-06-21 11:11:22 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00744367</AU>
<TI>A study of taspoglutide versus placebo for the treatment of patients with type 2 diabetes mellitus inadequately controlled with metformin plus pioglitazone</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00744367</SO>
<YR>accessed 17 June 2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taspoglutide-NCT00754988" MODIFIED="2011-06-21 11:11:35 +0200" MODIFIED_BY="[Empty name]" NAME="Taspoglutide NCT00754988" YEAR="2009">
<REFERENCE MODIFIED="2011-06-21 11:11:35 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00754988</AU>
<TI>A study of taspoglutide versus sitagliptin for the treatment of patients with type 2 diabetes mellitus inadequately controlled with metformin</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00754988</SO>
<YR>accessed 17 June 2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taspoglutide-NCT00755287" MODIFIED="2011-06-21 11:11:57 +0200" MODIFIED_BY="[Empty name]" NAME="Taspoglutide NCT00755287" YEAR="2009">
<REFERENCE MODIFIED="2011-06-21 11:11:57 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00755287</AU>
<TI>A study of the safety, tolerability and effect on glycemic control of taspoglutide versus insulin glargine in insulin naive type 2 diabetic patients inadequately controlled with metformin plus sulphonylurea</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00755287</SO>
<YR>accessed 17 June 2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taspoglutide-NCT00823992" MODIFIED="2011-06-21 11:12:11 +0200" MODIFIED_BY="[Empty name]" NAME="Taspoglutide NCT00823992" YEAR="2009">
<REFERENCE MODIFIED="2011-06-21 11:12:11 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00823992</AU>
<TI>A study of taspoglutide versus placebo for the treatment of obese patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00823992</SO>
<YR>accessed 17 June 2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taspoglutide-NCT00909597" MODIFIED="2011-06-21 11:12:33 +0200" MODIFIED_BY="[Empty name]" NAME="Taspoglutide NCT00909597" YEAR="2009">
<REFERENCE MODIFIED="2011-06-21 11:12:33 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00909597</AU>
<TI>A study of taspoglutide versus pioglitazone in patients with type 2 diabetes</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00909597</SO>
<YR>accessed 17 June 2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-01-15 16:04:49 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-08-30 12:25:20 +0200" MODIFIED_BY="Bernd Richter">
<ADDITIONAL_REFERENCES MODIFIED="2011-08-30 12:25:20 +0200" MODIFIED_BY="Bernd Richter">
<REFERENCE ID="REF-Abraham-2002" MODIFIED="2011-06-21 11:13:15 +0200" MODIFIED_BY="[Empty name]" NAME="Abraham 2002" TYPE="JOURNAL_ARTICLE">
<AU>Abraham EJ, Leech CA, Lin JC, Zulewski H, Habener JF</AU>
<TI>Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells</TI>
<SO>Endocrinology</SO>
<YR>2002</YR>
<VL>143</VL>
<NO>8</NO>
<PG>3152-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ADA-1997" MODIFIED="2009-12-23 19:25:31 +0100" MODIFIED_BY="[Empty name]" NAME="ADA 1997" TYPE="JOURNAL_ARTICLE">
<AU>American Diabetes Association</AU>
<TI>Report on the Expert Committee on the Diagnosis and Classication of Diabetes Mellitus</TI>
<SO>Diabetes Care</SO>
<YR>1997</YR>
<VL>20</VL>
<NO>Suppl 1</NO>
<PG>S5-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ADA-1999" MODIFIED="2009-12-23 19:26:39 +0100" MODIFIED_BY="[Empty name]" NAME="ADA 1999" TYPE="JOURNAL_ARTICLE">
<AU>The Expert Committee on the Diagnosis and Classication of Diabetes Mellitus</AU>
<TI>Report of the Expert Committee on the diagnosis and classification of diabetes mellitus</TI>
<SO>Diabetes Care</SO>
<YR>1999</YR>
<VL>22</VL>
<NO>Suppl 1</NO>
<PG>S5-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Amori-2007" MODIFIED="2011-06-24 10:03:43 +0200" MODIFIED_BY="[Empty name]" NAME="Amori 2007" TYPE="JOURNAL_ARTICLE">
<AU>Amori RE, Lau J, Pittas, AG</AU>
<TI>Efficacy and safety of incretin therapy in type 2 diabetes</TI>
<SO>Journal of the American Medical Association</SO>
<YR>2007</YR>
<VL>298</VL>
<NO>2</NO>
<PG>194-206</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baggio-2004" MODIFIED="2011-06-21 11:13:58 +0200" MODIFIED_BY="[Empty name]" NAME="Baggio 2004" TYPE="JOURNAL_ARTICLE">
<AU>Baggio LL,Huang Q, Brown TJ,Drucker DJ</AU>
<TI>A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis</TI>
<SO>Diabetes</SO>
<YR>2004</YR>
<VL>53</VL>
<NO>9</NO>
<PG>2492-500</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barnett-2009" MODIFIED="2011-06-21 11:14:06 +0200" MODIFIED_BY="[Empty name]" NAME="Barnett 2009" TYPE="JOURNAL_ARTICLE">
<AU>Barnett AH</AU>
<TI>New treatments in type 2 diabetes: a focus on the incretin-based therapies</TI>
<SO>Clinical Endocrinology</SO>
<YR>2009</YR>
<VL>70</VL>
<PG>343-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Butler-2010" MODIFIED="2010-01-13 13:47:56 +0100" MODIFIED_BY="[Empty name]" NAME="Butler 2010" TYPE="JOURNAL_ARTICLE">
<AU>Butler PC, Matveyenko AV, Dry S, Bhushan A, Elashoff R</AU>
<TI>Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?</TI>
<SO>Diabetologia</SO>
<YR>2010</YR>
<VL>53</VL>
<PG>1-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dore-2011" MODIFIED="2011-06-21 11:32:48 +0200" MODIFIED_BY="[Empty name]" NAME="Dore 2011" TYPE="JOURNAL_ARTICLE">
<AU>Dore DD, Bloomgren GL, Wenten M, Hoffman C, Clifford CR, Quinn SG, et al</AU>
<TI>A cohort study of acute pancreatitis in relation to exenatide use</TI>
<SO>Diabetes, Obesity and Metabolism</SO>
<YR>Jun 2011</YR>
<VL>13</VL>
<NO>6</NO>
<PG>559-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EMEA-2009" MODIFIED="2011-06-21 11:16:56 +0200" MODIFIED_BY="[Empty name]" NAME="EMEA 2009" TYPE="OTHER">
<AU>EMEA</AU>
<TI>Assessment report for Victoza (liraglutide)</TI>
<SO>http://www.emea.europa.eu/humandocs/PDFs/EPAR/victoza/H-1026-en6.pdf</SO>
<YR>accessed 10 March 2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Farilla-2003" MODIFIED="2011-06-21 11:17:08 +0200" MODIFIED_BY="[Empty name]" NAME="Farilla 2003" TYPE="JOURNAL_ARTICLE">
<AU>Farilla L, Bulotta A, Hirshberg B, Li CS, Khoury N, Noushmehr H, et al</AU>
<TI>Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets.[see comment]</TI>
<SO>Endocrinology</SO>
<YR>2003</YR>
<VL>144</VL>
<NO>12</NO>
<PG>5149-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-FDA-2008" MODIFIED="2011-06-21 11:32:54 +0200" MODIFIED_BY="[Empty name]" NAME="FDA 2008" TYPE="OTHER">
<AU>FDA</AU>
<TI>Information for Healthcare Professionals: Exenatide (marketed as Byetta)</TI>
<SO>http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm</SO>
<YR>accessed 10 March 2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-FDA-2009" MODIFIED="2011-06-21 11:18:49 +0200" MODIFIED_BY="[Empty name]" NAME="FDA 2009" TYPE="OTHER">
<AU>FDA</AU>
<TI>Byetta (exenatide) prescribing information</TI>
<SO>http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021773s9s11s18s22s25lbl.pdf</SO>
<YR>accessed 10 March 2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-FDA-2009-_x0028_kidney-function_x0029_" MODIFIED="2011-06-21 11:32:59 +0200" MODIFIED_BY="[Empty name]" NAME="FDA 2009 (kidney function)" TYPE="OTHER">
<AU>FDA</AU>
<TI>Information for Healthcare Professionals: Reports of Altered Kidney Function in patients using Exenatide (Marketed as Byetta)</TI>
<SO>http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm188656.htm</SO>
<YR>accessed 10 March 2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-FDA-2009-_x0028_safety-update_x0029_" MODIFIED="2011-06-21 11:33:04 +0200" MODIFIED_BY="[Empty name]" NAME="FDA 2009 (safety update)" TYPE="OTHER">
<AU>FDA</AU>
<TI>Byetta Safety Update for Healthcare Professionals</TI>
<SO>http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm190406.htm</SO>
<YR>accessed 10 March 2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Girman-2010" MODIFIED="2011-06-21 11:33:10 +0200" MODIFIED_BY="[Empty name]" NAME="Girman 2010" TYPE="JOURNAL_ARTICLE">
<AU>Girman CJ, Kou TD, Cai B, Alexander CM, O'Neill EA, Williams-Herman DE, et al</AU>
<TI>Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes</TI>
<SO>Diabetes Obesity and Metabolism</SO>
<YR>Sep 2010</YR>
<VL>12</VL>
<NO>9</NO>
<PG>766-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" MODIFIED="2011-08-30 12:25:20 +0200" MODIFIED_BY="Bernd Richter" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>1539-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2011-08-30 12:25:20 +0200" MODIFIED_BY="Bernd Richter" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analysis</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2011-08-30 12:25:20 +0200" MODIFIED_BY="Bernd Richter" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</TI>
<SO>The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Journal-Watch-2011" MODIFIED="2011-06-21 11:33:16 +0200" MODIFIED_BY="[Empty name]" NAME="Journal Watch 2011" TYPE="OTHER">
<AU>Journal Watch</AU>
<TI>FDA Reminds Clinicians of Liraglutide's Risks for Pancreatitis and Cancer</TI>
<SO>http://firstwatch.jwatch.org/cgi/content/full/2011/614/2?q=topic_diabetes</SO>
<YR>accessed 17 June 2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kaku-2010" MODIFIED="2011-06-21 11:21:10 +0200" MODIFIED_BY="[Empty name]" NAME="Kaku 2010" TYPE="JOURNAL_ARTICLE">
<AU>Kaku K, Rasmussen MF, Clauson P, Seino Y</AU>
<TI>Improved glycaemic control with minimal hypoglycaemiaand no weight change with the once-daily humanglucagon-like peptide-1 analogue liraglutide as add-onto sulphonylurea in Japanese patients with type 2 diabetes</TI>
<SO>Diabetes, Obesity and Metabolism</SO>
<YR>2010</YR>
<VL>12</VL>
<PG>341&#8211;7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Li-2003" MODIFIED="2011-06-21 11:21:28 +0200" MODIFIED_BY="[Empty name]" NAME="Li 2003" TYPE="JOURNAL_ARTICLE">
<AU>Li Y, Hansotia T, Yusta B, Ris F, Halban PA,Drucker DJ</AU>
<TI>Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis</TI>
<SO>The Journal of Biological Chemistry</SO>
<YR>2003</YR>
<VL>278</VL>
<NO>1</NO>
<PG>471-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Loh-and-Clement-2007" MODIFIED="2010-02-16 15:42:27 +0100" MODIFIED_BY="[Empty name]" NAME="Loh and Clement 2007" TYPE="JOURNAL_ARTICLE">
<AU>Loh JA, Clement SC</AU>
<TI>Efficacy of exenatide therapy over 12 months in a "real world" setting</TI>
<SO>Diabetes</SO>
<YR>2007</YR>
<VL>56</VL>
<PG>A152</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2009" MODIFIED="2011-06-21 11:22:04 +0200" MODIFIED_BY="[Empty name]" NAME="Moher 2009" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA group</AU>
<TI>Preferred reporting items for systematic reviews and meta-analysis: the PRISMA statement</TI>
<SO>British Medical Journal</SO>
<YR>2009</YR>
<VL>339</VL>
<PG>b2535</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Monami-2009" MODIFIED="2011-06-21 11:21:44 +0200" MODIFIED_BY="[Empty name]" NAME="Monami 2009" TYPE="JOURNAL_ARTICLE">
<AU>Monami M, Marchionni N, Mannucci E</AU>
<TI>Glucagon like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials</TI>
<SO>European Journal of Endocrinology</SO>
<YR>2009</YR>
<VL>160</VL>
<PG>909-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nathan-2009" MODIFIED="2011-06-21 11:22:37 +0200" MODIFIED_BY="[Empty name]" NAME="Nathan 2009" TYPE="JOURNAL_ARTICLE">
<AU>Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al; American Diabetes Association; European Association for Study of Diabetes</AU>
<TI>Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2009</YR>
<VL>32</VL>
<NO>1</NO>
<PG>193-03</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nauck-1993" MODIFIED="2011-06-21 11:22:48 +0200" MODIFIED_BY="[Empty name]" NAME="Nauck 1993" TYPE="JOURNAL_ARTICLE">
<AU>Nauck MA, Kleine N, Orskov C,Holst JJ,Willms B, Creutzfeldt W</AU>
<TI>Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients</TI>
<SO>Diabetologia</SO>
<YR>1993</YR>
<VL>36</VL>
<NO>8</NO>
<PG>741-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nauck-2002" MODIFIED="2011-06-21 11:24:50 +0200" MODIFIED_BY="[Empty name]" NAME="Nauck 2002" TYPE="JOURNAL_ARTICLE">
<AU>Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R, et a</AU>
<TI>Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycaemic clamp experiments in healthy volunteers</TI>
<SO>The Journal of Clinical Endocrinology and Metabolism</SO>
<YR>2002</YR>
<VL>87</VL>
<NO>3</NO>
<PG>1239-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-CG66-2008" MODIFIED="2011-06-21 11:24:49 +0200" MODIFIED_BY="[Empty name]" NAME="NICE CG66 2008" TYPE="OTHER">
<AU>National Collaborating Centre for Chronic Conditions</AU>
<TI>Type 2 diabetes: national clinical guideline for management in primary and secondary care</TI>
<SO>London: Royal College of Physicians</SO>
<YR>2008</YR>
<VL>http://www.nice.org.uk/nicemedia/pdf/CG66FullGuideline0509.pdf</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-CG87-2009" MODIFIED="2011-06-21 11:24:40 +0200" MODIFIED_BY="[Empty name]" NAME="NICE CG87 2009" TYPE="OTHER">
<AU>National Institute for Health and Clinical Excellence</AU>
<TI>Type 2 diabetes: the management of type 2 diabetes</TI>
<SO>NICE clinical guideline 87</SO>
<YR>2009</YR>
<VL>http://www.nice.org.uk/cg87</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-TA203-2010" MODIFIED="2011-06-24 10:23:12 +0200" MODIFIED_BY="[Empty name]" NAME="NICE TA203 2010" TYPE="OTHER">
<AU>National Institute for Health and Clinical Excellence</AU>
<TI>Liraglutide for the treatment of type 2 diabetes mellitus. NICE technology appraisal guidance 203</TI>
<SO>http://guidance.nice.org.uk/TA203</SO>
<YR>2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Norris-2009" MODIFIED="2011-06-21 11:25:02 +0200" MODIFIED_BY="[Empty name]" NAME="Norris 2009" TYPE="JOURNAL_ARTICLE">
<AU>Norris SL, Lee N, Thakurta S, Chan BKS</AU>
<TI>Exenatide efficacy and safety: a systematic review</TI>
<SO>Diabetic Medicine</SO>
<YR>2009</YR>
<VL>26</VL>
<PG>837-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pratley-2008" MODIFIED="2011-06-28 17:07:43 +0200" MODIFIED_BY="[Empty name]" NAME="Pratley 2008" TYPE="JOURNAL_ARTICLE">
<AU>Pratley RE</AU>
<TI>Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes</TI>
<SO>Medscape Journal of Medicine</SO>
<YR>2008</YR>
<VL>10</VL>
<NO>7</NO>
<PG>171</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shyangdan-2010" MODIFIED="2011-06-30 14:34:19 +0200" MODIFIED_BY="[Empty name]" NAME="Shyangdan 2010" TYPE="JOURNAL_ARTICLE">
<AU>Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh NR</AU>
<TI>Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis</TI>
<SO>BMC Endocrine Disorders</SO>
<YR>2010</YR>
<VL>10</VL>
<PG>20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shyangdan-2011" MODIFIED="2011-06-24 10:17:15 +0200" MODIFIED_BY="[Empty name]" NAME="Shyangdan 2011" TYPE="JOURNAL_ARTICLE">
<AU>Shyangdan D, Cummins E, Royle P, Waugh N</AU>
<TI>Liraglutide for the treatment of type 2 diabetes</TI>
<SO>Health Technology Assessment</SO>
<YR>2011</YR>
<VL>15</VL>
<NO>Suppl. 1</NO>
<PG>75-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Turner-1996" MODIFIED="2011-06-21 11:25:53 +0200" MODIFIED_BY="[Empty name]" NAME="Turner 1996" TYPE="JOURNAL_ARTICLE">
<AU>Turner RC, Holman RR</AU>
<TI>The UK Prospective Diabetes Study. UK Prospective Diabetes Study Group</TI>
<SO>Annals of Medicine</SO>
<YR>1996</YR>
<VL>28</VL>
<NO>5</NO>
<PG>439-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-UKPDS-16" MODIFIED="2011-06-21 11:26:04 +0200" MODIFIED_BY="[Empty name]" NAME="UKPDS 16" TYPE="JOURNAL_ARTICLE">
<AU>UKPDS Study Group</AU>
<TI>UKPDS 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group</TI>
<SO>Diabetes</SO>
<YR>1995</YR>
<VL>44</VL>
<PG>1249-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Waugh-2010" MODIFIED="2011-06-21 11:34:19 +0200" MODIFIED_BY="[Empty name]" NAME="Waugh 2010" TYPE="JOURNAL_ARTICLE">
<AU>Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, et al</AU>
<TI>Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation</TI>
<SO>Health Technology Assessment</SO>
<YR>July 2010</YR>
<VL>14</VL>
<NO>36</NO>
<PG>1-248</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1998" MODIFIED="2009-12-23 19:28:07 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 1998" TYPE="JOURNAL_ARTICLE">
<AU>Alberti KM, Zimmet PZ</AU>
<TI>Definition, diagnosis and classification of diabetes mellitus and its compliactions. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation</TI>
<SO>Diabetic Medicine</SO>
<YR>1998</YR>
<VL>15</VL>
<PG>539-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Xu-1999" MODIFIED="2011-06-21 11:27:04 +0200" MODIFIED_BY="[Empty name]" NAME="Xu 1999" TYPE="JOURNAL_ARTICLE">
<AU>Xu G, Stoffers DA, Habener JF, Bonner-Weir S</AU>
<TI>Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta- cell mass and improved glucose tolerance in diabetic rats</TI>
<SO>Diabetes</SO>
<YR>1999</YR>
<VL>48</VL>
<NO>12</NO>
<PG>2270-6</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2011-06-30 14:34:44 +0200" MODIFIED_BY="[Empty name]"/>
<PENDING_REFERENCES MODIFIED="2009-10-09 13:19:55 +0200" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2011-09-01 15:41:05 +0200" MODIFIED_BY="Bernd Richter">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2011-09-01 15:41:05 +0200" MODIFIED_BY="Bernd Richter" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2011-08-30 10:12:13 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-A-_x002d_-Rosenstock-2009">
<CHAR_METHODS MODIFIED="2010-02-10 13:23:57 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>: Randomised double-blind, placebo-controlled parallel group phase II trial, multi-centre (118 sites)</P>
<P>
<B>DURATION OF INTERVENTION</B>: 16 weeks</P>
<P>
<B>DURATION OF FOLLOW-UP</B>: 11 week washout phase to assess safety and immunogeneity</P>
<P>
<B>RUN-IN PERIOD:</B> None</P>
<P>
<B>SETTING</B>: Not reported (NR)</P>
<P>
<B>COUNTRY</B>: US (106 sites), Mexico (9 sites), Chile (2 sites), Dominican Republic (1 site)<B>
<I> </I>
</B>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-30 14:40:51 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA</B>: Patients with type 2 diabetes diagnosed &#8805; 3 months before screening, men and women aged 18 to 75 years, drug-naive (diet and exercise) or treated with metformin monotherapy and stable for &gt; 3 months before prescreening; BMI &#8805; 20 and &#8804; 40 kg/m<SUP>2</SUP>, HbA1c at screening &#8805; 7 and &#8804; 10%; only participants treated with metformin monotherapy were eligible for the exenatide arm (consistent with labelling).</P>
<P>
<B>EXCLUSION CRITERIA</B>: Any oral antidiabetic monotherapy (except metformin) &#8804; 3 months prior to screening or insulin &lt; 1 month prior to screening and not used for &gt; 7 days; history of pancreatitis, cardiovascular, cerebrovascular, renal or hepatobiliary diseases; fasting serum triglycerides &#8805; 9 mmol/L at screening; or haematological profiles considered to be clinically significant; use of lipid lowering medications must have been maintained at same dose for 3 months prior to treatment, no prescription or over the counter weight loss drugs 3 months prior to enrolment.</P>
<P>
<B>AGE</B>: mean 54.0 to 55.5 years (SD 9.7 to 10.6)</P>
<P>
<B>SEX</B>: 45.1% to 74.2% female (74.2% in ALBI 30 mg weekly group, 50% in ALBI 30 mg every 2 weeks group, 45.1% in placebo group)</P>
<P>
<B>DIABETES DURATION</B>: mean 4.9 years [range 3.9 to 5.5 years (SD 3.0 to 5.4)]</P>
<P>
<B>ETHNICITY</B>: Caucasian (43.8% to 71%) (87.1% and 12.9% of participants were from U.S. and Latin American clinics respectively)</P>
<P>
<B>HbA1c (%)</B>: ALBI Weekly 30 mg: 8.0 (SD 0.9), Placebo: 7.9 (SD 0.9), ALBI every 2 weeks 30 mg: 8.0 (SD 1.0)</P>
<P>
<B>BMI (kg/m<SUP>2</SUP>)</B>: ALBI weekly 30 mg: 33.0 (SD 3.9), ALBI every 2 weeks 30 mg: 31.2 (SD 4.1), Placebo: 31.8 (SD 5.4)</P>
<P>
<B>PREVIOUS THERAPY</B>: Diet and exercise only: 29.0% to 34.4%, MET: 65.6% to 71.0%</P>
<P>
<B>NUMBERS</B>: Randomised: 361, received treatment (and included in the safety analysis): 356, efficacy analysis: 345; ITT: placebo: 51, exenatide: 35; ALBI weekly 4 mg: 35, 15 mg: 35, 30 mg: 31; ALBI every 2 weeks 15 mg: 33, 30 mg: 32, 50 mg: 35; ALBI monthly 50 mg: 35, 100 mg: 34</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-30 14:41:10 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>COMPARISON:</B> Albiglutide (ALBI, 8 doses/schedules) +/- Metformin (MET) VERSUS Exenatide (EX) + MET VERSUS Placebo +/- MET</P>
<P>
<B>NO. OF COMPARISON GROUPS</B>: 10</P>
<P>For the current review, the following groups were excluded: EX (as this included co-medication with metformin in all patients, whereas only 65.6% to 74.3% of the patients in the other groups received metformin, so this was not really a comparison of exenatide versus albiglutide); ALBI 4 or 15 mg weekly or 15 mg every two weeks (smaller effect on HbA1c), and ALBI 50 mg every two weeks or 50 or 100 mg monthly (no improvement in HbA1c compared to groups with largest effect, significantly more adverse events)</P>
<P>
<B>DOSE ALBI: </B>30 mg weekly or 30 mg every 2 weeks injected subcutaneously to the abdomen</P>
<P>
<B>DOSE PLACEBO: </B>Placebo injections</P>
<P>
<B>DOSE MET:</B> Not reported, presumably pre study levels</P>
<P>
<B>OTHER TREATMENT: </B>Not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-15 14:11:52 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOMES</B>: Change from baseline in HbA1c at week 16</P>
<P>
<B>SECONDARY OUTCOMES</B>: Fasting plasma glucose (FPG), fasting fructosamine, C-peptide, glucagon, insulin, lipid profiles, beta-cell function (homeostasis model)</P>
<P>
<B>OTHER OUTCOMES: </B>Adverse event assessments and safety analyses (nausea and vomiting, immunogenicity), 11 week washout post-intervention (HbA1c, FPG, ALBI concentrations, fasting fructosamine, C-peptide, glucagon, insulin, lipid profiles, immunogenicity)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-30 10:12:13 +0200" MODIFIED_BY="Bernd Richter">
<P>
<B>AIM</B>: To evaluate the efficacy, safety and tolerability of incremental doses of albiglutide, administered using three dosing schedules in patients with type 2 diabetes inadequately controlled with diet and exercise or metformin monotherapy.</P>
<P>
<B>SOURCE OF FUNDING</B>: GlaxoSmithKline, Middlesex, UK</P>
<P>
<B>OTHER</B>: Conflict of interest: One author has received research grants and consulting honoraria for serving on scientific advisory boards from GlaxoSmithKline. Another author has received research grants from and acted as a consultant for GlaxoSmithKline, MB FY, and MS are employees/stockholders of GlaxoSmithKline.</P>
<P>
<B>SAMPLE SIZE:</B> With 30 participants planned in each arm, a two-sided 95% CI for each group mean response had a half-width of 0.36% on HbA1c scale, assuming a standard deviation of 1%.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-30 15:30:25 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-E-_x002d_-Bergenstal-2010">
<CHAR_METHODS MODIFIED="2011-01-18 11:43:49 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>:Randomised, double-blind, double-dummy, superiority trial</P>
<P>
<B>DURATION OF INTERVENTION</B>: 26 weeks</P>
<P>
<B>DURATION OF FOLLOW-UP</B>: NR</P>
<P>
<B>RUN-IN PERIOD: </B>NR</P>
<P>
<B>SETTING</B>: 72 hospitals and clinics</P>
<P>
<B>COUNTRY</B>: USA, India and Mexico.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-30 15:30:03 +0200" MODIFIED_BY="Bernd Richter">
<P>
<B>INCLUSION CRITERIA</B>: participants aged between 18 years and older; type 2 diabetes but otherwise healthy; treated with a stable metformin regimen for at least 2 months before screening; HbA1c of 7.1% to 11.0%; BMI 25 to 45 kg/m<SUP>2</SUP>; FPG &lt; 15.5 mmol/L; not taking or has been stable on other medications of a minimum of 2 months-hormone replacement therapy, OCPs, antihypertensives, lipid-lowering agents, thyroid replacement therapy, antidepressant agents and drugs known to affect body weight including prescription medications, sibutramine, topiramate and over-the-counter antiobesity agents.</P>
<P>
<B>EXCLUSION CRITERIA</B>: pregnant or lactating women; clinically significant medical conditions like hepatic disease, renal disease, cardiovascular disease, gastroparesis, malignancy, macular edema or chronic infections; drugs or alcohol abuse; fasting triglycerides &#8805; 600 mg/dL; previously exposed to exenatide LAR (long acting release); blood donated within 60 days of screening or is planning to do during study; major surgery or a blood transfusion within 2 months of screening; currently taking drugs that are excluded or is expected to be treated with one; received any investigational drug within 1 month of screening; known allergies or hypersensitivity to any component of study treatment; previous experience of clinically significant adverse events with TZD or DPP-4 inhibitors; immediate family or affiliation with the personnel; employed by Amylin, Eli Lilly or Alkermes</P>
<P>
<B>AGE</B>: 52 to 53 years (SD 10 to 11)</P>
<P>
<B>SEX</B>: 44% to 52% female [44% in EX 2 mg group; 48% in sitagliptin (SITA) 100 mg group; 52% in pioglitazone (PIO) 45 mg group]</P>
<P>
<B>DIABETES DURATION</B>: 5 to 6 years (SD 4 to 5)</P>
<P>
<B>ETHNICITY</B>: 30% to 39% White; 8% to 12% Black; 27% to 31% Hispanic; 23% to 25% Asian; 0% to 2% Native American; 1% to 2% other</P>
<P>
<B>HbA1c (%)</B>: EX 2 mg: 8.6 SD 1.2; SITA 100 mg: 8.5 SD 1.2; PIO 45 mg: 8.5 SD 1.1</P>
<P>
<B>BMI (kg/m<SUP>2</SUP>)</B>: EX 2 mg: 32 SD 5; SITA 100 mg: 32 SD 5; PIO 45 mg: 32 SD 6</P>
<P>
<B>PREVIOUS THERAPY</B>: NR</P>
<P>
<B>NUMBERS</B>: Screened: 958; randomised: 514 (EX 2 mg: 170, SITA 100 mg: 172, PIO 45 mg: 172); evaluable patient: 387 (EX 2 mg: 122, SITA 100 mg: 137, PIO 45 mg: 128); ITT: 491 (EX 2 mg: 160, SITA 100 mg: 166, PIO 45 mg: 165)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-23 18:33:42 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>COMPARISON: </B>EX 2 mg once weekly + MET + placebo, versus SITA 100 mg once daily + MET + placebo, versus PIO 45 mg once daily + MET + placebo</P>
<P>
<B>NO. OF COMPARISON GROUPS</B>: 3</P>
<P>
<B>DOSE EX: </B>EX 2 mg once weekly injection plus oral placebo once daily</P>
<P>
<B>DOSE SITA: </B>SITA 100 mg orally once daily plus placebo once weekly injection</P>
<P>
<B>DOSE PIO: </B>PIO 45 mg orally once daily plus placebo once weekly injection</P>
<P>
<B>DOSE MET: </B>Mean oral dose between 1480 to 1583 mg</P>
<P>
<B>OTHER TREATMENT: </B>NR</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-23 18:33:13 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOMES</B>: Change in HbA1c</P>
<P>
<B>SECONDARY OUTCOMES</B>: Proportion of participants achieving the HbA1c target of 6.5% or lower, or 7.0% or lower; FPG &#8804; 7 mmol/L; six-point self-monitored blood glucose profile; body weight; fasting lipid profile; fasting insulin profile; SBP and DBP; cardiovascular risk markers (urinary albumin-to-creatinine ratio, serum adiponectin, B-type natriuretic peptide, high-sensitivity C-reactive protein, and plasminogen activator inhibitor-1); patient-reported outcomes from the Impact of Weight on Quality of Life Questionnaire-Lite (IWQOL), Psychological General Well-being (PGWB) index, the Diabetes Treatment Satisfaction Questionnaire (DTSQ), and EuroQol-5 dimensions (EQ-5D).</P>
<P>
<B>OTHER OUTCOMES: </B>Safety and tolerability; exenatide antibodies; hypoglycaemia</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-30 15:30:25 +0200" MODIFIED_BY="Bernd Richter">
<P>
<B>AIM</B>: To compare the efficacy, safety, and tolerability of three recommended therapies for patients not sufficiently controlled on metformin.</P>
<P>
<B>SOURCE OF FUNDING</B>: Amylin Pharmaceuticals and Eli Lilly</P>
<P>
<B>OTHER</B>: Conflict of interest: First author's institution has received consultancy fees or research grant support, or both, with receipt of travel and accomodation expenses in some cases, from different pharmaceutical companies. This author also owns stock in Merck. Another author is a member of the scientific advisory board for Amylin Pharmaceuticals, is a consultant for Amylin Pharmaceuticals, Eli Lilly and AstraZeneca, is on the speaker's bureau of Amylin Pharmaceuticals, Eli Lilly, Merck, Novo Nordisk, and Sanofi-Aventis and has received travel and accomodation expenses from Amylin Pharmaceuticals. Some authors are employees and stockholders of Amylin Pharmaceuticals. One author is an employee and stockholder of Eli Lilly. All research activity and advisory or consultancy services were done under contract with the non-profit International Diabetes Center at Park Nicollet.</P>
<P>
<B>SAMPLE SIZE: </B>Estimated that 500 participants would provide at least 90% power to detect a statistically significant difference between exenatide and sitagliptin or pioglitazone, and assumptions of a difference of 0.5% between groups, a common SD of 1.2% and an early withdrawal of 10%.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-30 10:08:32 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-E-_x002d_-Blevins-2011">
<CHAR_METHODS MODIFIED="2011-04-25 12:50:12 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>: Randomised, open-label, comparator-controlled study</P>
<P>
<B>DURATION OF INTERVENTION</B>: 24 weeks</P>
<P>
<B>DURATION OF FOLLOW-UP</B>: NR</P>
<P>
<B>RUN-IN PERIOD: </B>NR</P>
<P>
<B>SETTING</B>: 43 sites</P>
<P>
<B>COUNTRY</B>: United States</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-30 11:44:05 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA</B>: At least 18 years of age and diagnosed with type 2 diabetes, otherwise healthy, and treated for at least 2 months with diet and exercise alone or with a stable, maximally effective regimen of metformin, sulphonylurea (SU), thiazolidinedione, or a combination of these medications; HbA1c of 7.1% to 11.0%, FPG less than 280 mg/dL (15.5 mmol/L), BMI from 25 to 45 kg/m<SUP>2</SUP>.</P>
<P>
<B>EXCLUSION CRITERIA</B>: Patients using concomitant weight loss agents.</P>
<P>
<B>AGE</B>: 55 to 56 years (SD 10 to 11)</P>
<P>
<B>SEX</B>: 40% to 45% female (40% in EX 2 mg once weekly group; 45% in EX 10 µg twice daily group)</P>
<P>
<B>DIABETES DURATION</B>: 7 SD5 years</P>
<P>
<B>ETHNICITY</B>: 55% to 63% Caucasian; 5% to 7% Black; 4% Asian; 29% to 33% Hispanic</P>
<P>
<B>HbA1c (%)</B>: EX 10 µg BID: 8.4 SD 1.2; EX 2 mg QW: 8.5 SD 1.1</P>
<P>
<B>BMI (kg/m<SUP>2</SUP>)</B>: EX 10 µg BID: 33.0 SD 5.3; EX 2 mg QW: 33.6 SD 5.5</P>
<P>
<B>PREVIOUS THERAPY</B>: Diet and exercise only: 16% to 21%; single oral antidiabetic therapy: 43% to 50%; combination oral antidiabetic therapy: 28% to 40% (alone or in combination of: 71% to 80% MET; 28% to 31% SU; 10% to 17% TZD)</P>
<P>
<B>NUMBERS</B>: EX 10 µg BID: 123; EX 2 mg QW: 129</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-22 15:34:34 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>COMPARISON: </B>EX 2 mg QW +/- MET +/- SU +/- TZD or EX 10 µg BID +/- MET +/- SU +/- TZD</P>
<P>
<B>NO. OF COMPARISON GROUPS</B>: 2</P>
<P>
<B>DOSE EX QW: </B>Subcutaneous injection of exenatide 2 mg once weekly or exenatide 10 µg twice daily.</P>
<P>lead-in for 2 mg EX QW: 2 mg once weekly for 24 weeks<BR/>lead-in for 10 µg EX BID: 5 µg EX twice daily for 4 weeks, then 10 µg EX twice daily for the remainder of the 20 weeks</P>
<P>
<B>OTHER TREATMENT: </B>Patients not allowed to change their oral antidiabetic, lipid-lowering, and antihypertensive medications during the study, unless instructed otherwise by the investigator.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-19 11:28:16 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOMES</B>: Change in HbA1c from baseline to week 24.</P>
<P>
<B>SECONDARY OUTCOMES</B>: Body weight, FPG, proportion of subjects achieving HbA1c targets of less than 7% and 6.5% or less at week 24, proportion of patients achieving FPG target of 126 mg/dL (7.0 mmol/L) or less at week 24, SBP, DBP, fasting lipid concentrations,</P>
<P>
<B>OTHER OUTCOMES: </B>Safety and tolerability; antibody titres.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-30 10:08:32 +0200" MODIFIED_BY="Bernd Richter">
<P>
<B>AIM</B>: To compare the effects of exenatide once weekly and exenatide twice daily on glycaemic control, body weight, and safety.</P>
<P>
<B>SOURCE OF FUNDING</B>: Amylin Pharmaceuticals</P>
<P>
<B>OTHER</B>: Two authors have received research grants from Amylin Pharmaceuticals, Inc. and serve as advisers and speaker's bureau members for Amylin Pharmaceuticals, Inc. First author has also served as an adviser and speaker's bureau member for Eli Lilly &amp; Co. Some authors are employees and stockholders of Amylin Pharmaceuticals, Inc. One author is an employee and stockholder of Eli Lilly &amp; Co.</P>
<P>
<B>SAMPLE SIZE: </B>A sample size of approximately 250 patients (ratio of 1:1) was estimated to provide 90% power to demonstrate that EX QW was non-inferior to EX BID by a 0.4% difference in the HbA1c change from baseline to week 24, using a one-sided, two-sample t test with a significance level of 0.025 and assuming a greater (0.1%) reduction in HbA1c by EX QW compared with EX BID, a 15% withdrawal rate, and a common SD of 1.1%.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-30 15:30:40 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-E-_x002d_-Diamant-2010">
<CHAR_METHODS MODIFIED="2011-01-18 15:46:10 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>: Phase 3, parallel, open-label, randomised controlled trial</P>
<P>
<B>DURATION OF INTERVENTION</B>: 26 weeks</P>
<P>
<B>DURATION OF FOLLOW-UP</B>: NR</P>
<P>
<B>RUN-IN PERIOD:</B> NR</P>
<P>
<B>SETTING</B>: 72 sites</P>
<P>
<B>COUNTRY</B>: USA (and Puerto Rico), the European Union, Russia, Australia, Korea, Taiwan, and Mexico.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-30 15:30:40 +0200" MODIFIED_BY="Bernd Richter">
<P>
<B>INCLUSION CRITERIA</B>: Participants with type 2 diabetes aged 18 years or older (no upper limit specified) with sub optimum glycaemic control despite maximum tolerated doses of metformin or combined metformin and sulphonylurea treatment for 3 months or longer; HbA1c between 7.1% and 11.0%, inclusive, BMI between 25 kg/m<SUP>2</SUP> and 45  kg/m<SUP>2</SUP>, stable bodyweight for 3 months or more; participants have had to be treated with a stable dose of metformin of 1500 mg or more per day for 8 or more weeks before screening.</P>
<P>
<B>EXCLUSION CRITERIA</B>: more than three episodes of major hypoglycaemia within 6 months of screening; treatment within 4 weeks of screening with systemic glucocorticoids; and treatment for longer than 2 weeks with insulin, thiazolidinediones, &#945;-glucosidase inhibitors, meglitinides, exenatide twice-a-day formulation, dipeptidyl peptidase-4 inhibitors or pramlintide acetate within 3 months of screening. Prescription and non-prescription weight-loss drugs were excluded within 3 months of screening and during the entire 26-week study.</P>
<P>
<B>AGE</B>: 58 SD 9 to 10 years</P>
<P>
<B>SEX</B>: 45% to 48% female (EX 2 mg: 48%, GLAR: 45%)</P>
<P>
<B>DIABETES DURATION</B>: 7.8 to 8.0 years (SD 6.0)</P>
<P>
<B>ETHNICITY</B>: &lt; 1% to 1% African American; 82% to 85% White; 6% Asian; 9% to 12% Hispanic</P>
<P>
<B>HbA1c (%)</B>: EX: 8.3 SD 1.1; GLAR: 8.3 SD 1.0</P>
<P>
<B>BMI (kg/m<SUP>2</SUP>)</B>: 32 SD 5.0 for both groups</P>
<P>
<B>PREVIOUS THERAPY</B>: 70% MET; 30% MET + SU</P>
<P>
<B>NUMBERS</B>: Screened: 659; randomised: 456 (EX: 233, GLAR: 223)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-19 17:06:16 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>COMPARISON: </B>EX 2 mg once weekly + 70% MET/30% MET + SU VERSUS GLAR + MET/MET + SU</P>
<P>
<B>NO. OF COMPARISON GROUPS</B>: 2</P>
<P>
<B>DOSE EX: </B>EX 2 mg injected into abdominal subcutaneous tissue at randomisation and once a week (within 2 days of date of first injection) thereafter.</P>
<P>
<B>DOSE GLAR:</B> GLAR implemented by INITIATE (Initiate Insulin by Aggressive Titration and Education) dosing algorithm; GLAR treatment started with 10 IU per day, measured FBG concentrations every morning and the dose of insulin adjusted to achieve a target glucose of 4.0 to 5.5 mmol/L. Participants and investigators were asked to adhere to titration targets however there was no central supervision to enforce titration. Insulin was injected at the same time every day, preferably at bedtime. Mean doses of GLAR increased from a baseline of 10 IU per day to 31 IU per day at endpoint (last measurement brought forward).</P>
<P>
<B>DOSE MET:</B> MET was continued in their stable dose until week 26. Mean doses of MET ~ 2000 mg throughout study,</P>
<P>
<B>DOSE SU:</B> If a participant taking metformin and sulphonylureas had confirmed hypoglycaemia, the dose of sulphonylurea was reduced. 46 (21%) of 223 patients had a reduction in SU dose.</P>
<P>
<B>BOTH GROUPS:</B> Specific instructions for eight-point self-monitored blood-glucose profiles (measured before and 2 hour after morning, midday, and evening meals, at bedtime, and at 0300 hours) were given to both treatment groups.</P>
<P>
<B>OTHER TREATMENT: </B>NR</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-22 15:53:22 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOMES</B>: Change in HbA1c at week 26 compared with baseline.</P>
<P>
<B>SECONDARY OUTCOMES</B>: Proportion of participants achieving HbA1c targets (&lt; 7.0% and &lt; 6.5%), fasting serum glucose concentrations, self-monitored blood glucose concentrations, bodyweight, fasting serum lipid concentrations, urinary albumin-to-creatinine ratio, high-sensitivity C-reactive protein, homeostasis model assessment of &#946;-cell function and insulin sensitivity, alanine aminotransferase, and 1,5-anhydroglucitol (a short term marker for glycaemic control). Administered five health outcomes questionnaires: Impact of weight on quality of life-lite (IWQOL-Lite), EuroQol instrument (EQ-5D), binge eating scale (BES) and diabetes treatment satisfaction questionnaire (status version; DTSQs).</P>
<P>
<B>OTHER OUTCOMES: </B>Adverse events, clinical laboratory assessments, vital signs, and hypoglycaemia.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-30 10:08:47 +0200" MODIFIED_BY="Bernd Richter">
<P>
<B>AIM</B>: To test the hypothesis that improvement in HbA1c concentration achieved with once-weekly exenatide is better than that achieved with the existing standard second-line treatment for patients not responding to oral blood-glucose lowering agents, insulin glargine titrated to glucose targets.</P>
<P>
<B>SOURCE OF FUNDING</B>: Amylin and Eli Lilly</P>
<P>
<B>OTHER</B>: Conflict of interest: First author is a consultant and speaker for Eli Lilly, Novo Nordisk, and Merck, Sharp and Dohme; and a consultant of Sanofi-Aventis. Through this author, the VU University Medical Centre in Amsterdam has received research grants from Amylin Pharmaceuticals, Eli Lilly, Novo Nordisk, Merck, Sharp and Dohme, Novartis and Takeda. Another author has served on advisory panels for Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Novo Nordisk and Sanofi-Aventis, and has received honoraria as member of the speakers's bureau for Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb and Eli Lilly. Another author has served on an advisory panel for Eli Lilly, has received travel grants from Novo Nordisk, Eli Lilly, Merck, Sharp and Dohme and Servier and has received research funding support from Sanofi-Aventis. Some authors are employees of Eli Lilly. One author is an employees of Amylin Pharmaceuticals.</P>
<P>
<B>SAMPLE SIZE: </B>A sample size of 205 patients per treatment was needed to achieve 92% power to detect a difference of 0.4% in change in HbA1c from baseline.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-30 10:08:57 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-E-_x002d_-Drucker-2008">
<CHAR_METHODS MODIFIED="2009-12-01 15:23:12 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN: </B>Randomised comparator-controlled, open label trial, non-inferiority study</P>
<P>
<B>DURATION OF INTERVENTION:</B> 30 weeks</P>
<P>
<B>DURATION OF FOLLOW-UP: </B>No post-intervention follow-up</P>
<P>
<B>SETTING:</B> Not reported</P>
<P>
<B>COUNTRY: </B>Canada/USA<I>
<B> </B>
</I>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-22 16:05:01 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA:</B> People with type 2 diabetes, aged at least 16 years old, HbA1c between 7% and 11%, FPG &lt; 16 mmol/L, BMI between 25 and 45 kg/m<SUP>2</SUP>, therapy with diet modification and exercise, or pharmacological treatment with MET, a SU, a TZD, or any combination of two of these agents; weight stable (weight did not vary &gt; 10%) for 6 months prior screening, no abnormal results of clinical significance on blood testing.<SUP> </SUP>
</P>
<P>
<B>EXCLUSION CRITERIA:</B> Patients who had used meglitinides, alpha-glucosidase inhibitors, insulin therapy, weight-loss drugs, corticosteroids, drugs known to affect gastrointestinal motility, or any investigational drug; any exposure to exenatide or a GLP-1 analogue; or evidence of clinically significant medical conditions that might preclude safe participation in the study.</P>
<P>
<B>AGE:</B> 55 SD 10 years</P>
<P>
<B>SEX: </B>45% to 49% female</P>
<P>
<B>DIABETES DURATION:</B> 6 to 7 years (SD 5 to 6)</P>
<P>
<B>ETHNICITY: </B>73% to 83% White, 6% to 13% Black, 11% to 14% Hispanic, 0% to 1% Asian</P>
<P>
<B>HbA1c (%) : </B>EX 2 mg QW: 8.3 SD 1.0; EX 10 µg BID: 8.3 SD 1.0</P>
<P>
<B>BMI (kg/m<SUP>2</SUP>): </B>EX 2 mg QW: 35 SD 5; EX 10 µg BID: 35 SD 5</P>
<P>
<B>PREVIOUS THERAPY: </B>Monotherapy: 43% to 46%, combination therapy: 36% to 39%; all MET: 69% to 77%, all SU: 37%, all TZD: 15% to 17%; diet/exercise only: 14% to 16%</P>
<P>
<B>NUMBERS:</B> Randomised: 303, Analysed as ITT: 295 (8 withdrew before lead-in); EX 2 mg QW: 148, EX 10 µg BID: 147</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-24 12:01:16 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>COMPARISON:</B> EX twice daily + previous therapy VERSUS EX once weekly + previous therapy</P>
<P>
<B>NO. OF COMPARISON GROUPS:</B> 2</P>
<P>
<B>RUN-IN: </B>None</P>
<P>
<B>DOSE EX: </B>subcutaneous injection of exenatide 2 mg once a week or 10 µg twice a day<BR/>lead-in for 2 mg QW: 3 days 5 µg EX BID, then 2 mg QW<BR/>lead-in for 10 µg EX BID: 5 µg EX BID for 28 days, then 10 µg EX BID for the remainder of the 30 weeks</P>
<P>
<B>PREVIOUS THERAPY: </B>Diet/exercise or metformin (MET), sulphonylurea (SU), or thiazolidinedione (TZD) as monotherapy or combination of any two; see above for combinations used, doses of MET, SU and TZD were not reported; to avoid hypoglycaemia, SU dose was reduced to minimum labelled dose until week 10, then up-titrated to reach target FPG of &#8804; 6 mmol/L</P>
<P>
<B>OTHER TREATMENT:</B> Not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-22 16:28:52 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOMES:</B> Change in HbA1c at the end of the study i.e. 30 weeks (non-inferiority within 0.4%)</P>
<P>
<B>SECONDARY OUTCOMES: </B>Safety and tolerability, body weight, fasting plasma glucose (FPG), postprandial glucose (PPG), fasting glucagon, fasting lipids, blood pressure, proportion of patients achieving HbA1c concentrations of &#8804; 7.0%, &#8804; 6.5%, &#8804; 6.0%, overall and by baseline HbA1c strata; HbA1c by antibody titre; bodyweight in the presence and absence of nausea</P>
<P>
<B>OTHER OUTCOMES:</B> Treatment-emergent adverse events (defined as those occurring on or after receiving the first injection of study medication): patients who lost glucose control (1.5% increase in HbA1c or HbA1c of &#8805;11.5% at or after week 14; patients with loss of glucose control withdrawn from the study); hypoglycaemic episodes: minor (symptoms of hypoglycaemia and a plasma glucose &lt; 3 mmol/L) and major (loss of consciousness, seizure, or coma; third party assistance to resolve or administration of glucose or glucagon; and a plasma glucose &lt; 3 mmol/L); vital signs, ECG reports, or haematological, chemistry, or urinalysis values</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-30 10:08:57 +0200" MODIFIED_BY="Bernd Richter">
<P>
<B>AIM: </B>To compare the efficacy and safety of exenatide once a week to that of exenatide given twice daily, over 30 weeks, in patients with type 2 diabetes.</P>
<P>
<B>SOURCE OF FUNDING: </B>Amylin Pharmaceuticals and Eli Lilly and Company.</P>
<P>
<B>OTHER: </B>Conflict of interest: One author has been a consultant for and received lecture honoraria from Amylin, Eli Lilly and Novo Nordisk.</P>
<P>
<B>SAMPLE SIZE: </B>A sample size of 300 patients was estimated to provide 90% power to test the hypothesis that the treatments were non-inferior with respect to HbA1c control.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-09-01 15:41:05 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-L-_x002d_-Kaku-2010">
<CHAR_METHODS MODIFIED="2011-06-22 16:36:18 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>: Double-blind, multicenter, randomised, parallel-group, three arm trial</P>
<P>
<B>DURATION OF INTERVENTION</B>: 24 weeks</P>
<P>
<B>DURATION OF FOLLOW-UP</B>: This trial was part of a 52 week, multicenter, double-blind, randomised, parallel-group trial in which the initial 24 week double-blind period was followed by a 28 week open label period</P>
<P>
<B>RUN-IN PERIOD: </B>4 week preceeded randomisation, after which subjects were stratified according to their pretrial SU therapy.</P>
<P>
<B>SETTING</B>: 49 centres</P>
<P>
<B>COUNTRY</B>: Japan</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-30 15:01:03 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA</B>: Japanese men and women &#8805; 20 years of age with type 2 diabetes mellitus currently treated with an SU [glibenclamide (1.25 to 10 mg), gliclazide (40 to 160 mg) or glimepiride (1 to 6 mg) for &#8805; 8 weeks, HbA1c between 7.0% to &lt; 10%, BMI &lt; 35.0 kg/m<SUP>2</SUP>.</P>
<P>
<B>EXCLUSION CRITERIA</B>: Treated with insulin within 12 weeks, were receiving or expecting to receive systemic corticosteroids, or had known hypoglycaemia unawareness or recurrent major hypoglycaemia, impaired renal or hepatic function, significant cardiovascular disease (heart failure, coronary artery disease or uncontrolled hypertension) or non stabilized proliferative retinopathy or maculopathy.</P>
<P>
<B>AGE</B>: 58.6 SD 9.7 to 61.3 SD 11.0 years</P>
<P>
<B>SEX</B>: 33% to 40% female (LIR 0.6 mg: 40%; LIR 0.9 mg: 33%; Placebo: 35%)</P>
<P>
<B>DIABETES DURATION</B>: 9.3 SD 5.8 to 11.6 SD 7.7 years</P>
<P>
<B>ETHNICITY</B>: All Japanese patients.</P>
<P>
<B>HbA1c (%)</B>: LIR 0.6 mg: 8.6 SD 0.91; LIR 0.9 mg: 8.21 SD 0.78; Placebo: 8.45 SD 0.99</P>
<P>
<B>BMI (kg/m<SUP>2</SUP>)</B>: LIR 0.6 mg: 25.3 SD 3.6; LIR 0.9 mg: 24.4 SD 3.4; Placebo: 24.9 SD 4.0</P>
<P>
<B>PREVIOUS THERAPY</B>: Treated with SU [glibenclamide (1.25 to 10 mg), gliclazide (40 to 160 mg) or glimepiride (1 to 6 mg)</P>
<P>
<B>NUMBERS</B>: Screened: 308; Randomised: 264 (LIR 0.6 mg: 88; LIR 0.9 mg: 88; Placebo: 88); Fully analysis set: 264 (LIR 0.6 mg: 88; LIR 0.9 mg: 88; Placebo: 88); per-protocol set: 235 (LIR 0.6 mg: 79; LIR 0.9 mg: 83; Placebo: 73)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-09-01 15:41:05 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>COMPARISON: </B>Liraglutide (LIR) 0.6 mg/0.9 mg + SU VERSUS Placebo + SU</P>
<P>
<B>NO. OF COMPARISON GROUPS</B>: 3</P>
<P>
<B>DOSE LIR: </B>LIR 0.6 mg or 0.9 mg once daily: LIR doses were up titrated from 0.3 mg/day (50 µl) to 0.6 mg/day (100 µl) after the first week, with an additional increase to 0.9 mg/day (150 µl) for the 0.9 mg cohort after the second week. LIR was injected once daily in the morning or evening s.c. into the upper arm, thigh or abdomen.</P>
<P>
<B>DOSE SU:</B> SU continued in prestudy dose.</P>
<P>
<B>OTHER TREATMENT:</B> NR</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-24 12:04:05 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOMES</B>: HbA1c level at 24 weeks</P>
<P>
<B>SECONDARY OUTCOMES</B>: 7-point self-measured PPG profiles, body weight, FPG, mean PPG, lipid profile and biomarkers for cardiovascular effects, proportions of subjects reaching HbA1c &#8804; 7% or &#8804; 6.5%</P>
<P>
<B>OTHER OUTCOMES: </B>Incidence of hypoglycaemic episodes (self-treated hypoglycaemic episodes were classified as minor, while those requiring third party assistance were considered as major and the remainder as symptoms-only), incidence of adverse events, vital signs and clinical laboratory assessments.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-30 10:09:08 +0200" MODIFIED_BY="Bernd Richter">
<P>
<B>AIM</B>: the efficacy and safety of two doses of liraglutide (0.6 and 0.9 mg/day) over 24 weeks compared with placebo, in each case as add-on to SU monotherapy</P>
<P>
<B>SOURCE OF FUNDING</B>: Novo Nordisk</P>
<P>
<B>OTHER</B>: Conflict of interest: NR</P>
<P>
<B>SAMPLE SIZE: </B>No information.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-30 13:57:39 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009">
<CHAR_METHODS MODIFIED="2010-01-21 20:02:38 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>: Randomised double-blind, double dummy, active control, five armed parallel trial, multi-centre (116 sites)</P>
<P>
<B>DURATION OF INTERVENTION</B>: 26 weeks</P>
<P>
<B>DURATION OF FOLLOW-UP</B>: No post-intervention follow-up</P>
<P>
<B>RUN-IN PERIOD: </B>2 weeks</P>
<P>
<B>SETTING</B>: NR</P>
<P>
<B>COUNTRY</B>: 21 countries (mainly in Europe and Asia)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-30 13:57:39 +0200" MODIFIED_BY="Bernd Richter">
<P>
<B>INCLUSION CRITERIA</B>: Patients with type 2 diabetes, OADs for &#8805; 3 months, aged 18 to 80 years old, HbA1c 7% to 11% (previous OAD monotherapy) or 7% to 10% (previous OAD combination therapy), BMI &#8804; 45 kg/m<SUP>2</SUP>
</P>
<P>
<B>EXCLUSION CRITERIA</B>: Using insulin within 3 months, impaired liver or renal function, uncontrolled hypertension (&#8805; 180/100 mm Hg), cancer, use of any drug apart from OAD likely to affect glucose concentrations</P>
<P>
<B>AGE</B>: 54.7 SD 10.0 to 57.7 SD 9.0 years</P>
<P>
<B>SEX</B>: 47% to 55% female</P>
<P>
<B>DIABETES DURATION</B>: (median, 25<SUP>th</SUP> and 75<SUP>th</SUP> percentile) 6.5 (3.7, 10.5) to 6.7 (4.0, 10.7) years</P>
<P>
<B>ETHNICITY</B>: NR</P>
<P>
<B>HbA1c (%)</B>: LIR 1.2 mg: 8.5 SD 1.1; LIR 1.8 mg: 8.5 SD 0.9; Placebo: 8.4 SD 1.0; ROS (rosiglitazone): 8.4 SD 1.0</P>
<P>
<B>BMI (kg/m<SUP>2</SUP>)</B>: LIR 1.2 mg: 29.8 SD 5.1; LIR 1.8 mg: 30 SD 5.1; Placebo: 30.3 SD 5.4; ROS: 29.4 SD 4.8</P>
<P>
<B>PREVIOUS THERAPY</B>: Previously on mono-therapy: 27% to 32%, on combination therapy: 68% to 73%</P>
<P>
<B>NUMBERS</B>: 1712 screened; Randomised: 1041 (1 to 37 participants per centre); LIR 0.6 mg: 233; LIR 1.2 mg: 228; LIR 1.8 mg: 234; Placebo: 114; ROS: 232</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-24 12:05:33 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>COMPARISON:</B> LIR (3 doses) + Glimepiride (SU) VERSUS Placebo + SU VERSUS ROS (TZD) + SU</P>
<P>
<B>NO. OF COMPARISON GROUPS</B>: 5 (LIR 0.6 mg not considered in the present review)</P>
<P>
<B>DOSE LIR:</B> 1.2 mg and 1.8 mg: LIR up-titrated weekly in 0.6 mg increments until the allocated dose reached; injected subcutaneously once daily</P>
<P>
<B>DOSE SU:</B> Forced glimepiride titration for 2 weeks and then 2 weeks maintenance period; glimepiride 2 to 4 mg/day</P>
<P>
<B>DOSE TZD:</B> 4 mg/day rosiglitazone</P>
<P>
<B>OTHER TREATMENT:</B> NR</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-24 12:05:52 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOMES:</B>  HbA1c (change from baseline to end of treatment)</P>
<P>
<B>SECONDARY OUTCOMES</B>: Proportion of participants reaching targeted goals of HbA1c (&#8804; 7%, &#8804; 6.5%), FPG (5 to &#8804; 7.2 mmol/L), PPG (10 mmol/L); body weight, FPG (fasting plasma glucose), PPG (post prandial glucose), beta-cell function, blood pressure; superiority of liraglutide to placebo and non-inferiority to rosiglitazone was tested</P>
<P>
<B>OTHER OUTCOMES</B>: Hypoglycaemic episodes based on PG levels (&lt; 3.1 mmol/L) (minor: self-treated; major: requiring third party assistance), liraglutide antibodies including cross-reacting and neutralizing antibodies, tolerability (gastrointestinal complaints), pulse, adverse events, vital signs, ECG, biochemical and haematological parameters, calcitonin</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-30 10:09:19 +0200" MODIFIED_BY="Bernd Richter">
<P>
<B>AIM</B>: To compare efficacy and safety of liraglutide and glimepiride combination therapy with either placebo or rosiglitazone added to glimepiride.<B> </B>
</P>
<P>
<B>SOURCE OF FUNDING</B>: Novo Nordisk</P>
<P>
<B>OTHER</B>: Conflict of interest: One author had received lecture fees from Novo Nordisk, Servier, MSD. The second author had received honoraria, grants and lecture fees from Novo Nordisk. The remaining authors had no conflict of interest</P>
<P>
<B>SAMPLE SIZE: </B>A combined power (calculated as the product of the marginal powers for HbA1c and body weight) of at least 85% was required.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-30 10:09:38 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009">
<CHAR_METHODS MODIFIED="2011-06-22 16:44:43 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN:</B> RCT, double dummy, active control, parallel group trial (part of a phase 3 clinical development program for liraglutide), multicenter (170 sites)</P>
<P>
<B>DURATION OF INTERVENTION:</B> 26 weeks</P>
<P>
<B>DURATION OF FOLLOW-UP: </B>No post-intervention follow-up</P>
<P>
<B>RUN-IN PERIOD:</B> 6 weeks</P>
<P>
<B>SETTING:</B> Not reported</P>
<P>
<B>COUNTRY: </B>Multinational (21 countries)<I>
<B> </B>
</I>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-22 16:46:39 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA:</B> People with type 2 diabetes, age 18 to 80 years old, HbA1c between 7% and 11% (prestudy OAD monotherapy for &#8805; 3 months) or between 7% and 10% (prestudy combination OAD therapy for &#8805; 3 months), BMI &#8804; 40 kg/m<SUP>2</SUP>
</P>
<P>
<B>EXCLUSION CRITERIA:</B> Patients who had used insulin during the previous 3 months (except short term treatment)</P>
<P>
<B>AGE:</B> mean 56 to 57 years (SD 9)</P>
<P>
<B>SEX: </B>40% to 46% female</P>
<P>
<B>DIABETES DURATION:</B> mean 7 to 8 years (SD 5)</P>
<P>
<B>ETHNICITY:</B> 88% to 89% White, 2% to 4% Black, 7% to 9% Asian, 1% to 3% other</P>
<P>
<B>HbA1c (%):</B> LIR 1.2 mg: 8.3 SD 1, LIR 1.8 mg: 8.4 SD 1, SU: 8.4 SD 1, Placebo: 8.4 SD 1.1</P>
<P>
<B>BMI (kg/m<SUP>2</SUP>):</B> LIR 1.2 mg: 31.1 SD 4.8, LIR 1.8 mg: 30.9 SD 4.6, SU: 31.2 SD 4.6, Placebo: 31.6 SD 4.4</P>
<P>
<B>PREVIOUS THERAPY:</B> 65% combination therapy, 35% monotherapy (88% metformin)</P>
<P>
<B>NUMBERS:</B> Randomised: 1091 (4 withdrew consent before treatment), Analysed as ITT: 1087; LIR 0.6 mg: 242, LIR 1.2 mg: 240, LIR 1.8 mg: 242, SU: 242, Placebo: 121</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-24 12:06:33 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>COMPARISON:</B> Liraglutide (LIR) (3 doses) + Metformin (MET) VERSUS Glimepiride (SU) + MET VERSUS Placebo + MET</P>
<P>
<B>NO. OF COMPARISON GROUPS: </B>5</P>
<P>
<B>RUN-IN: </B>Forced titration period of metformin for three weeks (dose increased up to 2000 mg/day: 1000 mg in the morning and 1000 mg in the evening) followed by a 3 week metformin maintenance period before randomisation.</P>
<P>
<B>DOSE LIR: </B>0.6, 1.2 or 1.8 mg/day injected subcutaneously once daily (0.6 mg not included in this review). LIR titrated after randomisation for 2 to 3 weeks (increase by 0.6 mg/day per week)</P>
<P>
<B>DOSE MET: </B>1500 to 2000 mg/day</P>
<P>
<B>DOSE SU: </B>4 mg glimepiride OD with  the first meal of the day. Glimepiride (SU) titrated after randomisation for 2 to 3 weeks (1 mg in week 1, 2 mg week 2, 4 mg week 3)</P>
<P>
<B>OTHER TREATMENT:</B> not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-21 20:03:00 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOMES: </B>Change in HbA1c at the end of the study</P>
<P>
<B>SECONDARY OUTCOMES: </B>Body weight, fasting plasma glucose (FPG), postprandial glucose (PPG) (7 point plasma glucose profiles: before each meal, 90 min after breakfast), beta cell function (based on fasting insulin, fasting C-peptide, fasting proinsulin-to-insulin ratio and the homeostasis model assessment index of beta cell function (HOMA-B))</P>
<P>
<B>OTHER OUTCOMES:</B> Adverse events, vital signs, electrocardiogram, biochemical and hematology measures, and subject-reported hypoglycaemic episodes (based on symptoms and plasma glucose &lt;3.1 mmol/L)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-30 10:09:38 +0200" MODIFIED_BY="Bernd Richter">
<P>
<B>AIM: </B>To study the efficacy and safety of Liraglutide as a combination therapy with metformin as compared with placebo and glimepiride in addition to metformin</P>
<P>
<B>SOURCE OF FUNDING:</B> Novo Nordisk (presumably)</P>
<P>
<B>OTHER:</B> Conflict of interest: Some authors are members of advisory board and have received honoraria from Novo Nordisk, and work for Novo Nordisk.</P>
<P>
<B>SAMPLE SIZE: </B>The combined power (calculated as the product of the marginal powers for A1C and weight) was at least 85%.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-30 10:09:50 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-L-_x002d_-LEAD-4-Zinman-2009">
<CHAR_METHODS MODIFIED="2011-06-24 12:06:49 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN:</B> RCT (1:1:1), placebo control, parallel group, multicenter (96 sites)</P>
<P>
<B>DURATION OF INTERVENTION: </B>26 weeks</P>
<P>
<B>DURATION OF FOLLOW-UP:</B> No post-intervention follow-up</P>
<P>
<B>RUN-IN PERIOD: </B>6 to 9 weeks<BR/>
</P>
<P>
<B>SETTING: </B>Not reported</P>
<P>
<B>COUNTRY: </B>USA and Canada<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-24 12:07:05 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA:</B> people with type 2 diabetes, 18 to 80 years of age HbA1c between 7% to 11% (prestudy OAD monotherapy for &#8805; 3 months or 7% to 10% (prestudy OAD combination therapy for &#8805; 3 months, BMI &#8804; 45kg/m<SUP>2</SUP>; eligibility for randomisation: participants tolerating maximum doses of OAD (metformin and rosiglitazone) and with FPG values of 135 to 230 mg/dL (7.5 to 12.8 mmol/L) after 6 weeks treatment with titrated dose</P>
<P>
<B>EXCLUSION CRITERIA: </B>Participants using insulin during the previous 3 months (except short term treatment)</P>
<P>
<B>AGE:</B> mean 55 years (SD 10)</P>
<P>
<B>SEX: </B>38% to 49% female</P>
<P>
<B>DIABETES DURATION: </B>mean 9 years (SD 6)</P>
<P>
<B>ETHNICITY: </B>81% to 84% White, 10% to 15% Black, 1% to 3% Asian, 1% American Indian, 2% to 3% other</P>
<P>
<B>HbA1c (%): </B>LIR 1.2 mg: 8.5 SD 1.2, LIR 1.8 mg: 8.6 SD 1.2, Placebo: 8.4 SD 1.2</P>
<P>
<B>BMI (kg/m<SUP>2</SUP>): </B>LIR 1.2 mg: 33.2 SD 5.4, LIR 1.8 mg: 33.5 SD 5.1, Placebo: 33.9 SD 5.2</P>
<P>
<B>PREVIOUS THERAPY: </B>17% monotherapy, 83% combination therapy</P>
<P>
<B>NUMBERS: </B>533 randomised; LIR 1.2 mg:178; LIR 1.8 mg:178; Placebo:177<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-19 11:15:59 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>COMPARISON:</B> Liraglutide (LIR) (2 doses) + Metformin (MET) + Rosiglitazone (TZD) VERSUS Placebo + MET + TZD</P>
<P>
<B>NO. OF COMPARISON GROUPS:</B> 3</P>
<P>
<B>RUN-IN: </B>Treatment with other OADs except MET and TZD were discontinued prior to randomisation. MET dose started at 500 mg and was titrated up to 2000 mg/day. Rosiglitazone (TZD) dose started at 4 mg and was titrated up to 8 mg/day.</P>
<P>
<B>DOSE LIR: </B>LIR 1.2 mg/day or 1.8 mg/day injected subcutaneously once daily. LIR started with 0.6 mg/day for a week and increased up to 1.2 mg/day and then to 1.8 mg/day after an additional week for those randomised to highest dose</P>
<P>
<B>DOSE MET:</B> 2000 mg/day (1000 mg in the morning and 1000 mg in the evening)</P>
<P>
<B>DOSE TZD:</B> Rosiglitazone 8 mg/day (4 mg in the morning and 4 mg in the evening)</P>
<P>
<B>OTHER TREATMENT: </B>None</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-24 13:28:59 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOMES:</B> HbA1c (change from randomisation to end of study)</P>
<P>
<B>SECONDARY OUTCOMES: </B>Change in following parameters: body weight, FPG (Fasting plasma glucose), PPG (Postprandial glucose) (from 7-point plasma glucose profiles), beta-cell function (based on fasting insulin, fasting C-peptide, fasting pro-insulin to insulin ratio, and the homeostasis model assessment (HOMA) for beta cells (HOMA-B) and insulin resistance (HOMA-IR)), blood pressure, lipids</P>
<P>
<B>OTHER OUTCOMES: </B>Safety variables including adverse events, vital signs, ECG, biochemical and haematology measures, and subject reported hypoglycaemic episodes (plasma glucose &lt; 3.1 mmol/L)</P>
<P>Superiority of liraglutide tested</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-30 10:09:50 +0200" MODIFIED_BY="Bernd Richter">
<P>
<B>AIM:</B>To study the efficacy and safety of Liraglutide as a combination therapy with metformin and rosiglitazone in type 2 diabetes</P>
<P>
<B>SOURCE OF FUNDING: </B>Novo Nordisk (presumably)</P>
<P>
<B>OTHER: </B>Conflict of interest Novo Nordisk, Denmark</P>
<P>
<B>SAMPLE SIZE: </B>The combined power (calculated as the product of the marginal powers for HbA1c and weight) was &gt; 95%.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-30 10:09:59 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009">
<CHAR_METHODS MODIFIED="2011-06-19 17:08:27 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN:</B> RCT (2:1:2), parallel group, placebo-controlled, multicenter (107 sites)</P>
<P>
<B>DURATION OF INTERVENTION:</B> 26 weeks</P>
<P>
<B>DURATION OF FOLLOW-UP: </B>1 week post-intervention follow-up (but no data given)</P>
<P>
<B>RUN-IN PERIOD:</B> 6 weeks</P>
<P>
<B>SETTING:</B> Not reported</P>
<P>
<B>COUNTRY: </B>Multinational (17 countries)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-24 12:07:58 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA: </B>People with type 2 diabetes, 18 to 80 years, treated with OAD for at least 3 months before screening, HbA1c level between 7.5% to 10% (monotherapy) or 7% to 10% (combination therapy), BMI &#8804; 45kg/m<SUP>2</SUP>
</P>
<P>
<B>EXCLUSION CRITERIA:</B> Patients who had used insulin within 3 months prior to the trial; patients with impaired renal or hepatic function, cardiovascular disease, cancer, hypertension, retinopathy, maculopathy; pregnant patients; those with recurrent hypoglycaemia or hypoglycaemia awareness; those who were seropositive for hepatitis B antigen or hepatitis C antibody; or who have used any other drugs except OAD that could affect blood glucose levels</P>
<P>
<B>AGE:</B> mean 57.5 years (SD10)</P>
<P>
<B>SEX: </B>40% to 51% female</P>
<P>
<B>DIABETES DURATION:</B> mean 9.2 to 9.7 years (SD 6)</P>
<P>
<B>ETHNICITY: </B>Not reported</P>
<P>
<B>HbA1c (%):</B> LIR: 8.3 SD 0.9, Placebo: 8.3 SD 0.9, GLAR (insulin glargine): 8.2 SD 0.9</P>
<P>
<B>BMI (kg/m<SUP>2</SUP>):</B> LIR: 30.4 SD5 .3, Placebo: 31.3 SD 5.0, GLAR: 30.3 SD 5.3</P>
<P>
<B>EXISTING THERAPY:</B> 5 to 6% monotherapy, 94% to 95% combination treatment</P>
<P>
<B>NUMBERS:</B> 581 randomised, ITT population 576; LIR: 230, Placebo: 114, GLAR: 232<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-24 12:08:12 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>COMPARISON: </B>Liraglutide (LIR) + Metformin (MET) + Glimepiride (SU) VERSUS Placebo + MET + SU VERSUS GLAR + MET + SU</P>
<P>
<B>NO. Of COMPARISON GROUPS:</B> 3</P>
<P>
<B>RUN-IN: </B>Forced MET and SU dose escalation over 3 weeks followed by 3 weeks maintenance</P>
<P>
<B>DOSE LIR:</B> 1.8 mg OD. Dose escalation starting at 0.6 mg and increasing weekly by 0.6 mg over 2 weeks.</P>
<P>
<B>DOSE MET:</B> 2 gm (1 gm BID)</P>
<P>
<B>DOSE SU: </B>Glimepiride 4 mg OD, reduction to 2 mg allowed in case of adverse events or hypoglycaemia</P>
<P>
<B>DOSE GLAR:</B> Insulin glargine (open label). Insulin was titrated according to patient-driven algorithm (average dose at the end of study was 24 IU/day)</P>
<P>
<B>OTHER TREATMENT:</B> None</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-20 14:40:22 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOMES:</B> HbA1c (change from baseline to end)</P>
<P>
<B>SECONDARY OUTCOMES:</B> Change in weight, FPG, eight point plasma glucose (PG) profiles, beta-cell function, and blood pressure</P>
<P>
<B>OTHER OUTCOMES: </B>Safety variables like hypoglycaemic episodes, adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-30 10:09:59 +0200" MODIFIED_BY="Bernd Richter">
<P>
<B>AIM: </B>To compare the efficacy and safety of liraglutide to insulin glargine all as add on to combination therapy of metformin and glimepiride</P>
<P>
<B>SOURCE OF FUNDING:</B> Novo Nordisk (presumably)</P>
<P>
<B>OTHER: </B>Conflict of interest: Novo Nordisk, Amylin Pharmaceuticals</P>
<P>
<B>SAMPLE SIZE: </B>Study was powered to determine a 3% difference in weight with a combined power &gt; 85%.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-30 10:10:08 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-L-_x002d_-LEAD-6-Buse-2009">
<CHAR_METHODS MODIFIED="2009-11-20 14:44:52 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN: </B>RCT, open label, active comparator, parallel group, multi-centre (132 sites)</P>
<P>
<B>DURATION OF INTERVENTION: </B>26 weeks</P>
<P>
<B>DURATION OF FOLLOW-UP:</B> No post-intervention follow-up</P>
<P>
<B>RUN-IN PERIOD: </B>None</P>
<P>
<B>COUNTRY: </B>15 countries<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-22 17:07:50 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA: </B>People with type 2 diabetes, 18 to 80 years old, HbA1c between 7% and 11%, BMI &#8804; 45 kg/m<SUP>2</SUP>, stable on treatment with maximally tolerated dose of metformin, sulphonylurea, or both, for 3 months or more</P>
<P>
<B>EXCLUSION CRITERIA:</B> Previous insulin treatment (except short term treatment), previous treatment with exenatide or liraglutide, impaired renal or liver function, diseases like retinopathy or maculopathy or related to cardiovascular requiring acute treatment, uncontrolled hypertension, cancer</P>
<P>
<B>AGE:</B> mean 56 to 57 years (SD 10)</P>
<P>
<B>SEX:</B> 45% to 51% female</P>
<P>
<B>DIABETES DURATION:</B> mean 7.9 to 8.5 years (SD 6)</P>
<P>
<B>ETHNICITY: </B>91% to 93% White, 1% to 5% Asian, 12% to 13% Black, 3% to 4% other</P>
<P>
<B>HbA1c (%): </B>LIR: 8.2 SD 1.0, EX: 8.1 SD 1.0</P>
<P>
<B>BMI (kg/m<SUP>2</SUP>): </B>LIR: 32.9 SD 5.5, EX: 32.9 SD 5.7</P>
<P>
<B>PREVIOUS THERAPY:</B> 62% to 64% MET plus SU, 27% MET monotherapy, 9% to 10% SU monotherapy<BR/>
</P>
<P>
<B>NUMBERS:</B> 464 randomised; LIR: 233; EX: 231; (exposed LIR: 235; EX: 232)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-24 12:09:22 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>COMPARISON: </B>LIR + existing therapy MET and/or SU VERSUS EX + existing MET and/or SU therapy</P>
<P>
<B>NO. OF COMPARSION GROUPS: </B>2</P>
<P>
<B>RUN-IN:</B> None</P>
<P>
<B>DOSE LIR:</B> Liraglutide 1.8 mg OD; 2 week dose escalation starting at 0.6 mg/day increasing weekly by 0.6 mg up to 1.8 mg</P>
<P>
<B>DOSE EX:</B> Exenatide 10 &#956;g BID; 4 week dose escalation starting at 5 &#956;g BID increasing to 10 &#956;g BID at 4 weeks</P>
<P>
<B>DOSE MET:</B> Prestudy dose</P>
<P>
<B>DOSE SU:</B> Prestudy dose, in case of unacceptable hypoglycaemia SU dose could be reduced to no less than 50% of starting dose</P>
<P>
<B>OTHER TREATMENT:</B> None</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-24 12:09:35 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOMES:</B> Change in HbA1c % from baseline to end point</P>
<P>
<B>SECONDARY OUTCOMES: </B>Reduction in FPG levels (mmol/L), % of patients who achieved a target HbA1c level &#8804; 7%, % of patients who achieved a target HbA1c level &#8804; 6.5%, mean change in body weight %, mean changes in self measured 7-point plasma glucose profiles, % change in HOMA-B from baseline, mean changes in glucagon, blood pressure and lipid profiles, overall treatment satisfaction (Diabetes Treatment Satisfaction questionnaire) assessed in a subgroup of patients</P>
<P>
<B>OTHER OUTCOMES:</B> Safety variables including adverse events, vital signs, electrocardiogram, biochemical and haematological measures, and patient reported hypoglycaemic episodes were assessed.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-30 10:10:08 +0200" MODIFIED_BY="Bernd Richter">
<P>
<B>AIM: </B>To compare the effectiveness of liraglutide to exenatide as an add on therapy to metformin and/or sulphonylurea.</P>
<P>
<B>SOURCE OF FUNDING: </B>Novo Nordisk</P>
<P>
<B>OTHER: </B>Conflict of interest: main author is a member of advisory board and have received honoraria from Novo Nordisk and various other pharmaceutical companies, and work as consultant for various other pharmaceutical companies.</P>
<P>
<B>SAMPLE SIZE: </B>85% power to detect an HbA1c difference of 0.4% between groups.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-30 15:30:55 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-L-_x002d_-Pratley-2010">
<CHAR_METHODS MODIFIED="2011-06-22 17:09:00 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>: Active comparator, parallel-group, open label trial; non-inferiority and superiority comparison</P>
<P>
<B>DURATION OF INTERVENTION</B>: 26 weeks</P>
<P>
<B>DURATION OF FOLLOW-UP</B>: After the 26 week study, participants could continue into a 12 month follow-up trial</P>
<P>
<B>RUN-IN PERIOD: </B>
</P>
<P>
<B>SETTING</B>: 158 office-based sites</P>
<P>
<B>COUNTRY</B>: Multinational (11 European countries: Croatia, Germany, Ireland, Italy, Netherlands, Romania, Serbia, Slovakia, Slovenia, Spain and UK; the USA and Canada)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-24 13:31:24 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA</B>: Participants aged between 18 to 80 years; type 2 diabetes mellitus, HbA1c of 7.5% to10.0%; BMI &#8804; 45 kg/m<SUP>2</SUP>; treated with metformin &#8805; 1500 mg daily for 3 months or longer.</P>
<P>
<B>EXCLUSION CRITERIA</B>: Previous treatment with any antihyperglycaemic drug apart from metformin within 3 months of the trial; recurrent major hypoglycaemia or hypoglycaemia unawareness; present use of any drug except metformin that could affect glucose; contraindications to trial drugs; impaired renal or hepatic function; clinically significant cardiovascular disease; or cancer.</P>
<P>
<B>AGE</B>: 55.0 SD 9.0 to 55.9 SD9.6 years</P>
<P>
<B>SEX</B>: 45% to 48% female (LIR 1.2 mg: 48%; LIR 1.8 mg: 48%; SITA: 45%)</P>
<P>
<B>DIABETES DURATION</B>: 6.0 SD 4.5 to 6.4 SD 5.4 years</P>
<P>
<B>ETHNICITY</B>: 82% to 91% White (15% to 17% Hispanic or Latino); 5% to 10% Black; 1% to 2% Asian or Pacific Islander; 4% to 5% Other</P>
<P>
<B>HbA1c (%)</B>: LIR 1.2 mg: 8.4 SD 8.0; LIR 1.8 mg: 8.4 SD 0.7; SITA: 8.5 SD 0.7</P>
<P>
<B>BMI (kg/m<SUP>2</SUP>)</B>: LIR 1.2 mg: 32.6 SD 5.2; LIR 1.8 mg: 33.1 SD 5.1; SITA: 32.6 SD 5.4</P>
<P>
<B>PREVIOUS THERAPY</B>: MET</P>
<P>
<B>NUMBERS</B>: Assessed: 1302; randomised: 665 (LIR 1.2 mg: 225; LIR 1.8 mg: 221; SITA: 219); full analysis set: 658 (LIR 1.2 mg: 221; LIR 1.8 mg: 218; SITA: 219); fully analysis/safety analysis set: 658 (LIR 1.2 mg: 221; LIR 1.8 mg: 218; SITA: 219)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-30 15:30:55 +0200" MODIFIED_BY="Bernd Richter">
<P>
<B>COMPARISON: </B>LIR 1.2 mg or 1.8 mg once daily  + MET VERSUS SITA 100 mg daily + MET</P>
<P>
<B>NO. OF COMPARISON GROUPS</B>: 3</P>
<P>
<B>DOSE LIR: </B>LIR started at 0.6 mg/day and escalated by 0.6 mg/week to the allocated dose; s.c. with a pen device.</P>
<P>
<B>DOSE SITA:</B> SITA was started and maintained at 100 mg/day.</P>
<P>
<B>DOSE MET:</B> Background treatment with MET remained stable.</P>
<P>
<B>OTHER TREATMENT:</B> NR</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-22 17:10:56 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOMES</B>: Change in HbA1c from baseline to week 26</P>
<P>
<B>SECONDARY OUTCOMES</B>: Superiority and non-inferiority comparisons; proportions of participants reaching HbA1c targets of less than 7.0% (ADA) or of 6.5% or lower (AACE, IDF, NICE); FPG; PPG; bodyweight; &#946;-cell function; fasting lipid profile; cardiovascular risk markers (high sensitivity C-reactive protein, plasminogen activator inhibitor type 1, N-terminal pro-B-type natriuretic peptide, adiponectin, interleukin-6, tumour necrosis factor &#945;, and von Willebrand factor); BP; HR; physical measures (waist circumference, waist-to-hip ratio); treatment satisfaction; and a composite endpoint of proportions of participants with HbA1c &lt; 7% with no hypoglycaemia, and weight change of 0kg or less.</P>
<P>
<B>OTHER OUTCOMES: </B>Adverse events, self-reported hypoglycaemia, and selected haematological and biochemical measures including calcitonin.<BR/>Minor hypoglycaemic episodes (PG &lt; 3.1 mmol/L); Major hypoglycaemic episodes (third-party assistance irrespective of glucose concentrations).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-30 10:10:19 +0200" MODIFIED_BY="Bernd Richter">
<P>
<B>AIM</B>: To compare the efficacy and safety of treatment with liraglutide or sitagliptin for 26 weeks in individuals with type 2 diabetes who did not achieve adequate glycaemic control with metformin.</P>
<P>
<B>SOURCE OF FUNDING</B>: Novo Nordisk</P>
<P>
<B>OTHER</B>: Conflict of interest: Authors have received grants and consultancy fees from different pharmaceutical companies.</P>
<P>
<B>SAMPLE SIZE: </B>To show that 1.8 mg liraglutide plus metformin was non-inferior to 100 mg sitagliptin with metformin with a margin of 0.4%, 163 participants per group were needed for 85% power and with a predicted withdrawal of 25%, 217 participants per group were needed. </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-30 10:10:48 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-L-_x002d_-Yang-2010">
<CHAR_METHODS MODIFIED="2011-01-19 13:05:04 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>: Double-blind, double dummy, randomised, four-arm, active control trial</P>
<P>
<B>DURATION OF INTERVENTION</B>: 16 weeks</P>
<P>
<B>DURATION OF FOLLOW-UP</B>:</P>
<P>
<B>RUN-IN PERIOD: </B>Eligible participants discontinued their pretrial OADs except metformin and entered a 3-week run-in with forced escalation of metformin to 2000 mg/day, followed by another 3-week metformin maintenance period.</P>
<P>
<B>SETTING</B>: China (17 sites), South Korea (10 sites) and India (24 sites)</P>
<P>
<B>COUNTRY</B>: China, South Korea and India</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-24 13:31:32 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA</B>: Participants diagnosed with type 2 diabetes and treated with one or more oral antidiabetic drugs (OADs) for at least 3 months, aged 18 to 80 years (18 to 75 years for Chinese subjects), with HbA1c &#8805; 7.0% and &#8804; 11.0% for subjects on OAD monotherapy or &#8805; 7.0% and &#8804; 10.0% for subjects on OAD combination therapy and BMI &#8804; 45.0 kg/m<SUP>2</SUP>.</P>
<P>
<B>EXCLUSION CRITERIA</B>: Participants treated with insulin within the last 3 months. </P>
<P>
<B>AGE</B>: 52.7 SD 9.1 to 53.6 SD9.7 years</P>
<P>
<B>SEX</B>: 41.6% to 46.2% female (LIR 1.2 mg: 45.1%; LIR 1.8 mg: 46.2%; GLIM (Glimepiride): 41.6%)</P>
<P>
<B>DIABETES DURATION</B>: 7.2 SD 5.2 to 7.8 SD 6.1 years</P>
<P>
<B>ETHNICITY</B>: NR</P>
<P>
<B>HbA1c (%)</B>: LIR 1.2 mg: 8.6 SD 1.1; LIR 1.8 mg: 8.6 SD 1.1; GLIM: 8.5 SD 1.1</P>
<P>
<B>BMI (kg/m<SUP>2</SUP>)</B>: LIR 1.2 mg: 25.4 SD 3.7; LIR 1.8 mg: 25.8 SD 3.8; GLIM: 25.3 SD 3.7</P>
<P>
<B>PREVIOUS THERAPY</B>: OAD monotherapy: 29.4% to 32.1%; OAD combination: 67.9% to 70.6%</P>
<P>
<B>NUMBERS</B>: Randomised: 926; Exposed: 928 (LIR 1.2 mg: 233; LIR 1.8 mg: 233; GLIM: 231); per-protocol set: 562 (LIR 1.2 mg: 179; LIR 1.8 mg: 172; GLIM: 211)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-24 12:13:26 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>COMPARISON: </B>LIR 0.6 mg/1.2 mg/1.8 mg + MET + GLIM Placebo VERSUS GLIM + MET + LIR placebo</P>
<P>
<B>NO. OF COMPARISON GROUPS</B>: 3 (LIR 0.6 mg arm excluded)</P>
<P>
<B>DOSE LIR 1.2 mg/ LIR 1.8 mg: </B>dose of LIR was increased from 0.6 mg/day to the respective target dose level (in steps of 0.6 mg/day per week) LIR was injected once daily at any time of the day.</P>
<P>
<B>DOSE GLIM:</B> Subjects were instructed to start dose escalation of GLIM by daily administration of a 1 mg capsule. Further dose escalation took place over a 2-week period, incrementing to a maximum dose of 4 mg/day.</P>
<P>
<B>DOSE LIR PLACEBO:</B> dose of LIR placebo was increased from 0.6 mg/day to the respective target dose level (in steps of 0.6 mg/day per week) LIR was injected once daily at any time of the day.</P>
<P>
<B>DOSE GLIM PLACEBO:</B> start dose escalation of GLIM placebo by daily administration of a 1 mg capsule. Further dose escalation took place over a 2-week period, incrementing to a maximum dose of 4 mg/day.</P>
<P>
<B>OTHER TREATMENT:</B>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-22 17:14:19 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOMES</B>: Change in HbA1c from baseline to the end of the trial</P>
<P>
<B>SECONDARY OUTCOMES</B>: Changes in body weight, FPG, 7-point self-measured plasma glucose profile [before each main meal (breakfast, lunch and dinner), 90 min after start of each main meal, and at bedtime], blood pressure (BP) and &#946;-cell function measured by the homeostasis model assessment index of &#946;-cell function and the pro-insulin to insulin ratio.</P>
<P>
<B>OTHER OUTCOMES: </B>Safety variables included AEs, physical examination, pulse rate, electrocardiogram, haematology, biochemistry and urine measures, formation of liraglutide antibodies and subject reported hypoglycaemic events (based on symptoms and plasma glucose &lt; 3.1 mmol/L). Minor hypoglycaemic events were self-treated; major events required third-party assistance.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-30 10:10:48 +0200" MODIFIED_BY="Bernd Richter">
<P>
<B>AIM</B>: To assess and compare the efficacy and safety of liraglutide with those of glimepiride, both in combination with metformin for the treatment of type 2 diabetes in Asian population from China, South Korea and India.</P>
<P>
<B>SOURCE OF FUNDING</B>: Novo Nordisk</P>
<P>
<B>OTHER</B>: Conflict of interest: Two authors are employees of Novo Nordisk. Other authors have no competing interests.</P>
<P>
<B>SAMPLE SIZE: </B>In order to be able to show that liraglutide was non-inferior to glimepiride when using a 1 : 1 : 1 : 1 randomisation and a non-inferiority margin of 0.4% (difference in HbA1c reduction) with a power of at least 85%, the sample size needed was 168 subjects per group. Assuming a drop out rate of 25%, the total number of subjects to be randomised was 896 (224 subjects for each dose of the liraglutide + metformin group and 224 in glimepiride + metformin group).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-30 10:11:15 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010">
<CHAR_METHODS MODIFIED="2011-01-19 16:07:06 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>: Multinational, randomised, double-blind, parallel-group, placebo controlled trial</P>
<P>
<B>DURATION OF INTERVENTION</B>: 13 weeks</P>
<P>
<B>DURATION OF FOLLOW-UP</B>:</P>
<P>
<B>RUN-IN PERIOD: </B>Initial 2 week screening phase, then, a 2 week, single-blind, placebo run-in period.</P>
<P>
<B>SETTING</B>: 133 centres</P>
<P>
<B>COUNTRY</B>: Multinational</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-24 12:14:21 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA</B>: Participants with type 2 diabetes at least 1 year's duration aged 30 to 75 years and inadequately controlled (HbA1c &#8805; 7.0 and &lt; 9.0%) on stable metformin monotherapy (&#8805; 1000 mg day) for at least 3 months prior to screening.</P>
<P>
<B>EXCLUSION CRITERIA</B>: History of gastrointestinal disease with prolonged nausea and vomiting during the previous 6 months; history of chronic pancreatitis or stomach/gastric surgery; severe cardiovascular events during the previous 6 months; or hepatic or renal disease at screening [serum creatinine &#8805; 114.4 µmol/L for males and &#8805; 106.8 µmol/L for females.</P>
<P>
<B>AGE</B>: 55.4 SD 9.2 to 56.8 SD 7.8 years</P>
<P>
<B>SEX</B>: 40.4% to 63% female</P>
<P>
<B>DIABETES DURATION</B>: 6.0 SD 4.8 to 7.2 SD 4.9 years</P>
<P>
<B>ETHNICITY</B>: 64.8% to 86.8% Caucasian, 1.8% to 16.7% Black, 9.3% to 21.8% Other</P>
<P>
<B>HbA1c (%)</B>: LIXI 5 &#956;g QD: 7.58 SD 0.7; LIXI 10 &#956;g QD: 7.52 SD 0.6; LIXI 20 &#956;g QD: 7.58 SD 0.7; LIXI 30 &#956;g QD: 7.52 SD 0.7; LIXI 5 &#956;g BID: 7.60 SD 0.6; LIXI 10 &#956;g BID: 7.54 SD 0.6; LIXI 20 &#956;g BID: 7.61 SD 0.7; LIXI 30 &#956;g BID: 7.46 SD 0.5; Placebo: 7.53 SD 0.6</P>
<P>
<B>BMI (kg/m<SUP>2</SUP>)</B>: LIXI 5 &#956;g QD: 30.7 SD 4.6; LIXI 10 &#956;g QD: 31.9 SD 4.0; LIXI 20 &#956;g QD: 32.0 SD 4.3; LIXI 30 &#956;g QD: 31.6 SD 3.6; LIXI 5 &#956;g BID: 31.6 SD 4.2; LIXI 10 &#956;g BID: 32.8 SD 4.4; LIXI 20 &#956;g BID: 32.7 SD 4.4; LIXI 30 &#956;g BID: 32.3 SD 4.5; Placebo: 31.7 SD 4.2</P>
<P>
<B>PREVIOUS THERAPY</B>: MET</P>
<P>
<B>NUMBERS</B>: Screened: 1466; randomised: 542 (LIXI 5 &#956;g QD: 55; LIXI 10 &#956;g QD: 52; LIXI 20 &#956;g QD: 55; LIXI 30 &#956;g QD: 54; LIXI 5 &#956;g BID: 53; LIXI 10 &#956;g BID: 56; LIXI 20 &#956;g BID: 54; LIXI 30 &#956;g BID: 54; Placebo: 55)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-24 12:12:16 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>COMPARISON: </B>Lixisenatide (LIXI) 5 &#956;g, 10 &#956;g, 20 &#956;g and 30 &#956;g QD or BID VERSUS Placebo</P>
<P>
<B>NO. OF COMPARISON GROUPS</B>: 9</P>
<P>
<B>DOSE LIXI: </B>Subcutaneous injections of LIXI doses of 5, 10, 20 or 30 &#956;g administered once daily or, twice daily within 1 hour before breakfast</P>
<P>
<B>DOSE PLACEBO:</B> One of four volume-matched placebo treatments administered twice daily.</P>
<P>
<B>DOSE MET:</B> Stable doses of MET</P>
<P>
<B>OTHER TREATMENT: </B>All patients received diet and lifestyle counselling according to the American Diabetes Association guidelines.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-24 12:14:52 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOMES</B>: Change in HbA1c from baseline to end of study.</P>
<P>
<B>SECONDARY OUTCOMES</B>: Percentage of patients achieving an HbA1c &#8804; 7.0 or &#8804; 6.5%, changes in body weight, FPG, and 2 h post-prandial plasma glucose after a standardized breakfast. Measurement of anti-lixisenatide antibody levels; safety and tolerability.</P>
<P>
<B>OTHER OUTCOMES: </B>Assessed by physical examination, adverse event reporting, blood pressure, heart rate, 12-lead ECG and standard laboratory measurements. Symptomatic hypoglycaemia was defined as symptoms consistent with hypoglycaemia, with an accompanying blood glucose &lt; 3.3 mmol/L or prompt recovery with carbohydrate.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-30 10:11:15 +0200" MODIFIED_BY="Bernd Richter">
<P>
<B>AIM</B>: To evaluate thoroughly the dose&#8211;response effect of lixisenatide using once- or twice-daily regimens (5 to 30 µg once or twice daily) on HbA1c changes over 13 weeks in metformin-treated patients with Type 2 diabetes.</P>
<P>
<B>SOURCE OF FUNDING</B>: sanofi-aventis, the manufacturer of lixisenatide.</P>
<P>
<B>OTHER</B>: Conflict of interest: First author has received research support from different pharmaceutical companies and has acted as a consultant for some of the companies. Another author has served on advisory boards and received honorarium or consulting fees from different pharmaceutical companies. He has also received research grants from Merck, Pfizer, sanofi-aventis, Novo Nordisk, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Forest, Takeda, Novartis, AstraZeneca, Amylin, Johnson &amp; Johnson, Daiichi Sankyo, Boehringer Ingelheim and MannKind. One author is an employee of sanofi-aventis.</P>
<P>
<B>SAMPLE SIZE: </B>Sample sizes of 50 patients in each active treatment group and 100 patients in the placebo group were calculated to provide a statistical power of 81% to detect a 0.6% (6.6 mmol/mol) difference in HbA1c between an active treatment and placebo assuming a standard deviation of 1.2% (13.1 mmol/L). Statistical significance was assumed at the 5% level.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-30 10:11:27 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-LY2189265-_x002d_Umpierrez-2011">
<CHAR_METHODS MODIFIED="2011-04-27 14:47:12 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>: Randomised, placebo-controlled, double-blind study</P>
<P>
<B>DURATION OF INTERVENTION</B>: 16 weeks</P>
<P>
<B>DURATION OF FOLLOW-UP</B>: </P>
<P>
<B>SETTING</B>: multiple (36 sites in United States and 3 sites in Puerto Rico)</P>
<P>
<B>COUNTRY</B>: United States; Puerto Rico</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-24 12:16:42 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA</B>: Participants at least 18 years of age with type 2 diabetes; BMI between 27 and 40 kg/m<SUP>2</SUP>; HbA1c &gt; 7.0% but &#8804; 10.5%; stable weight for at least 3 months at entry; receiving stable therapy for at least 3 months with an oral antihyperglycaemic medications from each of the two different classes (sulphonylurea, biguanide, thiazolidinedione or DPP-IV inhibitors).</P>
<P>
<B>EXCLUSION CRITERIA</B>: previous use of GLP-1 or a GLP-1 analogue, or current use of insulin or weight-loss medication; history of clinically significant gastric emptying abnormality, cardiovascular disorders or uncontrolled diabetes requiring hospitalisation more than once in the previous 6 months.</P>
<P>
<B>AGE</B>: 54 SD 11 to 59 SD 12 years</P>
<P>
<B>SEX</B>: 46% to 56% of female</P>
<P>
<B>DIABETES DURATION</B>: 7.5 SD 5.4 to 9.0 SD 7.6 years</P>
<P>
<B>ETHNICITY</B>: 55% to 61% Caucasians; 29% to 39% Hispanic;</P>
<P>
<B>HbA1c (%)</B>: LY 0.5/1.0 QW: 8.25 SD 0.9; LY 1.0/1.0 QW: 8.25 SD 1.0; LY 1.0/2.0 QW: 8.43 SD 1.0; Placebo: 8.05 SD 0.8</P>
<P>
<B>BMI (kg/m<SUP>2</SUP>)</B>: LY 0.5/1.0 QW: 33.7 SD 4.1; LY 1.0/1.0 QW: 33.9 SD 4.0; LY 1.0/2.0 QW: 34.2 SD 4.1; Placebo: 33.9 SD 4.3</P>
<P>
<B>PREVIOUS THERAPY</B>: 72.7% to 73.8% MET + SU; 12.3% to 13.6% MET + TZD; 7.6% to 9.1% MET + DPP-IV: 4.5% to 6.2% other; 9.1% to 13.8% discontinued</P>
<P>
<B>NUMBERS</B>: LY 0.5/1.0 QW: 66; LY 1.0/1.0 QW: 65; LY 1.0/2.0 QW: 65; Placebo: 66</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-24 12:17:03 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>COMPARISON</B>: LY 0.5/1.0 QW or LY 1.0/1.0 QW or LY 1.0/2.0 QW VERSUS Placebo</P>
<P>
<B>NO. OF COMPARISON GROUPS</B>: 4</P>
<P>
<B>LEAD- IN PERIOD</B>: All participants under went two weeks lead-in period of placebo injection</P>
<P>
<B>DOSE LY 0.5/1.0</B>: Once weekly subcutaneous injection of LY 0.5 mg for 4 weeks followed by 1.0 mg for 12 weeks.</P>
<P>
<B>DOSE LY 1.0/1.0</B>: Once weekly subcutaneous injection of LY 1.0 for 16 weeks</P>
<P>
<B>DOSE LY 1.0/2.0</B>: Once weekly subcutaneous injection of LY 1.0 for 4 weeks then 2.0 mg for 12 weeks.</P>
<P>
<B>DOSE Placebo</B>: Once weekly subcutaneous injection of placebo for 16 weeks</P>
<P>
<B>OTHER TREATMENT</B>: Participants continued their baseline oral antihyperglycaemic medications regimen.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-17 09:54:21 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOMES</B>: Change in HbA1c</P>
<P>
<B>SECONDARY OUTCOMES</B>: Changes in FPG, blood glucose responses following a solid mixed-meal test, body weight, HOMA-2 algorithm to assess &#946; -cell function (%-B), insulin sensitivity (%-S) and resistance (%-IR)</P>
<P>
<B>OTHER OUTCOMES</B>: Safety and tolerability that includes treatment emergent adverse events, hypoglycaemia, vital signs and laboratory tests.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-30 10:11:27 +0200" MODIFIED_BY="Bernd Richter">
<P>
<B>AIM</B>: To evaluate the efficacy and tolerability of once-weekly LY2189265 (LY), a GLP-1 IgG4-Fc fusion protein, in participants with type 2 diabetes failing oral antihyperglycaemic medications.</P>
<P>
<B>SOURCE OF FUNDING</B>: Eli Lilly and Company</P>
<P>
<B>OTHER</B>: First author has received research support from different pharmaceutical companies and has acted as a consultant for some of the companies. Another author has served on advisory boards and received honorarium or consulting fees from different pharmaceutical companies. He has also received research grants from some of these companies. Two authors are employees and shareholders of Eli Lilly and Company. One author was a shareholder, and during the conduct of the study and preparation of the paper, an employee, of Eli Lilly and Company.</P>
<P>
<B>SAMPLE SIZE: </B>Sixty patients per arm were estimated to provide 90% power at a 2-sided &#945; of 0.05 to detect a 0.9% change from baseline in HbA1c relative to placebo, assuming a standard deviation of 1.3 and 20% dropout rate.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-30 10:11:38 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-T-_x002d_-Nauck-2009">
<CHAR_METHODS MODIFIED="2009-11-17 17:41:14 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN:</B> RCT, parallel group, placebo controlled, multi-centre, phase 2b trial</P>
<P>
<B>DURATION OF INTERVENTION: </B>8 weeks</P>
<P>
<B>DURATION OF FOLLOW-UP:</B> 4 weeks post-intervention</P>
<P>
<B>RUN-IN PERIOD: </B>Up to 3 week screening period</P>
<P>
<B>COUNTRY:</B> Germany and Switzerland<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-24 12:18:43 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA:</B> Participants with type 2 diabetes, on metformin monotherapy (&#8805; 1500 mg/day) for at least 3 months before screening, age 18 to 75 years, HbA1c between 7.0% and 9.5%, BMI &gt; 25 and &#8804; 45 kg/m<SUP>2</SUP> and stable weight (± 10%) for at least 3 months before screening</P>
<P>
<B>EXCLUSION CRITERIA:</B> Type 1 diabetes; patient on any OAD other than metformin during the prior three months (except insulin); previous exposure to any GLP-1 analogues; impaired liver or kidney function, GI disease, uncontrolled hypertension or stroke or myocardial infarction</P>
<P>
<B>AGE: </B>mean 53 to 57 years (SD 6 to 11)</P>
<P>
<B>SEX:</B> 39% to 64% female</P>
<P>
<B>DIABETES DURATION: </B>mean 5 to 6 years (SD 4 to 5)</P>
<P>
<B>ETHNICITY: </B>Not reported</P>
<P>
<B>HbA1c (%):</B> Placebo: 8.0 SE 0.1, TAS 10 mg QW: 7.9 SE 0.1, TAS 20 mg QW: 7.8 SE 0.1, TAS 20 mg Q2W: 7.9 SE 0.1</P>
<P>
<B>BMI (kg/m<SUP>2</SUP>):</B> Placebo: 31.8 SE 4.9, TAS 10 mg QW: 32.6 SE 4.7, TAS 20 mg QW: 32.4 SE 5.2, TAS 20 mg Q2W: 33.2 SE 5.1</P>
<P>
<B>PREVIOUS THERAPY: </B>Metformin monotherapy (mean 1888 mg to 2019 mg)</P>
<P>
<B>NUMBERS: </B>306 randomised (safety database 297); Placebo: 49, TAS 5 mg QW: 50, TAS 10 mg QW: 49, TAS 20 mg QW: 50, TAS 10 mg Q2W: 50, TAS 20 mg Q2W: 49<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-18 17:28:18 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>COMPARISON: </B>Taspoglutide (TAS) (5 dose schedules) + Metformin (MET) VERSUS Placebo + MET</P>
<P>
<B>NO. OF COMPARISON GROUPS:</B> 6</P>
<P>For the current review, the following groups were excluded: 5 mg weekly and 10 mg every 2 weeks as the effect of those groups were less favourable than those of the other groups. </P>
<P>
<B>RUN-IN: </B>Screening only</P>
<P>
<B>DOSE TAS: </B>Taspoglutide 10 mg or 20 mg once weekly, or 20 mg once every 2 weeks</P>
<P>
<B>DOSE MET: </B>Pre-study MET regimen</P>
<P>
<B>OTHER TREATMENT: </B>Patients continued their prestudy diet and exercise plan throughout the study; patients were on a variety of other medication, such as ACE inhibitors, thiazide diuretics, angiotensin receptor blockers, statins, beta-blockers</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-24 12:19:06 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOMES: </B>Change in HbA1c from baseline to end of the study (assessed 1 week after 8 consecutive weeks of treatment)</P>
<P>
<B>SECONDARY OUTCOMES:</B> % of patients achieving HbA1c &#8804; 7% and &#8804; 6.5%; changes in following parameters from baseline: FPG, body weight, fructosamine, C-peptide, fasting insulin, pro-insulin, pro-insulin-to-insulin molar ratio, fasting glucagon, lipids</P>
<P>
<B>OTHER OUTCOMES: </B>Safety variables including adverse events, vital signs, physical examination, clinical laboratory tests, electrocardiogram, local tolerance at the injection site, anti-taspoglutide antibodies</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-30 10:11:38 +0200" MODIFIED_BY="Bernd Richter">
<P>
<B>AIM: </B>To assess the efficacy and safety of taspoglutide in patient with type 2 diabetes inadequately controlled with metformin therapy.</P>
<P>
<B>SOURCE OF FUNDING: </B>Hoffmann-La Roche, Switzerland.</P>
<P>
<B>OTHER: </B>Association of some of the authors with Roche</P>
<P>
<B>SAMPLE SIZE: </B>Sample size provided 90% power to detect a 1% difference in HbA1c.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-30 15:30:56 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-T_x002d_-Ratner-2010">
<CHAR_METHODS MODIFIED="2011-01-20 10:44:41 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>: Randomized, double-blind, placebo-controlled phase II trial</P>
<P>
<B>DURATION OF INTERVENTION</B>: 8 weeks</P>
<P>
<B>DURATION OF FOLLOW-UP</B>: 4 weeks follow up</P>
<P>
<B>RUN-IN PERIOD: </B>NR</P>
<P>
<B>SETTING</B>: 27 sites</P>
<P>
<B>COUNTRY</B>: Australia, France, Germany, Mexico, Peru and USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-24 12:20:37 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA</B>: Men and post-menopausal or surgically sterilised women aged 18 to 75 years with type 2 diabetes mellitus, treated with a stable daily dose of metformin monotherapy for at least 3 months before screening; dose of metformin not adjusted during the study; HbA1c between 7.0% and 9.5%; FPG &gt; 7 mmol/L and &#8804; 13.3 mmol/L; BMI &gt; 25 kg/m<SUP>2</SUP> and &#8804; 45.0 kg/m<SUP>2</SUP>; weight &#8804; ± 10% for at least 3 months before screening.</P>
<P>
<B>EXCLUSION CRITERIA</B>: Subjects with serious co-morbidities or abnormalities in laboratory tests; those who had previously been treated with GLP-1 receptor agonists (including GLP-1 itself) at any time, or with other glucose-lowering medications (apart from metformin) or weight-loss medications within 12 to 6 weeks respectively.</P>
<P>
<B>AGE</B>: 55 SE 2.0 to 60 SE 2.0 years</P>
<P>
<B>SEX</B>: 53% to 59% female (TAS 20/20 mg QW: 53%; TAS 20/30 mg QW; 55%; TAS 20/40 mg QW: 59%; Placebo: 59%)</P>
<P>
<B>DIABETES DURATION</B>: 6 SE 1.0 to 8 SE 1.0 years</P>
<P>
<B>ETHNICITY</B>: NR</P>
<P>
<B>HbA1c (%)</B>: TAS 20/20 mg QW: 8.0 SE0.1; TAS 20/30 mg QW: 8.0 SE0.1; TAS 20/40 mg QW: 7.8 SE0.1; Placebo: 7.8 SE0.1</P>
<P>
<B>BMI (kg/m<SUP>2</SUP>)</B>: TAS 20/20 mg QW: 33.3 SE0.9; TAS 20/30 mg QW: 31.6 SE1.0; TAS 20/40 mg QW: 31.5 SE0.9; Plaebo: 33.2 SE1.0</P>
<P>
<B>PREVIOUS THERAPY</B>: MET</P>
<P>
<B>NUMBERS</B>: Randomised: 133 (TAS 20 mg QW: 32, TAS 20/30 mg QW: 33; TAS 20/40 QW: 32; Placebo: 32); safety population: 129; ITT population: 125</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-30 15:30:56 +0200" MODIFIED_BY="Bernd Richter">
<P>
<B>COMPARISON: </B>TAS + MET VERSUS Placebo + MET</P>
<P>
<B>NO. OF COMPARISON GROUPS</B>: 4</P>
<P>
<B>DOSE TAS: </B>20 mg taspoglutide once weekly s.c. for 4 weeks followed by 4 weeks of 20 mg once weekly (20/20) or titration up to 30 mg once weekly (20/30) or 40 mg once weekly (20/40) taspoglutide;</P>
<P>
<B>DOSE PLACEBO:</B> placebo s.c. once weekly</P>
<P>
<B>DOSE MET: </B>pre-study metformin regimen throughout the study</P>
<P>
<B>DIET and EXERCISE:</B> pre-study diet and exercise plan throughout the study</P>
<P>
<B>OTHER TREATMENT: </B>Some patients received medications for cardiovascular risk factors: statins (22%); ACE-inhibitors (21%), fibrates (5%). ACE, thiazide diuretics, thyroid hormones and/or lipid-lowering medications were permitted but only with doses stable for at least 6 weeks prior to screening.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-20 10:44:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOMES</B>: GI tolerability, assessed by comparing the number of subjects who withdrew from study because of GI adverse events.</P>
<P>
<B>SECONDARY OUTCOMES</B>: FPG, HbA1c, body weight and pharmacokinetic parameters.</P>
<P>
<B>OTHER OUTCOMES:</B> NR</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-30 10:11:56 +0200" MODIFIED_BY="Bernd Richter">
<P>
<B>AIM</B>: To investigate the safety and tolerability of up titration to high doses of taspoglutide in patients with type 2 diabetes mellitus.</P>
<P>
<B>SOURCE OF FUNDING</B>: Hoffmann-La Roche</P>
<P>
<B>OTHER</B>: Conflict of interest: Two authors have received consulting and advisory board honoraria from F. Hoffmann-La Roche as well as from other pharmaceutical companies developing incretin-based therapies whose products may be perceived as competitive to taspoglutide. One author has received consulting and research fees from F. Hoffman-La Roche and Ispen. Some authors are employees of F. Hoffman-La Roche.</P>
<P>
<B>SAMPLE SIZE: </B>The paper says 'it was planned to enrol approximately 120 subjects into the study assigned randomly and equally to each of the treatment groups. This sample size was determined by practical considerations rather than formal calculations'.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>
<SUP>BMI: Body mass index, HbA1c: Glycosylated haemoglobin, ALBI: Albiglutide, MET: Metformin, EX: Exenatide, TZD: Thiazolidinedione, SU: Sulphonylurea, DPP-4: Dipeptidyl peptidase-4 inhibitor, SITA: Sitagliptin, PIO: Pioglitazone, GLAR: Insulin glargine, GLP: Glucagon like peptide, LIR: Liraglutide, ROS: Rosiglitazone, GLIM: Glimepiride, LIXI: Lixisenatide, LY: LY2189265, TAS: Taspoglutide, OCP: Oral contraceptive pill, LAR: Long acting release, ACE: Angiotensin-converting enzyme, FPG: Fasting plasma glucose, PPG: Post-prandial glucose, PG: Plasma glucose, HOMA-B: Homeostasis model assessment-beta cell function, ITT: Intention-to-treat, LOCF: Last observation carried forward, AE: Adverse event, ECG: Electrocardiography, GI: Gastrointestinal, SE: Standard error, SD: standard deviation, QD: Once daily, BID: Twice daily, QW: Once weekly, NR: Not reported, IWQOL: Impact of weight on quality of life questionnaire-lite, PGWB: Psychological general well-being index, DTSQ: Diabetes treatment satisfaction questionnaire, and EQ-5D: EuroQol-5 dimensions. </SUP>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2011-08-30 10:16:24 +0200" MODIFIED_BY="Bernd Richter" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2011-01-25 16:16:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Astrup-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-25 16:16:16 +0100" MODIFIED_BY="[Empty name]">
<P>Participants without type 2 diabetes mellitus</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-30 10:15:44 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Barnett-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-30 10:15:44 +0200" MODIFIED_BY="Bernd Richter">
<P>Patients failing on either metformin therapy or sulphonylurea treatment were included, but less than 70% of patients were on metformin therapy (only 55%).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-30 10:15:49 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Blonde-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-30 10:15:49 +0200" MODIFIED_BY="Bernd Richter">
<P>Combined analysis of three different trials, so patients included for analysis not actually randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-30 10:15:50 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Bode-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-30 10:15:50 +0200" MODIFIED_BY="Bernd Richter">
<P>Monotherpay compared to glimepiride only.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-30 10:15:52 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Brixner-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-30 10:15:52 +0200" MODIFIED_BY="Bernd Richter">
<P>All patient received exenatide.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-30 10:15:54 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Buse-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-30 10:15:54 +0200" MODIFIED_BY="Bernd Richter">
<P>Include patients failing on sulphonylurea only.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-30 10:16:00 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Feingloss-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-30 10:16:00 +0200" MODIFIED_BY="Bernd Richter">
<P>Liraglutide doses used in the study are clinically not relevant.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-30 10:16:02 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Gallwitz-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-30 10:16:02 +0200" MODIFIED_BY="Bernd Richter">
<P>Combined analysis of 3 LEAD trials (LEAD 1, 2 and 4).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-30 10:16:06 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Garber-2009-_x0028_LEAD-3_x0029_">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-30 10:16:06 +0200" MODIFIED_BY="Bernd Richter">
<P>Previous treatment with OADs discontinued at randomisation and compared to monotherapy only.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-30 10:16:08 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Kapitza-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-30 10:16:08 +0200" MODIFIED_BY="Bernd Richter">
<P>Single-dose administration of taspoglutide with follow up duration of less than 8 weeks.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-30 10:16:10 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Kim-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-30 10:16:10 +0200" MODIFIED_BY="Bernd Richter">
<P>Patients on diet/exercise or metformin were included, but less than 70% were on metformin therapy (60%).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-30 10:16:11 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Madsbad-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-30 10:16:11 +0200" MODIFIED_BY="Bernd Richter">
<P>Liraglutide doses used in the study are clinically not relevant.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-30 10:16:12 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Malloy-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-30 10:16:12 +0200" MODIFIED_BY="Bernd Richter">
<P>Participants aged less than 18 years of age.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-30 10:16:13 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Moretto-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-30 10:16:13 +0200" MODIFIED_BY="Bernd Richter">
<P>Monotherapy compared to placebo only.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-30 10:16:17 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Nauck-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-30 10:16:17 +0200" MODIFIED_BY="Bernd Richter">
<P>Combined analysis of subset of participants from two different trials, so patients included for analysis not actually randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-30 10:16:18 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Okerson-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-30 10:16:18 +0200" MODIFIED_BY="Bernd Richter">
<P>Combined analysis of six different trials.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-30 10:16:19 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Riddle-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-30 10:16:19 +0200" MODIFIED_BY="Bernd Richter">
<P>Combined analysis of two different trials, so patients included for analysis not actually randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-30 10:16:21 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Seino-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-30 10:16:21 +0200" MODIFIED_BY="Bernd Richter">
<P>Liraglutide doses used in the study are clinically not relevant.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-30 10:16:23 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Trescoli_x002d_Serrano-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-30 10:16:23 +0200" MODIFIED_BY="Bernd Richter">
<P>Published as abstract only.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-30 10:16:24 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Vilsboll-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-30 10:16:24 +0200" MODIFIED_BY="Bernd Richter">
<P>Monotherapy and compared to placebo only.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>
<SUP>LEAD: Liraglutide Effect and Action in Diabetes, OAD: Oral antidiabetic drug</SUP>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2010-01-15 11:02:13 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2011-08-30 15:31:09 +0200" MODIFIED_BY="Bernd Richter" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2011-08-30 15:31:00 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Albiglutide-NCT00838903">
<CHAR_STUDY_NAME MODIFIED="2011-06-24 15:46:04 +0200" MODIFIED_BY="[Empty name]">
<P>Efficacy and safety of albiglutide in treatment of type 2 diabetes</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-06-30 15:02:23 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>: Phase III, randomised, double-blind, placebo- and active-controlled, parallel-group study</P>
<P>
<B>DURATION OF INTERVENTION</B>: two years</P>
<P>
<B>COUNTRY</B>: USA, Germany, HongKong, Mexico, Peru, Phillipines, Russian Federation, South Africa, Spain, UK</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-24 15:49:23 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA</B>:</P>
<UL>
<LI>participants aged 18 years or more</LI>
<LI>type 2 diabetes</LI>
<LI>BMI 20 to 45 kg/m<SUP>2</SUP> inclusive</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-30 15:31:00 +0200" MODIFIED_BY="Bernd Richter">
<P>
<B>Albiglutide:</B> Alibiglutide + metformin + placebo sitagliptin + placebo glimepiride</P>
<P>
<B>Sitagliptin:</B> sitagliptin + metformin + placebo albiglutide + placebo glimepiride</P>
<P>
<B>Glimepiride:</B> glimepiride + metformin + placebo albiglutide + placebo sitagliptin</P>
<P>
<B>Metformin:</B> metformin + placebo albiglutide + placebo sitagliptin + placebo glimepiride</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-24 15:52:43 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOME</B>: change in HbA1c</P>
<P>
<B>SECONDARY OUTCOMES</B>: change in FPG and body weight</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-06-24 15:50:05 +0200" MODIFIED_BY="[Empty name]">
<P>February 2009, estimated completion date December 2012 (last updated on June 2, 2011)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-06-24 15:52:55 +0200" MODIFIED_BY="[Empty name]">
<P>GlaxoSmithKline</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-06-24 15:53:31 +0200" MODIFIED_BY="[Empty name]">
<P>ClinicalTrials.gov Identifier: NCT00838903; other study ID number: 112753</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2011-06-30 14:43:16 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Albiglutide-NCT00838916">
<CHAR_STUDY_NAME MODIFIED="2011-06-24 16:02:45 +0200" MODIFIED_BY="[Empty name]">
<P>A study to determine the safety and efficacy of albiglutide in patients with type 2 diabetes</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-06-30 14:43:16 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>: Phase III, randomised, open-label, parallel-group study</P>
<P>
<B>DURATION OF INTERVENTION</B>: one year</P>
<P>
<B>COUNTRY</B>: USA, Russian Federation, South Africa, UK</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-24 16:04:26 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA</B>:</P>
<UL>
<LI>participants aged 18 years or more</LI>
<LI>type 2 diabetes</LI>
<LI>BMI 20 to 45 kg/m<SUP>2</SUP>
</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-24 16:06:32 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Albiglutide:</B> albiglutide weekly injection</P>
<P>
<B>Insulin glargine:</B> insulin glargine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-24 16:06:42 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOME</B>: change in HbA1c</P>
<P>
<B>SECONDARY OUTCOMES</B>: change in FPG and body weight</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-06-24 16:07:19 +0200" MODIFIED_BY="[Empty name]">
<P>February 2009, estimated completion date December 2012 (last updated on June 9, 2011)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-06-24 16:04:45 +0200" MODIFIED_BY="[Empty name]">
<P>GlaxoSmithKline</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-06-24 16:05:47 +0200" MODIFIED_BY="[Empty name]">
<P>ClinicalTrials.gov identifier: NCT00838916; other study ID number: 112754</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2011-06-30 14:43:22 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Albiglutide-NCT00849017">
<CHAR_STUDY_NAME MODIFIED="2011-06-24 16:09:55 +0200" MODIFIED_BY="[Empty name]">
<P>Safety and efficacy study of albiglutide in type 2 diabetes</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-06-30 14:43:22 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>: Phase III, randomised, double-blind, placebo-controlled, parallel-group study</P>
<P>
<B>DURATION OF INTERVENTION</B>: one year</P>
<P>
<B>COUNTRY</B>: USA, Mexico</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-24 16:11:28 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA</B>:</P>
<UL>
<LI>participants aged 18 years or more</LI>
<LI>type 2 diabetes</LI>
<LI>BMI 20 to 45 kg/m<SUP>2</SUP>
</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-24 16:12:27 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Albiglutide:</B> albiglutide weekly injection</P>
<P>
<B>Placebo:</B> matching albiglutide placebo weekly injection</P>
<P>
<B>Albiglutide uptitration:</B> albiglutide uptitration at week 12</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-24 16:12:39 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOME</B>: change in HbA1c</P>
<P>
<B>SECONDARY OUTCOMES</B>: change in FPG and body weight</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-06-24 16:13:24 +0200" MODIFIED_BY="[Empty name]">
<P>January 2009, estimated completion date October 2012 (last updated on June 9, 2011)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-06-24 16:14:25 +0200" MODIFIED_BY="[Empty name]">
<P>GlaxoSmithKline</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-06-24 16:14:17 +0200" MODIFIED_BY="[Empty name]">
<P>ClinicalTrials.gov identifier: NCT00849017; other study ID number: 112756</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2011-06-30 14:43:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Albiglutide-NCT00849056">
<CHAR_STUDY_NAME MODIFIED="2011-06-24 15:55:58 +0200" MODIFIED_BY="[Empty name]">
<P>Safety and efficacy of albiglutide in type 2 diabetes</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-06-30 14:43:30 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>: Phase III, randomised, double-blind, placebo-controlled, parallel-group trial</P>
<P>
<B>DURATION OF INTERVENTION</B>: one year</P>
<P>
<B>COUNTRY</B>: USA, India, Peru, South Africa, UK</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-24 15:58:38 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA</B>:</P>
<UL>
<LI>participants aged 18 years or more</LI>
<LI>type 2 diabetes</LI>
<LI>BMI 20 to 45 kg/m<SUP>2</SUP>
</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-24 15:59:26 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Albiglutide:</B> albiglutide weekly injection + pioglitazone (with or without metformin)</P>
<P>
<B>Placebo:</B> placebo albiglutide weekly injection + pioglitazone (with or without metformin)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-24 16:00:34 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOME</B>: change in HbA1c</P>
<P>
<B>SECONDARY OUTCOMES</B>: change in FPG and body weight</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-06-24 16:00:11 +0200" MODIFIED_BY="[Empty name]">
<P>January 2009, estimated completion date October 2012 (last updated on June 9, 2011)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-06-24 15:57:32 +0200" MODIFIED_BY="[Empty name]">
<P>GlaxoSmithKline</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-06-24 15:58:02 +0200" MODIFIED_BY="[Empty name]">
<P>ClinicalTrials.gov identifier: NCT00849056; other study ID number: 112755</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2011-06-30 14:43:37 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Albiglutide-NCT01098461">
<CHAR_STUDY_NAME MODIFIED="2011-06-24 16:16:23 +0200" MODIFIED_BY="[Empty name]">
<P>Dose ranging study of albiglutide in Japanese subjects</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-06-24 16:31:23 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>: Phase II, double-blind, randomised, placebo-controlled, multicenter, 4-parallel-group, dose ranging study</P>
<P>
<B>DURATION OF INTERVENTION</B>: 16 weeks</P>
<P>
<B>COUNTRY</B>: Japan</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-24 16:32:21 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA</B>:</P>
<UL>
<LI>Participants aged between 20 and 75 years with a historical diagnosis of type 2 diabetes mellitus who is currently treated with diet and exercise only or one OAD</LI>
<LI>BMI &#8805; 18 kg/m<SUP>2</SUP> and &lt; 35 kg/m<SUP>2</SUP> at Screening</LI>
<LI>HbA1c between 7.0% and 10.0%</LI>
<LI>Fasting C-peptide &#8805; 0.8 ng/mL (&#8805; 0.26 nmol/L)</LI>
<LI>Female subjects of childbearing potential must be practicing adequate contraception .</LI>
<LI>Able and willing to monitor his/her own blood glucose concentrations with a home glucose monitor.</LI>
<LI>Able and willing to provide written informed consent</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-30 14:43:37 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Albiglutide:</B> subcutaneous injection albiglutide 15 mg or 30 mg weekly or 30 mg every two weeks</P>
<P>
<B>Placebo:</B> subcutaneous injection of placebo to match albiglutide</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-24 16:40:19 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOME</B>: change in HbA1c</P>
<P>
<B>SECONDARY OUTCOMES</B>: change in HbA1c over time, change in FPG and body weight; Proportion of subjects who achieve HbA1c treatment goal; pharmacokinetic levels of albiglutide</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-06-24 16:39:03 +0200" MODIFIED_BY="[Empty name]">
<P>April 2010, estimated completion date March 2011 (last updated on November 18, 2010)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-06-24 16:34:53 +0200" MODIFIED_BY="[Empty name]">
<P>GlaxoSmithKline</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-06-24 16:34:42 +0200" MODIFIED_BY="[Empty name]">
<P>ClinicalTrials.gov Identifier: NCT01098461; other study ID number: 110932</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2011-06-30 11:12:56 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Albiglutide-NCT01128894">
<CHAR_STUDY_NAME MODIFIED="2011-06-19 14:39:58 +0200" MODIFIED_BY="[Empty name]">
<P>A study to determine the efficacy and safety of albiglutide as compared with liraglutide.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-06-24 16:16:32 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>: Phase III, randomised, open-label, parallel-group, multicenter study</P>
<P>
<B>DURATION OF INTERVENTION</B>: 32 weeks</P>
<P>
<B>COUNTRY</B>: USA, Australia, Israel, Korea, Peru, Phillipines, Spain, UK</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-30 11:12:56 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA</B>:</P>
<UL>
<LI>Diagnosis of type 2 diabetes mellitus and experiencing inadequate glycaemic control on their current regimen of metformin, TZD, SU, or any combination of these oral antidiabetic medications</LI>
<LI>BMI &#8805; 20 kg/m<SUP>2</SUP> and &#8804; 45 kg/m<SUP>2</SUP>
</LI>
<LI>Fasting C-peptide &#8805; 0.8 ng/mL (&#8805; 0.26 nmol/L)</LI>
<LI>HbA1c between 7.0% and 10.0%, inclusive</LI>
<LI>Female subjects of childbearing potential must be practicing adequate contraception.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-19 14:39:59 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Albiglutide:</B> once weekly injection</P>
<P>
<B>Liraglutide:</B> liraglutide daily subcutaneous injection, starting at 0.6 mg, then up-titrating to 1.2 mg then 1.8 mg in accordance with prescribing information.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-24 12:22:12 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOME</B>: Evaluation of change from baseline of HbA1c levels of albiglutide as compared with liraglutide.</P>
<P>
<B>SECONDARY OUTCOMES</B>: HbA1c change from baseline over time; proportion of subjects at an HbA1c treatment goal of &lt; 7.0% and/or &lt; 6.5%; FPG, body weight, time for hyperglycaemia rescue</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-06-24 14:47:50 +0200" MODIFIED_BY="[Empty name]">
<P>May 2010, estimated completion date September 2011 (last updated on June 9, 2011)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-06-19 14:39:59 +0200" MODIFIED_BY="[Empty name]">
<P>GlaxoSmithKline</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-06-19 14:39:59 +0200" MODIFIED_BY="[Empty name]">
<P>ClinicalTrials.gov identifier: NCT01128894</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2011-06-30 14:44:02 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Exenatide-QW-NCT00641056">
<CHAR_STUDY_NAME MODIFIED="2011-06-24 14:29:43 +0200" MODIFIED_BY="[Empty name]">
<P>Efficacy of exenatide once weekly and once-daily insulin glargine in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylurea (DURATION - 3)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-06-24 14:35:24 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>: Phase III, open label, randomised, parallel assignment study (extension study)</P>
<P>
<B>DURATION OF INTERVENTION</B>: 26 weeks</P>
<P>
<B>COUNTRY</B>: USA, Australia, Belgium, Czech Republic, Denmark, France, Germany, Greece, Hungary, Korea, Mexico, Netherlands, Puerto Rico, Russian Federation, Spain, Taiwan, </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-30 11:13:37 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA</B>:</P>
<UL>
<LI>Has type 2 diabetes and at least 18 years of age at screening.</LI>
<LI>HbA1c of 7.1% to 11.0%, inclusive, at screening.</LI>
<LI>BMI of 25 kg/m<SUP>2</SUP> to 45 kg/m<SUP>2</SUP>, inclusive, at screening.</LI>
<LI>Have a history of stable body weight (not varying by &gt; 5% for at least 3 months prior to screening).</LI>
<LI>Have been treated with metformin for at least 3 months and have been taking a stable dose for at least 8 weeks prior to screening or,</LI>
<LI>Have been treated with metformin for at least 3 months and have been taking a stable dose for at least 8 weeks prior to screening and have been treated with SU for at least 3 months and have been taking a stable dose of at least an optimally effective dose of brand of SU for 8 weeks prior to screening.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-24 14:36:51 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Exenatide: </B>exenatide 2 mg once weekly subcutaneous injection</P>
<P>
<B>Insulin glargine:</B> variable dose once daily subcutaneous injection,</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-30 14:44:02 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOME</B>: Estimate the difference in change in HbA1c from baseline to treatment endpoint between 2.0 mg exenatide once weekly and insulin glargine QD in patients with type 2 diabetes and inadequate glycaemic control using Met alone or in combination with SU.</P>
<P>
<B>SECONDARY OUTCOMES</B>:</P>
<UL>
<LI>Compare exenatide once weekly and insulin glargine with respect to the proportion of patients achieving HbA1c &#8804; 7% and &#8804; 6.5%; fasting serum glucose; change in body weight; 1,5-anhydroglucitol; 8-point self-monitored blood glucose profile; serum lipids</LI>
<LI>Compare exenatide once weekly and insulin glargine with respect to frequency and rate of hypoglycaemic events; patient-reported health outcomes; long-term maintenance of glycaemic control, safety, and tolerability.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-06-24 14:47:44 +0200" MODIFIED_BY="[Empty name]">
<P>April 2008, estimated completion date January 2012 (last updated on December 3, 2010)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-06-24 14:43:18 +0200" MODIFIED_BY="[Empty name]">
<P>Eli Lilly and Company</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-06-24 15:40:34 +0200" MODIFIED_BY="[Empty name]">
<P>ClinicalTrials.gov identifier: NCT00641056; other study ID number: H8O-MC-GWBR (DURATION - 3)<BR/>
</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2011-06-30 14:44:13 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Exenatide-QW-NCT00917267">
<CHAR_STUDY_NAME MODIFIED="2011-06-24 15:20:33 +0200" MODIFIED_BY="[Empty name]">
<P>A study to examine the effects of exenatide once-weekly injection on glucose control and safety in Asian subjects</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-06-24 15:22:00 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>: Phase III, randomised, open-label trial</P>
<P>
<B>DURATION OF INTERVENTION</B>: 26 weeks</P>
<P>
<B>COUNTRY</B>: China, India, Japan, Korea, Taiwan</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-30 14:44:06 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA</B>:</P>
<UL>
<LI>Have been diagnosed with type 2 diabetes.</LI>
<LI>Have suboptimal glycaemic control as evidenced by an HbA1c between 7.1% and 11.0% inclusive.</LI>
<LI>Have a BMI of &gt; 21 kg/m<SUP>2</SUP> and &lt;<SUP> </SUP>35 kg/m2, inclusive.</LI>
<LI>Have a history of stable body weight (not varying by &gt; 5% for at least 90 days prior to study start).</LI>
<LI>Have been treated with a stable dose regimen of Met, SU, TZD, Met plus SU, Met plus TZD, or SU plus TZD for at least 90 days prior to study start.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-24 15:24:02 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Exenatide QW:</B> 2 mg once weekly subcutaneous injection</P>
<P>
<B>Exenatide BID:</B> 5 &#956;g subcutaneous injection twice a day in the first four weeks then, 10 &#956;g subcutaneous injection twice a day (22 weeks)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-30 14:44:13 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOME</B>: change in HbA1c</P>
<P>
<B>SECONDARY OUTCOMES</B>: proportion of patients achieving HbA1c &#8804; 7% and &#8804; 6.5%; fasting serum glucose; body weight; parameters related to glycaemic control, including fasting &amp; postprandial plasma glucose &amp; 6-point SMBG profiles; serum lipids; incidence and rate of hypoglycaemic events; safety, tolerability, and treatment-emergent events; beta-cell function (HOMA-B) and insulin sensitivity (HOMA-S)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-06-24 15:28:29 +0200" MODIFIED_BY="[Empty name]">
<P>July 2009, estimated completion date June 2011 (last updated on December 16, 2010)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-06-24 15:28:39 +0200" MODIFIED_BY="[Empty name]">
<P>Eli Lilly and Company</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-06-24 15:29:12 +0200" MODIFIED_BY="[Empty name]">
<P>ClinicalTrials.gov Identifier: NCT00917267; other study ID number: H8O-MC-GWCK</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2011-06-30 14:44:27 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Exenatide-QW-NCT00935532">
<CHAR_STUDY_NAME MODIFIED="2011-06-24 15:31:37 +0200" MODIFIED_BY="[Empty name]">
<P>Study to evaluate the efficacy and safety of exenatide once-weekly injection compared to once-daily insulin in type 2 diabetes mellitus</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-06-24 15:32:25 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>: Phase III, randomised, open-label study</P>
<P>
<B>DURATION OF INTERVENTION</B>: 26 weeks</P>
<P>
<B>COUNTRY</B>: Japan</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-30 14:44:24 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA</B>:</P>
<UL>
<LI>present with type 2 diabetes mellitus</LI>
<LI>HbA1c between 7.1% and 11.0% inclusive</LI>
<LI>BMI of &gt; 18 kg/m<SUP>2</SUP> and &lt; 35kg/m<SUP>2</SUP>, inclusive</LI>
<LI>treated with a stable dose regimen of either of biguanide (BG) alone, BG + thiazolidinedione (TZD), BG + sulphonylurea (SU), or BG + TZD + SU for 90 days prior to study start</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-24 15:33:39 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Exenatide:</B> 2 mg once weekly subcutaneous injection</P>
<P>
<B>Insulin glargine:</B> subcutaneous injection, titrated to achieve fasting serum glucose target, once a day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-30 14:44:27 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOME</B>: change in HbA1c</P>
<P>
<B>SECONDARY OUTCOMES</B>: proportion of subjects achieving HBA1c &#8804; 7% or &#8804; 6.5%; fasting serum glucose; body weight; 1,5-anhydroglucitol; self-monitored blood glucose profile at 7 time points; serum lipids; hypoglycaemia; vital signs; waist &amp; hip circumference; waist-hip ratio; safety &amp; tolerability; patient-reported health outcomes</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-06-24 15:38:25 +0200" MODIFIED_BY="[Empty name]">
<P>July 2009, estimated completion date June 2011 (last updated on February 28, 2011)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-06-24 15:38:38 +0200" MODIFIED_BY="[Empty name]">
<P>Eli Lilly and Company</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-06-24 15:39:20 +0200" MODIFIED_BY="[Empty name]">
<P>ClinicalTrials.gov Identifier: NCT00935532; other study ID number: H8O-JE-GWBX</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2011-08-30 15:31:09 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Exenatide-QW-NCT01003184">
<CHAR_STUDY_NAME MODIFIED="2011-06-24 14:51:04 +0200" MODIFIED_BY="[Empty name]">
<P>Efficacy of once-weekly exenatide versus once or twice daily insulin detemir in patients with type 2 diabetes</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-06-24 15:20:40 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>: Phase III, randomised, open-label trial</P>
<P>
<B>DURATION OF INTERVENTION</B>: 26 weeks</P>
<P>
<B>COUNTRY</B>: Ireland, UK,</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-30 11:15:21 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA</B>:</P>
<UL>
<LI>Have suboptimal glycaemic control as evidenced by an HbA1c 7.1% to 10.0%, inclusive</LI>
<LI>Have a BMI of 25 kg/m<SUP>2</SUP> to 45 kg/m<SUP>2</SUP>, inclusive</LI>
<LI>Are receiving metformin at a stable dose (consistent with country specific requirements) of a minimum of 1000mg for at least 3 months prior to start or are receiving metformin at a minimum dose (consistent with country specific requirements) of 1000 mg and sulphonylurea (as separate medications not as a fixed dose combination) at stable doses for 3 months prior to study start</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-30 15:31:09 +0200" MODIFIED_BY="Bernd Richter">
<P>
<B>Exenatide:</B> 2 mg once weekly subcutaneous injection</P>
<P>
<B>Insulin detemir:</B> subcutaneous injection, with dosage titrated according to the detemir label and published titration schedule, once or twice a day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-30 14:44:44 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOME</B>: To test the hypothesis that exenatide given once weekly is superior to a titration of insulin detemir given once or twice daily assessed by the proportion of patients who have achieved HbA1c concentration &#8804; 7.0% with weight loss (&#8805; 1.0 kg) at endpoint.</P>
<P>
<B>SECONDARY OUTCOMES</B>: Proportion of patients who have achieved HbA1c &#8804; 7.0% with weight loss (&#8805; 1.0 kg) at 12 weeks; proportion of patients who have achieved HbA1c &#8804; 7.4% with weight loss (&#8805; 1.0 kg) at endpoint; proportion of patients who have achieved HbA1c &#8804; 7.0% and &#8804; 7.4%, with minimal weight gain (&#8804; 1 kg) at endpoint; change in HbA1c and body weight; proportion of patients achieving HbA1c &#8804; 7.4%, &#8804; 7.0% and &#8804; 6.5% at endpoint; change in fasting serum glucose; 7-point self-monitored blood glucose (SMBG) profile; changes in CV risk parameters; incidence and rate of hypoglycaemic events; safety and tolerability</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-06-24 14:59:23 +0200" MODIFIED_BY="[Empty name]">
<P>October 2009, estimated completion date September 2011 (last updated on January 13, 2011)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-06-24 14:59:49 +0200" MODIFIED_BY="[Empty name]">
<P>Eli Lilly and Company</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-06-24 15:39:08 +0200" MODIFIED_BY="[Empty name]">
<P>ClinicalTrials.gov Identifier: NCT01003184; other study ID number: H8O-EW-GWDL</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2011-06-30 11:17:16 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Exenatide-QW-NCT01029886">
<CHAR_STUDY_NAME MODIFIED="2011-06-19 14:39:59 +0200" MODIFIED_BY="[Empty name]">
<P>Safety and efficacy of exenatide once weekly versus liraglutide in subjects with type 2 diabetes</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-06-19 17:18:24 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>: Phase III, randomised, parallel assignment, open-label trial</P>
<P>
<B>DURATION OF INTERVENTION</B>: 26 weeks</P>
<P>
<B>COUNTRY</B>: Argentina, Austria, Australia, Belgium, Canada, Czech Republic, France, Germany, Greece, Hungary, India, Israel, Italy, Korea, Mexico, Poland, Romania, Slovakia, South Africa, Spain, Taiwan<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-30 11:17:16 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA</B>:</P>
<UL>
<LI>Diagnosed with type 2 diabetes</LI>
<LI>Have suboptimal glycaemic control as evidenced by an HbA1c measurement at study start between 7.1% and 11.0%, inclusive</LI>
<LI>Have a BMI of &#8804; 45 kg/m<SUP>2</SUP>
</LI>
<LI>Have been treated with lifestyle modification (diet and exercise) and with one of the following single OADs or combinations of OADs administered at maximum tolerated dose:metformin, SU, metformin plus an SU' metformin plus pioglitazone</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-24 15:15:34 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Exenatide:</B> 2 mg once weekly subcutaneous injection</P>
<P>
<B>Liraglutide:</B> subcutaneous injection, forced titration to 1.8 mg, once daily</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-24 12:22:31 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOME</B>: change in HbA1c from baseline to treatment endpoint</P>
<P>
<B>SECONDARY OUTCOMES</B>: proportion of subjects achieving HbA1c &lt; 7%; FPG, body weight, lipid profile, safety and tolerability, hypoglycaemia and blood pressure</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-06-24 14:47:27 +0200" MODIFIED_BY="[Empty name]">
<P>January 2010, estimation completion date January 2011 (last updated on January 18, 2011)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-06-19 14:39:59 +0200" MODIFIED_BY="[Empty name]">
<P>Amylin Pharmaceuticals, Inc. and Eli Lilly and Company</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-06-24 15:09:13 +0200" MODIFIED_BY="[Empty name]">
<P>ClinicalTrials.gov Identifier: NCT01029886 ; other study ID number: H8O-MC-GWDE</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2011-06-30 14:45:00 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Exenatide-QW-NCT01144338">
<CHAR_STUDY_NAME MODIFIED="2011-06-24 15:03:20 +0200" MODIFIED_BY="[Empty name]">
<P>Exenatide study of cardiovascular event lowering trial (EXSCEL): a trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-06-24 15:08:16 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>:Phase III, randomised, double-blind, placebo-controlled trial</P>
<P>
<B>DURATION OF INTERVENTION</B>: 5.5 years</P>
<P>
<B>COUNTRY</B>: USA, Argentina, Australia, Austria, Brazil, Bulgaria, Chile, Colombia, Czech Republic, France, Germany, HongKong, Hungary, India, Israel, Italy, Korea, Latvia, Lithuania, Malaysia, Mexico, New Zealand, Peru, Phillipines, Poland, Romania, Russian Federation, Slovakia, Taiwan, Ukraine, UK</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-30 14:44:54 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA</B>:</P>
<UL>
<LI>Patient has type 2 diabetes mellitus</LI>
<LI>Patient has an HbA1c of &#8805; 7.0 % and &#8804; 10.0% on stable doses of up to three oral antihyperglycaemic agents for at least 3 months (i.e. no oral antihyperglycaemic agent adjustments in the past 3 months)</LI>
<LI>Female patients must not be breast feeding and agree to use an effective method of contraception or must not otherwise be at risk of becoming pregnant.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-24 15:15:55 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Exenatide:</B> 2 mg once weekly subcutaneous injection</P>
<P>
<B>Placebo:</B> matching volume of placebo, once weekly subcutaneous injection</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-30 14:45:00 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOME</B>: Time to first confirmed cardiovascular event in the primary composite cardiovascular endpoint</P>
<P>
<B>SECONDARY OUTCOMES</B>: Time to all-cause mortality; time to first confirmed cardiovascular event for each component of the primary composite endpoint; time to hospitalisation for acute coronary syndrome; time to hospitalisation for heart failure</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-06-24 15:18:20 +0200" MODIFIED_BY="[Empty name]">
<P>June 2010; estimation completion date March 2017 (last updated on June 3, 2011)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-06-24 15:08:32 +0200" MODIFIED_BY="[Empty name]">
<P>Amylin Pharmaceuticals, Inc.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-06-24 15:09:10 +0200" MODIFIED_BY="[Empty name]">
<P>ClinicalTrials.gov Identifier: NCT01144338; other study ID number: BCB109</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2011-06-24 14:47:19 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liraglutide-NCT00856986">
<CHAR_STUDY_NAME MODIFIED="2011-06-19 17:18:55 +0200" MODIFIED_BY="[Empty name]">
<P>The effect of insulin detemir in combination with liraglutide and metformin compared to liraglutide and metformin in participants with type 2 diabetes. A 26 week, randomised, open-label, parallel-group, multicenter, multinational trial with a 26 week extension</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-06-19 17:18:59 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>: Randomised, open label, active control, parallel group, phase III trial, multicenter and multinational</P>
<P>
<B>DURATION OF INTERVENTION</B>: 26 weeks with a 26 week extension</P>
<P>
<B>COUNTRY</B>: Europe and North America</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-24 12:28:44 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA</B>:</P>
<UL>
<LI>Patients (18 years to 80 years of both sexes) with type 2 diabetes, insulin naive and treated with metformin as monotherapy for at least 3 months prior to screening.</LI>
<LI>For at least 3 months: treatment with a stable dose of metformin &#8805; 1.5 g/day or a combination of metformin (&#8805; 1.5 g/day) and a sulphonylureas (&#8804; half of the maximum approved dose)</LI>
<LI>previous history of short term use of insulin during intercurrent illness is allowed</LI>
<LI>Level of HbA1c 7.0 to 10.0% on metformin monotherapy and HbA1c of 7.0% to 8.5% in participants on combination therapy of metformin and sulphonylureas</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-24 12:29:38 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Insulin detemir</B>: Liraglutide 1.8 mg/day and insulin detemir (dose titrated based on fasting plasma glucose) both as injection subcutaneously and metformin at least 1.5 g every day.</P>
<P>
<B>Liraglutide</B>: Liraglutide 1.8 mg/day subcutaneous injection and metformin at least 1.5 g every day (randomised treatment arm without intensification with insulin detemir despite HbA1c equal to or greater than 7.0%)</P>
<P>
<B>Liraglutide</B>: Liraglutide 1.8 mg/day subcutaneous injection and metformin at least 1.5 g every day (non-randomised trial arm with participants continuing liraglutide and metformin treatment without intensification with insulin detemir. Participants with HbA1c less than 7.0% after 12 weeks of run-in will continue in the trial in this arm)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-15 15:16:05 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOME</B>:Change in HbA1c from baseline at 26 weeks.</P>
<P>
<B>SECONDARY OUTCOMES</B>:All these outcomes measured at weeks 26 and 52. Change in fasting plasma glucose concentrations, 7 point plasma glucose profile, fasting insulin, fasting proinsulin, fasting C-peptide, lipids, body weight, waist and hip circumference, adverse events and hypoglycaemic events.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-06-24 14:47:19 +0200" MODIFIED_BY="[Empty name]">
<P>March 2010, completed (last updated April 2011)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2010-01-18 18:27:56 +0100" MODIFIED_BY="[Empty name]">
<P>Novo Nordisk</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2010-01-18 18:20:44 +0100" MODIFIED_BY="[Empty name]">
<P>Study ID number: NN2211-1842, EudraCT No: 2007-005317-19, ClinicalTrials.gov Identifier: NCT00856986 </P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2011-06-30 11:18:36 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liraglutide-NCT01117350">
<CHAR_STUDY_NAME MODIFIED="2011-06-19 14:39:59 +0200" MODIFIED_BY="[Empty name]">
<P>Efficacy assessment of insulin glargine versus liraglutide after oral agent failure (EAGLE)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-06-19 17:19:28 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>: Multicenter, international, randomised (1:1), parallel-group, open-label, comparative, phase IV study</P>
<P>
<B>DURATION OF INTERVENTION</B>: 24 weeks comparative period; 24 weeks extension period</P>
<P>
<B>COUNTRY</B>:USA, Austria, Brazil, Canada, Czech Republic, Finland, France, Ireland, Mexico, Netherlands, Slovakia, Spain, Sweden</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-30 11:18:36 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA (comparative period):</B>
</P>
<UL>
<LI>Patients with type 2 diabetes diagnosed for at least 1 year,</LI>
<LI>Treated with lifestyle interventions and metformin at the maximum tolerated dosage (with a minimum daily dosage of 1g), either alone or in combination with an oral insulin secretagogue (sulphonylurea, glinide or DPP-IV inhibitor), for more than 3 months,</LI>
<LI>HbA1c &lt; 7.5% to &#8804; 12%,</LI>
<LI>BMI between 25 and 40 kg/m<SUP>2</SUP> inclusively,</LI>
<LI>Ability and willingness to perform PG self monitoring using the sponsor-provided glucose meter and to complete the patient diary,</LI>
<LI>Willingness and ability to comply with the study protocol,</LI>
<LI>Signed informed consent obtained prior to any study procedure.</LI>
</UL>
<P>
<B>INCLUSION CRITERIA (extension period)</B>:Patients treated with liraglutide (at the maximal tolerated dosage), having a mean FPG &#8805; 250 mg/dL at visit 10 (Week 12) or visit 11 (Week 18), or a HbA1c &#8805; 7% at visit 12 (Week 24). Dosage of metformin compliant with the inclusion criteria of visit 1 (i.e. maximum tolerated dosage, with a minimum daily dosage of 1g), and maintained stable during the comparative period.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-19 14:40:00 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Liralutide:</B> 1.8 mg once a day</P>
<P>
<B>Insulin glargine:</B> 100 U/mL once a day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-24 12:32:55 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOME: </B>percentage of patients reaching HbA1c &lt; 7 %</P>
<P>
<B>SECONDARY OUTCOMES: </B>Percentage of patients whose HbA1c has decreased but remains &#8805; 7%; percentage of patients whose HbA1c has increased; HbA1c change; PPG; FPG, vital signs; hypoglycaemia; dose of insulin glargine or liraglutide</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-06-19 14:40:00 +0200" MODIFIED_BY="[Empty name]">
<P>July 2010, estimated completion date June 2012 (Last Updated on June 14, 2011)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-06-19 14:40:00 +0200" MODIFIED_BY="[Empty name]">
<P>Contact-us@sanofi-aventis.com</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-06-24 14:48:03 +0200" MODIFIED_BY="[Empty name]">
<P>ClinicalTrials.gov Identifier: NCT01117350; other study ID numbers: LANTU_C_03680, 2010-018437-21, U1111-1116-9684</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2011-06-30 11:19:26 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liraglutide-NCT01296412">
<CHAR_STUDY_NAME MODIFIED="2011-06-19 14:40:00 +0200" MODIFIED_BY="[Empty name]">
<P>Comparison of two treatment regimens (sitagliptin versus liraglutide) on participants who failed to achieve good glucose control on metformin alone (MK-0431-403)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-06-19 17:20:04 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>: Phase III, multicenter, randomised, open-label clinical trial </P>
<P>
<B>DURATION OF INTERVENTION</B>: 26 weeks</P>
<P>
<B>COUNTRY</B>: USA, Canada, France, Hungary, Italy, Lithuania, Puerto Rico, Slovenia, Sweden, UK</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-30 11:19:11 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA:</B>
</P>
<UL>
<LI>Type 2 diabetes mellitus.</LI>
<LI>On stable dose of metformin monotherapy at a dose of at least 1500 mg per day for at least 12 weeks and a HbA1c &#8805; 7.0% and &#8804; 11.0%.</LI>
<LI>Capable of using a liraglutide pen device.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-30 11:19:26 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Liraglutide:</B> 0.6 mg by subcutaneous (pen) injection, once daily, on days 1 to 7; in subsequent weeks, the dose may be up-titrated to 1.8 mg once daily.</P>
<P>
<B>Sitagliptin:</B> 100 mg tablet, orally, once daily.</P>
<P>
<B>Glimepiride:</B> starting dose of 1 mg tablet (up-titrated as needed), once daily, as needed, after week 12 therapy.</P>
<P>
<B>Metformin:</B> metformin tablets at a dose of &#8805; 1500 mg per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-24 12:34:01 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOME: </B>Glycaemic control</P>
<P>
<B>SECONDARY OUTCOMES: </B>Percentage of patients reaching haemoglobin A1C goals (&lt; 7.0% and &lt; 6.5%); FPG</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-06-24 14:47:03 +0200" MODIFIED_BY="[Empty name]">
<P>March 2011, estimated completion date May 2012 (last updated on May 3, 2011)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-06-19 14:40:00 +0200" MODIFIED_BY="[Empty name]">
<P>Toll Free Number 1-888-577-8839 (Merck)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-06-19 14:40:00 +0200" MODIFIED_BY="[Empty name]">
<P>ClinicalTrials.gov identifier: NCT01296412</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2011-06-30 11:21:13 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liraglutide-NCT01336023">
<CHAR_STUDY_NAME MODIFIED="2011-06-19 14:40:00 +0200" MODIFIED_BY="[Empty name]">
<P>Dual action of liraglutide and insulin degludec in type 2 diabetes: a trial comparing the efficacy and safety of insulin degludec/liraglutide, insulin degludec and liraglutide in subjects with type 2 diabetes (DUAL&#8482; I)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-06-19 14:40:00 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>: Phase III, randomised, parallel three-arm, open-label, multi-centre, multinational treat-to-target trial </P>
<P>
<B>DURATION OF INTERVENTION</B>: 26 weeks</P>
<P>
<B>COUNTRY</B>: USA, Australia, Canada, Finland, Germany, Hungary, India, Ireland, Italy, Malaysia, Mexico, Puerto Rico, Russian Federation, Singapore, Slovakia, South Africa, Spain, Taiwan, Thailand, UK</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-30 11:19:50 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA:</B>
</P>
<UL>
<LI>For certain countries the minimum age is 20 or 21, according to local legislation</LI>
<LI>Subjects with type 2 diabetes</LI>
<LI>HbA1c (glycosylated haemoglobin) 7.0 to 10.0% (both inclusive)</LI>
<LI>Subjects on stable dose of 1 to 2 OADs (metformin or metformin + pioglitazone for at least 90 days prior to trial start)</LI>
<LI>BMI below or equal to 40 kg/m<SUP>2</SUP>
</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-30 11:21:13 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Insulin degludec/liraglutide:</B> insulin degludec/liraglutide treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean SMPG (fasting). Insulin degludec/liraglutide is injected subcutaneously (under the skin) once daily.</P>
<P>
<B>Insulin degludec:</B> insulin degludec treatment will be initiated with 10 U and titrated (individually adjusted) twice weekly according to the mean SMPG (fasting). Insulin degludec is injected subcutaneously (under the skin) once daily.</P>
<P>
<B>Liraglutide:</B> liraglutide will be started with 0.6 mg and subsequent 0.6 mg weekly dose escalation to 1.8 mg. Liraglutide dose of 1.8 mg/day will be continued for the remaining part of the trial. Liraglutide is injected subcutaneously (under the skin) once daily.</P>
<P>Subjects should continue their pre-trial treatment with metformin or metformin + pioglitazone throughout the entire trial</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-19 14:40:01 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOME: </B>Change from baseline in HbA1c</P>
<P>
<B>SECONDARY OUTCOMES: </B>body weight, hypoglycaemia, meal test, daily insulin dose</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-06-24 14:46:56 +0200" MODIFIED_BY="[Empty name]">
<P>May 2011, estimated completion date October 2012 (last updated on May 23, 2011)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-06-19 14:40:01 +0200" MODIFIED_BY="[Empty name]">
<P>Klaus Kjær Laigaard (Novo Nordisk)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-06-24 14:48:09 +0200" MODIFIED_BY="[Empty name]">
<P>ClinicalTrials.gov Identifier: NCT01336023; other study ID numbers: NN9068-3697, U1111-1119-1174, 2010-021560-15</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2011-06-24 14:48:13 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lixisenatide-NCT00707031">
<CHAR_STUDY_NAME MODIFIED="2011-06-19 17:20:27 +0200" MODIFIED_BY="[Empty name]">
<P>GLP-1 agonist AVE0010 versus exenatide in patients with type 2 diabetes for glycaemic control and safety evaluation, on top of metformin (GETGOAL-X)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-06-19 17:20:29 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>: Phase III, randomised, open-label, active-controlled, 2-arm parallel-group, multicenter study</P>
<P>
<B>DURATION OF INTERVENTION</B>: 24 weeks</P>
<P>
<B>COUNTRY</B>: </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-19 14:40:01 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA: </B>
</P>
<UL>
<LI>Type 2 diabetes mellitus, diagnosed for at least 1 year before screening visit, insufficiently controlled with metformin</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-19 14:40:01 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Lixisenatide (AVE0010)</B> at least 24 weeks of treatment, extension period of variable duration</P>
<P>
<B>Exenatide: a</B>t least 24 weeks of treatment extension period of variable duration</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-19 14:40:01 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOME: </B>Absolute change from baseline in HbA1c </P>
<P>
<B>SECONDARY OUTCOMES: </B>body weight, FPG, treatment satisfaction </P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-06-24 14:46:50 +0200" MODIFIED_BY="[Empty name]">
<P>June 2008, completed (last updated on November 25, 2010)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-06-19 14:40:01 +0200" MODIFIED_BY="[Empty name]">
<P>Sanofi-Aventis</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-06-24 14:48:13 +0200" MODIFIED_BY="[Empty name]">
<P>ClinicalTrials.gov identifier: NCT00707031 other study ID numbers: EFC6019, EudraCT 2007-005883-28</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2011-06-24 14:46:46 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lixisenatide-NCT00713830">
<CHAR_STUDY_NAME MODIFIED="2011-06-19 17:20:37 +0200" MODIFIED_BY="[Empty name]">
<P>GLP-1 agonist AVE0010 in patients with type 2 diabetes for glycaemic control and safety evaluation, on top of sulphonylurea (GETGOAL-S)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-06-19 17:20:39 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>: Phase III, randomised, double-blind, placebo-controlled, 2-arm parallel-group, multicenter study</P>
<P>
<B>DURATION OF INTERVENTION</B>: 24 weeks</P>
<P>
<B>COUNTRY</B>: USA, Bulgaria, Czech Republic, Egypt, Germany, India, Israel, Japan, Korea, Netherlands, Romania, Russian Federation, Taiwan, Thailand, Tunisia, Turkey</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-19 17:20:42 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA:</B>
</P>
<UL>
<LI>Type 2 diabetes mellitus, diagnosed for at least 1 year before screening visit, insufficiently controlled with a sulphonylurea alone or a sulphonylurea in association with metformin</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-19 14:40:02 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Lixisenatide (AVE0010)</B> at least 24 weeks of treatment, extension period of variable duration</P>
<P>
<B>Placebo:</B> at least 24 weeks of treatment, extension period of variable duration</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-19 14:40:02 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOME: </B>Absolute change from baseline in HbA1c </P>
<P>
<B>SECONDARY OUTCOMES: </B>body weight, FPG, 2-hours post-prandial plasma glucose, glucagon, insulin, pro-insulin, C-peptide </P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-06-24 14:46:46 +0200" MODIFIED_BY="[Empty name]">
<P>July 2008, completed (last updated on January 25, 2011)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-06-19 14:40:02 +0200" MODIFIED_BY="[Empty name]">
<P>Sanofi-Aventis</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-06-24 14:44:54 +0200" MODIFIED_BY="[Empty name]">
<P>ClinicalTrials.gov Identifier: NCT00713830, other study ID numbers: EFC6015, EudraCT 2007-005881-11</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2011-06-24 14:46:43 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lixisenatide-NCT00763815">
<CHAR_STUDY_NAME MODIFIED="2011-06-19 17:20:44 +0200" MODIFIED_BY="[Empty name]">
<P>GLP-1 agonist AVE0010 in patients with type 2 diabetes for glycaemic control and safety evaluation, on top of pioglitazone (GETGOAL-P)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-06-19 17:20:46 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>: Phase III, randomised, double-blind, placebo-controlled, 2-arm parallel-group, multicenter study</P>
<P>
<B>DURATION OF INTERVENTION</B>:24 weeks</P>
<P>
<B>COUNTRY</B>:USA, Austria, Canada, France, Germany, Greece, Guatemala, India, Mexico, Peru, Puerto Rico, Romania, Turkey</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-19 14:40:02 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA:</B>
</P>
<UL>
<LI>Type 2 diabetes mellitus, diagnosed for at least 1 year before screening visit, insufficiently controlled with pioglitazone with or without metformin</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-19 14:40:02 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Lixisenatide: </B>AVE0010</P>
<P>
<B>Placebo:</B>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-19 14:40:02 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOME: </B>Glycaemic control</P>
<P>
<B>SECONDARY OUTCOMES: </B>body weight, FPG, fasting insulin levels</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-06-24 14:46:43 +0200" MODIFIED_BY="[Empty name]">
<P>September 2008, estimated completion date June 2011 (last updated on June 22, 2010)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-06-19 14:40:02 +0200" MODIFIED_BY="[Empty name]">
<P>Sanofi-Aventis</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-06-19 14:40:03 +0200" MODIFIED_BY="[Empty name]">
<P>ClinicalTrials.gov Identifier: NCT00763815</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2011-06-30 11:21:50 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lixisenatide-NCT00975286">
<CHAR_STUDY_NAME MODIFIED="2010-01-18 18:34:22 +0100" MODIFIED_BY="[Empty name]">
<P>A randomised, placebo-controlled, 2-arm parallel-group, multicenter study with a 24-week double-blind treatment period assessing the efficacy and safety of lixisenatide in patients with type 2 diabetes insufficiently controlled with insulin glargine and metformin</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-11-16 15:28:35 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>: Randomised, placebo-controlled parallel group phase III trial, multi-centre</P>
<P>
<B>DURATION OF INTERVENTION</B>: 24 weeks</P>
<P>
<B>COUNTRY</B>: USA, Canada, Sweden, Estonia</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-30 11:21:50 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA:</B>
</P>
<P>At screening:</P>
<UL>
<LI>Patients (18 years or older) with type 2 diabetes mellitus, as defined by WHO (fasting plasma glucose &#8805; 7 mmol/L (126 mg/dL) or 2 hours postprandial plasma glucose &#8805; 11.1 mmol/L (200 mg/dL), diagnosed at least 1 year before the screening visit</LI>
<LI>For at least 3 months: treatment with a stable dose of metformin &#8805; 1.5 g/day or combination of stable doses of metformin &#8805; 1.5 g/day with SUs (to be stopped at visit 1) and/or TZDs</LI>
<LI>HbA1c of &#8805; 7.0 and &#8804; 10%</LI>
</UL>
<P>At the end of the run in phase and before randomisation:</P>
<UL>
<LI>HbA1c &#8805; 7.0 and &#8804; 9%</LI>
<LI>Mean fasting SMPG calculated from the self measurements for the 7 days prior to visit 12 (week -1) is less than or equal to 126 mg/dL (7.0 mmol/L)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-16 15:19:32 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Lixisenatide: </B>Lixisenatide once daily on top of insulin glargine (both injected in the morning within 1 hour prior to breakfast) and metformin (at least 1.5 g/day)</P>
<P>
<B>Placebo: </B>Placebo once daily on top of insulin glargine (both injected in the morning within 1 hour prior to breakfast) and metformin (at least 1.5 g/day)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-24 12:37:22 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOME: </B>Glycaemic control</P>
<P>
<B>SECONDARY OUTCOMES: </B>percentage of patients reaching HbA1c &lt; 7% and &#8804; 6.5 %, on plasma glucose (fasting, post-prandial during a standardised meal challenge test, 7-point self monitored profiles), body weight, insulin glargine doses; safety and tolerability, treatment satisfaction (diabetes treatment satisfaction questionnaire)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-11-16 15:20:14 +0100" MODIFIED_BY="[Empty name]">
<P>October 2009, estimated completion August 2011</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-11-16 15:21:34 +0100" MODIFIED_BY="[Empty name]">
<P>GV-Contact-us@sanofi-aventis.com</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2009-11-16 15:22:20 +0100" MODIFIED_BY="[Empty name]">
<P>Study ID Numbers: EFC10781, EudraCT: 2008-007335-40; ClinicalTrials.gov identifier: NCT00975286</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2011-06-24 14:46:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lixisenatide-NCT00976937">
<CHAR_STUDY_NAME MODIFIED="2010-01-18 18:34:35 +0100" MODIFIED_BY="[Empty name]">
<P>A randomised, double-blind, double-dummy, 2-arm parallel-group, multicenter 24-week study comparing the efficacy and safety of ave0010 to sitagliptin as add-on to metformin in obese type 2 diabetic patients younger than 50 and not adequately controlled with metformin</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-11-16 15:30:13 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>: Randomised double-blind, placebo-controlled parallel group phase III trial, multi-centre</P>
<P>
<B>DURATION OF INTERVENTION</B>: 24 weeks</P>
<P>
<B>COUNTRY</B>: USA, Australia, Canada, Chile, Mexico, Russian Federation</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-24 12:37:43 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA:</B>
</P>
<UL>
<LI>Patients with type 2 diabetes mellitus, age 18 to 49 years, as defined by WHO, diagnosed for at least 1 year at the time of screening visit, insufficiently controlled with metformin at a stable dose of at least 1.5 g/day (1.0 g/day for patients from South Korea) for at least 3 months prior to the screening visit.</LI>
<LI>Patients with obesity (BMI &#8805; 30 kg/m<SUP>2</SUP>)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-04 20:01:09 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Lixisenatide:</B> Injection of lixisenatide once a day in the morning within 1 hour prior to breakfast (first 2 weeks of double-blind period: titration 10 to 15 µg, then 15 to 20 µg) and one capsule of sitagliptin placebo intake in the morning with or without food. On top of metformin background therapy</P>
<P>
<B>Sitagliptin: </B>One capsule of sitagliptin intake in the morning with or without food and lixisenatide matched placebo injection once a day in the morning within 1 hour prior to breakfast. On top of metformin background therapy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-24 12:37:59 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOME: </B>Percentage of patients with HbA1c values &lt; 7% and a weight loss of at least 5% of baseline body weight</P>
<P>
<B>SECONDARY OUTCOMES:</B> Absolute change in HbA1c values, percentage of patients with HbA1c values &#8804; 6.5%, absolute change in body weight, change in fasting plasma glucose, change in plasma glucose and in beta-cell function during a test meal, change in insulin resistance assessed by HOMA-IR, change in beta-cell function assessed by HOMA-beta, percentage of patients requiring rescue therapy during the double-blind treatment period; safety and tolerability</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-06-24 14:46:33 +0200" MODIFIED_BY="[Empty name]">
<P>August 2009, completed (last updated on May 6, 20 2011)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-11-16 15:30:36 +0100" MODIFIED_BY="[Empty name]">
<P>GV-Contact-us@sanofi-aventis.com</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2009-11-16 15:30:59 +0100" MODIFIED_BY="[Empty name]">
<P>Study ID Numbers: EFC10780, EudraCT: 2008-007 334-22</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2011-06-24 14:46:25 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Semaglutide-NCT00696657">
<CHAR_STUDY_NAME MODIFIED="2011-06-19 14:40:03 +0200" MODIFIED_BY="[Empty name]">
<P>A randomised controlled clinical trial in type 2 diabetes comparing semaglutide to placebo and liraglutide</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-06-19 14:40:03 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>: Phase II, multi-centre, multi national, double-blind, placebo-controlled, randomised, nine armed parallel group, dose finding trial</P>
<P>
<B>DURATION OF INTERVENTION</B>: 12 weeks</P>
<P>
<B>COUNTRY</B>: Austria, Bulgaria, Finland, Former Serbia and Montenegro, France, Germany, Hungary, India, Italy, South Africa, Spain, Switzerland, Turkey, UK</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-24 12:38:16 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA:</B>
</P>
<UL>
<LI>Men and women-not-of-childbearing potential diagnosed with type 2 diabetes for at least three months</LI>
<LI>Stable treatment regimen with either metformin (at least 1500 mg) or diet and exercise alone for at least three months</LI>
<LI>HbA1c: 7.0 to 10.0% (both inclusive)</LI>
<LI>Body weight between 60 kg and 110 kg</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-19 17:21:08 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Semaglutide:</B> 0.1 or 0.2 or 0.4 or 0.8 mg once weekly s.c. injection; 0.8 mg or 1.6 mg with titration, once weekly s.c. injection</P>
<P>
<B>Placebo:</B> 0.1 or 0.2 or 0.4 mg once weekly s.c. injection; 0.8 mg or 1.6 mg with titration, once weekly s.c. injection</P>
<P>
<B>Liraglutide:</B> 1.2 or 1.8 mg with titration, once daily, s.c. injection</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-19 14:40:03 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOME:</B> Change in HbA1c </P>
<P>
<B>SECONDARY OUTCOMES</B>: Percentage of subjects with an adverse events; percentage of subjects with hypoglycaemic episode; ECG, vital signs; safety laboratory parameters; percentage of subjects developing anti-semaglutide antibodies and calcitonin</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-06-24 14:46:25 +0200" MODIFIED_BY="[Empty name]">
<P>June 2008, Final data collection date for primary outcome measure February 2009 (last updated on March 16, 2011)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-06-19 14:40:03 +0200" MODIFIED_BY="[Empty name]">
<P>Novo Nordisk</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-06-24 14:45:10 +0200" MODIFIED_BY="[Empty name]">
<P>ClinicalTrials.gov Identifier: NCT00696657; other study ID numbers: NN9535-1821, 2007-003956-12</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2011-06-24 14:45:24 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Taspoglutide-NCT00717457">
<CHAR_STUDY_NAME MODIFIED="2010-01-18 18:23:28 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, active controlled, open label study to compare taspoglutide with exenatide as add-on treatment to metformin and/or thiazolidinediones in patients with type 2 diabetes mellitus</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-01-18 18:23:12 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>: Randomised, open label, active controlled, parallel assigned, phase III trial, multi centre, multinational, safety and efficacy study</P>
<P>
<B>DURATION OF INTERVENTION</B>: 3+ years</P>
<P>
<B>COUNTRY</B>: USA, Europe, America, South Africa, Asia</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-24 12:38:36 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA:</B>
</P>
<UL>
<LI>Patients (18 years to 75 years of age and both sexes) with type 2 diabetes treated with metformin and/or pioglitazone or rosiglitazone for at least 12 weeks</LI>
<LI>HbA1c &#8805; 7.0% and &#8804; 10% at screening</LI>
<LI>BMI &#8805; 25 kg/m<SUP>2</SUP> (&gt; 23 kg/m<SUP>2</SUP> for Asians) and &#8804; 45 kg/m<SUP>2</SUP> at screening</LI>
<LI>stable weight ± 5% for at least 12 weeks prior to screening</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-21 19:52:18 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Taspoglutide</B>: 10 mg subcutaneous injection once weekly</P>
<P>
<B>Taspoglutide</B>: 10 mg subcutaneous injection once weekly for 4 weeks followed by 20 mg subcutaneous once weekly</P>
<P>
<B>Exenatide</B>: Exenatide 5 mg twice daily for 4 weeks followed by 10 mg twice daily [should presumably read "µg"?]</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-24 12:38:56 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOME:</B> Change in HbA1c at 24 weeks</P>
<P>
<B>SECONDARY OUTCOMES</B>: All the outcomes measured at 24 weeks. Fasting body weight, proportion of participants reaching target HbA1c &#8804; 7.0%, &#8804; 6.5%, relative change in glucose, insulin, C-peptide and glucagon values during a meal tolerance test in a subset of patients, beta cell function (proinsulin/insulin ratio)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-06-24 14:45:24 +0200" MODIFIED_BY="[Empty name]">
<P>July 2008, estimated completion April 2012 (last updated on March 15, 2011)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2010-01-18 18:41:22 +0100" MODIFIED_BY="[Empty name]">
<P>Hoffmann-La Roche</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2010-01-18 18:26:22 +0100" MODIFIED_BY="[Empty name]">
<P>Study ID numbers:BC21625, 2008-001856-36, ClinicalTrials.gov Identifier: NCT00717457</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2011-06-24 14:46:14 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Taspoglutide-NCT00744367">
<CHAR_STUDY_NAME MODIFIED="2010-01-18 18:30:04 +0100" MODIFIED_BY="[Empty name]">
<P>A multicenter, randomised, double-blind, placebo-controlled study to assess the safety, tolerability and effect of taspoglutide on glycaemic control compared to placebo in patients with type 2 diabetes mellitus inadequately controlled with metformin plus pioglitazone</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-01-18 18:38:31 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>: Randomised, double-blind, placebo-controlled, phase III trial, multicenter, multinational, safety and efficacy study</P>
<P>
<B>DURATION OF INTERVENTION</B>: 1 to 2 years</P>
<P>
<B>COUNTRY</B>: USA, Europe and America</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-24 12:39:21 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA: </B>
</P>
<UL>
<LI>Patients (18 years to 75 years of age and both sexes) with type 2 diabetes receiving pioglitazone (&#8805; 30 mg/day) and metformin (&#8805; 1500 mg/day) for at least 12 weeks prior to screening</LI>
<LI>HbA1c &#8805; 7.0% and &#8804; 10.0% at screening</LI>
<LI>BMI &#8805; 25 (&gt; 23 for Asians) and &#8804; 45 kg/m<SUP>2</SUP> at screening</LI>
<LI>stable weight ± 5% for at least 12 weeks prior to screening</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-24 12:39:35 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Taspoglutide</B>: 10 mg subcutaneous injection once weekly, metformin &gt; 1.5 g/day, pioglitazone &#8805; 30 mg/day</P>
<P>
<B>Taspoglutide</B>: 10 mg subcutaneous injection once weekly for 4 weeks followed by 20 mg subcutaneous once weekly, metformin as prescribed and placebo orally once daily, metformin &gt; 1.5 g/day, pioglitazone &#8805; 30 mg/day</P>
<P>
<B>Placebo</B>: Placebo subcutaneous once weekly, metformin &gt; 1.5 g/day, pioglitazone &#8805; 30 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-24 12:39:41 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOME</B>: Absolute change from baseline in HbA1c at 24 weeks</P>
<P>
<B>SECONDARY OUTCOMES</B>: Change from baseline in fasting plasma glucose, change from baseline in body weight, responder rates for HbA1c (target &#8804; 7.0%, &#8804; 6.5%), responder rates for body weight and beta cell function at 24 weeks; safety: adverse events, vital signs, physical examination, clinical laboratory tests, ECG and anti-taspoglutide antibodies throughout the study</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-06-24 14:46:14 +0200" MODIFIED_BY="[Empty name]">
<P>October 2008, estimated completion September 2010 (last updated on March 15, 2011)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2010-01-18 18:41:16 +0100" MODIFIED_BY="[Empty name]">
<P>Hoffmann-La Roche</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2010-01-18 18:28:59 +0100" MODIFIED_BY="[Empty name]">
<P>Study ID numbers: BC20963, 2008-001744-39, ClinicalTrials.gov Identifier: NCT00744367</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2011-06-24 14:46:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Taspoglutide-NCT00754988">
<CHAR_STUDY_NAME MODIFIED="2010-01-18 18:35:08 +0100" MODIFIED_BY="[Empty name]">
<P>A multicenter, randomised, double-dummy, placebo and active-controlled study to assess the safety, tolerability and effect of taspoglutide on glycaemic control compared to sitagliptin and placebo in patients with type 2 diabetes mellitus inadequately controlled with metformin</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-06-19 17:21:28 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>: Randomised, double blind, placebo and active controlled, phase III trial, multicenter, multinational, safety and efficacy study</P>
<P>
<B>DURATION OF INTERVENTION</B>: 2+ years</P>
<P>
<B>COUNTRY</B>: USA, Europe, Asia, America, Australia</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-24 12:40:01 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA: </B>
</P>
<UL>
<LI>Patients (18 years to 75 years of age and both sexes) with type 2 diabetes receiving metformin &#8805; 1.5 g/day for at least 12 weeks</LI>
<LI>HbA1c &#8805; 7.0% and &#8804; 10.0% at screening</LI>
<LI>BMI &#8805; 25 (&gt; 23 for Asians) and &#8804; 45 kg/m<SUP>2</SUP> at screening</LI>
<LI>stable weight ± 5% for at least 12 weeks prior to screening</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-19 11:20:43 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Taspoglutide</B>: 10 mg subcutaneous injection once weekly, metformin as prescribed and placebo per orally once daily</P>
<P>
<B>Taspoglutide</B>: 10 mg subcutaneous injection once weekly for 4 weeks followed by 20 mg subcutaneous once weekly, metformin as prescribed and placebo per orally once daily</P>
<P>
<B>Sitagliptin</B>: Sitagliptin 100 mg per orally once daily, placebo subcutaneous once weekly and metformin as prescribed</P>
<P>
<B>Placebo</B>: Placebo subcutaneous once daily, metformin as prescribed and placebo per orally once daily</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-24 12:40:06 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOME</B>:Mean changes in HbA1c at 24 weeks</P>
<P>
<B>SECONDARY OUTCOMES</B>:Change from baseline in fasting plasma glucose, change from baseline in body weight, responder rates for HbA1c (target &#8804; 7.0%, &#8804; 6.5%), responder rates for body weight, change from baseline in lipid profile and beta cell function at 24 weeks; safety: adverse events, vital signs, physical examination, clinical laboratory tests, ECG and anti-taspoglutide antibodies throughout study</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-06-24 14:46:08 +0200" MODIFIED_BY="[Empty name]">
<P>October 2008, estimated completion May 2012 (last updated on March 15, 2011)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2010-01-18 18:41:06 +0100" MODIFIED_BY="[Empty name]">
<P>Hoffmann-La Roche</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2010-01-18 18:40:42 +0100" MODIFIED_BY="[Empty name]">
<P>Study ID numbers: BC21713, 2008-001854-42, ClinicalTrials.gov Identifier: NCT00754988</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2011-06-24 14:46:02 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Taspoglutide-NCT00755287">
<CHAR_STUDY_NAME MODIFIED="2010-01-18 18:42:11 +0100" MODIFIED_BY="[Empty name]">
<P>A multicenter, randomised, open-label, active-controlled study to compare the safety, tolerability and effect on glycaemic control of taspoglutide versus insulin glargine in insulin-naïve type 2 diabetic patients inadequately controlled with metformin and sulphonylurea combination therapy</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-06-19 17:21:35 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>: Randomised, open-label, active controlled, parallel assignment, multicenter, multinational, phase III trial</P>
<P>
<B>DURATION OF INTERVENTION</B>: 2+ years</P>
<P>
<B>COUNTRY</B>: USA, Australia, Asia, Europe</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-24 12:40:47 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA: </B>
</P>
<UL>
<LI>Patients (18 years to 75 years of age and both sexes) with type 2 diabetes treated with a stable dose of metformin and sulphonylurea for at least 12 weeks</LI>
<LI>C-peptide (fasting) &#8805;1.0 ng/mL</LI>
<LI>HbA1c &#8805; 7.0% and &#8804; 10.0% at screening</LI>
<LI>BMI &#8805; 25 (&gt; 23 for Asians) and &#8804; 45 kg/m<SUP>2</SUP> at screening</LI>
<LI>stable weight ± 5% for at least 12 weeks prior to screening</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-21 19:52:58 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Taspoglutide</B>: 10 mg subcutaneous injection once weekly and metformin as prescribed</P>
<P>
<B>Taspoglutide</B>: 10 mg subcutaneous injection once weekly for 4 weeks followed by 20 mg subcutaneous once weekly and metformin as prescribed</P>
<P>
<B>Insulin glargine</B>: Starting dose at 10 IU daily and metformin as prescribed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-24 12:41:43 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOME</B>: Absolute change from baseline in HbA1c at 24 weeks</P>
<P>
<B>SECONDARY OUTCOMES</B>: Change from baseline in fasting plasma glucose, change from baseline in body weight, responder rates for HbA1c (target &#8804; 7.0%, &#8804; 6.5%), incidence of hypoglycaemia and change from baseline in lipid profile at 24 weeks; relative change in glucose, insulin, C-peptide and glucagon during a meal tolerance test at 24 weeks; safety: adverse events, vital signs, physical examination, clinical laboratory tests, ECG and anti-taspoglutide antibodies measured throughout study</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-06-24 14:46:02 +0200" MODIFIED_BY="[Empty name]">
<P>October 2008, estimated completion June 2012 (last updated on March 15, 2011)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2010-01-18 18:41:43 +0100" MODIFIED_BY="[Empty name]">
<P>Hoffmann-La Roche</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2010-01-18 18:43:25 +0100" MODIFIED_BY="[Empty name]">
<P>Study ID numbers: BC20965, 2008-001855-23, ClinicalTrials.gov Identifier: NCT00755287</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2011-06-30 11:23:39 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Taspoglutide-NCT00823992">
<CHAR_STUDY_NAME MODIFIED="2010-01-18 18:44:07 +0100" MODIFIED_BY="[Empty name]">
<P>A randomised, double-blind, placebo-controlled study to assess the effect of taspoglutide on glycaemic control, and its safety and tolerability, in obese patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-06-19 17:21:38 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>: Randomised, double-blind, placebo-controlled, parallel assigned, phase III trial, multicenter, multinational, safety and efficacy study</P>
<P>
<B>DURATION OF INTERVENTION</B>: 52 weeks (12 months)</P>
<P>
<B>COUNTRY</B>: USA, Europe</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-24 12:42:06 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA: </B>
</P>
<UL>
<LI>Patients (18 years to 75 years of age and both sexes) with type 2 diabetes treated with stable dose of metformin of &#8805; 1.5 g/day for at least 12 weeks</LI>
<LI>HbA1c &#8805; 6.5% and &#8804; 9.5% at screening</LI>
<LI>BMI &#8805; 30 and &#8804; 50 kg/m<SUP>2 </SUP>at screening</LI>
<LI>Stable weight ± 5% for at least 12 weeks prior to screening</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-21 20:08:37 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Taspoglutide</B>: 10 mg subcutaneous injection once weekly for 4 weeks followed by 20 mg subcutaneous once weekly</P>
<P>
<B>Placebo</B>: Subcutaneous once weekly</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-30 11:23:39 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOME</B>: Absolute change from baseline in HbA1c at 24 weeks</P>
<P>
<B>SECONDARY OUTCOMES</B>: Change from baseline in body weight, % of patients achieving &#8805; 5% weight loss at weeks 24; % of patients achieving target HbA1c &#8804; 6.5%, &#8804; 7.0%, change from baseline in fasting plasma glucose, change from baseline in lipid profile, relative change in glucose, insulin, C-peptide and glucagon during a meal tolerance test and beta cell function at 24 weeks; safety: adverse events,clinical laboratory tests, vital signs, physical examination, ECG, anti-taspoglutide antibodies at planned clinical visits for 12 months</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-06-24 14:45:54 +0200" MODIFIED_BY="[Empty name]">
<P>January 2009, completed (last updated on April 18, 2011)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2010-01-18 18:41:45 +0100" MODIFIED_BY="[Empty name]">
<P>Hoffmann-La Roche</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2010-01-18 18:45:23 +0100" MODIFIED_BY="[Empty name]">
<P>Study ID numbers: BC22092, 2008-005809-20, ClinicalTrials.gov Identifier: NCT00823992</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2011-06-24 14:45:44 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Taspoglutide-NCT00909597">
<CHAR_STUDY_NAME MODIFIED="2010-01-18 18:46:05 +0100" MODIFIED_BY="[Empty name]">
<P>A multicenter, randomised, double blind (double dummy), active controlled study to compare the safety, tolerability and effect on glycaemic control of taspoglutide versus pioglitazone in type 2 diabetes patients inadequately controlled on therapy with sulphonylurea or metformin plus sulphonylurea</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-01-21 19:53:08 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>TRIAL DESIGN</B>:<B> </B>Randomised, double blind (participant, investigator), three arm, phase III trial, parallel assignment, multi centre, multinational, safety and efficacy study</P>
<P>
<B>DURATION OF INTERVENTION</B>: 104 weeks (24 months)</P>
<P>
<B>COUNTRY</B>: USA, Europe, North and South America</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-24 12:42:41 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA: </B>
</P>
<UL>
<LI>Patients (18 years to 75 years of age and both sexes) with type 2 diabetes treated with stable dose of sulphonylurea monotherapy or metformin plus sulphonylurea for &#8805; 12 weeks prior to screening.</LI>
<LI>HbA1c &#8805; 7.0% and &#8804; 10.0% at screening</LI>
<LI>stable weight ± 5% for &#8805; 12 weeks prior to screening</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-21 19:53:13 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Taspoglutide</B>: 10 mg subcutaneous injection once weekly</P>
<P>
<B>Taspoglutide</B>: 10 mg subcutaneous injection once weekly for 4 weeks followed by 20 mg subcutaneous once weekly</P>
<P>
<B>Pioglitazone</B>: 30 mg orally once daily for 4 weeks followed by 45 mg once daily</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-24 12:42:49 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>PRIMARY OUTCOME: </B>Absolute change in HbA1c from baseline at 24 weeks</P>
<P>
<B>SECONDARY OUTCOMES</B>: Proportion of participants achieving target HbA1c &#8804; 6.5%, &#8804; 7.0% at weeks 24, 52 and 104; absolute/percentage change from baseline in body weight, responder rates for body weight, absolute/percentage change from baseline in waist and hip circumference, absolute/percentage change from baseline in fasting plasma glucose at weeks 24, 52 and 104; adverse events, laboratory parameters, cardiovascular events at each clinic visit up to 106 weeks</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-06-24 14:45:44 +0200" MODIFIED_BY="[Empty name]">
<P>May 2009, completed (last updated on June 15, 2011)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2010-01-18 18:41:46 +0100" MODIFIED_BY="[Empty name]">
<P>Hoffmann-La Roche</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2010-01-18 18:45:39 +0100" MODIFIED_BY="[Empty name]">
<P>Study ID numbers: BC21893, 2009-009157-24, ClinicalTrials.gov Identifier: NCT00909597</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>
<SUP>BG: biguanide; BMI: body mass index; , CV: cardiovascular; DPP-4: dipeptidyl peptidase-4 inhibitor; ECG: electrocardiography; FPG: fasting plasma glucose; HbA1c: glycosylated haemoglobin A1c; HOMA-B: homeostatic model assessment-beta cell function; HOMA-IS: homeostatic model assessment-insulin sensitivity; HOMA-IR: homeostatic model assessment-insulin resistance; Met: metformin; OAD: oral antidiabetic drug; PG: plasma glucose; PPG: post-prandial glucose; QD: once daily; SMPG: self-measured plasma glucose; SU: sulphonylurea; TZD: thiazolidinedione; WHO: World Health Organization.</SUP>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2011-08-30 10:13:48 +0200" MODIFIED_BY="Bernd Richter">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2011-06-24 12:21:02 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-15 15:05:15 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-A-_x002d_-Rosenstock-2009">
<DESCRIPTION>
<P>No details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-18 12:17:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-E-_x002d_-Bergenstal-2010">
<DESCRIPTION>
<P>Computer-generated randomisation; done centrally by UBC Clinical Technologies via an interactive voice response system and was independent of the sponsor, investigators, study-site staff and participants; allocated in a 1:1:1 ratio </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-22 15:35:23 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-E-_x002d_-Blevins-2011">
<DESCRIPTION>
<P>Participants were randomised 1:1 to treatment with EX BID or EX QW, with randomisation performed centrally via an interactive voice or web response system. Randomization was stratified according to concomitant SU use at screening and baseline HbA1c stratum (&lt; 9.0% or &#8805; 9.0%).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-18 15:46:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-E-_x002d_-Diamant-2010">
<DESCRIPTION>
<P>One to one allocation and block (size four) randomisation, stratified according to country and oral blood glucose lowering treatment (70% metformin only; 30% metformin plus sulphonylurea). Computer-generated randomisation sequence administered by the sponsor via an automated voice-response system.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-22 16:29:02 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-E-_x002d_-Drucker-2008">
<DESCRIPTION>
<P>Randomisation method not stated; randomisation was stratified according to concomitant sulphonylurea use at screening and HbA1c strata (&lt; 9.0% vs &#8805; 9.0%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-19 11:40:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-L-_x002d_-Kaku-2010">
<DESCRIPTION>
<P>Subjects were stratified according to pretrial SU therapy. Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 15:01:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009">
<DESCRIPTION>
<P>Insufficient information; participants were stratified according to previous treatment (monotherapy or combination therapy)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-19 17:08:17 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009">
<DESCRIPTION>
<P>Randomly assigned as 2:2:2:1:2. Telephone or web based randomisation. Patients randomly assigned to the lowest available randomisation number and stratified with respect to their previous use of OAD monotherapy or combination therapy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-05 10:02:30 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L-_x002d_-LEAD-4-Zinman-2009">
<DESCRIPTION>
<P>Randomised as 1:1:1. Telephone or web based randomisation; protocol states: "Randomisation will be carried out centrally using a randomisation system, IVRS/IWRS" [Interactive voice (or web) response system]</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-05 16:49:42 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009">
<DESCRIPTION>
<P>Randomised as 2:1:1 using a telephone or web-based randomisation system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-05 17:25:20 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-L-_x002d_-LEAD-6-Buse-2009">
<DESCRIPTION>
<P>Randomly assigned (1:1) to the lowest available number of the numbers allocated to the site</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-19 17:09:14 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L-_x002d_-Pratley-2010">
<DESCRIPTION>
<P>Computer-generated by Novo Nordisk; participants randomly assigned in a 1:1:1 ratio, stratified by country, to receive 1.2 mg or 1.8 mg s.c. liraglutide once daily or 100 mg oral sitagliptin once daily.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-17 09:54:21 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-L-_x002d_-Yang-2010">
<DESCRIPTION>
<P>Inadequate information; participants were stratified with respect to their pretrial OAD therapy (monotherapy or combination) and randomised into 1:1:1:1 ratio</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-19 17:16:54 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-LY2189265-_x002d_Umpierrez-2011">
<DESCRIPTION>
<P>Randomisation was carried out using a computer-generated random sequence and was stratified according to oral antihyperglycaemic medication.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-19 16:17:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010">
<DESCRIPTION>
<P>Randomised to one of 12 treatment arms (2:2:2:2:2:2:2:2:1:1:1:1) using interactive voice response system.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-17 09:54:21 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-T-_x002d_-Nauck-2009">
<DESCRIPTION>
<P>Patients were randomly assigned by central randomisation system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-24 12:21:02 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-T_x002d_-Ratner-2010">
<DESCRIPTION>
<P>Central system using a stratified randomisation procedure based on disease severity (HbA1c &lt; 8.0% or &#8805; 8.0%) to avoid imbalances between treatment groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-06-17 09:54:21 +0200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-15 15:05:16 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-A-_x002d_-Rosenstock-2009">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-18 12:18:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-E-_x002d_-Bergenstal-2010">
<DESCRIPTION>
<P>Interactive voice response system to conceal allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-25 12:55:37 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-E-_x002d_-Blevins-2011">
<DESCRIPTION>
<P>Randomization performed centrally via an interactive voice or web response system.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-18 15:47:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-E-_x002d_-Diamant-2010">
<DESCRIPTION>
<P>Computer-generated randomisation sequence administered by the sponsor via an automated voice-response system.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-06 17:00:46 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-E-_x002d_-Drucker-2008">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-19 11:40:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-L-_x002d_-Kaku-2010">
<DESCRIPTION>
<P>No information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-09 13:46:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-02 15:42:20 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009">
<DESCRIPTION>
<P>Telephone or web based randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-17 16:59:08 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L-_x002d_-LEAD-4-Zinman-2009">
<DESCRIPTION>
<P>Telephone or web based randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-17 16:58:16 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009">
<DESCRIPTION>
<P>Central randomisation using a telephone or web-based randomisation system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-17 18:02:00 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L-_x002d_-LEAD-6-Buse-2009">
<DESCRIPTION>
<P>Randomisation was done with telephone based or web based system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-19 12:09:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L-_x002d_-Pratley-2010">
<DESCRIPTION>
<P>Computer-generated; consecutive allocation of the randomisation code to individual participants was concealed by use of a telephone-based (interactive voice response system) or web-based (interactive web response system) randomisation system.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-19 13:17:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-L-_x002d_-Yang-2010">
<DESCRIPTION>
<P>No information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-27 15:10:16 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-LY2189265-_x002d_Umpierrez-2011">
<DESCRIPTION>
<P>Inadequate information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-19 16:18:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010">
<DESCRIPTION>
<P> Interactive voice response system.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-17 09:54:21 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-T-_x002d_-Nauck-2009">
<DESCRIPTION>
<P>Patients were randomly assigned by interactive voice response system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-20 10:24:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-T_x002d_-Ratner-2010">
<DESCRIPTION>
<P>Central system; insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-04-28 17:29:50 +0200" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-15 11:41:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-A-_x002d_-Rosenstock-2009">
<DESCRIPTION>
<P>Double blind (study personnel and patients)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-01-18 12:18:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-E-_x002d_-Bergenstal-2010">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-25 12:55:44 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-E-_x002d_-Blevins-2011">
<DESCRIPTION>
<P>Open label; Sponsor personnel remained blinded to HbA1c and FPG data throughout treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-01-18 15:46:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-E-_x002d_-Diamant-2010">
<DESCRIPTION>
<P>Open label (study participants and clinical investigators were not blinded); investigators analysing data were blinded to treatment assignment. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-10-06 17:00:36 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-E-_x002d_-Drucker-2008">
<DESCRIPTION>
<P>Open label; the investigators, sponsor, patients, and all personnel involved with the study were not blinded to the identity of the study medication; blinding of HbA1c and FPG results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-01-19 11:40:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L-_x002d_-Kaku-2010">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-09 13:46:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-09-17 14:53:19 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009">
<DESCRIPTION>
<P>Double blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-09-17 16:59:15 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L-_x002d_-LEAD-4-Zinman-2009">
<DESCRIPTION>
<P>Double blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-10-05 16:50:36 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009">
<DESCRIPTION>
<P>Investigators, participants, and study monitors were blinded to liraglutide, open label glargine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-10-05 17:29:38 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-L-_x002d_-LEAD-6-Buse-2009">
<DESCRIPTION>
<P>Open label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-01-19 12:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-L-_x002d_-Pratley-2010">
<DESCRIPTION>
<P>Open label; data were masked from the statistician until database release</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-01-19 13:17:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L-_x002d_-Yang-2010">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-28 16:16:33 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-LY2189265-_x002d_Umpierrez-2011">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-01-19 16:18:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010">
<DESCRIPTION>
<P>The study drug, added-on to stable metformin, was double-blind regarding active treatment or placebo and open-label regarding the treatment volume.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-18 17:34:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-T-_x002d_-Nauck-2009">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-01-20 10:24:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-T_x002d_-Ratner-2010">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2011-06-24 12:08:35 +0200" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-22 15:28:45 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-A-_x002d_-Rosenstock-2009">
<DESCRIPTION>
<P>Comparisons made on the intent to treat population, using last observation carried forward, adequate description of withdrawals or losses to follow-up (28% withdrawals or losses to follow-up)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-22 15:31:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-E-_x002d_-Bergenstal-2010">
<DESCRIPTION>
<P>Intention-to-treat analysis; missing data were imputed by last-observation-carried forward method; adequate description of withdrawals and losses to follow up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-19 17:05:25 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-E-_x002d_-Blevins-2011">
<DESCRIPTION>
<P>intent-to-treat (ITT) population consisted of all randomised patients receiving at least one dose of randomised study medication; Missing post baseline efficacy data were imputed using the last observation carried forward (LOCF) approach; adequate description of withdrawals and loss to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-01-18 15:46:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-E-_x002d_-Diamant-2010">
<DESCRIPTION>
<P>Modified intention-to-treat analysis, details of withdrawals and losses to follow up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-01 15:26:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-E-_x002d_-Drucker-2008">
<DESCRIPTION>
<P>Missing data were imputed as the last observation carried forward, ITT analysis, adequate description of withdrawals and losses to follow-up (12% withdrawals, no significant difference between groups)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-01-19 11:41:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L-_x002d_-Kaku-2010">
<DESCRIPTION>
<P>Efficacy endpoints: Full analysis set; Per protocol set; LOCF; adequate description of adverse events, withdrawals and losses to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-24 15:04:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009">
<DESCRIPTION>
<P>Comparisons made on the intent to treat population, missing data imputed using last observation carried forward, adequate description of withdrawals and losses to follow-up (overall 14% withdrawals, 9 to 27% in the individual groups)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-22 16:50:37 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009">
<DESCRIPTION>
<P>Missing data were imputed as the last observation carried forward, ITT analysis, adequate description of withdrawals and losses to follow-up (19% withdrawals and losses to follow-up)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-22 16:52:40 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L-_x002d_-LEAD-4-Zinman-2009">
<DESCRIPTION>
<P>Missing data were imputed as the last observation carried forward (LOCF), ITT analysis, adequate description of withdrawals and losses to follow-up (24% withdrawals and losses to follow-up)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-24 12:08:35 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009">
<DESCRIPTION>
<P>Missing data were imputed as the last observation carried forward (LOCF), ITT analysis, adequate description of withdrawals and losses to follow-up (9.4% withdrawals and losses to follow-up)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-22 17:08:52 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L-_x002d_-LEAD-6-Buse-2009">
<DESCRIPTION>
<P>Last observation carried forward data with repeated measures analysis and multiple imputation methods, ITT analysis, adequate description of withdrawals and losses to follow-up (17% withdrawals and losses to follow-up)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-01-19 12:09:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L-_x002d_-Pratley-2010">
<DESCRIPTION>
<P>Primary efficacy analyses: full analysis set with missing values imputed by last observation carried forward; Secondary efficacy analyses: full analysis set, apart from treatment satisfaction analyses, in which missing data were no imputed; Superiority: full analysis set; Non-inferiority: full analysis and per-protocol sets.<BR/>Adequate description of withdrawals and loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-01-19 13:17:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L-_x002d_-Yang-2010">
<DESCRIPTION>
<P>Full analysis set (FAS) with LOCF; adequate description of adverse events, withdrawals and loss to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-27 15:39:34 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-LY2189265-_x002d_Umpierrez-2011">
<DESCRIPTION>
<P>All efficacy and safety analyses were performed using the intent-to-treat population</P>
<P>Adequate description of withdrawals and losses to follow up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-01-19 16:18:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010">
<DESCRIPTION>
<P>ITT analysis; adequate description of withdrawals and losses to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-21 20:07:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-T-_x002d_-Nauck-2009">
<DESCRIPTION>
<P>Missing data were imputed as the last observation carried forward, ITT analysis (ITT population comprised of all patients who were randomly assigned, received at least one dose of study medication, and had a baseline and at least post-baseline HbA1C assessment), adequate description of withdrawals and losses to follow-up (6.5% withdrawals / losses to follow-up)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-19 17:18:02 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-T_x002d_-Ratner-2010">
<DESCRIPTION>
<P>Descriptive statistics were used to report the safety results; data on secondary endpoints were analysed for the ITT population using the last observation carried forward; description of withdrawals and loss to follow up given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2011-06-15 15:12:16 +0200" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-15 11:41:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-A-_x002d_-Rosenstock-2009">
<DESCRIPTION>
<P>All pre-specified (primary and secondary) outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-18 12:17:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-E-_x002d_-Bergenstal-2010">
<DESCRIPTION>
<P>All the predefined and prespecified outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-15 15:05:42 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-E-_x002d_-Blevins-2011">
<DESCRIPTION>
<P>All the prespecified and predefined outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-18 15:47:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-E-_x002d_-Diamant-2010">
<DESCRIPTION>
<P>All the predefined and prespecified outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-21 19:59:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-E-_x002d_-Drucker-2008">
<DESCRIPTION>
<P>Included all expected and prespecified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-19 11:41:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L-_x002d_-Kaku-2010">
<DESCRIPTION>
<P>All predefined and prespecified outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 15:01:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009">
<DESCRIPTION>
<P>All pre-specified (primary and secondary) outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-17 14:53:07 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009">
<DESCRIPTION>
<P>Included all expected outcomes, including those prespecified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-17 16:59:23 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L-_x002d_-LEAD-4-Zinman-2009">
<DESCRIPTION>
<P>Included all prespecified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-17 17:01:09 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009">
<DESCRIPTION>
<P>Included all prespecified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-17 18:04:10 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L-_x002d_-LEAD-6-Buse-2009">
<DESCRIPTION>
<P>All prespecified outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-19 12:09:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L-_x002d_-Pratley-2010">
<DESCRIPTION>
<P>All prespecified outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-19 13:17:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L-_x002d_-Yang-2010">
<DESCRIPTION>
<P>All the pre-defined and pre-specified outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-27 15:39:54 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-LY2189265-_x002d_Umpierrez-2011">
<DESCRIPTION>
<P>All the prespecified and predefined outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-19 16:18:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010">
<DESCRIPTION>
<P>All the prespecified and predefined outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-17 17:42:20 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-T-_x002d_-Nauck-2009">
<DESCRIPTION>
<P>Included all expected outcomes, including those prespecified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-15 15:12:16 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-T_x002d_-Ratner-2010">
<DESCRIPTION>
<P>All prespecified and predefined outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2009-10-02 17:19:10 +0200" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="GROUP" NO="9">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="GROUP" NO="10">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2011-08-31 14:51:54 +0200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2011-08-31 14:51:54 +0200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-08-30 09:32:46 +0200" MODIFIED_BY="Bernd Richter">Overview of study populations</TITLE>
<TABLE COLS="7" ROWS="38">
<TR>
<TH>
<P>Characteristic &#9658;</P>
<P>GLP analogue &#9660;</P>
</TH>
<TH>
<P>[n] screened</P>
</TH>
<TH>
<P>[n] randomised</P>
</TH>
<TH>
<P>[n] safety</P>
</TH>
<TH>
<P>[n] ITT</P>
</TH>
<TH>
<P>[n] finishing study</P>
</TH>
<TH>
<P>[%] of randomised participants<BR/>finishing study</P>
</TH>
</TR>
<TR>
<TH>
<P>
<B>EXENATIDE</B>
</P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Exenatide versus TZD and DPP-4 inhibitors</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Bergenstal 2010</P>
</TD>
<TD>
<P>I1: -</P>
<P>C1: -</P>
<P>T: 958</P>
</TD>
<TD>
<P>I1: 170</P>
<P>C1: 172</P>
<P>C2: 172</P>
<P>T: 514</P>
</TD>
<TD>
<P>I1: 160</P>
<P>C1: 165</P>
<P>C2: 166</P>
<P>T: 491</P>
</TD>
<TD>
<P>I1: 160</P>
<P>C1: 165</P>
<P>C2: 166</P>
<P>T: 491</P>
</TD>
<TD>
<P>I1: 127</P>
<P>C1: 131</P>
<P>C2: 144</P>
<P>T: 402</P>
</TD>
<TD>
<P>I1: 74.70</P>
<P>C1: 76.16</P>
<P>C2: 83.72</P>
<P>T: 78.21</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Exenatide versus insulin glargine</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Diamant 2010</P>
</TD>
<TD>
<P>I1: -</P>
<P>C1: -</P>
<P>T: 659</P>
</TD>
<TD>
<P>I1: 233</P>
<P>C1: 223</P>
<P>T: 456</P>
</TD>
<TD>
<P>I1: 233</P>
<P>C1: 223</P>
<P>T: 456</P>
</TD>
<TD>
<P>I1: 233</P>
<P>C1: 223</P>
<P>T: 456</P>
</TD>
<TD>
<P>I1: 209</P>
<P>C1: 209</P>
<P>T: 418</P>
</TD>
<TD>
<P>I1: 89.69</P>
<P>C1: 93.72</P>
<P>T: 91.66</P>
</TD>
</TR>
<TR>
<TH>
<P>
<B>LIRAGLUTIDE</B>
</P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Liraglutide versus placebo and TZD</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>LEAD 1 (Marre 2009)</P>
</TD>
<TD>
<P>I1: -</P>
<P>I2: -</P>
<P>C1: -</P>
<P>C2: -</P>
<P>T: 1712</P>
</TD>
<TD>
<P>I1: 228</P>
<P>I2: 234</P>
<P>C1: 114</P>
<P>C2: 232</P>
<P>T*: 808</P>
</TD>
<TD>
<P>I1: 228</P>
<P>I2: 234</P>
<P>C1: 114</P>
<P>C2: 231</P>
<P>T*: 807</P>
</TD>
<TD>
<P>I1: 228</P>
<P>I2: 234</P>
<P>C1: 114</P>
<P>C2: 231</P>
<P>T*: 807</P>
</TD>
<TD>
<P>I1: 196</P>
<P>I2: 213</P>
<P>C1: 83</P>
<P>C2: 194</P>
<P>T*: 686</P>
</TD>
<TD>
<P>I1: 85.96</P>
<P>I2: 91.02</P>
<P>C1: 72.80</P>
<P>C2: 83.62</P>
<P>T*: 84.90</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Liraglutide versus placebo and SU</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>LEAD 2 (Nauck 2009)</P>
</TD>
<TD>
<P>I1: -</P>
<P>I2: -</P>
<P>C1: -</P>
<P>C2: -</P>
<P>T: 1662</P>
</TD>
<TD>
<P>I1: 241</P>
<P>I2: 242</P>
<P>C1: 122</P>
<P>C2: 244</P>
<P>T*: 849</P>
</TD>
<TD>
<P>I1: 240</P>
<P>I2: 242</P>
<P>C1:121</P>
<P>C2: 242</P>
<P>T*: 845</P>
</TD>
<TD>
<P>I1: 240</P>
<P>I2: 242</P>
<P>C1: 121</P>
<P>C2: 242</P>
<P>T*: 845</P>
</TD>
<TD>
<P>I1: 197</P>
<P>I2: 191</P>
<P>C1: 74</P>
<P>C2: 210</P>
<P>T*: 672</P>
</TD>
<TD>
<P>I1: 81.74</P>
<P>I2: 78.92</P>
<P>C1: 60.65</P>
<P>C2: 80.06</P>
<P>T*: 79.15</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Liraglutide versus placebo and insulin</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>LEAD 5 (Russell-Jones 2008)</P>
</TD>
<TD>
<P>I1: -</P>
<P>C1: -</P>
<P>C2: -</P>
<P>T: 973</P>
</TD>
<TD>
<P>I1: 232</P>
<P>C1: 115</P>
<P>C2: 234</P>
<P>T: 581</P>
</TD>
<TD>
<P>I1: 230</P>
<P>C1: 114</P>
<P>C2: 232</P>
<P>T: 576</P>
</TD>
<TD>
<P>I1: 230</P>
<P>C1: 114</P>
<P>C2: 232</P>
<P>T: 576</P>
</TD>
<TD>
<P>I1: 207</P>
<P>C1: 96</P>
<P>C2: 219</P>
<P>T: 522</P>
</TD>
<TD>
<P>I1: 89.22</P>
<P>C1: 83.48</P>
<P>C2: 93.59</P>
<P>T: 89.84</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Liraglutide versus placebo</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>LEAD 4 (Zinman 2009)</P>
</TD>
<TD>
<P>I1: -</P>
<P>I2: -</P>
<P>C1: -</P>
<P>T: 821</P>
</TD>
<TD>
<P>I1: 178</P>
<P>I2: 178</P>
<P>C1: 177</P>
<P>T: 533</P>
</TD>
<TD>
<P>I1: 178</P>
<P>I2: 178</P>
<P>C1: 177</P>
<P>T: 533</P>
</TD>
<TD>
<P>I1: 178</P>
<P>I2: 178</P>
<P>C1: 177</P>
<P>T: 533</P>
</TD>
<TD>
<P>I1: 153</P>
<P>I2: 133</P>
<P>C1: 121</P>
<P>T: 407</P>
</TD>
<TD>
<P>I1: 85.95</P>
<P>I2: 74.72</P>
<P>C1: 68.36</P>
<P>T: 76.36</P>
</TD>
</TR>
<TR>
<TD>
<P>Kaku 2010</P>
</TD>
<TD>
<P>I1: -</P>
<P>I2: -</P>
<P>C1: -</P>
<P>T: 308</P>
</TD>
<TD>
<P>I1: 88</P>
<P>I2: 88</P>
<P>C1: 88</P>
<P>T: 264</P>
</TD>
<TD>
<P>I1: 88</P>
<P>I2: 88</P>
<P>C1: 88</P>
<P>T: 264</P>
</TD>
<TD>
<P>I1: 88</P>
<P>I2: 88</P>
<P>C1: 88</P>
<P>T: 264</P>
</TD>
<TD>
<P>I1: 83</P>
<P>I2: 84</P>
<P>C1: 74</P>
<P>T: 241</P>
</TD>
<TD>
<P>I1: 94.32</P>
<P>I2: 95.45</P>
<P>C1: 84.09</P>
<P>T: 91.29</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Liraglutide versus SU</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Yang 2010</P>
</TD>
<TD>
<P>I1: -</P>
<P>I2: -</P>
<P>C1: -</P>
<P>T: -</P>
</TD>
<TD>
<P>I1: 233</P>
<P>I2: 234</P>
<P>C1: 231</P>
<P>T*: 698</P>
</TD>
<TD>
<P>I1: 233</P>
<P>I2: 233</P>
<P>C1: 231</P>
<P>T*: 697</P>
</TD>
<TD>
<P>I1: -</P>
<P>I2: -</P>
<P>C1: -</P>
<P>T*: -</P>
</TD>
<TD>
<P>I1: 187</P>
<P>I2: 175</P>
<P>C1: 215</P>
<P>T*: 577</P>
</TD>
<TD>
<P>I1: 80.25</P>
<P>I2: 74.79</P>
<P>C1: 93.07</P>
<P>T*: 82.66</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Liraglutide versus DPP-4 inhibitors</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pratley 2010</P>
</TD>
<TD>
<P>I1: -</P>
<P>I2: -</P>
<P>C1: -</P>
<P>T: 1302</P>
</TD>
<TD>
<P>I1: 225</P>
<P>I2: 221</P>
<P>C1: 219</P>
<P>T: 665</P>
</TD>
<TD>
<P>I1: 221</P>
<P>I2: 218</P>
<P>C1: 219</P>
<P>T: 658</P>
</TD>
<TD>
<P>I1: 221</P>
<P>I2: 218</P>
<P>C1: 219</P>
<P>T: 658</P>
</TD>
<TD>
<P>I1: 169</P>
<P>I2: 191</P>
<P>C1: 194</P>
<P>T: 554</P>
</TD>
<TD>
<P>I1: 75.11</P>
<P>I2: 86.42</P>
<P>C1: 88.58</P>
<P>T: 83.30</P>
</TD>
</TR>
<TR>
<TH>
<P>
<B>LIXISENATIDE</B>
</P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Lixisenatide versus placebo</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Ratner 2010</P>
</TD>
<TD>
<P>I1: -</P>
<P>I2: -</P>
<P>I3: -</P>
<P>I4: -</P>
<P>I5: -</P>
<P>I6: -</P>
<P>I7: -</P>
<P>I8: -</P>
<P>C1: -</P>
<P>T: 1466</P>
</TD>
<TD>
<P>I1: 55</P>
<P>I2: 52</P>
<P>I3: 55</P>
<P>I4: 54</P>
<P>I5: 53</P>
<P>I6: 56</P>
<P>I7: 54</P>
<P>I8: 54</P>
<P>C1: 109</P>
<P>T: 542</P>
</TD>
<TD>
<P>I1: 55</P>
<P>I2: 52</P>
<P>I3: 55</P>
<P>I4: 54</P>
<P>I5: 53</P>
<P>I6: 56</P>
<P>I7: 54</P>
<P>I8: 54</P>
<P>C1: 109</P>
<P>T: 542</P>
</TD>
<TD>
<P>I1: 55</P>
<P>I2: 50</P>
<P>I3: 53</P>
<P>I4: 51</P>
<P>I5: 51</P>
<P>I6: 54</P>
<P>I7: 52</P>
<P>I8: 53</P>
<P>C1: 107</P>
<P>T: 526</P>
</TD>
<TD>
<P>I1: 53</P>
<P>I2: 47</P>
<P>I3: 46</P>
<P>I4: 45</P>
<P>I5: 51</P>
<P>I6: 51</P>
<P>I7: 46</P>
<P>I8: 47</P>
<P>C1: 103</P>
<P>T: 489</P>
</TD>
<TD>
<P>I1: 96.36</P>
<P>I2: 90.38</P>
<P>I3: 83.64</P>
<P>I4: 83.33</P>
<P>I5: 96.23</P>
<P>I6: 91.10</P>
<P>I7: 85.18</P>
<P>I8: 87.04</P>
<P>C1: 94.50</P>
<P>T: 90.22</P>
</TD>
</TR>
<TR>
<TH>
<P>
<B>LY2189265 </B>
</P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>LY2189265 versus placebo</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Umpierrez 2011</P>
</TD>
<TD>
<P>I1: -</P>
<P>I2: -</P>
<P>I3: -</P>
<P>C1: -</P>
<P>T: -</P>
</TD>
<TD>
<P>I1: 66</P>
<P>I2: 65</P>
<P>I3: 65</P>
<P>C1: 66</P>
<P>T: 262</P>
</TD>
<TD>
<P>I1: 66</P>
<P>I2: 65</P>
<P>I3: 65</P>
<P>C1: 66</P>
<P>T: 262</P>
</TD>
<TD>
<P>I1: 66</P>
<P>I2: 65</P>
<P>I3: 65</P>
<P>C1: 66</P>
<P>T: 262</P>
</TD>
<TD>
<P>I1: 58</P>
<P>I2: 58</P>
<P>I3: 56</P>
<P>C1: 60</P>
<P>T: 232</P>
</TD>
<TD>
<P>I1: 87.88</P>
<P>I2: 89.23</P>
<P>I3: 86.15</P>
<P>C1: 90.90</P>
<P>T: 88.55</P>
</TD>
</TR>
<TR>
<TH>
<P>
<B>TASPOGLUTIDE</B>
</P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Taspoglutide versus placebo</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Nauck 2009</P>
</TD>
<TD>
<P>I1: -</P>
<P>I2: -</P>
<P>I3: -</P>
<P>I4: -</P>
<P>I5: -</P>
<P>C1: -</P>
<P>T: 572</P>
</TD>
<TD>
<P>I1: -</P>
<P>I2: -</P>
<P>I3: -</P>
<P>I4: -</P>
<P>I5: -</P>
<P>C1: -</P>
<P>T: 306</P>
</TD>
<TD>
<P>I1: 50</P>
<P>I2: 49</P>
<P>I3: 50</P>
<P>I4: 50</P>
<P>I5: 49</P>
<P>C1: 49</P>
<P>T:297</P>
</TD>
<TD>
<P>I1: 50</P>
<P>I2: 49</P>
<P>I3: 50</P>
<P>I4: 50</P>
<P>I5: 49</P>
<P>C1: 49</P>
<P>T:297</P>
</TD>
<TD>
<P>I1: 49</P>
<P>I2: 45</P>
<P>I3: 44</P>
<P>I4: 46</P>
<P>I5: 46</P>
<P>C1: 47</P>
<P>T: 277</P>
</TD>
<TD>
<P>I1: -</P>
<P>I2: -</P>
<P>I3: -</P>
<P>I4: -</P>
<P>I5: -</P>
<P>C1: -</P>
<P>T: 90.52</P>
</TD>
</TR>
<TR>
<TD>
<P>Ratner 2010</P>
</TD>
<TD>
<P>I1: -</P>
<P>I2: -</P>
<P>I3: -</P>
<P>C1: -</P>
<P>T: -</P>
</TD>
<TD>
<P>I1: 33</P>
<P>I2: 34</P>
<P>I3: 33</P>
<P>C1: 33</P>
<P>T: 133</P>
</TD>
<TD>
<P>I1: 32</P>
<P>I2: 33</P>
<P>I3: 32</P>
<P>C1: 32</P>
<P>T: 129</P>
</TD>
<TD>
<P>I1: -</P>
<P>I2: -</P>
<P>I3: -</P>
<P>C1: -</P>
<P>T: 125</P>
</TD>
<TD>
<P>I1: 32</P>
<P>I2: 31</P>
<P>I3: 27</P>
<P>C1: 27</P>
<P>T: 117</P>
</TD>
<TD>
<P>I1: 96.97</P>
<P>I2: 91.18</P>
<P>I3: 81.82</P>
<P>C1: 81.82</P>
<P>T: 87.97</P>
</TD>
</TR>
<TR>
<TH>
<P>
<B>ALBIGLUTIDE</B>
</P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Albiglutide versus placebo</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Rosenstock 2009</P>
</TD>
<TD>
<P>I1: -</P>
<P>I2: -</P>
<P>C1: -</P>
<P>T: 774</P>
</TD>
<TD>
<P>I1: 31</P>
<P>I2: 33</P>
<P>C1: 52</P>
<P>T*: 116</P>
</TD>
<TD>
<P>I1: 31</P>
<P>I2: 32</P>
<P>C1: 51</P>
<P>T*: 114</P>
</TD>
<TD>
<P>I1: 29</P>
<P>I2: 32</P>
<P>C1: 50</P>
<P>T*: 111</P>
</TD>
<TD>
<P>I1: 22</P>
<P>I2: 24</P>
<P>C1: 40</P>
<P>T*: 86</P>
</TD>
<TD>
<P>I3: 70.97</P>
<P>I5: 72.73</P>
<P>C1: 76.92</P>
<P>T*: 74.14</P>
</TD>
</TR>
<TR>
<TH>
<P>
<B>GLP-1 versus GLP-1</B>
</P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Blevins 2011</P>
</TD>
<TD>
<P>I1: -</P>
<P>C1: -</P>
<P>T: -</P>
</TD>
<TD>
<P>I1: -</P>
<P>C1: -</P>
<P>T: 303</P>
</TD>
<TD>
<P>I1: 148</P>
<P>C1: 147</P>
<P>T: 295</P>
</TD>
<TD>
<P>I1: 148</P>
<P>C1: 147</P>
<P>T: 295</P>
</TD>
<TD>
<P>I1: 128</P>
<P>C1: 130</P>
<P>T: 258</P>
</TD>
<TD>
<P>I1: 86.49</P>
<P>C1: 88.43</P>
<P>T: 87.46</P>
</TD>
</TR>
<TR>
<TD>
<P>Drucker 2008</P>
</TD>
<TD>
<P>I1: -</P>
<P>C1: -</P>
<P>T: -</P>
</TD>
<TD>
<P>I1: -</P>
<P>C1: -</P>
<P>T: 254</P>
</TD>
<TD>
<P>I1: 129</P>
<P>C1: 123</P>
<P>T: 252</P>
</TD>
<TD>
<P>I1: 129</P>
<P>C1: 123</P>
<P>T: 252</P>
</TD>
<TD>
<P>I1: 109</P>
<P>C1: 95</P>
<P>T: 204</P>
</TD>
<TD>
<P>I1: 84.5</P>
<P>C1: 77.23</P>
<P>T: 80.95</P>
</TD>
</TR>
<TR>
<TD>
<P>LEAD 6 (Buse 2009)</P>
</TD>
<TD>
<P>I1: -</P>
<P>C1: -</P>
<P>T:663</P>
</TD>
<TD>
<P>I1: 233</P>
<P>C1: 231</P>
<P>T: 464</P>
</TD>
<TD>
<P>I1: 235</P>
<P>C1: 232</P>
<P>T: 467</P>
</TD>
<TD>
<P>I1: 233</P>
<P>C1: 231</P>
<P>T: 464</P>
</TD>
<TD>
<P>I1: 202</P>
<P>C1: 187</P>
<P>T: 389</P>
</TD>
<TD>
<P>I1: 86.69</P>
<P>C1: 80.95</P>
<P>T: 83.84</P>
</TD>
</TR>
<TR>
<TH>
<P>
<I>
<B>Total</B>
</I>
</P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P>
<I>
<B>I#: 4051</B>
</I>
</P>
<P>
<I>
<B>C#: 2679</B>
</I>
</P>
<P>
<I>
<B>T##: 6899</B>
</I>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>
<I>
<B>I: 3878</B>
</I>
</P>
<P>
<I>
<B>C: 2653</B>
</I>
</P>
<P>
<I>
<B>T: 6531</B>
</I>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>"-" denotes not reported</P>
<P>C: control; GLP: glucagon-like peptide; I: intervention; ITT: intention-to-treat; T: Total</P>
<P>&#8220;*&#8221; indicate totals of the patients whose data were included in this review</P>
<P>&#8216;#&#8217; indicate that the total is missing for some data for both I and C group as they were not reported</P>
<P>&#8216;##&#8217; indicate that this is the actual total number of patients randomised. Please note &#8216;T&#8217; for all trials were added to get this number</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2011-08-30 10:46:03 +0200" MODIFIED_BY="Bernd Richter" NO="2">
<TITLE MODIFIED="2009-12-04 11:23:19 +0100" MODIFIED_BY="[Empty name]">Overview of comparisons</TITLE>
<TABLE COLS="5" ROWS="38">
<TR>
<TH>
<P>Characteristic &#9658;</P>
<P>GLP analogue &#9660;</P>
</TH>
<TH>
<P>
<B>Intervention</B>
</P>
</TH>
<TH>
<P>
<B>Control</B>
</P>
</TH>
<TH>
<P>
<B>Duration</B>
</P>
</TH>
<TH>
<P>
<B>Quality (of 7)</B>
</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>
<B>EXENATIDE</B>
</P>
</TH>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Exenatide versus TZD</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Bergenstal 2010</P>
</TD>
<TD VALIGN="TOP">
<P>E QW+M+Placebo</P>
</TD>
<TD VALIGN="TOP">
<P>TZD+M+Placebo</P>
</TD>
<TD VALIGN="TOP">
<P>26 weeks</P>
</TD>
<TD>
<P>7</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Exenatide versus DPP-4 inhibitors</B>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Bergenstal 2010</P>
</TD>
<TD VALIGN="TOP">
<P>E QW+M+Placebo</P>
</TD>
<TD VALIGN="TOP">
<P>DPP-4+M+Placebo</P>
</TD>
<TD VALIGN="TOP">
<P>26 weeks</P>
</TD>
<TD>
<P>7</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Exenatide versus insulin glargine</B>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Diamant 2010</P>
</TD>
<TD VALIGN="TOP">
<P>E QW+M/(M+SU)</P>
</TD>
<TD VALIGN="TOP">
<P>GLAR+M/(M+SU)</P>
</TD>
<TD VALIGN="TOP">
<P>26 weeks</P>
</TD>
<TD>
<P>6</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>
<B>LIRAGLUTIDE</B>
</P>
</TH>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Liraglutide versus placebo</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>LEAD 1 (Marre 2009)</P>
</TD>
<TD VALIGN="TOP">
<P>L+SU</P>
</TD>
<TD VALIGN="TOP">
<P>SU</P>
</TD>
<TD VALIGN="TOP">
<P>26 weeks</P>
</TD>
<TD>
<P>5</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>LEAD 2 (Nauck 2009)</P>
</TD>
<TD VALIGN="TOP">
<P>L+M</P>
</TD>
<TD VALIGN="TOP">
<P>M</P>
</TD>
<TD VALIGN="TOP">
<P>26 weeks</P>
</TD>
<TD>
<P>7</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>LEAD 5 (Russell-Jones 2008)</P>
</TD>
<TD VALIGN="TOP">
<P>L+M+SU</P>
</TD>
<TD VALIGN="TOP">
<P>M+SU</P>
</TD>
<TD VALIGN="TOP">
<P>26 weeks</P>
</TD>
<TD>
<P>6</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>LEAD 4 (Zinman 2009)</P>
</TD>
<TD VALIGN="TOP">
<P>L+M+TZD</P>
</TD>
<TD VALIGN="TOP">
<P>M+TZD</P>
</TD>
<TD VALIGN="TOP">
<P>26 weeks</P>
</TD>
<TD>
<P>7</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Liraglutide versus insulin</B>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>LEAD 5 (Russell-Jones 2008)</P>
</TD>
<TD VALIGN="TOP">
<P>L+M+SU</P>
</TD>
<TD VALIGN="TOP">
<P>GLAR+M+SU</P>
</TD>
<TD>
<P>26 weeks</P>
</TD>
<TD>
<P>6</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Liraglutide versus SU</B>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>LEAD 2 (Nauck 2009)</P>
</TD>
<TD>
<P>L+M</P>
</TD>
<TD>
<P>M+SU</P>
</TD>
<TD>
<P>26 weeks</P>
</TD>
<TD>
<P>7</P>
</TD>
</TR>
<TR>
<TD>
<P>Yang 2010</P>
</TD>
<TD>
<P>L+M+Placebo</P>
</TD>
<TD>
<P>SU+M+Placebo</P>
</TD>
<TD>
<P>16 weeks</P>
</TD>
<TD>
<P>5</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Liraglutide versus TZD</B>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>LEAD 1 (Marre 2009)</P>
</TD>
<TD VALIGN="TOP">
<P>L+SU</P>
</TD>
<TD VALIGN="TOP">
<P>TZD+SU</P>
</TD>
<TD VALIGN="TOP">
<P>26 weeks</P>
</TD>
<TD>
<P>5</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Liraglutide versus DPP-4 inhibitors</B>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Pratley 2010</P>
</TD>
<TD>
<P>L+M</P>
</TD>
<TD>
<P>DPP-4+M</P>
</TD>
<TD>
<P>26 weeks</P>
</TD>
<TD>
<P>6</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>
<B>LIXISENATIDE</B>
</P>
</TH>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Lixisenatide versus placebo</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Ratner 2010</P>
</TD>
<TD VALIGN="TOP">
<P>LIXI QD or BID</P>
</TD>
<TD VALIGN="TOP">
<P>Placebo</P>
</TD>
<TD VALIGN="TOP">
<P>13 weeks</P>
</TD>
<TD>
<P>7</P>
</TD>
</TR>
<TR>
<TH>
<P>
<B>LY2189265 </B>
</P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>LY2189265 versus placebo</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Umpierrez 2011</P>
</TD>
<TD>
<P>LY QW</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>16 weeks</P>
</TD>
<TD>
<P>6</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>
<B>TASPOGLUTIDE</B>
</P>
</TH>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Nauck 2009</P>
</TD>
<TD VALIGN="TOP">
<P>T+M</P>
</TD>
<TD VALIGN="TOP">
<P>M</P>
</TD>
<TD VALIGN="TOP">
<P>8 weeks</P>
</TD>
<TD>
<P>7</P>
</TD>
</TR>
<TR>
<TD>
<P>Ratner 2010</P>
</TD>
<TD>
<P>T+M</P>
</TD>
<TD>
<P>Placebo+M</P>
</TD>
<TD>
<P>8 weeks</P>
</TD>
<TD>
<P>5</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>
<B>ALBIGLUTIDE</B>
</P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Rosenstock 2009</P>
</TD>
<TD VALIGN="TOP">
<P>A+M</P>
</TD>
<TD VALIGN="TOP">
<P>M</P>
</TD>
<TD VALIGN="TOP">
<P>16 weeks</P>
</TD>
<TD>
<P>5</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>
<B>GLP1 versus GLP1</B>
</P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Blevins 2011</P>
</TD>
<TD>
<P>E QW+/-M+/-SU+/-TZD</P>
</TD>
<TD>
<P>E BID+/-M+/-SU+/-TZD</P>
</TD>
<TD>
<P>24 weeks</P>
</TD>
<TD>
<P>5</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Drucker 2008</P>
</TD>
<TD VALIGN="TOP">
<P>E BID+M</P>
</TD>
<TD VALIGN="TOP">
<P>E QW+M </P>
</TD>
<TD VALIGN="TOP">
<P>30 weeks</P>
</TD>
<TD>
<P>4</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>LEAD 6 (Buse 2009)</P>
</TD>
<TD VALIGN="TOP">
<P>L+M/SU</P>
</TD>
<TD VALIGN="TOP">
<P>E+M/SU</P>
</TD>
<TD VALIGN="TOP">
<P>26 weeks</P>
</TD>
<TD>
<P>5</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>A: albiglutide; BID: twice daily; DPP-4: dipeptidyl peptidase-4 inhibitor; E: exenatide; GLAR: glargine; GLP: glucagon-like peptide; L: liraglutide; LIXI: lixisenatide; LY: LY2189265; M: metformin; QD: once daily; QW: once weekly; SU: sulphonylurea; T: taspoglutide; TZD: thiazolidinedione.</SUP>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-09-01 14:43:46 +0200" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2011-08-30 13:58:16 +0200" MODIFIED_BY="Bernd Richter" NO="1">
<NAME>Albiglutide versus placebo</NAME>
<OTHER_OUTCOME COLS="3" ID="CMP-001.01" MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" NO="1" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>HbA1c (%)</NAME>
<TR>
<TH>
<P>ALBI 30 mg weekly</P>
</TH>
<TH>
<P>ALBI 30 mg every 2 weeks</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" ORDER="1166" STUDY_ID="STD-A-_x002d_-Rosenstock-2009">
<TR>
<TD>
<P>-0.87% (SD 0.65)</P>
<P>7.1%</P>
<P>P &lt; 0.05 versus placebo</P>
</TD>
<TD>
<P>-0.79% (SD 0.98)</P>
<P>7.2%</P>
<P>P &lt; 0.05 versus placebo</P>
</TD>
<TD>
<P>-0.17% (SD 1.01)</P>
<P>7.7%</P>
<P/>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.07495420867275918" CI_END="-0.38559906642923497" CI_START="-0.9488704073990855" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6672347369141602" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2011-06-30 12:13:19 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7842554975396382" P_Q="0.7842554975396382" P_Z="3.4266899122246916E-6" Q="0.07495420867275918" RANDOM="YES" SCALE="1.46" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="61" TOTAL_2="100" UNITS="" WEIGHT="200.0" Z="4.643431889625681">
<NAME>HbA1c - with plot</NAME>
<GROUP_LABEL_1>Albiglutide</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Albiglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.33347643465338134" CI_START="-1.0665235653466185" DF="0" EFFECT_SIZE="-0.7" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" MODIFIED="2009-11-26 15:26:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.8168403812543908E-4" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="50" WEIGHT="100.0" Z="3.743210311404047">
<NAME>ALBI 30 mg weekly</NAME>
<CONT_DATA CI_END="-0.33347643465338134" CI_START="-1.0665235653466185" EFFECT_SIZE="-0.7" ESTIMABLE="YES" MEAN_1="-0.87" MEAN_2="-0.17" MODIFIED="2009-11-26 15:25:12 +0100" MODIFIED_BY="[Empty name]" ORDER="57" SD_1="0.65" SD_2="1.01" SE="0.18700525531984757" STUDY_ID="STD-A-_x002d_-Rosenstock-2009" TOTAL_1="29" TOTAL_2="50" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.17992588611020982" CI_START="-1.0600741138897902" DF="0" EFFECT_SIZE="-0.62" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" MODIFIED="2009-11-26 15:26:15 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.005757135740735037" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="50" WEIGHT="100.00000000000001" Z="2.7613023171800473">
<NAME>ALBI 30 mg every 2 weeks</NAME>
<CONT_DATA CI_END="-0.17992588611020982" CI_START="-1.0600741138897902" EFFECT_SIZE="-0.62" ESTIMABLE="YES" MEAN_1="-0.79" MEAN_2="-0.17" MODIFIED="2009-11-26 15:25:27 +0100" MODIFIED_BY="[Empty name]" ORDER="58" SD_1="0.98" SD_2="1.01" SE="0.2245317349507637" STUDY_ID="STD-A-_x002d_-Rosenstock-2009" TOTAL_1="32" TOTAL_2="50" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-001.03" MODIFIED="2011-08-30 10:26:28 +0200" MODIFIED_BY="Bernd Richter" NO="3" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>HbA1c &lt; 7%</NAME>
<TR>
<TH>
<P>ALBI 30 mg weekly</P>
</TH>
<TH>
<P>ALBI 30 mg every 2 weeks</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:26:28 +0200" MODIFIED_BY="Bernd Richter" ORDER="1169" STUDY_ID="STD-A-_x002d_-Rosenstock-2009">
<TR>
<TD>
<P>52%</P>
<P>(P value not given)</P>
</TD>
<TD>
<P>50%</P>
<P>(P value not given)</P>
</TD>
<TD>
<P>20%</P>
<P/>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.04" MODIFIED="2011-08-30 10:27:51 +0200" MODIFIED_BY="Bernd Richter" NO="4" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Hypoglycaemia</NAME>
<TR>
<TH>
<P>Definition</P>
</TH>
<TH>
<P>ALBI 30 mg weekly</P>
</TH>
<TH>
<P>ALBI 30 mg every 2 weeks</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:27:51 +0200" MODIFIED_BY="Bernd Richter" ORDER="1170" STUDY_ID="STD-A-_x002d_-Rosenstock-2009">
<TR>
<TD>
<P>not given</P>
</TD>
<TD>
<P>n = 0, P = NS</P>
</TD>
<TD>
<P>n=1 (3.1%), P = NS</P>
</TD>
<TD>
<P>n = 2 (3.9%)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.05476952241330578" CI_END="0.03702647890181621" CI_START="-1.6379324187391484" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8004529699186661" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2011-06-30 12:13:33 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.8149625503631809" P_Q="0.814962550363181" P_Z="0.0610255294585211" Q="0.054769522413305724" RANDOM="YES" SCALE="4.51" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="61" TOTAL_2="100" UNITS="" WEIGHT="200.0" Z="1.8733104371316953">
<NAME>Weight change - with plot</NAME>
<GROUP_LABEL_1>Albiglutide</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Albiglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.48706637299224553" CI_START="-1.8870663729922454" DF="0" EFFECT_SIZE="-0.7" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.01" MODIFIED="2011-06-28 16:17:02 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.24777558145263934" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="50" WEIGHT="100.0" Z="1.1557692311001049">
<NAME>ALBI 30 mg weekly</NAME>
<CONT_DATA CI_END="0.48706637299224553" CI_START="-1.8870663729922454" EFFECT_SIZE="-0.7" ESTIMABLE="YES" MEAN_1="-1.4" MEAN_2="-0.7" MODIFIED="2009-11-26 15:30:25 +0100" MODIFIED_BY="[Empty name]" ORDER="60" SD_1="2.4" SD_2="2.9" SE="0.6056572377633842" STUDY_ID="STD-A-_x002d_-Rosenstock-2009" TOTAL_1="29" TOTAL_2="50" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.3907916905411255E-32" CI_END="0.2817014426485115" CI_START="-2.0817014426485114" DF="0" EFFECT_SIZE="-0.9" ESTIMABLE="YES" I2="99.99999999999999" ID="CMP-001.05.02" MODIFIED="2011-06-28 16:17:02 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.13550646075579117" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="50" WEIGHT="100.0" Z="1.4927354088123324">
<NAME>ALBI 30 mg every 2 weeks</NAME>
<CONT_DATA CI_END="0.2817014426485114" CI_START="-2.0817014426485114" EFFECT_SIZE="-0.9000000000000001" ESTIMABLE="YES" MEAN_1="-1.6" MEAN_2="-0.7" MODIFIED="2009-11-26 15:30:42 +0100" MODIFIED_BY="[Empty name]" ORDER="61" SD_1="2.5" SD_2="2.9" SE="0.6029199781065477" STUDY_ID="STD-A-_x002d_-Rosenstock-2009" TOTAL_1="32" TOTAL_2="50" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-001.06" MODIFIED="2011-08-30 10:27:51 +0200" MODIFIED_BY="Bernd Richter" NO="6" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Weight change (kg)</NAME>
<TR>
<TH>
<P>ALBI 30 mg weekly</P>
</TH>
<TH>
<P>ALBI 30 mg every 2 weeks</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:27:51 +0200" MODIFIED_BY="Bernd Richter" ORDER="1173" STUDY_ID="STD-A-_x002d_-Rosenstock-2009">
<TR>
<TD>
<P>-1.4 kg (SD 2.4), P = NS</P>
</TD>
<TD>
<P>-1.6 kg (SD 2.5), P = NS</P>
</TD>
<TD>
<P>-0.7 kg (SD 2.9)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.07" MODIFIED="2011-06-30 12:02:28 +0200" MODIFIED_BY="[Empty name]" NO="7" ROWS_PER_STUDY="10" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Adverse events</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>ALBI 30 mg weekly</P>
</TH>
<TH>
<P>ALBI 30 mg every 2 weeks</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-06-30 12:02:28 +0200" MODIFIED_BY="[Empty name]" ORDER="1174" STUDY_ID="STD-A-_x002d_-Rosenstock-2009">
<TR>
<TD>
<P>any adverse event</P>
</TD>
<TD>
<P>83.9%</P>
</TD>
<TD>
<P>84.4%</P>
</TD>
<TD>
<P>66.7%</P>
</TD>
</TR>
<TR>
<TD>
<P>withdrawals</P>
</TD>
<TD>
<P>32.2%</P>
</TD>
<TD>
<P>42.8%</P>
</TD>
<TD>
<P>23.5%</P>
</TD>
</TR>
<TR>
<TD>
<P>adverse events similar across groups for:</P>
<P>abdominal pain, headache, dizziness, hyperglycaemia, nasopharyngitis,</P>
<P>influenza, upper respiratory tract infection, back pain</P>
<P>no systemic allergic reactions to albiglutide</P>
</TD>
<TD/>
<TD/>
<TD/>
</TR>
<TR>
<TD>
<P>nausea</P>
</TD>
<TD>
<P>n = 8 (25.8%)</P>
</TD>
<TD>
<P>n = 8 (25%)</P>
</TD>
<TD>
<P>n = 6 (11.8%)</P>
</TD>
</TR>
<TR>
<TD>
<P>vomiting</P>
</TD>
<TD>
<P>n = 4 (12.9%)</P>
</TD>
<TD>
<P>n = 3 (9.4%)</P>
</TD>
<TD>
<P>n = 1 (2%)</P>
</TD>
</TR>
<TR>
<TD>
<P>diarrhoea</P>
</TD>
<TD>
<P>n = 5 (16.1%)</P>
</TD>
<TD>
<P>n = 7 (21.9%)</P>
</TD>
<TD>
<P>n = 2 (3.9%)</P>
</TD>
</TR>
<TR>
<TD>
<P>cardiac disorders</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>n = 1</P>
</TD>
</TR>
<TR>
<TD>
<P>pancreatitis</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>none</P>
</TD>
</TR>
<TR>
<TD>
<P>skin reactions</P>
</TD>
<TD>
<P>15 events in 7 patients</P>
</TD>
<TD>
<P>11 events in 6 patients</P>
</TD>
<TD>
<P>3 events in 3 patients</P>
</TD>
</TR>
<TR>
<TD>
<P>positive immunogenicity test</P>
</TD>
<TD>
<P>2 of 31 (6.4%)</P>
</TD>
<TD>
<P>1 of 32 (3.1%)</P>
</TD>
<TD>
<P>1 of 51 (2%)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.08" MODIFIED="2011-08-30 13:58:16 +0200" MODIFIED_BY="Bernd Richter" NO="8" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Blood pressure (mm Hg)</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>ALBI 30 mg weekly</P>
</TH>
<TH>
<P>ALBI 30 mg every 2 weeks</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 13:58:16 +0200" MODIFIED_BY="Bernd Richter" ORDER="1175" STUDY_ID="STD-A-_x002d_-Rosenstock-2009">
<TR>
<TD>
<P>systolic BP (mm Hg)</P>
</TD>
<TD>
<P>-5.8 (SD 11.2), P = NS</P>
</TD>
<TD>
<P>-7.4 (SD 14.2), P = NS</P>
</TD>
<TD>
<P>-0.7 (SD 13.9)</P>
</TD>
</TR>
<TR>
<TD>
<P>diastolic BP (mm Hg)</P>
</TD>
<TD>
<P>-1.9 (SD 8.1), P = NS</P>
</TD>
<TD>
<P>-4.4 (SD 8.9), P = NS</P>
</TD>
<TD>
<P>-1.0 (SD 8.2)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.09" MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" NO="9" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Fasting plasma glucose (mmol/L)</NAME>
<TR>
<TH>
<P>ALBI 30 mg weekly</P>
</TH>
<TH>
<P>ALBI 30 mg every 2 weeks</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
<TH>
<P>FPG fluctuations</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" ORDER="1176" STUDY_ID="STD-A-_x002d_-Rosenstock-2009">
<TR>
<TD>
<P>-1.44% (SD 2.03), P &lt; 0.05 versus placebo</P>
</TD>
<TD>
<P>-1.58% (SD 2.06), P &lt; 0.05 versus placebo</P>
</TD>
<TD>
<P>-0.10% (SD 2.90)</P>
</TD>
<TD>
<P>according to figure 1C in the paper, the once weekly dosing schedules seemed to cause less fluctuation in FPG than the less frequent dosing schedules; however, data are only shown for 50 mg every 2 weeks and not for 30 mg every 2 weeks</P>
<P>COMMENT: paper says "%" but should probably be "mmol/L"??</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.10" MODIFIED="2011-08-30 10:27:51 +0200" MODIFIED_BY="Bernd Richter" NO="10" ROWS_PER_STUDY="5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Lipid profiles</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>ALBI 30 mg weekly</P>
</TH>
<TH>
<P>ALBI 30 mg every 2 weeks</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:27:51 +0200" MODIFIED_BY="Bernd Richter" ORDER="1177" STUDY_ID="STD-A-_x002d_-Rosenstock-2009">
<TR>
<TD>
<P>triglycerides (mmol/L)</P>
</TD>
<TD>
<P>+0.1 (SD 0.9), P = NS</P>
</TD>
<TD>
<P>-0.3 (SD 1.0), P = NS</P>
</TD>
<TD>
<P>-0.4 (SD 1.7)</P>
</TD>
</TR>
<TR>
<TD>
<P>total cholesterol (mmol/L)</P>
</TD>
<TD>
<P>+0.01 (SD 0.6), P = NS</P>
</TD>
<TD>
<P>-0.18 (SD 0.45), P = NS</P>
</TD>
<TD>
<P>+0.1 (SD 0.77)</P>
</TD>
</TR>
<TR>
<TD>
<P>HDL (mmol/L)</P>
</TD>
<TD>
<P>-0.05 (SD 0.17), P = NS</P>
</TD>
<TD>
<P>-0.03 (SD 0.14), P = NS</P>
</TD>
<TD>
<P>-0.002 (SD 0.13)</P>
</TD>
</TR>
<TR>
<TD>
<P>LDL (mmol/L)</P>
</TD>
<TD>
<P>+0.003 (SD 0.6), P = NS</P>
</TD>
<TD>
<P>-0.06 (SD 0.39), P = NS</P>
</TD>
<TD>
<P>+0.19 (SD 0.6)</P>
</TD>
</TR>
<TR>
<TD>
<P>free fatty acids (mmol/L)</P>
</TD>
<TD>
<P>+0.05 (SD 0.17), P = NS</P>
</TD>
<TD>
<P>-0.01 (SD 0.25), P = NS</P>
</TD>
<TD>
<P>+0.08 (SD 0.2)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.11" MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" NO="11" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Beta-cell function</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>ALBI 30 mg weekly</P>
</TH>
<TH>
<P>ALBI 30 mg every 2 weeks</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" ORDER="1178" STUDY_ID="STD-A-_x002d_-Rosenstock-2009">
<TR>
<TD>
<P>HOMA-B endpoint</P>
</TD>
<TD>
<P>95.4</P>
</TD>
<TD>
<P>74.7</P>
</TD>
<TD>
<P>50.4</P>
</TD>
</TR>
<TR>
<TD>
<P>HOMA-B ratio at endpoint</P>
</TD>
<TD>
<P>1.4, P &lt; 0.05 versus placebo</P>
</TD>
<TD>
<P>1.2, P = NS</P>
</TD>
<TD>
<P>1.0</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-001.12" MODIFIED="2011-06-30 12:04:03 +0200" MODIFIED_BY="[Empty name]" NO="12" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Subgroups</NAME>
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Results / comments</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-06-30 12:04:03 +0200" MODIFIED_BY="[Empty name]" ORDER="1179" STUDY_ID="STD-A-_x002d_-Rosenstock-2009">
<TR>
<TD>
<P>HbA1c</P>
</TD>
<TD>
<P>Numerically greater reductions were seen in participants with baseline HbA1c &#8805; 8.5% (no details given)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2011-08-30 14:39:14 +0200" MODIFIED_BY="Bernd Richter" NO="2">
<NAME>Exenatide 2 mg once weekly versus thiazolidinedione</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.04991265791822985" CI_START="-0.5500873420817702" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2011-08-30 14:37:10 +0200" MODIFIED_BY="Bernd Richter" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.01871622342596096" Q="0.0" RANDOM="YES" SCALE="1.81" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="160" TOTAL_2="165" UNITS="" WEIGHT="0.0" Z="2.3511353692173818">
<NAME>HbA1c (%)</NAME>
<GROUP_LABEL_1>Exenatide 2 mg QW</GROUP_LABEL_1>
<GROUP_LABEL_2>Pioglitazone 45 mg QD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Exenatide 2 mg QW</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Pioglitazone QD</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.04991265791822985" CI_START="-0.5500873420817702" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" MEAN_1="-1.5" MEAN_2="-1.2" MODIFIED="2011-06-30 12:18:51 +0200" MODIFIED_BY="[Empty name]" ORDER="373" SD_1="0.97" SD_2="1.31" SE="0.12759792733663844" STUDY_ID="STD-E-_x002d_-Bergenstal-2010" TOTAL_1="160" TOTAL_2="165" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3967446916935045" CI_START="0.9487601983152184" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1511627906976745" ESTIMABLE="NO" EVENTS_1="96" EVENTS_2="86" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.14511702950590885" LOG_CI_START="-0.022843542797944424" LOG_EFFECT_SIZE="0.06113674335398221" METHOD="MH" MODIFIED="2011-08-30 14:38:44 +0200" MODIFIED_BY="Bernd Richter" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.15362813466133624" Q="0.0" RANDOM="YES" SCALE="3.27" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="160" TOTAL_2="165" WEIGHT="0.0" Z="1.4268326603353052">
<NAME>HbA1c &lt; 7%</NAME>
<GROUP_LABEL_1>Exenatide 2 mg QW</GROUP_LABEL_1>
<GROUP_LABEL_2>Pioglitazone 45 mg QD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Pioglitazone QD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Exenatide 2 mg QW</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3967446916935045" CI_START="0.9487601983152184" EFFECT_SIZE="1.1511627906976745" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="86" LOG_CI_END="0.14511702950590885" LOG_CI_START="-0.022843542797944424" LOG_EFFECT_SIZE="0.06113674335398221" MODIFIED="2011-06-30 12:19:09 +0200" MODIFIED_BY="[Empty name]" ORDER="374" O_E="0.0" SE="0.09866087158952525" STUDY_ID="STD-E-_x002d_-Bergenstal-2010" TOTAL_1="160" TOTAL_2="165" VAR="0.00973396758280479" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="22.52225717408742" CI_START="0.18887566273305217" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0625" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="1.3526119132276044" LOG_CI_START="-0.7238239987836789" LOG_EFFECT_SIZE="0.31439395722196267" METHOD="MH" MODIFIED="2011-08-30 14:38:53 +0200" MODIFIED_BY="Bernd Richter" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.5528346798242805" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="160" TOTAL_2="165" WEIGHT="0.0" Z="0.5935177960924468">
<NAME>Hypoglycaemia (minor)</NAME>
<GROUP_LABEL_1>Exenatide 2 mg QW</GROUP_LABEL_1>
<GROUP_LABEL_2>Pioglitazone 45 mg QD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Exenatide 2 mg QW</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Pioglitazone QD</GRAPH_LABEL_2>
<DICH_DATA CI_END="22.52225717408742" CI_START="0.18887566273305217" EFFECT_SIZE="2.0625" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3526119132276044" LOG_CI_START="-0.7238239987836789" LOG_EFFECT_SIZE="0.31439395722196267" MODIFIED="2011-06-30 12:20:25 +0200" MODIFIED_BY="[Empty name]" ORDER="375" O_E="0.0" SE="1.2197087332389622" STUDY_ID="STD-E-_x002d_-Bergenstal-2010" TOTAL_1="160" TOTAL_2="165" VAR="1.4876893939393938" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-4.251964828057494" CI_START="-5.9480351719425055" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.1" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2011-06-30 12:20:31 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="4.5531390762063067E-32" Q="0.0" RANDOM="YES" SCALE="6.91" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="160" TOTAL_2="165" UNITS="" WEIGHT="0.0" Z="11.787030363679252">
<NAME>Weight change (kg)</NAME>
<GROUP_LABEL_1>Exenatide 2 mg QW</GROUP_LABEL_1>
<GROUP_LABEL_2>Pioglitazone 45 mg QD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Exenatide 2 mg QW</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Pioglitazone QD</GRAPH_LABEL_2>
<CONT_DATA CI_END="-4.251964828057494" CI_START="-5.9480351719425055" EFFECT_SIZE="-5.1" ESTIMABLE="YES" MEAN_1="-2.3" MEAN_2="2.8" MODIFIED="2011-06-30 12:20:31 +0200" MODIFIED_BY="[Empty name]" ORDER="376" SD_1="3.87" SD_2="3.93" SE="0.43267895667047934" STUDY_ID="STD-E-_x002d_-Bergenstal-2010" TOTAL_1="160" TOTAL_2="165" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-002.05" MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" NO="5" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Quality of life</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Exenatide 2 mg QW</P>
</TH>
<TH>
<P>Pioglitazone 45 mg QD</P>
</TH>
<TH>
<P>Difference between groups</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" ORDER="1184" STUDY_ID="STD-E-_x002d_-Bergenstal-2010">
<TR>
<TD>
<P>IWQOL total score</P>
</TD>
<TD>
<P>5.15, 95% CI 3.11 to 7.19</P>
</TD>
<TD>
<P>1.20, 95% CI -0.87 to 3.28</P>
</TD>
<TD>
<P>EX vs PIO: 3.94, 95% CI 1.28 to 6.61, P = 0.0038</P>
</TD>
</TR>
<TR>
<TD>
<P>Overall treatment satisfaction</P>
</TD>
<TD>
<P>3.96, 95% CI 2.78 to 5.15</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-002.06" MODIFIED="2011-06-30 12:05:47 +0200" MODIFIED_BY="[Empty name]" NO="6" ROWS_PER_STUDY="10" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Adverse events</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Exenatide 2 mg QW</P>
</TH>
<TH>
<P>Pioglitazone 45 mg QD</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-06-30 12:05:47 +0200" MODIFIED_BY="[Empty name]" ORDER="1185" STUDY_ID="STD-E-_x002d_-Bergenstal-2010">
<TR>
<TD>
<P>Withdrawals due to adverse events</P>
</TD>
<TD>
<P>6.9%</P>
</TD>
<TD>
<P>3.6%</P>
</TD>
</TR>
<TR>
<TD>
<P>Nausea</P>
</TD>
<TD>
<P>24%</P>
</TD>
<TD>
<P>5%</P>
</TD>
</TR>
<TR>
<TD>
<P>Diarrhoea</P>
</TD>
<TD>
<P>18%</P>
</TD>
<TD>
<P>7%</P>
</TD>
</TR>
<TR>
<TD>
<P>Vomiting</P>
</TD>
<TD>
<P>11%</P>
</TD>
<TD>
<P>3%</P>
</TD>
</TR>
<TR>
<TD>
<P>Urinary tract infection</P>
</TD>
<TD>
<P>6%</P>
</TD>
<TD>
<P>4%</P>
</TD>
</TR>
<TR>
<TD>
<P>Headache</P>
</TD>
<TD>
<P>9%</P>
</TD>
<TD>
<P>4%</P>
</TD>
</TR>
<TR>
<TD>
<P>Injection-site pruritus</P>
</TD>
<TD>
<P>5%</P>
</TD>
<TD>
<P>1%</P>
</TD>
</TR>
<TR>
<TD>
<P>Serious adverse events</P>
</TD>
<TD>
<P>3%</P>
</TD>
<TD>
<P>6%</P>
</TD>
</TR>
<TR>
<TD>
<P>Anti-Exenatide antibodies</P>
</TD>
<TD>
<P>either low (&lt; 1/625; n = 74, 48%) or not detectable (n = 61, 40%) titres</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Severe hypoglycaemia</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-002.07" MODIFIED="2011-08-30 13:58:16 +0200" MODIFIED_BY="Bernd Richter" NO="7" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Blood pressure (mm Hg)</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Exenatide 2 mg QW</P>
</TH>
<TH>
<P>Pioglitazone 45 mg QD</P>
</TH>
<TH>
<P>Difference between groups</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:27:51 +0200" MODIFIED_BY="Bernd Richter" ORDER="1186" STUDY_ID="STD-E-_x002d_-Bergenstal-2010">
<TR>
<TD>
<P>Systolic blood pressure</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>EX vs. PIO: P = NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Diastolic blood pressure</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>EX vs. PIO: P = NS</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.3014405031514378" CI_START="-0.9014405031514379" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.08" MODIFIED="2011-08-30 14:39:14 +0200" MODIFIED_BY="Bernd Richter" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.32825496775679486" Q="0.0" RANDOM="YES" SCALE="2.87" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="160" TOTAL_2="165" UNITS="" WEIGHT="0.0" Z="0.9776348488022687">
<NAME>Fasting plasma glucose (mmol/L)</NAME>
<GROUP_LABEL_1>Exenatide 2 mg QW</GROUP_LABEL_1>
<GROUP_LABEL_2>Pioglitazone 45 mg QD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Exenatide 2 mg QW</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Pioglitazone QD</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.3014405031514378" CI_START="-0.9014405031514379" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" MEAN_1="-1.8" MEAN_2="-1.5" MODIFIED="2011-06-30 12:21:10 +0200" MODIFIED_BY="[Empty name]" ORDER="377" SD_1="2.9" SD_2="2.62" SE="0.3068630382473983" STUDY_ID="STD-E-_x002d_-Bergenstal-2010" TOTAL_1="160" TOTAL_2="165" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-002.09" MODIFIED="2011-08-30 10:27:51 +0200" MODIFIED_BY="Bernd Richter" NO="9" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Post-prandial glucose / glucose profiles</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Exenatide 2 mg QW</P>
</TH>
<TH>
<P>Pioglitazone 45 mg QD</P>
</TH>
<TH>
<P>Description</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:27:51 +0200" MODIFIED_BY="Bernd Richter" ORDER="1188" STUDY_ID="STD-E-_x002d_-Bergenstal-2010">
<TR>
<TD>
<P>Self-monitored blood glucose</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>EX vs PIO: P = NS</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-002.10" MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" NO="10" ROWS_PER_STUDY="4" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Lipid profiles</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Exenatide 2 mg QW</P>
</TH>
<TH>
<P>Sitagliptin 100 mg QD</P>
</TH>
<TH>
<P>Difference between groups</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" ORDER="1189" STUDY_ID="STD-E-_x002d_-Bergenstal-2010">
<TR>
<TD>
<P>Fasting triglycerides (mmol/l)</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>EX vs. SITA: P = NS; PIO vs. SITA: P = 0.0062</P>
</TD>
</TR>
<TR>
<TD>
<P>Total cholesterol (mmol/l)</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>EX vs. SITA: P = NS; PIO vs. SITA: P = NS</P>
</TD>
</TR>
<TR>
<TD>
<P>HDL (mmol/l)</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>EX vs. SITA: P = NS; PIO vs. SITA: P &lt; 0.0001</P>
</TD>
</TR>
<TR>
<TD>
<P>LDL (mmol/l)</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>EX vs. SITA: P = NS; PIO vs. SITA: P = NS</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2011-08-30 14:40:44 +0200" MODIFIED_BY="Bernd Richter" NO="3">
<NAME>Exenatide 2 mg once weekly versus DPP-4 inhibitors</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.35039432110780266" CI_START="-0.8496056788921973" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.01" MODIFIED="2011-08-30 14:40:00 +0200" MODIFIED_BY="Bernd Richter" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="2.4608759836614004E-6" Q="0.0" RANDOM="YES" SCALE="1.68" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="160" TOTAL_2="166" UNITS="" WEIGHT="0.0" Z="4.711344693531305">
<NAME>HbA1c (%)</NAME>
<GROUP_LABEL_1>Exenatide 2 mg QW</GROUP_LABEL_1>
<GROUP_LABEL_2>Sitagliptin 100 mg QD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours exenatide QW</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sitagliptin QD</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.35039432110780266" CI_START="-0.8496056788921973" EFFECT_SIZE="-0.6" ESTIMABLE="YES" MEAN_1="-1.5" MEAN_2="-0.9" MODIFIED="2011-06-08 17:26:18 +0200" MODIFIED_BY="[Empty name]" ORDER="350" SD_1="0.97" SD_2="1.31" SE="0.1273521762956131" STUDY_ID="STD-E-_x002d_-Bergenstal-2010" TOTAL_1="160" TOTAL_2="166" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.189815965481593" CI_START="1.3466510434209744" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.717241379310345" ESTIMABLE="NO" EVENTS_1="96" EVENTS_2="58" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.34040761779252515" LOG_CI_START="0.12925507192899782" LOG_EFFECT_SIZE="0.2348313448607615" METHOD="MH" MODIFIED="2011-08-30 14:40:11 +0200" MODIFIED_BY="Bernd Richter" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="1.3035309032270688E-5" Q="0.0" RANDOM="YES" SCALE="6.62" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="160" TOTAL_2="166" WEIGHT="0.0" Z="4.359511522685357">
<NAME>HbA1c &lt; 7%</NAME>
<GROUP_LABEL_1>Exenatide 2 mg QW</GROUP_LABEL_1>
<GROUP_LABEL_2>Sitagliptin 100 mg QD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Sitagliptin QD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Exenatide QW</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.189815965481593" CI_START="1.3466510434209744" EFFECT_SIZE="1.717241379310345" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="58" LOG_CI_END="0.34040761779252515" LOG_CI_START="0.12925507192899782" LOG_EFFECT_SIZE="0.2348313448607615" MODIFIED="2011-06-27 16:12:25 +0200" MODIFIED_BY="[Empty name]" ORDER="351" O_E="0.0" SE="0.12403205066219507" STUDY_ID="STD-E-_x002d_-Bergenstal-2010" TOTAL_1="160" TOTAL_2="166" VAR="0.015383949591469324" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.1083517904174878" CI_START="0.08168703191885099" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.415" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.32394307707667397" LOG_CI_START="-1.0878468836524886" LOG_EFFECT_SIZE="-0.3819519032879073" METHOD="MH" MODIFIED="2011-08-30 14:40:21 +0200" MODIFIED_BY="Bernd Richter" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.28891054039355757" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="160" TOTAL_2="166" WEIGHT="0.0" Z="1.0605146588295336">
<NAME>Hypoglycaemia (minor)</NAME>
<GROUP_LABEL_1>Exenatide 2 mg QW</GROUP_LABEL_1>
<GROUP_LABEL_2>Sitagliptin 100 mg QD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Exenatide QW</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Sitagliptin QD</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1083517904174878" CI_START="0.08168703191885099" EFFECT_SIZE="0.415" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.32394307707667397" LOG_CI_START="-1.0878468836524886" LOG_EFFECT_SIZE="-0.3819519032879073" MODIFIED="2011-06-08 17:41:25 +0200" MODIFIED_BY="[Empty name]" ORDER="358" O_E="0.0" SE="0.8292924114053244" STUDY_ID="STD-E-_x002d_-Bergenstal-2010" TOTAL_1="160" TOTAL_2="166" VAR="0.6877259036144578" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.6159663499752662" CI_START="-2.384033650024733" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.4999999999999998" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.04" MODIFIED="2011-08-30 14:40:30 +0200" MODIFIED_BY="Bernd Richter" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="8.822713082866748E-4" Q="0.0" RANDOM="YES" SCALE="5.31" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="160" TOTAL_2="166" UNITS="" WEIGHT="0.0" Z="3.325604151751268">
<NAME>Weight change (kg)</NAME>
<GROUP_LABEL_1>Exenatide 2 mg QW</GROUP_LABEL_1>
<GROUP_LABEL_2>Sitagliptin 100 mg QD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Exenatide QW</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Sitagliptin QD</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.6159663499752662" CI_START="-2.384033650024733" EFFECT_SIZE="-1.4999999999999998" ESTIMABLE="YES" MEAN_1="-2.3" MEAN_2="-0.8" MODIFIED="2011-06-08 17:28:11 +0200" MODIFIED_BY="[Empty name]" ORDER="352" SD_1="3.87" SD_2="4.27" SE="0.45104586461683893" STUDY_ID="STD-E-_x002d_-Bergenstal-2010" TOTAL_1="160" TOTAL_2="166" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-003.05" MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" NO="5" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Quality of life</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Exenatide 2 mg QW</P>
</TH>
<TH>
<P>Sitagliptin 100 mg QD</P>
</TH>
<TH>
<P>Difference between groups</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" ORDER="1194" STUDY_ID="STD-E-_x002d_-Bergenstal-2010">
<TR>
<TD>
<P>IWQOL total score</P>
</TD>
<TD>
<P>5.15, 95% CI 3.11 to 7.19</P>
</TD>
<TD>
<P>4.56, 95% CI 2.56 to 6.57</P>
</TD>
<TD>
<P>EX vs PIO: 3.94, 95% CI 1.28 to 6.61, P = 0.0038</P>
</TD>
</TR>
<TR>
<TD>
<P>Overall treatment satisfaction</P>
</TD>
<TD>
<P>3.96, 95% CI 2.78 to 5.15</P>
</TD>
<TD>
<P>2.35, 95% CI 1.19 to 3.51</P>
</TD>
<TD>
<P>EX vs. SITA: 1.61, 95% CI 0.07 to 3.16, P = 0.0406</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-003.06" MODIFIED="2011-06-30 12:24:36 +0200" MODIFIED_BY="[Empty name]" NO="6" ROWS_PER_STUDY="10" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Adverse events</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Exenatide 2 mg QW</P>
</TH>
<TH>
<P>Sitagliptin 100 mg QD</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-06-30 12:24:36 +0200" MODIFIED_BY="[Empty name]" ORDER="1195" STUDY_ID="STD-E-_x002d_-Bergenstal-2010">
<TR>
<TD>
<P>Withdrawals due to adverse events</P>
</TD>
<TD>
<P>6.9%</P>
</TD>
<TD>
<P>3%</P>
</TD>
</TR>
<TR>
<TD>
<P>Nausea</P>
</TD>
<TD>
<P>24%</P>
</TD>
<TD>
<P>10%</P>
</TD>
</TR>
<TR>
<TD>
<P>Diarrhoea</P>
</TD>
<TD>
<P>18%</P>
</TD>
<TD>
<P>10%</P>
</TD>
</TR>
<TR>
<TD>
<P>Vomiting</P>
</TD>
<TD>
<P>11%</P>
</TD>
<TD>
<P>2%</P>
</TD>
</TR>
<TR>
<TD>
<P>Urinary tract infection</P>
</TD>
<TD>
<P>6%</P>
</TD>
<TD>
<P>5%</P>
</TD>
</TR>
<TR>
<TD>
<P>Headache</P>
</TD>
<TD>
<P>9%</P>
</TD>
<TD>
<P>9%</P>
</TD>
</TR>
<TR>
<TD>
<P>Injection-site pruritus</P>
</TD>
<TD>
<P>5%</P>
</TD>
<TD>
<P>5%</P>
</TD>
</TR>
<TR>
<TD>
<P>Serious adverse events</P>
</TD>
<TD>
<P>3%</P>
</TD>
<TD>
<P>3%</P>
</TD>
</TR>
<TR>
<TD>
<P>Anti-Exenatide antibodies</P>
</TD>
<TD>
<P>either low (&lt; 1/625; n = 74, 48%) or not detectable (n = 61, 40%) titres</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Severe hypoglycaemia</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-003.07" MODIFIED="2011-08-30 13:58:16 +0200" MODIFIED_BY="Bernd Richter" NO="7" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Blood pressure (mm Hg)</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Exenatide 2 mg QW</P>
</TH>
<TH>
<P>Sitagliptin 100 mg QD</P>
</TH>
<TH>
<P>Difference between groups</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 13:58:16 +0200" MODIFIED_BY="Bernd Richter" ORDER="1196" STUDY_ID="STD-E-_x002d_-Bergenstal-2010">
<TR>
<TD>
<P>Systolic blood pressure</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>EX vs. SITA: -4 mm Hg (95% CI -6 to -1); P = 0.0055</P>
</TD>
</TR>
<TR>
<TD>
<P>Diastolic blood pressure</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>EX vs. SITA: P = NS</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.298349883155304" CI_START="-1.5016501168446958" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8999999999999999" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.08" MODIFIED="2011-08-30 14:40:44 +0200" MODIFIED_BY="Bernd Richter" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0033691394326789597" Q="0.0" RANDOM="YES" SCALE="4.3" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="160" TOTAL_2="166" UNITS="" WEIGHT="0.0" Z="2.931882728348879">
<NAME>Fasting plasma glucose (mmol/L)</NAME>
<GROUP_LABEL_1>Exenatide 2 mg QW</GROUP_LABEL_1>
<GROUP_LABEL_2>Sitagliptin 100 mg QD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Exenatide QW</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Sitagliptin QD</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.2983498831553041" CI_START="-1.5016501168446958" EFFECT_SIZE="-0.9" ESTIMABLE="YES" MEAN_1="-1.8" MEAN_2="-0.9" MODIFIED="2011-06-08 17:28:49 +0200" MODIFIED_BY="[Empty name]" ORDER="353" SD_1="2.9" SD_2="2.63" SE="0.30696998597445424" STUDY_ID="STD-E-_x002d_-Bergenstal-2010" TOTAL_1="160" TOTAL_2="166" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-003.09" MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" NO="9" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Post-prandial glucose / glucose profiles</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Exenatide 2 mg QW</P>
</TH>
<TH>
<P>Sitagliptin 100 mg QD</P>
</TH>
<TH>
<P>Description</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" ORDER="1198" STUDY_ID="STD-E-_x002d_-Bergenstal-2010">
<TR>
<TD>
<P>Self-monitored blood glucose</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>EX vs SITA: P &lt; 0.05</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-003.10" MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" NO="10" ROWS_PER_STUDY="4" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Lipid profiles</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Exenatide 2 mg QW</P>
</TH>
<TH>
<P>Sitagliptin 100 mg QD</P>
</TH>
<TH>
<P>Difference between groups</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" ORDER="1199" STUDY_ID="STD-E-_x002d_-Bergenstal-2010">
<TR>
<TD>
<P>Fasting triglycerides (mmol/l)</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>EX vs. SITA: P = 0.9718; PIO vs. SITA: p=0.0062</P>
</TD>
</TR>
<TR>
<TD>
<P>Total cholesterol (mmol/l)</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>EX vs. SITA: P = 0.3424; PIO vs. SITA: P = 0.3424</P>
</TD>
</TR>
<TR>
<TD>
<P>HDL (mmol/l)</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>EX vs. SITA: P = 0.9546; PIO vs. SITA: P &lt; 0.0001</P>
</TD>
</TR>
<TR>
<TD>
<P>LDL (mmol/l)</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>EX vs. SITA: P = 0.6113; PIO vs. SITA: P = 0.9965</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2011-09-01 14:43:46 +0200" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Exenatide 2 mg once weekly versus insulin glargine</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.01" MODIFIED="2011-09-01 14:39:25 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.58" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="233" TOTAL_2="223" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>HbA1c (%)</NAME>
<GROUP_LABEL_1>Exenatide 2 mg QW</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin glargine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Exenatide QW</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Insulin glargine</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.04678073904993868" CI_START="-0.35321926095006123" EFFECT_SIZE="-0.19999999999999996" ESTIMABLE="YES" MEAN_1="-1.5" MEAN_2="-1.3" MODIFIED="2011-09-01 14:35:57 +0200" MODIFIED_BY="[Empty name]" ORDER="301" SD_1="0.76" SD_2="0.9" SE="0.07817452879677139" STUDY_ID="STD-E-_x002d_-Diamant-2010" TOTAL_1="233" TOTAL_2="223" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="126" EVENTS_2="101" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-30 14:41:43 +0200" MODIFIED_BY="Bernd Richter" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="216" TOTAL_2="212" WEIGHT="0.0" Z="0.0">
<NAME>HbA1c &lt; 7%</NAME>
<GROUP_LABEL_1>Exenatide 2 mg QW</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin glargine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Insulin glargine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Exenatide QW</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.46678380958615" CI_START="1.0221072166690401" EFFECT_SIZE="1.2244224422442245" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="101" LOG_CI_END="0.16636610755649456" LOG_CI_START="0.009496454668987199" LOG_EFFECT_SIZE="0.08793128111274089" MODIFIED="2011-01-31 15:41:22 +0100" MODIFIED_BY="[Empty name]" ORDER="302" O_E="0.0" SE="0.09214601062342709" STUDY_ID="STD-E-_x002d_-Diamant-2010" TOTAL_1="216" TOTAL_2="212" VAR="0.008490887273812739" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.5699463500543467" CI_START="0.2571484375862315" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3828326180257511" ESTIMABLE="NO" EVENTS_1="28" EVENTS_2="70" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="-0.24416602322565628" LOG_CI_START="-0.5898161100741355" LOG_EFFECT_SIZE="-0.4169910666498959" METHOD="MH" MODIFIED="2011-08-30 14:41:50 +0200" MODIFIED_BY="Bernd Richter" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="2.2564225794302283E-6" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="233" TOTAL_2="223" WEIGHT="0.0" Z="4.728987514283526">
<NAME>Hypoglycaemia (symptoms only)</NAME>
<GROUP_LABEL_1>Exenatide 2 mg QW</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin glargine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Exenatide QW</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Insulin glargine</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.5699463500543467" CI_START="0.2571484375862315" EFFECT_SIZE="0.3828326180257511" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="70" LOG_CI_END="-0.24416602322565628" LOG_CI_START="-0.5898161100741355" LOG_EFFECT_SIZE="-0.4169910666498959" MODIFIED="2011-05-04 11:12:46 +0200" MODIFIED_BY="[Empty name]" ORDER="313" O_E="0.0" SE="0.2030365720103212" STUDY_ID="STD-E-_x002d_-Diamant-2010" TOTAL_1="233" TOTAL_2="223" VAR="0.04122384957370234" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="19" EVENTS_2="58" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-30 14:42:01 +0200" MODIFIED_BY="Bernd Richter" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.59" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="233" TOTAL_2="223" WEIGHT="0.0" Z="0.0">
<NAME>Hypoglycaemia (minor)</NAME>
<GROUP_LABEL_1>Exenatide 2 mg QW</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin glargine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Exenatide QW</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Insulin glargine</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.5089470203419377" CI_START="0.1931419103752238" EFFECT_SIZE="0.31352671303833063" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="58" LOG_CI_END="-0.29332742389246647" LOG_CI_START="-0.7141234772834667" LOG_EFFECT_SIZE="-0.5037254505879666" MODIFIED="2011-05-04 11:09:48 +0200" MODIFIED_BY="[Empty name]" ORDER="323" O_E="0.0" SE="0.2471776847359316" STUDY_ID="STD-E-_x002d_-Diamant-2010" TOTAL_1="233" TOTAL_2="223" VAR="0.06109680783141559" WEIGHT="0.0"/>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-004.05" MODIFIED="2011-06-30 10:14:27 +0200" MODIFIED_BY="[Empty name]" NO="5" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Severe hypoglycaemia</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Exenatide 2 mg QW</P>
</TH>
<TH>
<P>Insulin glargine</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-01-31 17:56:12 +0100" MODIFIED_BY="[Empty name]" ORDER="1204" STUDY_ID="STD-E-_x002d_-Diamant-2010">
<TR>
<TD>
<P>Taking metformin only</P>
</TD>
<TD>
<P>1 (0.4%)</P>
</TD>
<TD>
<P>1 (0.4%)</P>
</TD>
</TR>
<TR>
<TD>
<P>Taking both metformin and sulphonylureas</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>1 (0.4%)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.06" MODIFIED="2011-09-01 14:43:46 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.21" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="233" TOTAL_2="223" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Weight change (kg)</NAME>
<GROUP_LABEL_1>Exenatide 2 mg QW</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin glargine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Exenatide QW</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Insulin glargine</GRAPH_LABEL_2>
<CONT_DATA CI_END="-3.445586406955665" CI_START="-4.554413593044335" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="-2.6" MEAN_2="1.4" MODIFIED="2011-09-01 14:42:17 +0200" MODIFIED_BY="[Empty name]" ORDER="322" SD_1="3.05" SD_2="2.99" SE="0.2828692758731684" STUDY_ID="STD-E-_x002d_-Diamant-2010" TOTAL_1="233" TOTAL_2="223" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-004.07" MODIFIED="2011-06-28 16:50:48 +0200" MODIFIED_BY="[Empty name]" NO="7" ROWS_PER_STUDY="10" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Adverse events</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Exenatide 2 mg QW</P>
</TH>
<TH>
<P>Insulin glargine</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-06-28 16:50:48 +0200" MODIFIED_BY="[Empty name]" ORDER="1206" STUDY_ID="STD-E-_x002d_-Diamant-2010">
<TR>
<TD>
<P>withdrawal due to adverse events</P>
</TD>
<TD>
<P>11 (4.7%)</P>
</TD>
<TD>
<P>2 (0.9%)</P>
</TD>
</TR>
<TR>
<TD>
<P>nausea</P>
</TD>
<TD>
<P>30 (13%)</P>
</TD>
<TD>
<P>3 (1%)</P>
</TD>
</TR>
<TR>
<TD>
<P>vomiting</P>
</TD>
<TD>
<P>10 (4%)</P>
</TD>
<TD>
<P>3 (1%)</P>
</TD>
</TR>
<TR>
<TD>
<P>diarrhoea</P>
</TD>
<TD>
<P>20 (9%)</P>
</TD>
<TD>
<P>8 (4%)</P>
</TD>
</TR>
<TR>
<TD>
<P>Nasopharyngitis</P>
</TD>
<TD>
<P>30 (13%)</P>
</TD>
<TD>
<P>39 (17%)</P>
</TD>
</TR>
<TR>
<TD>
<P>Headache</P>
</TD>
<TD>
<P>23 (10%)</P>
</TD>
<TD>
<P>16 (7%)</P>
</TD>
</TR>
<TR>
<TD>
<P>Injection-site reaction</P>
</TD>
<TD>
<P>30 (13%)</P>
</TD>
<TD>
<P>4 (2%)</P>
</TD>
</TR>
<TR>
<TD>
<P>Patients with one or more serious adverse events</P>
<P/>
<P>Pancreatitis</P>
</TD>
<TD>
<P>11 (5%)</P>
<P/>
<P>1 (0.4%)</P>
</TD>
<TD>
<P>10 (4%)</P>
<P/>
<P>None</P>
</TD>
</TR>
<TR>
<TD>
<P>Deaths</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>None</P>
</TD>
</TR>
<TR>
<TD>
<P>Anti-exenatide antibodies</P>
</TD>
<TD>
<P>127/233 (54.5%) tested positive for anti-exenatide antibodies. No effect on HbA1c</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-004.08" MODIFIED="2011-06-30 12:40:49 +0200" MODIFIED_BY="[Empty name]" NO="8" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Quality of life</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Exenatide 2 mg QW</P>
</TH>
<TH>
<P>Insulin glargine</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-06-30 12:40:49 +0200" MODIFIED_BY="[Empty name]" ORDER="1207" STUDY_ID="STD-E-_x002d_-Diamant-2010">
<TR>
<TD>
<P>IWQOL-Lite (self-esteem)</P>
</TD>
<TD>
<P>Significant improvement compared with insulin glargine; no data given</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.09" MODIFIED="2011-08-30 14:42:23 +0200" MODIFIED_BY="Bernd Richter" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.58" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="214" TOTAL_2="207" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Fasting plasma glucose (mmol/L)</NAME>
<GROUP_LABEL_1>Exenatide 2 mg QW</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin glargine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Exenatide QW</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Insulin glargine</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.2550053252475109" CI_START="0.14499467475248862" EFFECT_SIZE="0.6999999999999997" ESTIMABLE="YES" MEAN_1="-2.1" MEAN_2="-2.8" MODIFIED="2011-01-31 18:09:56 +0100" MODIFIED_BY="[Empty name]" ORDER="326" SD_1="2.93" SD_2="2.88" SE="0.28317118560612453" STUDY_ID="STD-E-_x002d_-Diamant-2010" TOTAL_1="214" TOTAL_2="207" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-004.10" MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" NO="10" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Postprandial glucose / glucose profiles</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Exenatide 2 mg QW</P>
</TH>
<TH>
<P>Insulin glargine</P>
</TH>
<TH>
<P>Comment</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" ORDER="1209" STUDY_ID="STD-E-_x002d_-Diamant-2010">
<TR>
<TD>
<P>8-point SMBG</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>Both treatments reduced PPG at all eight timepoints (all P &lt; 0.0001)</P>
<P>0300 hour and before breafast: participants receiving insulin glargine had lower glucose concentrations than exenatide at 0300 hour (P = 0.022) and before breakfast (P &lt; 0.0001)</P>
<P>Dinner, morning and evening meals: participants receiving exenatide had lower glucose concentrations after dinner than insulin glargine (P = 0.004).</P>
<P>Morning and evening meals: participants receiving exenatide had lower postprandial glucose excursions than insulin glargine after morning (P = 0.001) and evening meals (P = 0.033).</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2011-08-30 14:44:00 +0200" MODIFIED_BY="Bernd Richter" NO="5">
<NAME>Liraglutide 0.6 mg daily versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.01" MODIFIED="2011-08-30 14:43:35 +0200" MODIFIED_BY="Bernd Richter" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="88" TOTAL_2="88" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>HbA1c (%)</NAME>
<GROUP_LABEL_1>Liraglutide 0.6 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.782237136790481" CI_START="-1.337762863209519" EFFECT_SIZE="-1.06" ESTIMABLE="YES" MEAN_1="-1.46" MEAN_2="-0.4" MODIFIED="2011-02-01 11:20:11 +0100" MODIFIED_BY="[Empty name]" ORDER="300" SD_1="0.95" SD_2="0.93" SE="0.14171835064341848" STUDY_ID="STD-L-_x002d_-Kaku-2010" TOTAL_1="88" TOTAL_2="88" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="41" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-30 14:44:00 +0200" MODIFIED_BY="Bernd Richter" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="88" TOTAL_2="88" WEIGHT="0.0" Z="0.0">
<NAME>HbA1c &lt; 7%</NAME>
<GROUP_LABEL_1>Liraglutide 0.6 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Liraglutide</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.463356778480087" CI_START="1.8206289586120303" EFFECT_SIZE="3.1538461538461537" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="13" LOG_CI_END="0.7374595625621267" LOG_CI_START="0.26022144626367066" LOG_EFFECT_SIZE="0.49884050441289873" MODIFIED="2011-02-01 11:22:11 +0100" MODIFIED_BY="[Empty name]" ORDER="301" O_E="0.0" SE="0.2803320318804885" STUDY_ID="STD-L-_x002d_-Kaku-2010" TOTAL_1="88" TOTAL_2="88" VAR="0.07858604809824321" WEIGHT="0.0"/>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-005.03" MODIFIED="2011-02-01 11:25:13 +0100" MODIFIED_BY="[Empty name]" NO="3" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Hypoglycaemia rate (events/patient-year)</NAME>
<TR>
<TH>
<P>Liraglutide 0.6 mg daily</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-02-01 11:25:13 +0100" MODIFIED_BY="[Empty name]" ORDER="1212" STUDY_ID="STD-L-_x002d_-Kaku-2010">
<TR>
<TD>
<P>2.17</P>
</TD>
<TD>
<P>1.01</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-005.04" MODIFIED="2011-02-01 11:34:58 +0100" MODIFIED_BY="[Empty name]" NO="4" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Severe hypoglycaemia</NAME>
<TR>
<TH>
<P>Liraglutide 0.6 mg daily</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-02-01 11:34:00 +0100" MODIFIED_BY="[Empty name]" ORDER="1213" STUDY_ID="STD-L-_x002d_-Kaku-2010">
<TR>
<TD>
<P>None</P>
</TD>
<TD>
<P>None</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-005.05" MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" NO="5" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Weight change (kg)</NAME>
<TR>
<TH>
<P>Liraglutide 0.6 mg daily</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" ORDER="1214" STUDY_ID="STD-L-_x002d_-Kaku-2010">
<TR>
<TD>
<P>+0.06. P &lt; 0.0001 versus placebo</P>
</TD>
<TD>
<P>-1.12</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-005.06" MODIFIED="2011-06-30 10:15:26 +0200" MODIFIED_BY="[Empty name]" NO="6" ROWS_PER_STUDY="6" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Adverse events</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 0.6 mg daily</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-02-01 11:55:54 +0100" MODIFIED_BY="[Empty name]" ORDER="1215" STUDY_ID="STD-L-_x002d_-Kaku-2010">
<TR>
<TD>
<P>Withdrawals due to adverse events</P>
</TD>
<TD>
<P>3 (3%)</P>
</TD>
<TD>
<P>2 (2%)</P>
</TD>
</TR>
<TR>
<TD>
<P>Overall adverse events</P>
</TD>
<TD>
<P>67 (76.1%)</P>
</TD>
<TD>
<P>66 (75%)</P>
</TD>
</TR>
<TR>
<TD>
<P>Gastrointestinal adverse events</P>
</TD>
<TD>
<P>More subjects in the two liraglutide groups reported gastrointestinal adverse events during the first 4 weeks of the trial than subjects on placebo. No major differences in gastrointestinal adverse events across groups.</P>
</TD>
<TD/>
</TR>
<TR>
<TD>
<P>Serious adverse events</P>
</TD>
<TD>
<P>3 (3%)</P>
</TD>
<TD>
<P>2 (2%)</P>
</TD>
</TR>
<TR>
<TD>
<P>Pancreatitis</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>None</P>
</TD>
</TR>
<TR>
<TD>
<P>Deaths</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>None</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-005.07" MODIFIED="2011-08-30 13:58:16 +0200" MODIFIED_BY="Bernd Richter" NO="7" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Blood pressure (mm Hg)</NAME>
<TR>
<TH>
<P>Results</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:27:51 +0200" MODIFIED_BY="Bernd Richter" ORDER="1216" STUDY_ID="STD-L-_x002d_-Kaku-2010">
<TR>
<TD>
<P>SBP did not change in both groups; P = NS between groups</P>
<P>DBP did not change in both groups; P = NS between groups</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-005.08" MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" NO="8" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Fasting plasma glucose (mmol/L)</NAME>
<TR>
<TH>
<P>Liraglutide 0.6 mg daily</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" ORDER="1217" STUDY_ID="STD-L-_x002d_-Kaku-2010">
<TR>
<TD>
<P>-2.3, P &lt; 0.0001 versus placebo</P>
</TD>
<TD>
<P>-0.64</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-005.09" MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" NO="9" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Post-prandial glucose / glucose profiles</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 0.6 mg daily</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" ORDER="1218" STUDY_ID="STD-L-_x002d_-Kaku-2010">
<TR>
<TD>
<P>7-point SMBG profile</P>
</TD>
<TD>
<P>-2.66, P &lt; 0.0001 versus placebo</P>
</TD>
<TD>
<P>-0.35</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2011-08-30 14:44:47 +0200" MODIFIED_BY="Bernd Richter" NO="6">
<NAME>Liraglutide 0.9 mg daily versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-006.01" MODIFIED="2011-08-30 14:44:38 +0200" MODIFIED_BY="Bernd Richter" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.99" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="88" TOTAL_2="88" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>HbA1c (%)</NAME>
<GROUP_LABEL_1>Liraglutide 0.9 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.8981661899848554" CI_START="-1.4218338100151449" EFFECT_SIZE="-1.1600000000000001" ESTIMABLE="YES" MEAN_1="-1.56" MEAN_2="-0.4" MODIFIED="2011-02-01 11:21:36 +0100" MODIFIED_BY="[Empty name]" ORDER="302" SD_1="0.84" SD_2="0.93" SE="0.13359113334758002" STUDY_ID="STD-L-_x002d_-Kaku-2010" TOTAL_1="88" TOTAL_2="88" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="63" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-30 14:44:47 +0200" MODIFIED_BY="Bernd Richter" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="33.54" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="88" TOTAL_2="88" WEIGHT="0.0" Z="0.0">
<NAME>HbA1c &lt; 7%</NAME>
<GROUP_LABEL_1>Liraglutide 0.9 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Liraglutide</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.141691365580797" CI_START="2.884561210447747" EFFECT_SIZE="4.846153846153846" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="13" LOG_CI_END="0.9107146351637803" LOG_CI_START="0.4600797591297096" LOG_EFFECT_SIZE="0.6853971971467449" MODIFIED="2011-02-01 11:22:25 +0100" MODIFIED_BY="[Empty name]" ORDER="303" O_E="0.0" SE="0.2647051568610254" STUDY_ID="STD-L-_x002d_-Kaku-2010" TOTAL_1="88" TOTAL_2="88" VAR="0.07006882006882006" WEIGHT="0.0"/>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-006.03" MODIFIED="2011-02-01 11:26:15 +0100" MODIFIED_BY="[Empty name]" NO="3" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Hypoglycaemia rate (events/patient-year)</NAME>
<TR>
<TH>
<P>Liraglutide 0.9 mg daily</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-02-01 11:26:15 +0100" MODIFIED_BY="[Empty name]" ORDER="1221" STUDY_ID="STD-L-_x002d_-Kaku-2010">
<TR>
<TD>
<P>1.96</P>
</TD>
<TD>
<P>1.01</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-006.04" MODIFIED="2011-02-01 11:34:48 +0100" MODIFIED_BY="[Empty name]" NO="4" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Severe hypoglycaemia</NAME>
<TR>
<TH>
<P>Liraglutide 0.9 mg daily</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-02-01 11:34:48 +0100" MODIFIED_BY="[Empty name]" ORDER="1222" STUDY_ID="STD-L-_x002d_-Kaku-2010">
<TR>
<TD>
<P>None</P>
</TD>
<TD>
<P>None</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-006.05" MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" NO="5" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Weight change (kg)</NAME>
<TR>
<TH>
<P>Liraglutide 0.9 mg daily</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" ORDER="1223" STUDY_ID="STD-L-_x002d_-Kaku-2010">
<TR>
<TD>
<P>-0.37, P = 0.0071 versus placebo</P>
</TD>
<TD>
<P>-1.12</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-006.06" MODIFIED="2011-06-30 10:16:25 +0200" MODIFIED_BY="[Empty name]" NO="6" ROWS_PER_STUDY="6" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Adverse events</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 0.9 mg daily</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-02-01 11:57:34 +0100" MODIFIED_BY="[Empty name]" ORDER="1224" STUDY_ID="STD-L-_x002d_-Kaku-2010">
<TR>
<TD>
<P>Withdrawals due to adverse events</P>
</TD>
<TD>
<P>2 (2%)</P>
</TD>
<TD>
<P>2 (2%)</P>
</TD>
</TR>
<TR>
<TD>
<P>Overall adverse events</P>
</TD>
<TD>
<P>69 (78.4%)</P>
</TD>
<TD>
<P>66 (75%)</P>
</TD>
</TR>
<TR>
<TD>
<P>Gastrointestinal adverse events</P>
</TD>
<TD>
<P>More subjects in the two liraglutide groups reported gastrointestinal adverse events during the first 4 weeks of the trial than subjects on placebo. No major differences in gastrointestinal adverse events across groups.</P>
</TD>
<TD/>
</TR>
<TR>
<TD>
<P>Serious adverse events</P>
</TD>
<TD>
<P>2 (2%)</P>
</TD>
<TD>
<P>2 (2%)</P>
</TD>
</TR>
<TR>
<TD>
<P>Pancreatitis</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>None</P>
</TD>
</TR>
<TR>
<TD>
<P>Deaths</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>None</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-006.07" MODIFIED="2011-08-30 13:58:16 +0200" MODIFIED_BY="Bernd Richter" NO="7" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Blood pressure (mm Hg)</NAME>
<TR>
<TH>
<P>Results</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:27:51 +0200" MODIFIED_BY="Bernd Richter" ORDER="1225" STUDY_ID="STD-L-_x002d_-Kaku-2010">
<TR>
<TD>
<P>SBP did not change in both groups; P = NS between groups</P>
<P>DBP did not change in both groups; P = NS between groups</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-006.08" MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" NO="8" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Fasting plasma glucose (mmol/L)</NAME>
<TR>
<TH>
<P>Liraglutide 0.9 mg daily</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" ORDER="1226" STUDY_ID="STD-L-_x002d_-Kaku-2010">
<TR>
<TD>
<P>-2.28, P &lt; 0.0001 versus placebo</P>
</TD>
<TD>
<P>-0.64</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-006.09" MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" NO="9" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Postprandial glucose / glucose profiles</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 0.9 mg daily</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" ORDER="1227" STUDY_ID="STD-L-_x002d_-Kaku-2010">
<TR>
<TD>
<P>7-point SMBG profile</P>
</TD>
<TD>
<P>-2.89, P &lt; 0.0001 versus placebo</P>
</TD>
<TD>
<P>-0.35</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2011-08-30 14:46:20 +0200" MODIFIED_BY="Bernd Richter" NO="7">
<NAME>Liraglutide 1.2 mg versus placebo</NAME>
<CONT_OUTCOME CHI2="2.9611407098416365" CI_END="-0.9627354174086783" CI_START="-1.3332932766880838" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.148014347048381" ESTIMABLE="YES" I2="32.45846124931492" I2_Q="0.0" ID="CMP-007.01" MODIFIED="2011-06-30 12:46:46 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.22750795053225115" P_Q="1.0" P_Z="6.157223359819955E-34" Q="0.0" RANDOM="YES" SCALE="3.23" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.008723564148223962" TOTALS="YES" TOTAL_1="646" TOTAL_2="412" UNITS="" WEIGHT="100.0" Z="12.144212935197867">
<NAME>HbA1c</NAME>
<GROUP_LABEL_1>Liraglutide 1.2 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.0701861509698514" CI_START="-1.5498138490301487" EFFECT_SIZE="-1.31" ESTIMABLE="YES" MEAN_1="-1.08" MEAN_2="0.23" MODIFIED="2010-01-08 10:53:24 +0100" MODIFIED_BY="[Empty name]" ORDER="227" SD_1="1.06" SD_2="1.07" SE="0.12235625293207923" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009" TOTAL_1="228" TOTAL_2="114" WEIGHT="37.71431248198062"/>
<CONT_DATA CI_END="-0.8227470620355279" CI_START="-1.3772529379644722" EFFECT_SIZE="-1.1" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="0.1" MODIFIED="2009-11-26 13:02:03 +0100" MODIFIED_BY="[Empty name]" ORDER="41" SD_1="1.55" SD_2="1.1" SE="0.14145817992136994" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009" TOTAL_1="240" TOTAL_2="121" WEIGHT="31.099978354240776"/>
<CONT_DATA CI_END="-0.7232948296554157" CI_START="-1.2767051703445844" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="-1.5" MEAN_2="-0.5" MODIFIED="2009-11-26 13:02:28 +0100" MODIFIED_BY="[Empty name]" ORDER="42" SD_1="1.33" SD_2="1.33" SE="0.14117870151043557" STUDY_ID="STD-L-_x002d_-LEAD-4-Zinman-2009" TOTAL_1="178" TOTAL_2="177" WEIGHT="31.18570916377861"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="7.003430996213897" CI_END="4.868482934560727" CI_START="1.7427923779672734" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="2.912860269669004" ESTIMABLE="YES" EVENTS_1="267" EVENTS_2="72" I2="71.44256863412785" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="0.687393652017356" LOG_CI_START="0.24124565189833153" LOG_EFFECT_SIZE="0.46431965195784386" METHOD="MH" MODIFIED="2011-06-30 13:07:32 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.030145660364257365" P_Q="1.0" P_Z="4.5115779129776806E-5" Q="0.0" RANDOM="YES" SCALE="15.68" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.1448485972028545" TOTALS="YES" TOTAL_1="646" TOTAL_2="412" WEIGHT="100.0" Z="4.079587020041607">
<NAME>HbA1c &lt; 7%</NAME>
<GROUP_LABEL_1>Liraglutide 1.2 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Liraglutide</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.525308058211438" CI_START="2.316993859327727" EFFECT_SIZE="4.444444444444445" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="9" LOG_CI_END="0.9307100809858396" LOG_CI_START="0.3649248827914355" LOG_EFFECT_SIZE="0.6478174818886375" MODIFIED="2010-01-08 11:08:13 +0100" MODIFIED_BY="[Empty name]" ORDER="244" O_E="0.0" SE="0.3323450261012928" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009" TOTAL_1="228" TOTAL_2="114" VAR="0.110453216374269" WEIGHT="26.901667791860735"/>
<DICH_DATA CI_END="5.663770733644578" CI_START="1.9186410803713405" EFFECT_SIZE="3.296474358974359" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="13" LOG_CI_END="0.7531056650333599" LOG_CI_START="0.28299373899124036" LOG_EFFECT_SIZE="0.5180497020123" MODIFIED="2010-01-08 11:08:12 +0100" MODIFIED_BY="[Empty name]" ORDER="60" O_E="0.0" SE="0.27614607244870576" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009" TOTAL_1="240" TOTAL_2="121" VAR="0.07625665332884585" WEIGHT="31.06233144167985"/>
<DICH_DATA CI_END="2.648943276519303" CI_START="1.5534390007389636" EFFECT_SIZE="2.0285393258426967" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="50" LOG_CI_END="0.42307265857717885" LOG_CI_START="0.19129420438044398" LOG_EFFECT_SIZE="0.30718343147881144" MODIFIED="2010-01-08 11:18:12 +0100" MODIFIED_BY="[Empty name]" ORDER="61" O_E="0.0" SE="0.1361478113170141" STUDY_ID="STD-L-_x002d_-LEAD-4-Zinman-2009" TOTAL_1="178" TOTAL_2="177" VAR="0.01853622652641327" WEIGHT="42.036000766459416"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.654453843425956" CI_END="4.417102982930442" CI_START="0.5398781682198763" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5442465694516012" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="15" I2="57.0304042691316" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="0.6451375247727777" LOG_CI_START="-0.2677042343241673" LOG_EFFECT_SIZE="0.18871664522430526" METHOD="MH" MODIFIED="2011-08-22 15:30:26 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.09756611096755041" P_Q="1.0" P_Z="0.4177174413233654" Q="0.0" RANDOM="YES" SCALE="23.88" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.48617736246142557" TOTALS="YES" TOTAL_1="646" TOTAL_2="412" WEIGHT="100.0" Z="0.8103876148014382">
<NAME>Hypoglycaemia</NAME>
<GROUP_LABEL_1>Liraglutide 1.2 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="11.489159584180042" CI_START="1.0662224604197852" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="3" LOG_CI_END="1.0602882618212737" LOG_CI_START="0.02784782687927773" LOG_EFFECT_SIZE="0.5440680443502757" MODIFIED="2009-12-21 13:04:02 +0100" MODIFIED_BY="[Empty name]" ORDER="263" O_E="0.0" SE="0.606460622147505" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009" TOTAL_1="228" TOTAL_2="114" VAR="0.3677944862155388" WEIGHT="33.66841317278468"/>
<DICH_DATA CI_END="1.9847351759434024" CI_START="0.05691977467908153" EFFECT_SIZE="0.33611111111111114" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.2977025668678294" LOG_CI_START="-1.2447368277695037" LOG_EFFECT_SIZE="-0.47351713045083715" MODIFIED="2010-01-12 14:42:37 +0100" MODIFIED_BY="[Empty name]" ORDER="266" O_E="0.0" SE="0.9060365356081118" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009" TOTAL_1="240" TOTAL_2="121" VAR="0.8209022038567493" WEIGHT="21.997036584522576"/>
<DICH_DATA CI_END="3.8939976960545923" CI_START="0.8025383307744368" EFFECT_SIZE="1.7677902621722847" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="9" LOG_CI_END="0.5903956902268805" LOG_CI_START="-0.0955342156878554" LOG_EFFECT_SIZE="0.2474307372695126" MODIFIED="2009-11-27 20:44:49 +0100" MODIFIED_BY="[Empty name]" ORDER="74" O_E="0.0" SE="0.4029186221421106" STUDY_ID="STD-L-_x002d_-LEAD-4-Zinman-2009" TOTAL_1="178" TOTAL_2="177" VAR="0.1623434160688969" WEIGHT="44.33455024269275"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="16.338586440386454" CI_END="0.4540971879592941" CI_START="-1.9512535727088796" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7485781923747927" ESTIMABLE="YES" I2="87.75903896400543" I2_Q="0.0" ID="CMP-007.04" MODIFIED="2011-06-30 12:47:42 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="2.8321899225380864E-4" P_Q="1.0" P_Z="0.22248937958668646" Q="0.0" RANDOM="YES" SCALE="3.23" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.9894213404578979" TOTALS="YES" TOTAL_1="646" TOTAL_2="412" UNITS="" WEIGHT="100.0" Z="1.2199354211933113">
<NAME>Weight change</NAME>
<GROUP_LABEL_1>Liraglutide 1.2 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.0581500959060794" CI_START="-0.2581500959060795" EFFECT_SIZE="0.4" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="-0.1" MODIFIED="2010-01-11 15:39:01 +0100" MODIFIED_BY="[Empty name]" ORDER="253" SD_1="3.02" SD_2="2.88" SE="0.3357970356075333" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009" TOTAL_1="228" TOTAL_2="114" WEIGHT="34.162350437979406"/>
<CONT_DATA CI_END="-0.3932116954317708" CI_START="-1.8067883045682294" EFFECT_SIZE="-1.1" ESTIMABLE="YES" MEAN_1="-2.6" MEAN_2="-1.5" MODIFIED="2009-11-27 20:58:31 +0100" MODIFIED_BY="[Empty name]" ORDER="85" SD_1="3.1" SD_2="3.3" SE="0.3606129041876714" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009" TOTAL_1="240" TOTAL_2="121" WEIGHT="33.63495977312383"/>
<CONT_DATA CI_END="-0.768846523268852" CI_START="-2.431153476731148" EFFECT_SIZE="-1.6" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="0.6" MODIFIED="2009-11-27 20:59:00 +0100" MODIFIED_BY="[Empty name]" ORDER="84" SD_1="4.0" SD_2="3.99" SE="0.42406568859794397" STUDY_ID="STD-L-_x002d_-LEAD-4-Zinman-2009" TOTAL_1="178" TOTAL_2="177" WEIGHT="32.202689788896755"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-007.05" MODIFIED="2011-06-30 12:48:10 +0200" MODIFIED_BY="[Empty name]" NO="5" ROWS_PER_STUDY="10" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO">
<NAME>Adverse events</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.2 mg daily</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-06-30 12:47:55 +0200" MODIFIED_BY="[Empty name]" ORDER="1240" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009">
<TR>
<TD>
<P>withdrawal due to adverse events</P>
</TD>
<TD>
<P>5%</P>
</TD>
<TD>
<P>5%</P>
</TD>
</TR>
<TR>
<TD>
<P>no significant differences across groups for: blood pressure; no significant changes is: ophthalmoscopy, biochemistry, urinalysis, haematology, ECG</P>
<P>no deaths</P>
</TD>
<TD/>
<TD/>
</TR>
<TR>
<TD>
<P>nausea</P>
</TD>
<TD>
<P>10.5% (highest)</P>
</TD>
<TD>
<P>1.8% (lowest)</P>
</TD>
</TR>
<TR>
<TD>
<P>vomiting</P>
</TD>
<TD>
<P>4.4%</P>
</TD>
<TD/>
</TR>
<TR>
<TD>
<P>diarrhoea</P>
</TD>
<TD>
<P>7.9%</P>
</TD>
<TD/>
</TR>
<TR>
<TD>
<P>serious adverse events (mostly judged to be unlikely to be related to study medication)</P>
</TD>
<TD>
<P>4%</P>
</TD>
<TD>
<P>3%</P>
</TD>
</TR>
<TR>
<TD>
<P>liraglutide auto-antibodies</P>
</TD>
<TD>
<P>9 to13%, no effect on HbA1c</P>
</TD>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2011-06-30 12:48:10 +0200" MODIFIED_BY="[Empty name]" ORDER="1241" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009">
<TR>
<TD>
<P>withdrawal due to adverse events</P>
</TD>
<TD>
<P>10%</P>
</TD>
<TD>
<P>2%</P>
</TD>
</TR>
<TR>
<TD>
<P>withdrawal due to nausea/vomiting/diarrhoea</P>
</TD>
<TD>
<P>5%</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>no significant differences across groups for: physical examination findings, laboratory analyses, ECG, ophthalmoscopy</P>
</TD>
<TD/>
<TD/>
</TR>
<TR>
<TD>
<P>any GI event</P>
</TD>
<TD>
<P>40%</P>
</TD>
<TD>
<P>17%</P>
</TD>
</TR>
<TR>
<TD>
<P>nausea</P>
</TD>
<TD>
<P>16%</P>
</TD>
<TD>
<P>3 to 4%</P>
</TD>
</TR>
<TR>
<TD>
<P>vomiting</P>
</TD>
<TD>
<P>5 to 7%</P>
</TD>
<TD>
<P>1%</P>
</TD>
</TR>
<TR>
<TD>
<P>diarrhoea</P>
</TD>
<TD>
<P>8%</P>
</TD>
<TD>
<P>4%</P>
</TD>
</TR>
<TR>
<TD>
<P>serious adverse events: 2 deaths unrelated to liraglutide treatment; 1 participant in 1.2 mg liraglutide group withdrawn due to acute pancreatitis</P>
</TD>
<TD/>
<TD/>
</TR>
<TR>
<TD>
<P>injection site reactions</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>auto-immune response</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2009-12-21 13:01:20 +0100" MODIFIED_BY="[Empty name]" ORDER="1242" STUDY_ID="STD-L-_x002d_-LEAD-4-Zinman-2009">
<TR>
<TD>
<P>withdrawal due to adverse events</P>
</TD>
<TD>
<P>6%</P>
</TD>
<TD>
<P>3%</P>
</TD>
</TR>
<TR>
<TD>
<P>withdrawal due to nausea/vomiting/diarrhoea</P>
</TD>
<TD>
<P>3%</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>no significant differences across groups for: physical examination findings, laboratory analyses, ECG, ophthalmoscopy, cardiovascular adverse events</P>
</TD>
<TD/>
<TD/>
</TR>
<TR>
<TD>
<P>any GI event</P>
</TD>
<TD>
<P>45%</P>
</TD>
<TD>
<P>19%</P>
</TD>
</TR>
<TR>
<TD>
<P>nausea</P>
</TD>
<TD>
<P>29%</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>vomiting</P>
</TD>
<TD>
<P>7%</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>diarrhoea</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>serious adverse events</P>
</TD>
<TD>
<P>8 events in 8 participants</P>
</TD>
<TD>
<P>13 events in 12 participants</P>
</TD>
</TR>
<TR>
<TD>
<P>injection site reactions</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>auto-immune response</P>
</TD>
<TD>
<P>4.1% (no effect on HbA1c)</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="4.415447509846892" CI_END="1.1991115915397552" CI_START="-7.7148406629254245" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.2578645356928346" ESTIMABLE="YES" I2="77.35223897985654" I2_Q="0.0" ID="CMP-007.06" MODIFIED="2011-06-30 12:48:36 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.03561497288830162" P_Q="1.0" P_Z="0.15195722386219218" Q="0.0" RANDOM="YES" SCALE="13.71" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="8.006923637402396" TOTALS="YES" TOTAL_1="418" TOTAL_2="298" UNITS="" WEIGHT="100.0" Z="1.432652312731367">
<NAME>Systolic blood pressure</NAME>
<GROUP_LABEL_1>Liraglutide 1.2 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.7486062122350166" CI_START="-3.8486062122350164" EFFECT_SIZE="-1.05" ESTIMABLE="YES" MEAN_1="-2.81" MEAN_2="-1.76" MODIFIED="2009-12-22 13:55:50 +0100" MODIFIED_BY="[Empty name]" ORDER="96" SD_1="13.32" SD_2="12.54" SE="1.4278865501152394" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009" TOTAL_1="240" TOTAL_2="121" WEIGHT="51.47550471004758"/>
<CONT_DATA CI_END="-2.40953457357516" CI_START="-8.79046542642484" EFFECT_SIZE="-5.6" ESTIMABLE="YES" MEAN_1="-6.7" MEAN_2="-1.1" MODIFIED="2009-11-30 15:18:59 +0100" MODIFIED_BY="[Empty name]" ORDER="97" SD_1="14.68" SD_2="15.96" SE="1.6278183944148075" STUDY_ID="STD-L-_x002d_-LEAD-4-Zinman-2009" TOTAL_1="178" TOTAL_2="177" WEIGHT="48.52449528995242"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.205949145628454" CI_END="-1.6792535391364742" CI_START="-2.589446426276683" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.1343499827065786" ESTIMABLE="YES" I2="52.448307605460606" I2_Q="0.0" ID="CMP-007.07" MODIFIED="2011-06-30 12:48:56 +0200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.12209276771656563" P_Q="1.0" P_Z="3.855836949736663E-20" Q="0.0" RANDOM="YES" SCALE="4.13" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.08481824837042744" TOTALS="YES" TOTAL_1="646" TOTAL_2="412" UNITS="" WEIGHT="100.0" Z="9.19200568497561">
<NAME>Fasting plasma glucose (mmol/L)</NAME>
<GROUP_LABEL_1>Liraglutide 1.2 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.0463678244921963" CI_START="-3.113632175507804" EFFECT_SIZE="-2.58" ESTIMABLE="YES" MEAN_1="-1.57" MEAN_2="1.01" MODIFIED="2010-01-11 15:49:37 +0100" MODIFIED_BY="[Empty name]" ORDER="246" SD_1="2.42" SD_2="2.35" SE="0.2722663169920603" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009" TOTAL_1="228" TOTAL_2="114" WEIGHT="33.920155230959786"/>
<CONT_DATA CI_END="-1.4824556843088064" CI_START="-2.5175443156911936" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="-1.6" MEAN_2="0.4" MODIFIED="2009-11-30 15:44:21 +0100" MODIFIED_BY="[Empty name]" ORDER="105" SD_1="2.48" SD_2="2.31" SE="0.26405807442050827" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009" TOTAL_1="240" TOTAL_2="121" WEIGHT="34.88638595254597"/>
<CONT_DATA CI_END="-1.2185050440952025" CI_START="-2.381494955904798" EFFECT_SIZE="-1.8000000000000003" ESTIMABLE="YES" MEAN_1="-2.2" MEAN_2="-0.4" MODIFIED="2009-11-30 15:44:48 +0100" MODIFIED_BY="[Empty name]" ORDER="106" SD_1="2.8" SD_2="2.79" SE="0.29668655163643604" STUDY_ID="STD-L-_x002d_-LEAD-4-Zinman-2009" TOTAL_1="178" TOTAL_2="177" WEIGHT="31.19345881649424"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-007.08" MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" NO="8" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO">
<NAME>Post-prandial glucose (mmol/L)</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.2 mg daily</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" ORDER="1248" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009">
<TR>
<TD>
<P>average of values obtained 90 min after breakfast, lunch and evening meal</P>
</TD>
<TD>
<P>-2.5 mmol/L</P>
<P/>
</TD>
<TD>
<P>-0.4 mmol/L</P>
</TD>
<TD>
<P>Liraglutide 1.2 mg versus placebo: P &lt; 0.0001</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" ORDER="1249" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009">
<TR>
<TD>
<P>from self-monitored 7-point plasma glucose measurements</P>
</TD>
<TD>
<P>-2.3 mmol/L</P>
<P/>
</TD>
<TD>
<P>-0.6 mmol/L</P>
</TD>
<TD>
<P>Liraglutide 1.2 mg versus placebo: P &lt; 0.001</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" ORDER="1250" STUDY_ID="STD-L-_x002d_-LEAD-4-Zinman-2009">
<TR>
<TD>
<P>from self-monitored 7-point plasma glucose measurements</P>
</TD>
<TD>
<P>-2.6 mmol/L</P>
</TD>
<TD>
<P>-0.8 mmol/L</P>
</TD>
<TD>
<P>Liraglutide 1.2 mg versus placebo: P &lt; 0.001; the postprandial increment (postmeal value minus premeal) was significantly reduced over breakfast with liraglutide treatment (-0.9, -0.8, -0.3 mmol/L respectively; P &lt; 0.05 for both liraglutide groups versus placebo) but not for lunch and dinner.</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.04496972762348439" CI_START="-0.5449697276234844" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.25" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-007.09" MODIFIED="2011-08-30 14:45:56 +0200" MODIFIED_BY="Bernd Richter" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0966819406767357" Q="0.0" RANDOM="YES" SCALE="1.4" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="178" TOTAL_2="177" UNITS="" WEIGHT="0.0" Z="1.661156892548869">
<NAME>Triglycerides (mmol/L)</NAME>
<GROUP_LABEL_1>Liraglutide 1.2 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.04496972762348439" CI_START="-0.5449697276234844" EFFECT_SIZE="-0.25" ESTIMABLE="YES" MEAN_1="-0.38" MEAN_2="-0.13" MODIFIED="2009-11-30 17:23:48 +0100" MODIFIED_BY="[Empty name]" ORDER="121" SD_1="1.33" SD_2="1.5" SE="0.15049752441890155" STUDY_ID="STD-L-_x002d_-LEAD-4-Zinman-2009" TOTAL_1="178" TOTAL_2="177" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.07029849378635505" CI_START="-0.45029849378635506" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.19" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-007.10" MODIFIED="2011-08-30 14:46:05 +0200" MODIFIED_BY="Bernd Richter" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.1525337258380084" Q="0.0" RANDOM="YES" SCALE="2.32" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="178" TOTAL_2="177" UNITS="" WEIGHT="0.0" Z="1.4306389239741781">
<NAME>Total cholesterol (mmol/L)</NAME>
<GROUP_LABEL_1>Liraglutide 1.2 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.07029849378635505" CI_START="-0.45029849378635506" EFFECT_SIZE="-0.19" ESTIMABLE="YES" MEAN_1="-0.21" MEAN_2="-0.02" MODIFIED="2010-06-02 13:36:27 +0200" MODIFIED_BY="[Empty name]" ORDER="122" SD_1="1.2" SD_2="1.3" SE="0.13280779434701676" STUDY_ID="STD-L-_x002d_-LEAD-4-Zinman-2009" TOTAL_1="178" TOTAL_2="177" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.05938481088842391" CI_START="-0.05938481088842391" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-007.11" MODIFIED="2011-08-30 14:46:13 +0200" MODIFIED_BY="Bernd Richter" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="0.31" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="178" TOTAL_2="177" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>HDL-cholesterol (mmol/L)</NAME>
<GROUP_LABEL_1>Liraglutide 1.2 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.05938481088842391" CI_START="-0.05938481088842391" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.03" MEAN_2="-0.03" MODIFIED="2009-11-30 17:28:00 +0100" MODIFIED_BY="[Empty name]" ORDER="123" SD_1="0.27" SD_2="0.3" SE="0.030298929652199588" STUDY_ID="STD-L-_x002d_-LEAD-4-Zinman-2009" TOTAL_1="178" TOTAL_2="177" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.010381623489072622" CI_START="-0.37038162348907266" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.18000000000000002" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-007.12" MODIFIED="2011-08-30 14:46:20 +0200" MODIFIED_BY="Bernd Richter" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0638700360946569" Q="0.0" RANDOM="YES" SCALE="0.4" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="178" TOTAL_2="177" UNITS="" WEIGHT="0.0" Z="1.853085979369533">
<NAME>LDL-cholesterol (mmol/L)</NAME>
<GROUP_LABEL_1>Liraglutide 1.2 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.010381623489072622" CI_START="-0.37038162348907266" EFFECT_SIZE="-0.18000000000000002" ESTIMABLE="YES" MEAN_1="-0.28" MEAN_2="-0.1" MODIFIED="2009-11-30 17:29:02 +0100" MODIFIED_BY="[Empty name]" ORDER="124" SD_1="0.93" SD_2="0.9" SE="0.09713526625528764" STUDY_ID="STD-L-_x002d_-LEAD-4-Zinman-2009" TOTAL_1="178" TOTAL_2="177" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-007.13" MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" NO="13" ROWS_PER_STUDY="3" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO">
<NAME>Beta-cell function</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.2 mg daily</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" ORDER="1255" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009">
<TR>
<TD>
<P>HOMA-B (%)</P>
</TD>
<TD>
<P>99% SE 184.3 (+28%), P = 0.01 versus placebo</P>
</TD>
<TD>
<P>52% SE 107.3 (-4%)</P>
</TD>
</TR>
<TR>
<TD>
<P>proinsulin-to-insulin ratio</P>
</TD>
<TD>
<P>0.33 SE 0.2 (-0.12), p &#8804; 0.02 versus placebo</P>
</TD>
<TD>
<P>0.46 SE 0.29 (+0.02)</P>
</TD>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" ORDER="1256" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009">
<TR>
<TD>
<P>HOMA-B (%)</P>
</TD>
<TD>
<P>+23%</P>
</TD>
<TD>
<P>-2%</P>
</TD>
</TR>
<TR>
<TD>
<P>proinsulin-to-insulin ratio</P>
</TD>
<TD>
<P>-0.1, P &lt; 0.0001 versus placebo</P>
</TD>
<TD>
<P>+0.1</P>
</TD>
</TR>
<TR>
<TD>
<P>proinsulin-to-C-peptide ratio</P>
</TD>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" ORDER="1257" STUDY_ID="STD-L-_x002d_-LEAD-4-Zinman-2009">
<TR>
<TD>
<P>HOMA-B (%)</P>
</TD>
<TD>
<P>+27% SD 59, P &lt; 0.05 vs placebo</P>
</TD>
<TD>
<P>6% SD 60</P>
</TD>
</TR>
<TR>
<TD>
<P>proinsulin-to-insulin ratio</P>
</TD>
<TD>
<P>-0.029 SD 0.35, P &lt; 0.05 vs placebo</P>
</TD>
<TD>
<P>0.036 SD 39</P>
</TD>
</TR>
<TR>
<TD>
<P>proinsulin-to-C-peptide ratio</P>
</TD>
<TD>
<P>-0.007 SD 0.01, P &lt; 0.05 vs placebo</P>
</TD>
<TD>
<P>-0.002 SD 0.01</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2011-08-30 14:48:07 +0200" MODIFIED_BY="Bernd Richter" NO="8">
<NAME>Liraglutide 1.8 mg versus placebo</NAME>
<CONT_OUTCOME CHI2="4.397903474326382" CI_END="-0.987560017358602" CI_START="-1.3105209431237044" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.1490404802411531" ESTIMABLE="YES" I2="31.785678846452996" I2_Q="0.0" ID="CMP-008.01" MODIFIED="2011-06-30 12:52:18 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.22158009808550683" P_Q="1.0" P_Z="3.306945835878713E-44" Q="0.0" RANDOM="YES" SCALE="1.95" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.008633858634001615" TOTALS="YES" TOTAL_1="884" TOTAL_2="526" UNITS="" WEIGHT="100.0" Z="13.946442299272212">
<NAME>HbA1c</NAME>
<GROUP_LABEL_1>Liraglutide 1.8 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.1212003507585842" CI_START="-1.5987996492414156" EFFECT_SIZE="-1.3599999999999999" ESTIMABLE="YES" MEAN_1="-1.13" MEAN_2="0.23" MODIFIED="2010-01-08 10:51:40 +0100" MODIFIED_BY="[Empty name]" ORDER="228" SD_1="1.06" SD_2="1.07" SE="0.12183879455185755" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009" TOTAL_1="234" TOTAL_2="114" WEIGHT="28.911625393227336"/>
<CONT_DATA CI_END="-0.8224300807902867" CI_START="-1.3775699192097135" EFFECT_SIZE="-1.1" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="0.1" MODIFIED="2009-11-26 13:06:10 +0100" MODIFIED_BY="[Empty name]" ORDER="44" SD_1="1.56" SD_2="1.1" SE="0.14161990801828478" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009" TOTAL_1="242" TOTAL_2="121" WEIGHT="23.65987132905792"/>
<CONT_DATA CI_END="-0.7232948296554157" CI_START="-1.2767051703445844" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="-1.5" MEAN_2="-0.5" MODIFIED="2009-11-26 13:06:30 +0100" MODIFIED_BY="[Empty name]" ORDER="45" SD_1="1.33" SD_2="1.33" SE="0.14117870151043557" STUDY_ID="STD-L-_x002d_-LEAD-4-Zinman-2009" TOTAL_1="178" TOTAL_2="177" WEIGHT="23.76321717051828"/>
<CONT_DATA CI_END="-0.812475509420991" CI_START="-1.3675244905790092" EFFECT_SIZE="-1.09" ESTIMABLE="YES" MEAN_1="-1.33" MEAN_2="-0.24" MODIFIED="2009-11-26 13:06:48 +0100" MODIFIED_BY="[Empty name]" ORDER="46" SD_1="1.36" SD_2="1.17" SE="0.14159672971956974" STUDY_ID="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009" TOTAL_1="230" TOTAL_2="114" WEIGHT="23.665286107196465"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="14.844851950560294" CI_END="5.363215728700898" CI_START="1.9742297303719145" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="3.253954508286738" ESTIMABLE="YES" EVENTS_1="419" EVENTS_2="90" I2="79.79097393499589" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="0.729425266271307" LOG_CI_START="0.29539768776003134" LOG_EFFECT_SIZE="0.5124114770156691" METHOD="MH" MODIFIED="2011-06-30 13:08:11 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0019541623231044136" P_Q="1.0" P_Z="3.6947509028373045E-6" Q="0.0" RANDOM="YES" SCALE="22.22" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.20097285404484352" TOTALS="YES" TOTAL_1="884" TOTAL_2="526" WEIGHT="99.99999999999999" Z="4.62785357400783">
<NAME>HbA1c &lt; 7%</NAME>
<GROUP_LABEL_1>Liraglutide 1.8 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Liraglutide</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.110091081806555" CI_START="2.78349247907194" EFFECT_SIZE="5.304843304843305" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="9" LOG_CI_END="1.0047550681674409" LOG_CI_START="0.44459005219155867" LOG_EFFECT_SIZE="0.7246725601794998" MODIFIED="2010-01-08 11:29:26 +0100" MODIFIED_BY="[Empty name]" ORDER="245" O_E="0.0" SE="0.32904370324578236" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009" TOTAL_1="234" TOTAL_2="114" VAR="0.10826975864569849" WEIGHT="21.018926035096257"/>
<DICH_DATA CI_END="6.757457052279614" CI_START="2.322439767035479" EFFECT_SIZE="3.9615384615384617" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="13" LOG_CI_END="0.8297832941758321" LOG_CI_START="0.36594445929287645" LOG_EFFECT_SIZE="0.5978638767343543" MODIFIED="2010-01-08 11:34:30 +0100" MODIFIED_BY="[Empty name]" ORDER="62" O_E="0.0" SE="0.2724612276495108" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009" TOTAL_1="242" TOTAL_2="121" VAR="0.07423512057227856" WEIGHT="23.61831125019306"/>
<DICH_DATA CI_END="2.504053479794035" CI_START="1.4556782247823867" EFFECT_SIZE="1.9092134831460674" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="50" LOG_CI_END="0.39864359999023674" LOG_CI_START="0.1630653855226878" LOG_EFFECT_SIZE="0.28085449275646224" MODIFIED="2010-01-08 11:37:07 +0100" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="0.13837980930920699" STUDY_ID="STD-L-_x002d_-LEAD-4-Zinman-2009" TOTAL_1="178" TOTAL_2="177" VAR="0.019148971624452487" WEIGHT="29.52886467881533"/>
<DICH_DATA CI_END="5.221543662436234" CI_START="2.161373228587411" EFFECT_SIZE="3.3594202898550725" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="18" LOG_CI_END="0.7177989139163062" LOG_CI_START="0.3347297678643375" LOG_EFFECT_SIZE="0.5262643408903219" MODIFIED="2010-01-08 11:37:02 +0100" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="0.22501671261378126" STUDY_ID="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009" TOTAL_1="230" TOTAL_2="114" VAR="0.05063252095551303" WEIGHT="25.833898035895338"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6024078259846688" CI_END="2.3969221911939114" CI_START="1.1520470328355" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6617361698845308" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="0.37965393620987486" LOG_CI_START="0.061470209715637554" LOG_EFFECT_SIZE="0.22056207296275618" METHOD="MH" MODIFIED="2011-08-22 15:30:45 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6588440367948375" P_Q="1.0" P_Z="0.006582517189296259" Q="0.0" RANDOM="YES" SCALE="11.87" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="884" TOTAL_2="526" WEIGHT="100.0" Z="2.717258510518621">
<NAME>Hypoglycaemia</NAME>
<GROUP_LABEL_1>Liraglutide 1.8 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.212350739289775" CI_START="0.9322168706666315" EFFECT_SIZE="3.0854700854700856" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="3" LOG_CI_END="1.0091257220666379" LOG_CI_START="-0.030483041747645292" LOG_EFFECT_SIZE="0.4893213401594963" MODIFIED="2009-12-21 13:05:04 +0100" MODIFIED_BY="[Empty name]" ORDER="264" O_E="0.0" SE="0.6106713340108868" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009" TOTAL_1="234" TOTAL_2="114" VAR="0.37291947818263604" WEIGHT="9.36733525798114"/>
<DICH_DATA CI_END="3.9299054457421296" CI_START="0.2544590483935062" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.5943821012949081" LOG_CI_START="-0.5943821012949081" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-11 17:06:10 +0100" MODIFIED_BY="[Empty name]" ORDER="267" O_E="0.0" SE="0.6982859770789644" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009" TOTAL_1="242" TOTAL_2="121" VAR="0.487603305785124" WEIGHT="7.164147032890582"/>
<DICH_DATA CI_END="3.4810376348309218" CI_START="0.6873356372264391" EFFECT_SIZE="1.546816479400749" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.5417087186336255" LOG_CI_START="-0.1628311380499739" LOG_EFFECT_SIZE="0.1894387902918258" MODIFIED="2009-11-27 20:46:05 +0100" MODIFIED_BY="[Empty name]" ORDER="75" O_E="0.0" SE="0.413850199344483" STUDY_ID="STD-L-_x002d_-LEAD-4-Zinman-2009" TOTAL_1="178" TOTAL_2="177" VAR="0.17127198749746836" WEIGHT="20.395990187360734"/>
<DICH_DATA CI_END="2.606667254674427" CI_START="1.0361970017873297" EFFECT_SIZE="1.6434782608695653" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="19" LOG_CI_END="0.41608559630763964" LOG_CI_START="0.015442331331625368" LOG_EFFECT_SIZE="0.21576396381963248" MODIFIED="2009-11-27 20:46:52 +0100" MODIFIED_BY="[Empty name]" ORDER="76" O_E="0.0" SE="0.2353398370630573" STUDY_ID="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009" TOTAL_1="230" TOTAL_2="114" VAR="0.05538483890886636" WEIGHT="63.07252752176754"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="21.819925277326423" CI_END="-0.267960429895961" CI_START="-2.3826743135462793" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.3253173717211202" ESTIMABLE="YES" I2="86.25109865468986" I2_Q="0.0" ID="CMP-008.04" MODIFIED="2011-06-30 12:53:15 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="7.110800565646169E-5" P_Q="1.0" P_Z="0.014023245540029072" Q="0.0" RANDOM="YES" SCALE="4.01" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.9961177749904927" TOTALS="YES" TOTAL_1="884" TOTAL_2="526" UNITS="" WEIGHT="100.00000000000001" Z="2.456667388190472">
<NAME>Weight change</NAME>
<GROUP_LABEL_1>Liraglutide 1.8 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.5581898728377809" CI_START="-0.7581898728377808" EFFECT_SIZE="-0.1" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="-0.1" MODIFIED="2010-01-11 16:01:36 +0100" MODIFIED_BY="[Empty name]" ORDER="254" SD_1="3.06" SD_2="2.88" SE="0.33581733033336253" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009" TOTAL_1="234" TOTAL_2="114" WEIGHT="26.245701175644168"/>
<CONT_DATA CI_END="-0.5934136686181393" CI_START="-2.00658633138186" EFFECT_SIZE="-1.2999999999999998" ESTIMABLE="YES" MEAN_1="-2.8" MEAN_2="-1.5" MODIFIED="2010-01-02 14:06:41 +0100" MODIFIED_BY="[Empty name]" ORDER="87" SD_1="3.11" SD_2="3.3" SE="0.36050985475004815" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009" TOTAL_1="242" TOTAL_2="121" WEIGHT="25.844958310796596"/>
<CONT_DATA CI_END="-1.768846523268852" CI_START="-3.431153476731148" EFFECT_SIZE="-2.6" ESTIMABLE="YES" MEAN_1="-2.0" MEAN_2="0.6" MODIFIED="2010-01-11 16:01:38 +0100" MODIFIED_BY="[Empty name]" ORDER="88" SD_1="4.0" SD_2="3.99" SE="0.42406568859794397" STUDY_ID="STD-L-_x002d_-LEAD-4-Zinman-2009" TOTAL_1="178" TOTAL_2="177" WEIGHT="24.749042083442834"/>
<CONT_DATA CI_END="-0.37965166087066127" CI_START="-2.380348339129339" EFFECT_SIZE="-1.3800000000000001" ESTIMABLE="YES" MEAN_1="-1.8" MEAN_2="-0.42" MODIFIED="2009-12-28 14:46:14 +0100" MODIFIED_BY="[Empty name]" ORDER="86" SD_1="5.0" SD_2="4.16" SE="0.510391184236016" STUDY_ID="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009" TOTAL_1="230" TOTAL_2="114" WEIGHT="23.160298430116416"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-008.05" MODIFIED="2011-06-30 12:53:30 +0200" MODIFIED_BY="[Empty name]" NO="5" ROWS_PER_STUDY="10" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO">
<NAME>Adverse events</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.8 mg daily</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-06-30 12:53:24 +0200" MODIFIED_BY="[Empty name]" ORDER="1274" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009">
<TR>
<TD>
<P>withdrawal due to adverse events</P>
</TD>
<TD>
<P>4%</P>
</TD>
<TD>
<P>5%</P>
</TD>
</TR>
<TR>
<TD>
<P>no significant differences across groups for: blood pressure; no significant changes is: ophthalmoscopy, biochemistry, urinalysis, haematology, ECG</P>
<P>no deaths</P>
</TD>
<TD/>
<TD/>
</TR>
<TR>
<TD>
<P>nausea</P>
</TD>
<TD/>
<TD>
<P>1.8% (lowest)</P>
</TD>
</TR>
<TR>
<TD>
<P>vomiting</P>
</TD>
<TD/>
<TD/>
</TR>
<TR>
<TD>
<P>diarrhoea</P>
</TD>
<TD/>
<TD/>
</TR>
<TR>
<TD>
<P>serious adverse events (mostly judged to be unlikely to be related to study medication)</P>
</TD>
<TD>
<P>5%</P>
</TD>
<TD>
<P>3%</P>
</TD>
</TR>
<TR>
<TD>
<P>liraglutide auto-antibodies</P>
</TD>
<TD>
<P>9 to13%, no effect on HbA1c</P>
</TD>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2011-06-30 12:53:30 +0200" MODIFIED_BY="[Empty name]" ORDER="1275" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009">
<TR>
<TD>
<P>withdrawal due to adverse events</P>
</TD>
<TD>
<P>12%</P>
</TD>
<TD>
<P>2%</P>
</TD>
</TR>
<TR>
<TD>
<P>withdrawal due to nausea/vomiting/diarrhoea</P>
</TD>
<TD>
<P>8%</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>no significant differences across groups for: physical examination findings, laboratory analyses, ECG, ophthalmoscopy</P>
</TD>
<TD/>
<TD/>
</TR>
<TR>
<TD>
<P>any GI event</P>
</TD>
<TD>
<P>44%</P>
</TD>
<TD>
<P>17%</P>
</TD>
</TR>
<TR>
<TD>
<P>nausea</P>
</TD>
<TD>
<P>19%</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>vomiting</P>
</TD>
<TD>
<P>5 to 7%</P>
</TD>
<TD>
<P>1%</P>
</TD>
</TR>
<TR>
<TD>
<P>diarrhoea</P>
</TD>
<TD>
<P>15%</P>
</TD>
<TD>
<P>4%</P>
</TD>
</TR>
<TR>
<TD>
<P>serious adverse events: 2 deaths unrelated to liraglutide treatment</P>
</TD>
<TD/>
<TD/>
</TR>
<TR>
<TD>
<P>injection site reactions</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>anti-liraglutide antibodies</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2009-12-21 12:58:39 +0100" MODIFIED_BY="[Empty name]" ORDER="1276" STUDY_ID="STD-L-_x002d_-LEAD-4-Zinman-2009">
<TR>
<TD>
<P>withdrawal due to adverse events</P>
</TD>
<TD>
<P>15%</P>
</TD>
<TD>
<P>3%</P>
</TD>
</TR>
<TR>
<TD>
<P>withdrawal due to nausea/vomiting/diarrhoea</P>
</TD>
<TD>
<P>11%</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>no significant differences across groups for: physical examination findings, laboratory analyses, ECG, ophthalmoscopy, cardiovascular adverse events</P>
</TD>
<TD/>
<TD/>
</TR>
<TR>
<TD>
<P>any GI event</P>
</TD>
<TD>
<P>56%</P>
</TD>
<TD>
<P>19%</P>
</TD>
</TR>
<TR>
<TD>
<P>nausea</P>
</TD>
<TD>
<P>40%</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>vomiting</P>
</TD>
<TD>
<P>17%</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>diarrhoea</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>serious adverse events</P>
</TD>
<TD>
<P>10 events in 7 participants</P>
</TD>
<TD>
<P>13 events in 12 participants</P>
</TD>
</TR>
<TR>
<TD>
<P>injection site reactions</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>anti-liraglutide antibodies</P>
</TD>
<TD>
<P>6.7% (no effect on HbA1c)</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2010-01-04 13:52:56 +0100" MODIFIED_BY="[Empty name]" ORDER="1277" STUDY_ID="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009">
<TR>
<TD>
<P>withdrawal due to adverse events</P>
</TD>
<TD>
<P>5%</P>
</TD>
<TD>
<P>0.9%</P>
</TD>
</TR>
<TR>
<TD>
<P>no significant differences across groups for: nasopharyngitis, headache; no pancreatitis</P>
</TD>
<TD/>
<TD/>
</TR>
<TR>
<TD>
<P>nausea</P>
</TD>
<TD>
<P>13.9%</P>
</TD>
<TD>
<P>3.5%</P>
</TD>
</TR>
<TR>
<TD>
<P>diarrhoea</P>
</TD>
<TD>
<P>10.%</P>
</TD>
<TD>
<P>5.3%</P>
</TD>
</TR>
<TR>
<TD>
<P>dyspepsia</P>
</TD>
<TD>
<P>6.5%</P>
</TD>
<TD>
<P>0.9%</P>
</TD>
</TR>
<TR>
<TD>
<P>vomiting</P>
</TD>
<TD>
<P>6.5%</P>
</TD>
<TD>
<P>3.5%</P>
</TD>
</TR>
<TR>
<TD>
<P>serious adverse events</P>
</TD>
<TD>
<P>4%</P>
</TD>
<TD>
<P>7%</P>
</TD>
</TR>
<TR>
<TD>
<P>injection site reactions</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>anti-liraglutide antibodies</P>
</TD>
<TD>
<P>9.8% (no effect on HbA1c)</P>
</TD>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="3.4236201377766435" CI_END="0.047668287193169956" CI_START="-4.895290399349713" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.423811056078272" ESTIMABLE="YES" I2="41.58230412504719" I2_Q="0.0" ID="CMP-008.06" MODIFIED="2011-06-30 12:54:01 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.1805389835532828" P_Q="1.0" P_Z="0.0545854429445851" Q="0.0" RANDOM="YES" SCALE="32.16" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="1.990349332702844" TOTALS="YES" TOTAL_1="650" TOTAL_2="412" UNITS="" WEIGHT="100.00000000000001" Z="1.922161473118026">
<NAME>Systolic blood pressure</NAME>
<GROUP_LABEL_1>Liraglutide 1.8 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.23369597322814" CI_START="-3.2936959732281403" EFFECT_SIZE="-0.53" ESTIMABLE="YES" MEAN_1="-2.29" MEAN_2="-1.76" MODIFIED="2009-12-23 11:41:49 +0100" MODIFIED_BY="[Empty name]" ORDER="98" SD_1="12.91" SD_2="12.54" SE="1.410074876389475" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009" TOTAL_1="242" TOTAL_2="121" WEIGHT="39.96510025114017"/>
<CONT_DATA CI_END="-1.3095345735751605" CI_START="-7.69046542642484" EFFECT_SIZE="-4.5" ESTIMABLE="YES" MEAN_1="-5.6" MEAN_2="-1.1" MODIFIED="2009-11-30 15:21:51 +0100" MODIFIED_BY="[Empty name]" ORDER="99" SD_1="14.68" SD_2="15.96" SE="1.6278183944148075" STUDY_ID="STD-L-_x002d_-LEAD-4-Zinman-2009" TOTAL_1="178" TOTAL_2="177" WEIGHT="34.267822698782815"/>
<CONT_DATA CI_END="1.407447852288414" CI_START="-6.607447852288415" EFFECT_SIZE="-2.6" ESTIMABLE="YES" MEAN_1="-4.0" MEAN_2="-1.4" MODIFIED="2009-11-30 15:22:09 +0100" MODIFIED_BY="[Empty name]" ORDER="100" SD_1="19.87" SD_2="16.76" SE="2.0446538221613517" STUDY_ID="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009" TOTAL_1="230" TOTAL_2="114" WEIGHT="25.767077050077017"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.9179099176504355" CI_END="-1.9301099277621205" CI_START="-2.4854907351825615" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.207800331472341" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.07" MODIFIED="2011-06-30 12:54:24 +0200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.40445593777160427" P_Q="1.0" P_Z="9.520667595482057E-55" Q="0.0" RANDOM="YES" SCALE="3.54" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="884" TOTAL_2="526" UNITS="" WEIGHT="100.0" Z="15.582854419618243">
<NAME>Fasting plasma glucose (mmol/L)</NAME>
<GROUP_LABEL_1>Liraglutide 1.8 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.066491136339845" CI_START="-3.1335088636601554" EFFECT_SIZE="-2.6" ESTIMABLE="YES" MEAN_1="-1.59" MEAN_2="1.01" MODIFIED="2010-01-11 16:07:20 +0100" MODIFIED_BY="[Empty name]" ORDER="247" SD_1="2.45" SD_2="2.35" SE="0.2722034016279917" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009" TOTAL_1="234" TOTAL_2="114" WEIGHT="27.091837716141708"/>
<CONT_DATA CI_END="-1.5944452657425954" CI_START="-2.605554734257405" EFFECT_SIZE="-2.1" ESTIMABLE="YES" MEAN_1="-1.7" MEAN_2="0.4" MODIFIED="2009-11-30 15:45:45 +0100" MODIFIED_BY="[Empty name]" ORDER="107" SD_1="2.33" SD_2="2.31" SE="0.25794082863009526" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009" TOTAL_1="242" TOTAL_2="121" WEIGHT="30.170699574598935"/>
<CONT_DATA CI_END="-1.4318539170544753" CI_START="-2.5681460829455247" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="-2.4" MEAN_2="-0.4" MODIFIED="2009-11-30 15:46:09 +0100" MODIFIED_BY="[Empty name]" ORDER="108" SD_1="2.67" SD_2="2.79" SE="0.2898757770178373" STUDY_ID="STD-L-_x002d_-LEAD-4-Zinman-2009" TOTAL_1="178" TOTAL_2="177" WEIGHT="23.889205708144615"/>
<CONT_DATA CI_END="-1.4403752290827307" CI_START="-2.719624770917269" EFFECT_SIZE="-2.08" ESTIMABLE="YES" MEAN_1="-1.55" MEAN_2="0.53" MODIFIED="2009-11-30 15:46:37 +0100" MODIFIED_BY="[Empty name]" ORDER="109" SD_1="3.18" SD_2="2.67" SE="0.3263451655043398" STUDY_ID="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009" TOTAL_1="230" TOTAL_2="114" WEIGHT="18.848257001114746"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-008.08" MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" NO="8" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO">
<NAME>Post-prandial glucose (mmol/L)</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.8 mg daily</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" ORDER="1285" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009">
<TR>
<TD>
<P>average of values obtained 90 min after breakfast, lunch and evening meal</P>
</TD>
<TD>
<P>-2.7 mmol/L</P>
<P/>
</TD>
<TD>
<P>-0.4 mmol/L</P>
</TD>
<TD>
<P>Liraglutide 1.8 mg versus placebo: P &lt; 0.0001</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" ORDER="1286" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009">
<TR>
<TD>
<P>from self-monitored 7-point plasma glucose measurements</P>
</TD>
<TD>
<P>-2.6 mmol/L</P>
<P/>
</TD>
<TD>
<P>-0.6 mmol/L</P>
</TD>
<TD>
<P>Liraglutide 1.8 mg versus placebo: P &lt; 0.001</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" ORDER="1287" STUDY_ID="STD-L-_x002d_-LEAD-4-Zinman-2009">
<TR>
<TD>
<P>from self-monitored 7-point plasma glucose measurements</P>
</TD>
<TD>
<P>-2.7 mmol/L</P>
</TD>
<TD>
<P>-0.8 mmol/L</P>
</TD>
<TD>
<P>Liraglutide 1.8 mg versus placebo: P &lt; 0.001; the postprandial increment (postmeal value minus premeal) was significantly reduced over breakfast with liraglutide treatment (-0.9, -0.8, -0.3 mmol/L respectively; P &lt; 0.05 for both liraglutide groups versus placebo) but not for lunch and dinner.</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" ORDER="1288" STUDY_ID="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009">
<TR>
<TD>
<P>from self-monitored 7-point plasma glucose measurements</P>
</TD>
<TD>
<P>-1.81 mmol/L</P>
</TD>
<TD>
<P>-0.03 mmol/L</P>
</TD>
<TD>
<P>Liraglutide 1.8 mg versus placebo: P &lt; 0.0001; there was a statistically significantly higher likelihood of achieving ADA targets for PPG (&#8804; 10 mmol/l) (P &lt; 0.0001) with liraglutide versus placebo.</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.10496972762348442" CI_START="-0.48496972762348434" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.18999999999999997" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-008.09" MODIFIED="2011-08-30 14:47:38 +0200" MODIFIED_BY="Bernd Richter" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.20677641733066365" Q="0.0" RANDOM="YES" SCALE="1.77" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="178" TOTAL_2="177" UNITS="" WEIGHT="0.0" Z="1.2624792383371402">
<NAME>Triglycerides (mmol/L)</NAME>
<GROUP_LABEL_1>Liraglutide 1.8 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.10496972762348439" CI_START="-0.4849697276234844" EFFECT_SIZE="-0.19" ESTIMABLE="YES" MEAN_1="-0.32" MEAN_2="-0.13" MODIFIED="2009-11-30 17:31:24 +0100" MODIFIED_BY="[Empty name]" ORDER="125" SD_1="1.33" SD_2="1.5" SE="0.15049752441890155" STUDY_ID="STD-L-_x002d_-LEAD-4-Zinman-2009" TOTAL_1="178" TOTAL_2="177" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.08029849378635504" CI_START="-0.4402984937863551" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.18000000000000002" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-008.10" MODIFIED="2011-08-30 14:47:50 +0200" MODIFIED_BY="Bernd Richter" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.1753085753367531" Q="0.0" RANDOM="YES" SCALE="1.19" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="178" TOTAL_2="177" UNITS="" WEIGHT="0.0" Z="1.3553421385018531">
<NAME>Total cholesterol (mmol/L)</NAME>
<GROUP_LABEL_1>Liraglutide 1.8 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.08029849378635504" CI_START="-0.4402984937863551" EFFECT_SIZE="-0.18000000000000002" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="-0.02" MODIFIED="2009-11-30 17:32:17 +0100" MODIFIED_BY="[Empty name]" ORDER="126" SD_1="1.2" SD_2="1.3" SE="0.13280779434701676" STUDY_ID="STD-L-_x002d_-LEAD-4-Zinman-2009" TOTAL_1="178" TOTAL_2="177" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.049384810888423905" CI_START="-0.06938481088842391" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.010000000000000002" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-008.11" MODIFIED="2011-08-30 14:47:59 +0200" MODIFIED_BY="Bernd Richter" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.7413662161493795" Q="0.0" RANDOM="YES" SCALE="0.42" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="178" TOTAL_2="177" UNITS="" WEIGHT="0.0" Z="0.33004466213129213">
<NAME>HDL-cholesterol (mmol/L)</NAME>
<GROUP_LABEL_1>Liraglutide 1.8 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.049384810888423905" CI_START="-0.06938481088842391" EFFECT_SIZE="-0.010000000000000002" ESTIMABLE="YES" MEAN_1="-0.04" MEAN_2="-0.03" MODIFIED="2009-11-30 17:33:16 +0100" MODIFIED_BY="[Empty name]" ORDER="127" SD_1="0.27" SD_2="0.3" SE="0.030298929652199588" STUDY_ID="STD-L-_x002d_-LEAD-4-Zinman-2009" TOTAL_1="178" TOTAL_2="177" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.06038162348907264" CI_START="-0.3203816234890726" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.13" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-008.12" MODIFIED="2011-08-30 14:48:07 +0200" MODIFIED_BY="Bernd Richter" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.18078566920983288" Q="0.0" RANDOM="YES" SCALE="1.1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="178" TOTAL_2="177" UNITS="" WEIGHT="0.0" Z="1.3383398739891068">
<NAME>LDL-cholesterol (mmol/L)</NAME>
<GROUP_LABEL_1>Liraglutide 1.8 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.06038162348907264" CI_START="-0.3203816234890726" EFFECT_SIZE="-0.13" ESTIMABLE="YES" MEAN_1="-0.23" MEAN_2="-0.1" MODIFIED="2009-11-30 17:34:09 +0100" MODIFIED_BY="[Empty name]" ORDER="128" SD_1="0.93" SD_2="0.9" SE="0.09713526625528764" STUDY_ID="STD-L-_x002d_-LEAD-4-Zinman-2009" TOTAL_1="178" TOTAL_2="177" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-008.13" MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" NO="13" ROWS_PER_STUDY="3" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO">
<NAME>Beta-cell function</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.8 mg daily</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" ORDER="1293" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009">
<TR>
<TD>
<P>HOMA-B (%)</P>
</TD>
<TD>
<P>91% SE 108.2 (+35%), P = 0.051 versus placebo</P>
</TD>
<TD>
<P>52% SE 107.3 (-4%)</P>
</TD>
</TR>
<TR>
<TD>
<P>proinsulin-to-insulin ratio</P>
</TD>
<TD>
<P>0.36 SE 0.2 (-0.12), p &#8804; 0.02 versus placebo</P>
</TD>
<TD>
<P>0.46 SE 0.29 (+0.02)</P>
</TD>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" ORDER="1294" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009">
<TR>
<TD>
<P>HOMA-B (%)</P>
</TD>
<TD>
<P>+28%</P>
</TD>
<TD>
<P>-2%</P>
</TD>
</TR>
<TR>
<TD>
<P>proinsulin-to-insulin ratio</P>
</TD>
<TD>
<P>-0.1, P &lt; 0.0001 versus placebo</P>
</TD>
<TD>
<P>+0.1</P>
</TD>
</TR>
<TR>
<TD>
<P>proinsulin-to-C-peptide ratio</P>
</TD>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" ORDER="1295" STUDY_ID="STD-L-_x002d_-LEAD-4-Zinman-2009">
<TR>
<TD>
<P>HOMA-B (%)</P>
</TD>
<TD>
<P>+27% SD 56, P &lt; 0.05 vs placebo</P>
</TD>
<TD>
<P>6% SD 60</P>
</TD>
</TR>
<TR>
<TD>
<P>proinsulin-to-insulin ratio</P>
</TD>
<TD>
<P>-0.085 SD 3.47, P &lt; 0.05 vs placebo</P>
</TD>
<TD>
<P>0.036 SD 39</P>
</TD>
</TR>
<TR>
<TD>
<P>proinsulin-to-C-peptide ratio</P>
</TD>
<TD>
<P>-0.008 SD 0.01, P &lt; 0.05 vs placebo</P>
</TD>
<TD>
<P>-0.002 SD 0.01</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" ORDER="1296" STUDY_ID="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009">
<TR>
<TD>
<P>proinsulin-to-C-peptide ratio</P>
</TD>
<TD>
<P>-0.00671 (95% CI: -0.00964, -0.00377, P &lt; 0.0001) versus placebo</P>
</TD>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2011-08-30 14:49:00 +0200" MODIFIED_BY="Bernd Richter" NO="9">
<NAME>Liraglutide 1.2 mg versus 1.8 mg</NAME>
<CONT_OUTCOME CHI2="4.216172025356034" CI_END="0.23456649839425536" CI_START="-0.03143980153433529" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="0.10156334842996004" ESTIMABLE="YES" I2="28.845408063095682" I2_Q="0.0" ID="CMP-009.01" MODIFIED="2011-06-30 12:58:44 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.23904788311822356" P_Q="1.0" P_Z="0.1344817285131973" Q="0.0" RANDOM="YES" SCALE="0.55" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0053346468991668375" TOTALS="YES" TOTAL_1="867" TOTAL_2="872" UNITS="" WEIGHT="100.0" Z="1.496660080046616">
<NAME>HbA1c</NAME>
<GROUP_LABEL_1>Liraglutide 1.2 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Liraglutide 1.8 mg daily</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide 1.2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Liraglutide 1.8</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.24423238358129667" CI_START="-0.14423238358129703" EFFECT_SIZE="0.04999999999999982" ESTIMABLE="YES" MEAN_1="-1.08" MEAN_2="-1.13" MODIFIED="2009-12-30 17:57:44 +0100" MODIFIED_BY="[Empty name]" ORDER="286" SD_1="1.06" SD_2="1.07" SE="0.09909997587372886" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009" TOTAL_1="228" TOTAL_2="234" WEIGHT="30.384967383537457"/>
<CONT_DATA CI_END="0.2776419911435151" CI_START="-0.2776419911435151" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="-1.0" MODIFIED="2009-12-30 17:57:44 +0100" MODIFIED_BY="[Empty name]" ORDER="287" SD_1="1.55" SD_2="1.56" SE="0.141656680088777" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009" TOTAL_1="240" TOTAL_2="242" WEIGHT="18.128938627003745"/>
<CONT_DATA CI_END="0.2763151699106697" CI_START="-0.2763151699106697" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-1.5" MEAN_2="-1.5" MODIFIED="2009-12-30 17:57:44 +0100" MODIFIED_BY="[Empty name]" ORDER="288" SD_1="1.33" SD_2="1.33" SE="0.14097971804084589" STUDY_ID="STD-L-_x002d_-LEAD-4-Zinman-2009" TOTAL_1="178" TOTAL_2="178" WEIGHT="18.26653062861597"/>
<CONT_DATA CI_END="0.440992925733822" CI_START="0.07900707426617803" EFFECT_SIZE="0.26" ESTIMABLE="YES" MEAN_1="-1.24" MEAN_2="-1.5" MODIFIED="2011-05-04 16:25:55 +0200" MODIFIED_BY="[Empty name]" ORDER="354" SD_1="1.04" SD_2="0.89" SE="0.09234502631756046" STUDY_ID="STD-L-_x002d_-Pratley-2010" TOTAL_1="221" TOTAL_2="218" WEIGHT="33.21956336084283"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="12.112785054535845" CI_END="1.165105949961824" CI_START="0.8444375519869594" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.991896776983978" ESTIMABLE="YES" EVENTS_1="491" EVENTS_2="496" I2="66.97704134936225" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="0.06636542011875514" LOG_CI_START="-0.07343246193698325" LOG_EFFECT_SIZE="-0.003533520909114033" METHOD="MH" MODIFIED="2011-06-30 13:00:07 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.016532009649361745" P_Q="1.0" P_Z="0.9210749033538015" Q="0.0" RANDOM="YES" SCALE="5.84" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.02248628018635114" TOTALS="YES" TOTAL_1="1100" TOTAL_2="1106" WEIGHT="100.0" Z="0.09907980891615313">
<NAME>Patients reaching HbA1c &lt; 7%</NAME>
<GROUP_LABEL_1>Liraglutide 1.2 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Liraglutide 1.8 mg daily</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide 1.8</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Liraglutide 1.2</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0568680989019577" CI_START="0.664154400199324" EFFECT_SIZE="0.8378088077336198" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="98" LOG_CI_END="0.024020789111104678" LOG_CI_START="-0.17773094569282905" LOG_EFFECT_SIZE="-0.07685507829086222" MODIFIED="2009-12-30 17:58:24 +0100" MODIFIED_BY="[Empty name]" ORDER="289" O_E="0.0" SE="0.11850996771102458" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009" TOTAL_1="228" TOTAL_2="234" VAR="0.014044612446868087" WEIGHT="18.459337209997937"/>
<DICH_DATA CI_END="1.0420464996751047" CI_START="0.6644840357361763" EFFECT_SIZE="0.8321197411003236" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="103" LOG_CI_END="0.017887099099519663" LOG_CI_START="-0.17751544854362805" LOG_EFFECT_SIZE="-0.07981417472205422" MODIFIED="2009-12-30 17:58:24 +0100" MODIFIED_BY="[Empty name]" ORDER="290" O_E="0.0" SE="0.11478042374379556" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009" TOTAL_1="240" TOTAL_2="242" VAR="0.013174545674805267" WEIGHT="18.909715336496024"/>
<DICH_DATA CI_END="1.279416770063235" CI_START="0.8823600537487123" EFFECT_SIZE="1.0625" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="96" LOG_CI_END="0.10701203897040716" LOG_CI_START="-0.05435416152570888" LOG_EFFECT_SIZE="0.02632893872234915" MODIFIED="2009-12-30 17:58:24 +0100" MODIFIED_BY="[Empty name]" ORDER="291" O_E="0.0" SE="0.09478730494699351" STUDY_ID="STD-L-_x002d_-LEAD-4-Zinman-2009" TOTAL_1="178" TOTAL_2="178" VAR="0.00898463317911434" WEIGHT="21.42727978269624"/>
<DICH_DATA CI_END="1.5582405181330548" CI_START="1.0638737829215945" EFFECT_SIZE="1.2875446534889259" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="95" LOG_CI_END="0.19263449289756987" LOG_CI_START="0.026890106688193024" LOG_EFFECT_SIZE="0.10976229979288142" MODIFIED="2011-05-04 16:27:44 +0200" MODIFIED_BY="[Empty name]" ORDER="356" O_E="0.0" SE="0.09735907290733171" STUDY_ID="STD-L-_x002d_-Pratley-2010" TOTAL_1="221" TOTAL_2="218" VAR="0.009478789077375132" WEIGHT="21.096030173914087"/>
<DICH_DATA CI_END="1.1865995419398059" CI_START="0.7858669375465746" EFFECT_SIZE="0.9656652360515021" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="104" LOG_CI_END="0.07430417635180322" LOG_CI_START="-0.1046509821811162" LOG_EFFECT_SIZE="-0.0151734029146565" MODIFIED="2011-05-04 16:27:18 +0200" MODIFIED_BY="[Empty name]" ORDER="357" O_E="0.0" SE="0.10511914596455829" STUDY_ID="STD-L-_x002d_-Yang-2010" TOTAL_1="233" TOTAL_2="234" VAR="0.011050034848318112" WEIGHT="20.107637496895727"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.499780039228221" CI_END="0.798200179703406" CI_START="0.15737468878864808" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="0.477787434246027" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.03" MODIFIED="2011-06-30 13:00:38 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.4753311172154029" P_Q="1.0" P_Z="0.0034709474450396447" Q="0.0" RANDOM="YES" SCALE="1.95" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="867" TOTAL_2="872" UNITS="" WEIGHT="100.0" Z="2.9226245730370852">
<NAME>Weight</NAME>
<GROUP_LABEL_1>Liraglutide 1.2 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Liraglutide 1.8 mg daily</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide 1.2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Liraglutide 1.8</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.0544209090785106" CI_START="-0.054420909078510604" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="-0.2" MODIFIED="2009-12-30 17:58:56 +0100" MODIFIED_BY="[Empty name]" ORDER="292" SD_1="3.02" SD_2="3.06" SE="0.2828730086122561" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009" TOTAL_1="228" TOTAL_2="234" WEIGHT="33.3995307521781"/>
<CONT_DATA CI_END="0.7543927880529882" CI_START="-0.3543927880529887" EFFECT_SIZE="0.19999999999999973" ESTIMABLE="YES" MEAN_1="-2.6" MEAN_2="-2.8" MODIFIED="2009-12-30 17:58:56 +0100" MODIFIED_BY="[Empty name]" ORDER="293" SD_1="3.1" SD_2="3.11" SE="0.2828586608866122" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009" TOTAL_1="240" TOTAL_2="242" WEIGHT="33.40291915440006"/>
<CONT_DATA CI_END="1.8310230674005101" CI_START="0.16897693259948976" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="-2.0" MODIFIED="2009-12-30 17:58:56 +0100" MODIFIED_BY="[Empty name]" ORDER="294" SD_1="4.0" SD_2="4.0" SE="0.423999152002544" STUDY_ID="STD-L-_x002d_-LEAD-4-Zinman-2009" TOTAL_1="178" TOTAL_2="178" WEIGHT="14.865975352196411"/>
<CONT_DATA CI_END="1.2683588454539692" CI_START="-0.22835884545396912" EFFECT_SIZE="0.52" ESTIMABLE="YES" MEAN_1="-2.86" MEAN_2="-3.38" MODIFIED="2011-05-04 16:29:13 +0200" MODIFIED_BY="[Empty name]" ORDER="358" SD_1="4.01" SD_2="3.99" SE="0.3818227535592124" STUDY_ID="STD-L-_x002d_-Pratley-2010" TOTAL_1="221" TOTAL_2="218" WEIGHT="18.33157474122543"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.6299384271879194" CI_END="1.0352855089846846" CI_START="-1.480102353008379" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.22240842201184724" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.04" MODIFIED="2011-08-30 14:49:00 +0200" MODIFIED_BY="Bernd Richter" NO="4" P_CHI2="0.8895457485435645" P_Q="1.0" P_Z="0.7288943673463731" Q="0.0" RANDOM="YES" SCALE="8.71" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="867" TOTAL_2="872" UNITS="" WEIGHT="100.0" Z="0.3465966450646792">
<NAME>Systolic blood pressure</NAME>
<GROUP_LABEL_1>Liraglutide 1.2 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Liraglutide 1.8 mg daily</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide 1.2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Liraglutide 1.8</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.619918444512561" CI_START="-2.119918444512561" EFFECT_SIZE="0.25" ESTIMABLE="YES" MEAN_1="-2.56" MEAN_2="-2.81" MODIFIED="2009-12-30 17:59:27 +0100" MODIFIED_BY="[Empty name]" ORDER="295" SD_1="12.83" SD_2="13.16" SE="1.2091642822042523" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009" TOTAL_1="228" TOTAL_2="234" WEIGHT="28.16327322554146"/>
<CONT_DATA CI_END="1.8221128061751615" CI_START="-2.8621128061751615" EFFECT_SIZE="-0.52" ESTIMABLE="YES" MEAN_1="-2.81" MEAN_2="-2.29" MODIFIED="2009-12-30 17:59:27 +0100" MODIFIED_BY="[Empty name]" ORDER="296" SD_1="13.32" SD_2="12.91" SE="1.194977471346131" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009" TOTAL_1="240" TOTAL_2="242" WEIGHT="28.835953267822063"/>
<CONT_DATA CI_END="1.949854657359872" CI_START="-4.149854657359873" EFFECT_SIZE="-1.1000000000000005" ESTIMABLE="YES" MEAN_1="-6.7" MEAN_2="-5.6" MODIFIED="2009-12-30 17:59:27 +0100" MODIFIED_BY="[Empty name]" ORDER="297" SD_1="14.68" SD_2="14.68" SE="1.5560768878493365" STUDY_ID="STD-L-_x002d_-LEAD-4-Zinman-2009" TOTAL_1="178" TOTAL_2="178" WEIGHT="17.005587641284098"/>
<CONT_DATA CI_END="2.6367691121919172" CI_START="-2.2967691121919174" EFFECT_SIZE="0.16999999999999993" ESTIMABLE="YES" MEAN_1="-0.55" MEAN_2="-0.72" MODIFIED="2011-05-04 16:30:49 +0200" MODIFIED_BY="[Empty name]" ORDER="360" SD_1="13.23" SD_2="13.14" SE="1.2585787961663975" STUDY_ID="STD-L-_x002d_-Pratley-2010" TOTAL_1="221" TOTAL_2="218" WEIGHT="25.995185865352383"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2011-08-30 14:49:57 +0200" MODIFIED_BY="Bernd Richter" NO="10">
<NAME>Liraglutide versus insulin glargine</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.008937226496939316" CI_START="-0.48893722649693927" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.24" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-010.01" MODIFIED="2011-08-30 14:49:15 +0200" MODIFIED_BY="Bernd Richter" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.05881170670722305" Q="0.0" RANDOM="YES" SCALE="1.65" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="230" TOTAL_2="232" UNITS="" WEIGHT="0.0" Z="1.8895982851138435">
<NAME>HbA1c</NAME>
<GROUP_LABEL_1>Liraglutide 1.8 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin glargine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Insulin glargine</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.008937226496939316" CI_START="-0.48893722649693927" EFFECT_SIZE="-0.24" ESTIMABLE="YES" MEAN_1="-1.33" MEAN_2="-1.09" MODIFIED="2009-11-27 20:09:19 +0100" MODIFIED_BY="[Empty name]" ORDER="59" SD_1="1.36" SD_2="1.37" SE="0.12701112288823896" STUDY_ID="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009" TOTAL_1="230" TOTAL_2="232" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3977927201754339" CI_START="0.9642406898581467" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1609515996718622" ESTIMABLE="NO" EVENTS_1="122" EVENTS_2="106" I2="0.0" I2_Q="0.0" ID="CMP-010.02" LOG_CI_END="0.1454427743007251" LOG_CI_START="-0.015814545734155548" LOG_EFFECT_SIZE="0.0648141142832848" METHOD="MH" MODIFIED="2011-08-30 14:49:23 +0200" MODIFIED_BY="Bernd Richter" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.11513285227348423" Q="0.0" RANDOM="YES" SCALE="3.12" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="230" TOTAL_2="232" WEIGHT="0.0" Z="1.5755356675606842">
<NAME>HbA1c &lt; 7%</NAME>
<GROUP_LABEL_1>Liraglutide 1.8 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin glargine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Insulin glargine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Liraglutide</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3977927201754339" CI_START="0.9642406898581467" EFFECT_SIZE="1.1609515996718622" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="106" LOG_CI_END="0.1454427743007251" LOG_CI_START="-0.015814545734155548" LOG_EFFECT_SIZE="0.0648141142832848" MODIFIED="2010-01-11 16:20:18 +0100" MODIFIED_BY="[Empty name]" ORDER="68" O_E="0.0" SE="0.09472334802509688" STUDY_ID="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009" TOTAL_1="230" TOTAL_2="232" VAR="0.008972512661083626" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3938879582084263" CI_START="0.6192108725537793" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9290374474930736" ESTIMABLE="NO" EVENTS_1="63" EVENTS_2="67" I2="0.0" I2_Q="0.0" ID="CMP-010.03" LOG_CI_END="0.1442278662387482" LOG_CI_START="-0.20816142660059161" LOG_EFFECT_SIZE="-0.03196678018092171" METHOD="MH" MODIFIED="2011-08-30 14:49:30 +0200" MODIFIED_BY="Bernd Richter" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.7221447286347051" Q="0.0" RANDOM="YES" SCALE="8.51" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="230" TOTAL_2="232" WEIGHT="0.0" Z="0.3555938794365142">
<NAME>Hypoglycaemia</NAME>
<GROUP_LABEL_1>Liraglutide 1.8 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin glargine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Insulin glargine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3938879582084263" CI_START="0.6192108725537793" EFFECT_SIZE="0.9290374474930736" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="67" LOG_CI_END="0.1442278662387482" LOG_CI_START="-0.20816142660059161" LOG_EFFECT_SIZE="-0.03196678018092171" MODIFIED="2009-11-27 20:53:43 +0100" MODIFIED_BY="[Empty name]" ORDER="82" O_E="0.0" SE="0.20699521496896034" STUDY_ID="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009" TOTAL_1="230" TOTAL_2="232" VAR="0.0428470190200461" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-2.485405837747103" CI_START="-4.314594162252898" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.4000000000000004" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-010.04" MODIFIED="2011-08-30 14:49:38 +0200" MODIFIED_BY="Bernd Richter" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="3.189190037627674E-13" Q="0.0" RANDOM="YES" SCALE="5.67" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="230" TOTAL_2="232" UNITS="" WEIGHT="0.0" Z="7.286157973085264">
<NAME>Weight change</NAME>
<GROUP_LABEL_1>Liraglutide 1.8 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin glargine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Insulin glargine</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.485405837747103" CI_START="-4.314594162252898" EFFECT_SIZE="-3.4000000000000004" ESTIMABLE="YES" MEAN_1="-1.8" MEAN_2="1.6" MODIFIED="2009-11-27 21:04:52 +0100" MODIFIED_BY="[Empty name]" ORDER="91" SD_1="5.0" SD_2="5.03" SE="0.46663824920615854" STUDY_ID="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009" TOTAL_1="230" TOTAL_2="232" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-010.05" MODIFIED="2011-06-30 13:10:29 +0200" MODIFIED_BY="[Empty name]" NO="5" ROWS_PER_STUDY="9" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Adverse events</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.8 mg daily</P>
</TH>
<TH>
<P>Insulin glargine</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2010-01-04 13:52:18 +0100" MODIFIED_BY="[Empty name]" ORDER="1318" STUDY_ID="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009">
<TR>
<TD>
<P>withdrawal due to adverse events</P>
</TD>
<TD>
<P>5%</P>
</TD>
<TD>
<P>2%</P>
</TD>
</TR>
<TR>
<TD>
<P>no significant differences across groups for: nasopharyngitis, headache; no pancreatitis</P>
</TD>
<TD/>
<TD/>
</TR>
<TR>
<TD>
<P>nausea</P>
</TD>
<TD>
<P>13.9%</P>
</TD>
<TD>
<P>1.3%</P>
</TD>
</TR>
<TR>
<TD>
<P>diarrhoea</P>
</TD>
<TD>
<P>10.%</P>
</TD>
<TD>
<P>1.3%</P>
</TD>
</TR>
<TR>
<TD>
<P>dyspepsia</P>
</TD>
<TD>
<P>6.5%</P>
</TD>
<TD>
<P>1.7%</P>
</TD>
</TR>
<TR>
<TD>
<P>vomiting</P>
</TD>
<TD>
<P>6.5%</P>
</TD>
<TD>
<P>0.4%</P>
</TD>
</TR>
<TR>
<TD>
<P>serious adverse events</P>
</TD>
<TD>
<P>4%</P>
</TD>
<TD>
<P>7%</P>
</TD>
</TR>
<TR>
<TD>
<P>injection site reactions</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>anti-liraglutide antibodies</P>
</TD>
<TD>
<P>9.8% (no effect on HbA1c)</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.9089725870782828" CI_START="-8.171027412921717" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.54" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-010.06" MODIFIED="2011-08-30 14:49:49 +0200" MODIFIED_BY="Bernd Richter" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.014261389954123155" Q="0.0" RANDOM="YES" SCALE="12.76" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="230" TOTAL_2="232" UNITS="" WEIGHT="0.0" Z="2.4506112121725496">
<NAME>Systolic blood pressure</NAME>
<GROUP_LABEL_1>Liraglutide 1.8 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin glargine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Insulin glargine</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.9089725870782828" CI_START="-8.171027412921717" EFFECT_SIZE="-4.54" ESTIMABLE="YES" MEAN_1="-4.0" MEAN_2="0.54" MODIFIED="2009-11-30 15:28:23 +0100" MODIFIED_BY="[Empty name]" ORDER="103" SD_1="19.87" SD_2="19.95" SE="1.8525990485349721" STUDY_ID="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009" TOTAL_1="230" TOTAL_2="232" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.8217656722849095" CI_START="-0.3417656722849095" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.24" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-010.07" MODIFIED="2011-08-30 14:49:57 +0200" MODIFIED_BY="Bernd Richter" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.4187693718914317" Q="0.0" RANDOM="YES" SCALE="1.93" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="230" TOTAL_2="232" UNITS="" WEIGHT="0.0" Z="0.8085581166075525">
<NAME>Fasting plasma glucose (mmol/L)</NAME>
<GROUP_LABEL_1>Liraglutide 1.8 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin glargine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Insulin glargine</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.8217656722849095" CI_START="-0.3417656722849095" EFFECT_SIZE="0.24" ESTIMABLE="YES" MEAN_1="-1.55" MEAN_2="-1.79" MODIFIED="2009-11-30 15:49:34 +0100" MODIFIED_BY="[Empty name]" ORDER="113" SD_1="3.18" SD_2="3.2" SE="0.296824674776579" STUDY_ID="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009" TOTAL_1="230" TOTAL_2="232" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-010.08" MODIFIED="2011-06-30 13:12:01 +0200" MODIFIED_BY="[Empty name]" NO="8" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Post-prandial glucose (mmol/L)</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.8 mg daily</P>
</TH>
<TH>
<P>Insulin glargine</P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2009-11-30 16:44:56 +0100" MODIFIED_BY="[Empty name]" ORDER="1321" STUDY_ID="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009">
<TR>
<TD>
<P>from self-monitored 7-point plasma glucose measurements</P>
</TD>
<TD>
<P>-1.81 mmol/L</P>
</TD>
<TD>
<P>-1.61 mmol/L</P>
</TD>
<TD>
<P>no significant difference</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-010.09" MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" NO="9" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Beta-cell function</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.8 mg</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" ORDER="1322" STUDY_ID="STD-L-_x002d_-LEAD-5-Russell_x002d_J-2009">
<TR>
<TD>
<P>proinsulin-to-C-peptide ratio</P>
</TD>
<TD>
<P>-0.00366 (95% CI -0.0057 to -0.00136, P = 0.0019) versus insulin glargine;</P>
<P>-0.00671 (95% CI -0.00964 to -0.00377, P &lt; 0.0001) versus placebo</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2011-08-30 14:51:16 +0200" MODIFIED_BY="Bernd Richter" NO="11">
<NAME>Liraglutide 1.2 mg daily versus thiazolidinedione</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-011.01" MODIFIED="2011-08-30 14:50:34 +0200" MODIFIED_BY="Bernd Richter" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="0.87" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="228" TOTAL_2="232" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>HbA1c (%)</NAME>
<GROUP_LABEL_1>Liraglutide 1.2 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Rosiglitazone 4 mg QD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Rosiglitazone QD</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.44625903606786804" CI_START="-0.8337409639321323" EFFECT_SIZE="-0.6400000000000001" ESTIMABLE="YES" MEAN_1="-1.08" MEAN_2="-0.44" MODIFIED="2011-06-30 13:15:04 +0200" MODIFIED_BY="[Empty name]" ORDER="378" SD_1="1.06" SD_2="1.06" SE="0.09884924695572779" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009" TOTAL_1="228" TOTAL_2="232" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.1543379499368065" CI_START="1.182584182085248" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5961472308221534" ESTIMABLE="NO" EVENTS_1="80" EVENTS_2="51" I2="0.0" I2_Q="0.0" ID="CMP-011.02" LOG_CI_END="0.33331383186830443" LOG_CI_START="0.07283206570060172" LOG_EFFECT_SIZE="0.2030729487844531" METHOD="MH" MODIFIED="2011-08-30 14:50:41 +0200" MODIFIED_BY="Bernd Richter" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0022431397207059163" Q="0.0" RANDOM="YES" SCALE="3.74" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="228" TOTAL_2="232" WEIGHT="0.0" Z="3.0559963694013463">
<NAME>HbA1c &lt; 7%</NAME>
<GROUP_LABEL_1>Liraglutide 1.2 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Rosiglitazone 4 mg QD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Rosiglitazone QD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Liraglutide</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1543379499368065" CI_START="1.182584182085248" EFFECT_SIZE="1.5961472308221534" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="51" LOG_CI_END="0.33331383186830443" LOG_CI_START="0.07283206570060172" LOG_EFFECT_SIZE="0.2030729487844531" MODIFIED="2011-06-30 13:15:14 +0200" MODIFIED_BY="[Empty name]" ORDER="379" O_E="0.0" SE="0.1530082788524464" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009" TOTAL_1="228" TOTAL_2="232" VAR="0.02341153339738799" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.436445712722473" CI_START="1.0292234997334053" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.136842105263158" ESTIMABLE="NO" EVENTS_1="21" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-011.03" LOG_CI_END="0.6470351715735857" LOG_CI_START="0.012509693675144658" LOG_EFFECT_SIZE="0.3297724326243652" METHOD="MH" MODIFIED="2011-08-30 14:50:49 +0200" MODIFIED_BY="Bernd Richter" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.04162544512323062" Q="0.0" RANDOM="YES" SCALE="28.75" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="228" TOTAL_2="232" WEIGHT="0.0" Z="2.037245511964667">
<NAME>Hypoglycaemia (mild/moderate/overall)</NAME>
<GROUP_LABEL_1>Liraglutide 1.2 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Rosiglitazone 4 mg QD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Rosiglitazone QD</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.436445712722473" CI_START="1.0292234997334053" EFFECT_SIZE="2.136842105263158" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="10" LOG_CI_END="0.6470351715735857" LOG_CI_START="0.012509693675144658" LOG_EFFECT_SIZE="0.3297724326243652" MODIFIED="2011-06-30 13:15:29 +0200" MODIFIED_BY="[Empty name]" ORDER="380" O_E="0.0" SE="0.3727234066693165" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009" TOTAL_1="228" TOTAL_2="232" VAR="0.13892273787918072" WEIGHT="0.0"/>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-011.04" MODIFIED="2011-06-30 13:15:49 +0200" MODIFIED_BY="[Empty name]" NO="4" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Severe hypoglycaemia</NAME>
<TR>
<TH>
<P>Liraglutide 1.2 mg daily</P>
</TH>
<TH>
<P>Rosiglitazone 4 mg QD</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-06-30 13:15:49 +0200" MODIFIED_BY="[Empty name]" ORDER="1326" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009">
<TR>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-1.2452964752856455" CI_START="-2.3547035247143544" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.8" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-011.05" MODIFIED="2011-08-30 14:51:02 +0200" MODIFIED_BY="Bernd Richter" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="2.0170460980804583E-10" Q="0.0" RANDOM="YES" SCALE="4.82" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="228" TOTAL_2="232" UNITS="" WEIGHT="0.0" Z="6.3600374163636575">
<NAME>Weight change</NAME>
<GROUP_LABEL_1>Liraglutide 1.2 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Rosiglitazone 4 mg QD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Rosiglitazone QD</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.2452964752856455" CI_START="-2.3547035247143544" EFFECT_SIZE="-1.8" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="2.1" MODIFIED="2011-06-30 13:16:22 +0200" MODIFIED_BY="[Empty name]" ORDER="382" SD_1="3.02" SD_2="3.05" SE="0.283017202912801" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009" TOTAL_1="228" TOTAL_2="232" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-011.06" MODIFIED="2011-06-30 13:16:55 +0200" MODIFIED_BY="[Empty name]" NO="6" ROWS_PER_STUDY="10" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Adverse events</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.2 mg daily</P>
</TH>
<TH>
<P>Rosiglitazone 4 mg QD</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-06-30 13:16:55 +0200" MODIFIED_BY="[Empty name]" ORDER="1328" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009">
<TR>
<TD>
<P>withdrawal due to adverse events</P>
</TD>
<TD>
<P>11 (5%)</P>
</TD>
<TD>
<P>7 (3%)</P>
</TD>
</TR>
<TR>
<TD>
<P>overall adverse events</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>nausea</P>
</TD>
<TD>
<P>24 (10.5%)</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>vomiting</P>
</TD>
<TD>
<P>10 (4.4%)</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>diarrhoea</P>
</TD>
<TD>
<P>18 (7.9%)</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>serious adverse events (mostly judged to be unlikely to be related to study medication)</P>
</TD>
<TD>
<P>9 (4%)</P>
</TD>
<TD>
<P>7 (3%)</P>
</TD>
</TR>
<TR>
<TD>
<P>liraglutide auto-antibodies</P>
</TD>
<TD>
<P>9 to 13%, no effect on HbA1c</P>
</TD>
<TD/>
</TR>
<TR>
<TD>
<P>deaths</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>None</P>
</TD>
</TR>
<TR>
<TD>
<P>pancreatitis</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>None</P>
</TD>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-011.07" MODIFIED="2011-08-30 13:58:16 +0200" MODIFIED_BY="Bernd Richter" NO="7" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Systolic blood pressure (mm Hg)</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.2 mg daily</P>
</TH>
<TH>
<P>Rosiglitazone 4 mg QD</P>
</TH>
<TH>
<P>p values</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:27:51 +0200" MODIFIED_BY="Bernd Richter" ORDER="1329" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009">
<TR>
<TD>
<P>Change from baseline</P>
</TD>
<TD>
<P>-2.6 to -2.8</P>
</TD>
<TD>
<P>0.9 to 2.3</P>
</TD>
<TD>
<P>P = NS between groups</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-011.08" MODIFIED="2011-08-30 13:58:16 +0200" MODIFIED_BY="Bernd Richter" NO="8" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Diastolic blood pressure (mm Hg)</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.2 mg daily</P>
</TH>
<TH>
<P>Rosiglitazone 4 mg QD</P>
</TH>
<TH>
<P>p values</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:27:51 +0200" MODIFIED_BY="Bernd Richter" ORDER="1330" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009">
<TR>
<TD>
<P>Change from baseline</P>
</TD>
<TD>
<P>-0.7 to -1.4</P>
</TD>
<TD>
<P>-0.7 to -1.4</P>
</TD>
<TD>
<P>P = NS between groups</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.24587011171824108" CI_START="-1.134129888281759" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6900000000000001" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-011.09" MODIFIED="2011-08-30 14:51:16 +0200" MODIFIED_BY="Bernd Richter" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.002326809378631656" Q="0.0" RANDOM="YES" SCALE="2.27" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="228" TOTAL_2="232" UNITS="" WEIGHT="0.0" Z="3.0449991883335756">
<NAME>Fasting plasma glucose (mmol/L)</NAME>
<GROUP_LABEL_1>Liraglutide 1.2 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Rosiglitazone 4 mg QD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Rosiglitazone QD</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.24587011171824108" CI_START="-1.134129888281759" EFFECT_SIZE="-0.6900000000000001" ESTIMABLE="YES" MEAN_1="-1.57" MEAN_2="-0.88" MODIFIED="2011-06-30 13:18:01 +0200" MODIFIED_BY="[Empty name]" ORDER="386" SD_1="2.42" SD_2="2.44" SE="0.22660104562379657" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009" TOTAL_1="228" TOTAL_2="232" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-011.10" MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" NO="10" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Post-prandial glucose (mmol/L)</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.2 mg daily</P>
</TH>
<TH>
<P>Rosiglitazone 4 mg QD</P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" ORDER="1332" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009">
<TR>
<TD>
<P>average of values obtained 90 min after breakfast, lunch and evening meal</P>
</TD>
<TD>
<P>-2.5 mmol/L</P>
</TD>
<TD>
<P>-1.8 mmol/L</P>
</TD>
<TD>
<P>P = 0.043 1.2 mg versus rosiglitazone </P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-011.11" MODIFIED="2011-06-30 13:19:22 +0200" MODIFIED_BY="[Empty name]" NO="11" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Beta-cell function</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.2 mg</P>
</TH>
<TH>
<P>TZD</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-06-30 13:19:22 +0200" MODIFIED_BY="[Empty name]" ORDER="1333" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009">
<TR>
<TD>
<P>HOMA-B (%)</P>
</TD>
<TD>
<P>99% SE 184.3 (+28%)</P>
</TD>
<TD>
<P>59% SE 63.3 (+13%)</P>
</TD>
</TR>
<TR>
<TD>
<P>proinsulin-to-insulin ratio</P>
</TD>
<TD>
<P>0.33 SE 0.2 (-0.12)</P>
</TD>
<TD>
<P>0.40 SE 0.2 (-0.05)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" MODIFIED="2011-08-30 14:52:29 +0200" MODIFIED_BY="Bernd Richter" NO="12">
<NAME>Liraglutide 1.8 mg daily versus thiazolidinedione</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-012.01" MODIFIED="2011-08-30 14:51:49 +0200" MODIFIED_BY="Bernd Richter" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.28" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="234" TOTAL_2="232" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>HbA1c (%)</NAME>
<GROUP_LABEL_1>Liraglutide 1.8 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Rosiglitazone 4 mg QD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Rosiglitazone QD</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.4966096624747057" CI_START="-0.8833903375252942" EFFECT_SIZE="-0.69" ESTIMABLE="YES" MEAN_1="-1.13" MEAN_2="-0.44" MODIFIED="2011-06-30 13:19:50 +0200" MODIFIED_BY="[Empty name]" ORDER="389" SD_1="1.07" SD_2="1.06" SE="0.098670352644606" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009" TOTAL_1="234" TOTAL_2="232" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="98" EVENTS_2="51" I2="0.0" I2_Q="0.0" ID="CMP-012.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-30 14:51:57 +0200" MODIFIED_BY="Bernd Richter" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="9.49" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="234" TOTAL_2="232" WEIGHT="0.0" Z="0.0">
<NAME>HbA1c &lt; 7%</NAME>
<GROUP_LABEL_1>Liraglutide 1.8 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Rosiglitazone 4 mg QD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Rosiglitazone QD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Liraglutide</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.534818578933355" CI_START="1.4318884057027184" EFFECT_SIZE="1.9051449639684934" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="51" LOG_CI_END="0.4039468816229455" LOG_CI_START="0.15590917252768516" LOG_EFFECT_SIZE="0.27992802707531533" MODIFIED="2011-06-30 13:20:44 +0200" MODIFIED_BY="[Empty name]" ORDER="390" O_E="0.0" SE="0.1456985781290177" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009" TOTAL_1="234" TOTAL_2="232" VAR="0.02122807566881748" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="19" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-012.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-30 14:52:04 +0200" MODIFIED_BY="Bernd Richter" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="234" TOTAL_2="232" WEIGHT="0.0" Z="0.0">
<NAME>Hypoglycaemia</NAME>
<GROUP_LABEL_1>Liraglutide 1.8 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Rosiglitazone 4 mg QD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Rosiglitazone QD</GRAPH_LABEL_2>
<DICH_DATA CI_END="636.6874868989903" CI_START="2.3484375561973194" EFFECT_SIZE="38.66808510638298" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="0" LOG_CI_END="2.8039263145660223" LOG_CI_START="0.3707790169955417" LOG_EFFECT_SIZE="1.587352665780782" MODIFIED="2011-06-30 13:21:20 +0200" MODIFIED_BY="[Empty name]" ORDER="391" O_E="0.0" SE="1.4292427668662706" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009" TOTAL_1="234" TOTAL_2="232" VAR="2.0427348866395527" WEIGHT="0.0"/>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-012.04" MODIFIED="2011-06-30 13:21:45 +0200" MODIFIED_BY="[Empty name]" NO="4" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Severe hypoglycaemia</NAME>
<TR>
<TH>
<P>Liraglutide 1.8 mg daily</P>
</TH>
<TH>
<P>Rosiglitazone 4 mg QD</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-06-30 13:21:45 +0200" MODIFIED_BY="[Empty name]" ORDER="1337" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009">
<TR>
<TD>
<P>1</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-012.05" MODIFIED="2011-08-30 14:52:15 +0200" MODIFIED_BY="Bernd Richter" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.51" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="234" TOTAL_2="232" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Weight change (kg)</NAME>
<GROUP_LABEL_1>Liraglutide 1.8 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Rosiglitazone 4 mg QD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Rosiglitazone QD</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.7452492809418265" CI_START="-2.854750719058174" EFFECT_SIZE="-2.3000000000000003" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="2.1" MODIFIED="2011-06-30 13:22:08 +0200" MODIFIED_BY="[Empty name]" ORDER="393" SD_1="3.06" SD_2="3.05" SE="0.2830412821021084" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009" TOTAL_1="234" TOTAL_2="232" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-012.06" MODIFIED="2011-06-30 13:22:42 +0200" MODIFIED_BY="[Empty name]" NO="6" ROWS_PER_STUDY="9" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Adverse events</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.8 mg daily</P>
</TH>
<TH>
<P>Rosiglitazone 4 mg QD</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-06-30 13:22:42 +0200" MODIFIED_BY="[Empty name]" ORDER="1339" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009">
<TR>
<TD>
<P>withdrawal due to adverse events</P>
</TD>
<TD>
<P>9 (4%)</P>
</TD>
<TD>
<P>7 (3%)</P>
</TD>
</TR>
<TR>
<TD>
<P>overall adverse events</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>nausea</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>vomiting</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD/>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>serious adverse events (mostly judged to be unlikely to be related to study medication)</P>
</TD>
<TD>
<P>12 (5%)</P>
</TD>
<TD>
<P>7 (3%)</P>
</TD>
</TR>
<TR>
<TD>
<P>liraglutide auto-antibodies</P>
</TD>
<TD>
<P>9 to 13%, no effect on HbA1c</P>
</TD>
<TD/>
</TR>
<TR>
<TD>
<P>deaths</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>None</P>
</TD>
</TR>
<TR>
<TD>
<P>pancreatitis</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>None</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-012.07" MODIFIED="2011-08-30 13:58:16 +0200" MODIFIED_BY="Bernd Richter" NO="7" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Systolic blood pressure (mm Hg)</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.8 mg daily</P>
</TH>
<TH>
<P>Rosiglitazone 4 mg QD</P>
</TH>
<TH>
<P>p values</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:27:51 +0200" MODIFIED_BY="Bernd Richter" ORDER="1340" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009">
<TR>
<TD>
<P>Change from baseline</P>
</TD>
<TD>
<P>-2.6 to -2.8</P>
</TD>
<TD>
<P>0.9 to 2.3</P>
</TD>
<TD>
<P>P = NS between groups</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-012.08" MODIFIED="2011-08-30 13:58:16 +0200" MODIFIED_BY="Bernd Richter" NO="8" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Diastolic blood pressure (mm Hg)</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.8 mg daily</P>
</TH>
<TH>
<P>Rosiglitazone 4 mg QD</P>
</TH>
<TH>
<P>p values</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:27:51 +0200" MODIFIED_BY="Bernd Richter" ORDER="1341" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009">
<TR>
<TD>
<P>Change from baseline</P>
</TD>
<TD>
<P>-0.7 to 1.4</P>
</TD>
<TD>
<P>-0.7 to -1.4</P>
</TD>
<TD>
<P>P = NS between groups</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-012.09" MODIFIED="2011-08-30 14:52:28 +0200" MODIFIED_BY="Bernd Richter" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.51" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="234" TOTAL_2="232" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Fasting plasma glucose (mmol/L)</NAME>
<GROUP_LABEL_1>Liraglutide 1.8 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Rosiglitazone 4 mg QD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Rosiglitazone QD</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.266018281308874" CI_START="-1.153981718691126" EFFECT_SIZE="-0.7100000000000001" ESTIMABLE="YES" MEAN_1="-1.59" MEAN_2="-0.88" MODIFIED="2011-06-30 13:23:50 +0200" MODIFIED_BY="[Empty name]" ORDER="397" SD_1="2.45" SD_2="2.44" SE="0.22652544750474865" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009" TOTAL_1="234" TOTAL_2="232" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-012.10" MODIFIED="2011-08-30 14:52:29 +0200" MODIFIED_BY="Bernd Richter" NO="10" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Post-prandial glucose (mmol/L)</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.8 mg daily</P>
</TH>
<TH>
<P>Rosiglitazone 4 mg QD</P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" ORDER="1343" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009">
<TR>
<TD>
<P>average of values obtained 90 min after breakfast, lunch and evening meal</P>
</TD>
<TD>
<P>-2.7 mmol/L</P>
</TD>
<TD>
<P>-1.8 mmol/L</P>
</TD>
<TD>
<P>P = 0.0022 1.8 mg versus rosiglitazone</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-012.11" MODIFIED="2011-06-30 13:42:41 +0200" MODIFIED_BY="[Empty name]" NO="11" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Beta-cell function</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.8 mg daily</P>
</TH>
<TH>
<P>Rosiglitazone 4 mg QD</P>
</TH>
<TH>
<P>Difference between groups</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-06-30 13:42:41 +0200" MODIFIED_BY="[Empty name]" ORDER="1344" STUDY_ID="STD-L-_x002d_-LEAD-1-Marre-2009">
<TR>
<TD>
<P>HOMA-B (%)</P>
</TD>
<TD>
<P>91% SE 108.2 (+35%)</P>
</TD>
<TD>
<P>59% SE 63.3 (+13%)</P>
</TD>
<TD>
<P>30, 95% CI 2.00 to 58.6, p &#8804; 0.05</P>
</TD>
</TR>
<TR>
<TD>
<P>proinsulin-to-insulin ratio</P>
</TD>
<TD>
<P>0.36 SE 0.2 (-0.12)</P>
</TD>
<TD>
<P>0.40 SE 0.2 (-0.05)</P>
</TD>
<TD>
<P>-0.05, 95% CI -0.10 to -0.01, p &#8804; 0.05</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" MODIFIED="2011-08-30 14:53:43 +0200" MODIFIED_BY="Bernd Richter" NO="13">
<NAME>Liraglutide 1.2 mg daily versus DPP-4 inhibitors</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.14564774932356694" CI_START="-0.534352250676433" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.33999999999999997" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-013.01" MODIFIED="2011-08-30 14:52:59 +0200" MODIFIED_BY="Bernd Richter" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="6.063393407490243E-4" Q="0.0" RANDOM="YES" SCALE="1.42" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="221" TOTAL_2="219" UNITS="" WEIGHT="0.0" Z="3.428762735827808">
<NAME>HbA1c (%)</NAME>
<GROUP_LABEL_1>Liraglutide 1.2 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Sitagliptin 100 mg daily</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Sitagliptin</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.14564774932356694" CI_START="-0.534352250676433" EFFECT_SIZE="-0.33999999999999997" ESTIMABLE="YES" MEAN_1="-1.24" MEAN_2="-0.9" MODIFIED="2011-06-08 17:46:50 +0200" MODIFIED_BY="[Empty name]" ORDER="360" SD_1="1.04" SD_2="1.04" SE="0.0991611336787098" STUDY_ID="STD-L-_x002d_-Pratley-2010" TOTAL_1="221" TOTAL_2="219" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.3730857742431217" CI_START="1.9428407003109223" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.559954751131222" ESTIMABLE="NO" EVENTS_1="124" EVENTS_2="48" I2="0.0" I2_Q="0.0" ID="CMP-013.02" LOG_CI_END="0.528027385009789" LOG_CI_START="0.2884371928735221" LOG_EFFECT_SIZE="0.40823228894165553" METHOD="MH" MODIFIED="2011-08-30 14:53:06 +0200" MODIFIED_BY="Bernd Richter" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="2.4045300346550453E-11" Q="0.0" RANDOM="YES" SCALE="6.58" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="221" TOTAL_2="219" WEIGHT="0.0" Z="6.679076272011381">
<NAME>HbA1c &lt; 7%</NAME>
<GROUP_LABEL_1>Liraglutide 1.2 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Sitagliptin 100 mg daily</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Sitagliptin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Liraglutide</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.3730857742431217" CI_START="1.9428407003109218" EFFECT_SIZE="2.5599547511312215" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="48" LOG_CI_END="0.528027385009789" LOG_CI_START="0.288437192873522" LOG_EFFECT_SIZE="0.4082322889416555" MODIFIED="2011-06-08 17:47:31 +0200" MODIFIED_BY="[Empty name]" ORDER="361" O_E="0.0" SE="0.14073646485142163" STUDY_ID="STD-L-_x002d_-Pratley-2010" TOTAL_1="221" TOTAL_2="219" VAR="0.019806752538875434" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.694911265338961" CI_START="0.5247128554747031" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1891402714932127" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-013.03" LOG_CI_END="0.4305444698537095" LOG_CI_START="-0.28007829544844454" LOG_EFFECT_SIZE="0.07523308720263247" METHOD="MH" MODIFIED="2011-08-30 14:53:13 +0200" MODIFIED_BY="Bernd Richter" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.6781420740519986" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="221" TOTAL_2="219" WEIGHT="0.0" Z="0.4149997679858285">
<NAME>Hypoglycaemia (mild/moderate/overall)</NAME>
<GROUP_LABEL_1>Liraglutide 1.2 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Sitagliptin 100 mg daily</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Sitagliptin</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.694911265338961" CI_START="0.5247128554747031" EFFECT_SIZE="1.1891402714932127" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.4305444698537095" LOG_CI_START="-0.28007829544844454" LOG_EFFECT_SIZE="0.07523308720263247" MODIFIED="2011-06-08 17:48:27 +0200" MODIFIED_BY="[Empty name]" ORDER="362" O_E="0.0" SE="0.41742332997790527" STUDY_ID="STD-L-_x002d_-Pratley-2010" TOTAL_1="221" TOTAL_2="219" VAR="0.17424223640984318" WEIGHT="0.0"/>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-013.04" MODIFIED="2011-06-30 13:44:33 +0200" MODIFIED_BY="[Empty name]" NO="4" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Severe hypoglycaemia</NAME>
<TR>
<TH>
<P>Liraglutide 1.2 mg daily</P>
</TH>
<TH>
<P>Sitagliptin 100 mg daily</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-06-08 17:49:40 +0200" MODIFIED_BY="[Empty name]" ORDER="1348" STUDY_ID="STD-L-_x002d_-Pratley-2010">
<TR>
<TD>
<P>1 (0.45%)</P>
</TD>
<TD>
<P>None</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-1.1515606216868042" CI_START="-2.6484393783131956" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.9" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-013.05" MODIFIED="2011-08-30 14:53:23 +0200" MODIFIED_BY="Bernd Richter" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="6.504736919686774E-7" Q="0.0" RANDOM="YES" SCALE="6.78" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="221" TOTAL_2="219" UNITS="" WEIGHT="0.0" Z="4.975595457068225">
<NAME>Weight change (kg)</NAME>
<GROUP_LABEL_1>Liraglutide 1.2 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Sitagliptin 100 mg daily</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Sitagliptin</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.1515606216868042" CI_START="-2.6484393783131956" EFFECT_SIZE="-1.9" ESTIMABLE="YES" MEAN_1="-2.86" MEAN_2="-0.96" MODIFIED="2011-06-08 17:50:11 +0200" MODIFIED_BY="[Empty name]" ORDER="364" SD_1="4.01" SD_2="4.0" SE="0.3818638425077144" STUDY_ID="STD-L-_x002d_-Pratley-2010" TOTAL_1="221" TOTAL_2="219" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-013.06" MODIFIED="2011-06-30 13:45:05 +0200" MODIFIED_BY="[Empty name]" NO="6" ROWS_PER_STUDY="10" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Adverse events</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.2 mg daily</P>
</TH>
<TH>
<P>Sitagliptin 100 mg daily</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-06-30 13:45:05 +0200" MODIFIED_BY="[Empty name]" ORDER="1350" STUDY_ID="STD-L-_x002d_-Pratley-2010">
<TR>
<TD>
<P>withdrawal due to adverse events</P>
</TD>
<TD>
<P>14 (6.3%)</P>
</TD>
<TD>
<P>4 (1.8%)</P>
</TD>
</TR>
<TR>
<TD>
<P>overall adverse events</P>
</TD>
<TD>
<P>146 (66%)</P>
</TD>
<TD>
<P>127 (58%)</P>
</TD>
</TR>
<TR>
<TD>
<P>nausea</P>
</TD>
<TD>
<P>46 (21%)</P>
</TD>
<TD>
<P>10 (5%)</P>
</TD>
</TR>
<TR>
<TD>
<P>vomiting</P>
</TD>
<TD>
<P>17 (8%)</P>
</TD>
<TD>
<P>9 (4%)</P>
</TD>
</TR>
<TR>
<TD>
<P>diarrhoea</P>
</TD>
<TD>
<P>16 (7%)</P>
</TD>
<TD>
<P>10 (5%)</P>
</TD>
</TR>
<TR>
<TD>
<P>other gastrointestinal adverse events</P>
</TD>
<TD>
<P>17 (8%)</P>
</TD>
<TD>
<P>6 (3%)</P>
</TD>
</TR>
<TR>
<TD>
<P>serious adverse events (mostly judged to be unlikely to be related to study medication)</P>
</TD>
<TD>
<P>6 (3%)</P>
</TD>
<TD>
<P>4 (2%)</P>
</TD>
</TR>
<TR>
<TD>
<P>liraglutide auto-antibodies</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>deaths</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>1 (&lt; 1%) unrelated to drug</P>
</TD>
</TR>
<TR>
<TD>
<P>pancreatitis</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>None</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.8567594537665233" CI_START="-2.076759453766523" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.3899999999999999" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-013.07" MODIFIED="2011-08-30 14:53:33 +0200" MODIFIED_BY="Bernd Richter" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.7566563641544478" Q="0.0" RANDOM="YES" SCALE="10.55" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="221" TOTAL_2="219" UNITS="" WEIGHT="0.0" Z="0.30987454119349633">
<NAME>Systolic blood pressure (mm Hg)</NAME>
<GROUP_LABEL_1>Liraglutide 1.2 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Sitagliptin 100 mg daily</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Sitagliptin</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.8567594537665233" CI_START="-2.076759453766523" EFFECT_SIZE="0.3899999999999999" ESTIMABLE="YES" MEAN_1="-0.55" MEAN_2="-0.94" MODIFIED="2011-06-08 17:51:59 +0200" MODIFIED_BY="[Empty name]" ORDER="366" SD_1="13.23" SD_2="13.17" SE="1.2585738683077887" STUDY_ID="STD-L-_x002d_-Pratley-2010" TOTAL_1="221" TOTAL_2="219" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-013.08" MODIFIED="2011-08-30 13:58:16 +0200" MODIFIED_BY="Bernd Richter" NO="8" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Diastolic blood pressure (mm Hg)</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.2 mg daily</P>
</TH>
<TH>
<P>Sitagliptin 100 mg daily</P>
</TH>
<TH>
<P>p values</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:27:51 +0200" MODIFIED_BY="Bernd Richter" ORDER="1352" STUDY_ID="STD-L-_x002d_-Pratley-2010">
<TR>
<TD>
<P>Change from baseline</P>
</TD>
<TD>
<P>-0.71</P>
</TD>
<TD>
<P>-1.78</P>
</TD>
<TD>
<P>P = NS between groups</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.6242015071997605" CI_START="-1.4557984928002394" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.04" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-013.09" MODIFIED="2011-08-30 14:53:43 +0200" MODIFIED_BY="Bernd Richter" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="9.47284654562928E-7" Q="0.0" RANDOM="YES" SCALE="4.26" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="221" TOTAL_2="219" UNITS="" WEIGHT="0.0" Z="4.90228459029297">
<NAME>Fasting plasma glucose (mmol/L)</NAME>
<GROUP_LABEL_1>Liraglutide 1.2 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Sitagliptin 100 mg daily</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Sitagliptin</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.6242015071997605" CI_START="-1.4557984928002394" EFFECT_SIZE="-1.04" ESTIMABLE="YES" MEAN_1="-1.87" MEAN_2="-0.83" MODIFIED="2011-06-08 17:53:27 +0200" MODIFIED_BY="[Empty name]" ORDER="368" SD_1="2.23" SD_2="2.22" SE="0.212145986395671" STUDY_ID="STD-L-_x002d_-Pratley-2010" TOTAL_1="221" TOTAL_2="219" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-013.10" MODIFIED="2011-06-30 13:46:38 +0200" MODIFIED_BY="[Empty name]" NO="10" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Post-prandial glucose (mmol/L)</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.2 mg daily</P>
</TH>
<TH>
<P>Sitagliptin 100 mg daily</P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-06-24 11:12:37 +0200" MODIFIED_BY="[Empty name]" ORDER="1354" STUDY_ID="STD-L-_x002d_-Pratley-2010">
<TR>
<TD>
<P>PPG</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>Reported in the paper that ' PPG was highly variable suggesting that glucose values were not PPG in many cases</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-013.11" MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" NO="11" ROWS_PER_STUDY="5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Beta-cell function</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.2 mg daily</P>
</TH>
<TH>
<P>Sitagliptin 100 mg daily</P>
</TH>
<TH>
<P>Difference between groups</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" ORDER="1355" STUDY_ID="STD-L-_x002d_-Pratley-2010">
<TR>
<TD>
<P>HOMA-B (%), mean change from baseline</P>
</TD>
<TD>
<P>27.23 % (95% CI 19.73 to 34.73)</P>
</TD>
<TD>
<P>4.18 % (95% CI -3.27 to 11.62)</P>
</TD>
<TD>
<P>23.05% (95% CI 12.95 to 33.15), P &lt; 0.0001</P>
</TD>
</TR>
<TR>
<TD>
<P>HOMA-IR (%), mean change from baseline</P>
</TD>
<TD>
<P>-1.06 % (95% CI -1.70 to -0.42)</P>
</TD>
<TD>
<P>-0.94 % (95% CI, -1.58 to -0.30)</P>
</TD>
<TD>
<P>-0.12% (95% CI -0.99 to 0.75), P = 0.7834</P>
</TD>
</TR>
<TR>
<TD>
<P>Fasting insulin (pmol/L)</P>
</TD>
<TD>
<P>5.12 (95% CI -4.34 to 14.59)</P>
</TD>
<TD>
<P>-6.77 (95% CI -16.18 to 2.64)</P>
</TD>
<TD>
<P>11.89 (95% CI -0.84 to 24.63), P = 0.0672</P>
</TD>
</TR>
<TR>
<TD>
<P>Fasting C-peptide (nmol/L)</P>
</TD>
<TD>
<P>0.09 (95% CI 0.03 to 0.15)</P>
</TD>
<TD>
<P>-0.04 (95% CI -0.10 to 0.02)</P>
</TD>
<TD>
<P>0.13 (95% CI 0.05 to 0.21), P = 0.0011</P>
</TD>
</TR>
<TR>
<TD>
<P>Fasting proinsulin-to-insulin ratio</P>
</TD>
<TD>
<P>-0.08 (95% CI -0.11 to -0.05)</P>
</TD>
<TD>
<P>-0.03 (95% CI -0.06 to -0.00)</P>
</TD>
<TD>
<P>-0.05 (95% CI -0.09 to -0.01), P = 0.0121</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" MODIFIED="2011-08-30 14:55:12 +0200" MODIFIED_BY="Bernd Richter" NO="14">
<NAME>Liraglutide 1.8 mg daily versus DPP-4 inhibitors</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.4185333813092169" CI_START="-0.781466618690783" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-014.01" MODIFIED="2011-08-30 14:54:21 +0200" MODIFIED_BY="Bernd Richter" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="9.147270202868124E-11" Q="0.0" RANDOM="YES" SCALE="1.95" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="218" TOTAL_2="219" UNITS="" WEIGHT="0.0" Z="6.480411654817273">
<NAME>HbA1c (%)</NAME>
<GROUP_LABEL_1>Liraglutide 1.8 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Sitagliptin 100 mg daily</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Sitagliptin</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.4185333813092169" CI_START="-0.781466618690783" EFFECT_SIZE="-0.6" ESTIMABLE="YES" MEAN_1="-1.5" MEAN_2="-0.9" MODIFIED="2011-06-10 10:07:05 +0200" MODIFIED_BY="[Empty name]" ORDER="355" SD_1="0.89" SD_2="1.04" SE="0.09258671083865243" STUDY_ID="STD-L-_x002d_-Pratley-2010" TOTAL_1="218" TOTAL_2="219" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.6626501577124544" CI_START="1.4846561085935424" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9882454128440368" ESTIMABLE="NO" EVENTS_1="95" EVENTS_2="48" I2="0.0" I2_Q="0.0" ID="CMP-014.02" LOG_CI_END="0.4253141087762196" LOG_CI_START="0.17162586952132852" LOG_EFFECT_SIZE="0.2984699891487741" METHOD="MH" MODIFIED="2011-08-30 14:54:28 +0200" MODIFIED_BY="Bernd Richter" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="3.990347116913168E-6" Q="0.0" RANDOM="YES" SCALE="12.15" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="218" TOTAL_2="219" WEIGHT="0.0" Z="4.61188449977686">
<NAME>HbA1c &lt; 7%</NAME>
<GROUP_LABEL_1>Liraglutide 1.8 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Sitagliptin 100 mg daily</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Sitagliptin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Liraglutide</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.6626501577124544" CI_START="1.4846561085935424" EFFECT_SIZE="1.9882454128440368" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="48" LOG_CI_END="0.4253141087762196" LOG_CI_START="0.17162586952132852" LOG_EFFECT_SIZE="0.2984699891487741" MODIFIED="2011-06-10 10:07:37 +0200" MODIFIED_BY="[Empty name]" ORDER="356" O_E="0.0" SE="0.14901772751536027" STUDY_ID="STD-L-_x002d_-Pratley-2010" TOTAL_1="218" TOTAL_2="219" VAR="0.022206283113842165" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.548423017209295" CI_START="0.47916941967829557" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.105045871559633" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-014.03" LOG_CI_END="0.4062715189503596" LOG_CI_START="-0.3195109061628825" LOG_EFFECT_SIZE="0.04338030639373852" METHOD="MH" MODIFIED="2011-08-30 14:54:37 +0200" MODIFIED_BY="Bernd Richter" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.8147554508676448" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="218" TOTAL_2="219" WEIGHT="0.0" Z="0.23429566555507067">
<NAME>Hypoglycaemia</NAME>
<GROUP_LABEL_1>Liraglutide 1.8 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Sitagliptin 100 mg daily</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Sitagliptin</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.548423017209295" CI_START="0.47916941967829557" EFFECT_SIZE="1.105045871559633" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.4062715189503596" LOG_CI_START="-0.3195109061628825" LOG_EFFECT_SIZE="0.04338030639373852" MODIFIED="2011-06-10 10:09:18 +0200" MODIFIED_BY="[Empty name]" ORDER="357" O_E="0.0" SE="0.4263281891924648" STUDY_ID="STD-L-_x002d_-Pratley-2010" TOTAL_1="218" TOTAL_2="219" VAR="0.18175572490012606" WEIGHT="0.0"/>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-014.04" MODIFIED="2011-06-30 13:48:18 +0200" MODIFIED_BY="[Empty name]" NO="4" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Severe hypoglycaemia</NAME>
<TR>
<TH>
<P>Liraglutide 1.8 mg daily</P>
</TH>
<TH>
<P>Sitagliptin 100 mg daily</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-06-10 10:09:57 +0200" MODIFIED_BY="[Empty name]" ORDER="1359" STUDY_ID="STD-L-_x002d_-Pratley-2010">
<TR>
<TD>
<P>NR, presumably none</P>
</TD>
<TD>
<P>NR, presumably none</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-1.6708748369030837" CI_START="-3.1691251630969153" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.4199999999999995" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-014.05" MODIFIED="2011-08-30 14:54:46 +0200" MODIFIED_BY="Bernd Richter" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="2.427327200521697E-10" Q="0.0" RANDOM="YES" SCALE="8.24" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="218" TOTAL_2="219" UNITS="" WEIGHT="0.0" Z="6.331535871760999">
<NAME>Weight change (kg)</NAME>
<GROUP_LABEL_1>Liraglutide 1.8 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Sitagliptin 100 mg daily</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Sitagliptin</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.6708748369030841" CI_START="-3.1691251630969157" EFFECT_SIZE="-2.42" ESTIMABLE="YES" MEAN_1="-3.38" MEAN_2="-0.96" MODIFIED="2011-06-10 10:10:55 +0200" MODIFIED_BY="[Empty name]" ORDER="359" SD_1="3.99" SD_2="4.0" SE="0.3822137391329225" STUDY_ID="STD-L-_x002d_-Pratley-2010" TOTAL_1="218" TOTAL_2="219" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-014.06" MODIFIED="2011-06-30 13:48:52 +0200" MODIFIED_BY="[Empty name]" NO="6" ROWS_PER_STUDY="10" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Adverse events</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.8 mg daily</P>
</TH>
<TH>
<P>Sitagliptin 100 mg daily</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-06-30 13:48:52 +0200" MODIFIED_BY="[Empty name]" ORDER="1361" STUDY_ID="STD-L-_x002d_-Pratley-2010">
<TR>
<TD>
<P>withdrawal due to adverse events</P>
</TD>
<TD>
<P>15 (6.9%)</P>
</TD>
<TD>
<P>4 (1.8%)</P>
</TD>
</TR>
<TR>
<TD>
<P>overall adverse events</P>
</TD>
<TD>
<P>159 (73%)</P>
</TD>
<TD>
<P>127 (58%)</P>
</TD>
</TR>
<TR>
<TD>
<P>nausea</P>
</TD>
<TD>
<P>59 (27%)</P>
</TD>
<TD>
<P>10 (5%)</P>
</TD>
</TR>
<TR>
<TD>
<P>vomiting</P>
</TD>
<TD>
<P>21 (10%)</P>
</TD>
<TD>
<P>9 (4%)</P>
</TD>
</TR>
<TR>
<TD>
<P>diarrhoea</P>
</TD>
<TD>
<P>25 (11%)</P>
</TD>
<TD>
<P>10 (5%)</P>
</TD>
</TR>
<TR>
<TD>
<P>other gastrointestinal adverse events</P>
</TD>
<TD>
<P>11 (5%)</P>
</TD>
<TD>
<P>6 (3%)</P>
</TD>
</TR>
<TR>
<TD>
<P>serious adverse events (mostly judged to be unlikely to be related to study medication)</P>
</TD>
<TD>
<P>6 (3%)</P>
</TD>
<TD>
<P>4 (2%)</P>
</TD>
</TR>
<TR>
<TD>
<P>liraglutide auto-antibodies</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>deaths</P>
</TD>
<TD>
<P>1 (&lt; 1%) unrelated to drug</P>
</TD>
<TD>
<P>1 (&lt; 1%) unrelated to drug</P>
</TD>
</TR>
<TR>
<TD>
<P>pancreatitis</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>None</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.6867691411502657" CI_START="-2.246769141150266" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.21999999999999997" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-014.07" MODIFIED="2011-08-30 14:55:02 +0200" MODIFIED_BY="Bernd Richter" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.8612365237852042" Q="0.0" RANDOM="YES" SCALE="15.82" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="218" TOTAL_2="219" UNITS="" WEIGHT="0.0" Z="0.17480033676671705">
<NAME>Systolic blood pressure (mm Hg)</NAME>
<GROUP_LABEL_1>Liraglutide 1.8 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Sitagliptin 100 mg daily</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Sitagliptin</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.6867691411502657" CI_START="-2.246769141150266" EFFECT_SIZE="0.21999999999999997" ESTIMABLE="YES" MEAN_1="-0.72" MEAN_2="-0.94" MODIFIED="2011-06-10 10:12:52 +0200" MODIFIED_BY="[Empty name]" ORDER="361" SD_1="13.14" SD_2="13.17" SE="1.2585788109413367" STUDY_ID="STD-L-_x002d_-Pratley-2010" TOTAL_1="218" TOTAL_2="219" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-014.08" MODIFIED="2011-08-30 13:58:16 +0200" MODIFIED_BY="Bernd Richter" NO="8" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Diastolic blood pressure (mm Hg)</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.8 mg daily</P>
</TH>
<TH>
<P>Sitagliptin 100 mg daily</P>
</TH>
<TH>
<P>p values</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" ORDER="1363" STUDY_ID="STD-L-_x002d_-Pratley-2010">
<TR>
<TD>
<P>Change from baseline</P>
</TD>
<TD>
<P>0.07</P>
</TD>
<TD>
<P>-1.78</P>
</TD>
<TD>
<P>P = 0.0210 versus SITA</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.8946529799072815" CI_START="-1.7253470200927186" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.31" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-014.09" MODIFIED="2011-08-30 14:55:12 +0200" MODIFIED_BY="Bernd Richter" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="6.341287649265995E-10" Q="0.0" RANDOM="YES" SCALE="4.09" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="218" TOTAL_2="219" UNITS="" WEIGHT="0.0" Z="6.181705165897935">
<NAME>Fasting plasma glucose (mmol/L)</NAME>
<GROUP_LABEL_1>Liraglutide 1.8 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Sitaglipin 100 mg daily</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Sitagliptin</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.8946529799072815" CI_START="-1.7253470200927186" EFFECT_SIZE="-1.31" ESTIMABLE="YES" MEAN_1="-2.14" MEAN_2="-0.83" MODIFIED="2011-06-10 10:15:08 +0200" MODIFIED_BY="[Empty name]" ORDER="363" SD_1="2.21" SD_2="2.22" SE="0.21191563894485957" STUDY_ID="STD-L-_x002d_-Pratley-2010" TOTAL_1="218" TOTAL_2="219" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-014.10" MODIFIED="2011-06-30 13:50:21 +0200" MODIFIED_BY="[Empty name]" NO="10" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Post-prandial glucose (mmol/L)</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.8 mg daily</P>
</TH>
<TH>
<P>Sitagliptin 100 mg daily </P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-06-30 13:50:21 +0200" MODIFIED_BY="[Empty name]" ORDER="1365" STUDY_ID="STD-L-_x002d_-Pratley-2010">
<TR>
<TD>
<P>PPG</P>
</TD>
<TD>
<P>NR </P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>Reported in the paper that ' PPG was highly variable suggesting that glucose values were not PPG in many cases</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-014.11" MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" NO="11" ROWS_PER_STUDY="5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Beta-cell function</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.8 mg daily</P>
</TH>
<TH>
<P>Sitagliptin 100 mg daily</P>
</TH>
<TH>
<P>Difference between groups</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" ORDER="1366" STUDY_ID="STD-L-_x002d_-Pratley-2010">
<TR>
<TD>
<P>Fasting insulin (pmol/L)</P>
</TD>
<TD>
<P>1.29 (95% CI -8.04 to 10.62)</P>
</TD>
<TD>
<P>-6.77 (95% CI -16.18 to 2.64)</P>
</TD>
<TD>
<P>8.06 (95% CI -4.51 to 20.63), P = 0.2083</P>
</TD>
</TR>
<TR>
<TD/>
<TD>
<P>0.09 (95% CI 0.03 to 0.15)</P>
</TD>
<TD>
<P>-0.04 (95% CI -0.10 to 0.02)</P>
</TD>
<TD>
<P>0.14 (95% CI 0.06 to 0.21), P = 0.0008</P>
</TD>
</TR>
<TR>
<TD>
<P>Fasting insulin (pmol/L)</P>
</TD>
<TD>
<P>1.29 (95% CI -8.04 to 10.62)</P>
</TD>
<TD>
<P>-6.77 (95% CI -16.18 to 2.64)</P>
</TD>
<TD>
<P>8.06 (95% CI -4.51 to 20.63), P = 0.2083</P>
</TD>
</TR>
<TR>
<TD/>
<TD>
<P>0.09 (95% CI 0.03 to 0.15)</P>
</TD>
<TD>
<P>-0.04 (95% CI -0.10 to 0.02)</P>
</TD>
<TD>
<P>0.14 (95% CI 0.06 to 0.21), P = 0.0008</P>
</TD>
</TR>
<TR>
<TD/>
<TD>
<P>-0.10 (95% CI -0.12 to -0.07)</P>
</TD>
<TD>
<P>-0.03 (95% CI -0.06 to -0.00)</P>
</TD>
<TD>
<P>-0.07 (95% CI -0.10 to -0.03), P = 0.0004</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-015" MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" NO="15">
<NAME>Lixisenatide versus placebo</NAME>
<OTHER_OUTCOME COLS="10" ID="CMP-015.01" MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" NO="1" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>HbA1c (%)</NAME>
<TR>
<TH>
<P>LIXI 5 &#956;g QD</P>
</TH>
<TH>
<P>LIXI 10 &#956;g QD</P>
</TH>
<TH>
<P>LIXI 20 &#956;g QD</P>
</TH>
<TH>
<P>LIXI 30 &#956;g QD</P>
</TH>
<TH>
<P>LIXI 5 &#956;g BID</P>
</TH>
<TH>
<P>LIXI 10 &#956;g BID</P>
</TH>
<TH>
<P>LIXI 20 &#956;g BID</P>
</TH>
<TH>
<P>LIXI 30 &#956;g BID</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
<TH>
<P>p values</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" ORDER="1367" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010">
<TR>
<TD>
<P>-0.47</P>
</TD>
<TD>
<P>-0.5</P>
</TD>
<TD>
<P>-0.69</P>
</TD>
<TD>
<P>-0.76</P>
</TD>
<TD>
<P>-0.65</P>
</TD>
<TD>
<P>-0.78</P>
</TD>
<TD>
<P>-0.75</P>
</TD>
<TD>
<P>-0.87</P>
</TD>
<TD>
<P>-0.18</P>
</TD>
<TD>
<P>change from baseline to end:</P>
<P>LIXI: P &lt; 0.05 for all doses</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="257" EVENTS_2="272" I2="0.0" I2_Q="0.0" ID="CMP-015.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-06-30 14:12:27 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="3.8" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="419" TOTAL_2="856" WEIGHT="0.0" Z="0.0">
<NAME>HbA1c &lt; 7%</NAME>
<GROUP_LABEL_1>Lixisenatide</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lixisenatide</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="26" EVENTS_2="34" I2="0.0" ID="CMP-015.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-06-19 17:44:39 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="107" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 5 µg QD</NAME>
<DICH_DATA CI_END="2.205412725258416" CI_START="1.0035549608357077" EFFECT_SIZE="1.4877005347593584" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="34" LOG_CI_END="0.34348987613000737" LOG_CI_START="0.0015411621090499785" LOG_EFFECT_SIZE="0.17251551911952867" MODIFIED="2011-05-02 10:38:23 +0200" MODIFIED_BY="[Empty name]" ORDER="290" O_E="0.0" SE="0.20086236728934387" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="55" TOTAL_2="107" VAR="0.04034569059307928" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="26" EVENTS_2="34" I2="0.0" ID="CMP-015.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-06-19 17:44:43 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="107" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 10 µg QD</NAME>
<DICH_DATA CI_END="2.4042834395772057" CI_START="1.1138603469439956" EFFECT_SIZE="1.6364705882352941" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="34" LOG_CI_END="0.3809856650728716" LOG_CI_START="0.04683074348263574" LOG_EFFECT_SIZE="0.21390820427775367" MODIFIED="2011-05-02 10:38:28 +0200" MODIFIED_BY="[Empty name]" ORDER="291" O_E="0.0" SE="0.19628425503564328" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="50" TOTAL_2="107" VAR="0.038527508774897454" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="36" EVENTS_2="34" I2="0.0" ID="CMP-015.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-06-19 17:44:48 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="107" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 20 µg QD</NAME>
<DICH_DATA CI_END="2.9841830321406153" CI_START="1.531219767113806" EFFECT_SIZE="2.1376248612652606" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="34" LOG_CI_END="0.47482545667292064" LOG_CI_START="0.18503752694598471" LOG_EFFECT_SIZE="0.3299314918094527" MODIFIED="2011-05-02 10:38:33 +0200" MODIFIED_BY="[Empty name]" ORDER="292" O_E="0.0" SE="0.17022286439498918" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="53" TOTAL_2="107" VAR="0.028975823562834874" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="35" EVENTS_2="34" I2="0.0" ID="CMP-015.02.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-06-19 17:44:54 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="107" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 30 µg QD</NAME>
<DICH_DATA CI_END="3.0159974899819773" CI_START="1.546587451120385" EFFECT_SIZE="2.1597462514417534" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="34" LOG_CI_END="0.47943097576291205" LOG_CI_START="0.18937448202767557" LOG_EFFECT_SIZE="0.3344027288952938" MODIFIED="2011-05-02 10:38:40 +0200" MODIFIED_BY="[Empty name]" ORDER="293" O_E="0.0" SE="0.17038062022287823" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="51" TOTAL_2="107" VAR="0.02902955574753266" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="26" EVENTS_2="34" I2="0.0" ID="CMP-015.02.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-06-19 17:44:59 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="107" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 5 µg BID</NAME>
<DICH_DATA CI_END="2.3617485069916015" CI_START="1.0898893668432534" EFFECT_SIZE="1.6043829296424452" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="34" LOG_CI_END="0.3732336494837266" LOG_CI_START="0.0373824155479457" LOG_EFFECT_SIZE="0.20530803251583613" MODIFIED="2011-05-02 10:38:42 +0200" MODIFIED_BY="[Empty name]" ORDER="294" O_E="0.0" SE="0.197280677304298" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="51" TOTAL_2="107" VAR="0.038919665637642556" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="35" EVENTS_2="34" I2="0.0" ID="CMP-015.02.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-06-19 17:45:05 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="54" TOTAL_2="107" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 10 µg BID</NAME>
<DICH_DATA CI_END="2.866179609812849" CI_START="1.4516265014971261" EFFECT_SIZE="2.039760348583878" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="34" LOG_CI_END="0.4573034020789494" LOG_CI_START="0.16185488826157396" LOG_EFFECT_SIZE="0.30957914517026164" MODIFIED="2011-05-02 10:38:45 +0200" MODIFIED_BY="[Empty name]" ORDER="295" O_E="0.0" SE="0.1735479195100565" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="54" TOTAL_2="107" VAR="0.030118880366269044" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="32" EVENTS_2="34" I2="0.0" ID="CMP-015.02.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-06-19 17:45:10 +0200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="107" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 20 µg BID</NAME>
<DICH_DATA CI_END="2.7511966272180817" CI_START="1.3632683755070352" EFFECT_SIZE="1.9366515837104072" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="34" LOG_CI_END="0.4395216303984752" LOG_CI_START="0.13458136025764744" LOG_EFFECT_SIZE="0.28705149532806135" MODIFIED="2011-05-02 10:38:47 +0200" MODIFIED_BY="[Empty name]" ORDER="296" O_E="0.0" SE="0.179123424159404" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="52" TOTAL_2="107" VAR="0.032085201082589755" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="41" EVENTS_2="34" I2="0.0" ID="CMP-015.02.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-06-28 16:10:54 +0200" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="107" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 30 µg BID</NAME>
<DICH_DATA CI_END="3.330994699592171" CI_START="1.7793105503748743" EFFECT_SIZE="2.4345172031076583" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="34" LOG_CI_END="0.5225739416255198" LOG_CI_START="0.25025175389828214" LOG_EFFECT_SIZE="0.386412847761901" MODIFIED="2011-05-02 10:38:50 +0200" MODIFIED_BY="[Empty name]" ORDER="297" O_E="0.0" SE="0.15996340108754917" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="53" TOTAL_2="107" VAR="0.02558828968749613" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-015.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-22 15:32:47 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="433" TOTAL_2="872" WEIGHT="0.0" Z="0.0">
<NAME>Symptomatic hypoglycaemia</NAME>
<GROUP_LABEL_1>Lixisenatide</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lixisenatide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-015.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-06-19 17:46:20 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="109" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 5 µg QD</NAME>
<DICH_DATA CI_END="31.087337871372693" CI_START="0.12634093411394753" EFFECT_SIZE="1.981818181818182" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.4925835333241748" LOG_CI_START="-0.8984559164314153" LOG_EFFECT_SIZE="0.2970638084463798" MODIFIED="2011-05-02 10:31:11 +0200" MODIFIED_BY="[Empty name]" ORDER="282" O_E="0.0" SE="1.4045084086225958" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="55" TOTAL_2="109" VAR="1.9726438698915765" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-015.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-06-19 17:46:25 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="109" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 10 µg QD</NAME>
<DICH_DATA CI_END="45.18974452931852" CI_START="0.388925495597337" EFFECT_SIZE="4.1923076923076925" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.6550398861459645" LOG_CI_START="-0.41013358620635304" LOG_EFFECT_SIZE="0.6224531499698057" MODIFIED="2011-05-02 10:31:21 +0200" MODIFIED_BY="[Empty name]" ORDER="283" O_E="0.0" SE="1.2130931204333102" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="52" TOTAL_2="109" VAR="1.4715949188426254" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-015.03.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-06-19 17:46:29 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="109" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 20 µg QD</NAME>
<DICH_DATA CI_END="31.087337871372693" CI_START="0.12634093411394753" EFFECT_SIZE="1.981818181818182" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.4925835333241748" LOG_CI_START="-0.8984559164314153" LOG_EFFECT_SIZE="0.2970638084463798" MODIFIED="2011-05-02 10:31:32 +0200" MODIFIED_BY="[Empty name]" ORDER="284" O_E="0.0" SE="1.4045084086225958" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="55" TOTAL_2="109" VAR="1.9726438698915765" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-015.03.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-06-19 17:46:34 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="54" TOTAL_2="109" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 30 µg QD</NAME>
<DICH_DATA CI_END="31.65559129444152" CI_START="0.12871081673074392" EFFECT_SIZE="2.0185185185185186" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.500450430115104" LOG_CI_START="-0.8903849538797937" LOG_EFFECT_SIZE="0.30503273811765513" MODIFIED="2011-05-02 10:31:42 +0200" MODIFIED_BY="[Empty name]" ORDER="285" O_E="0.0" SE="1.4043885393846234" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="54" TOTAL_2="109" VAR="1.972307169554876" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-015.03.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-06-19 17:46:38 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="109" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 5 µg BID</NAME>
<DICH_DATA CI_END="57.91139163930549" CI_START="0.6573244167711663" EFFECT_SIZE="6.169811320754717" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.7627640013693837" LOG_CI_START="-0.18222023525038955" LOG_EFFECT_SIZE="0.790271883059497" MODIFIED="2011-05-02 10:31:49 +0200" MODIFIED_BY="[Empty name]" ORDER="286" O_E="0.0" SE="1.1424933684177017" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="53" TOTAL_2="109" VAR="1.305291096878426" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-015.03.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-06-19 17:46:43 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="109" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 10 µg BID</NAME>
<DICH_DATA CI_END="30.53912407332337" CI_START="0.12405674028427315" EFFECT_SIZE="1.9464285714285714" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.484856576414651" LOG_CI_START="-0.9063796345458045" LOG_EFFECT_SIZE="0.28923847093442323" MODIFIED="2011-05-02 10:31:55 +0200" MODIFIED_BY="[Empty name]" ORDER="287" O_E="0.0" SE="1.4046239871283175" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="56" TOTAL_2="109" VAR="1.9729685452162518" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-015.03.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-06-19 17:46:49 +0200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="54" TOTAL_2="109" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 20 µg BID</NAME>
<DICH_DATA CI_END="56.85599482462254" CI_START="0.644958428737918" EFFECT_SIZE="6.055555555555555" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.7547762629022554" LOG_CI_START="-0.19046827722762022" LOG_EFFECT_SIZE="0.7821539928373176" MODIFIED="2011-05-02 10:32:02 +0200" MODIFIED_BY="[Empty name]" ORDER="288" O_E="0.0" SE="1.142646271988059" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="54" TOTAL_2="109" VAR="1.3056405028882092" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-015.03.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-06-19 17:46:54 +0200" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="54" TOTAL_2="109" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 30 µg BID</NAME>
<DICH_DATA CI_END="31.65559129444152" CI_START="0.12871081673074392" EFFECT_SIZE="2.0185185185185186" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.500450430115104" LOG_CI_START="-0.8903849538797937" LOG_EFFECT_SIZE="0.30503273811765513" MODIFIED="2011-05-02 10:32:06 +0200" MODIFIED_BY="[Empty name]" ORDER="289" O_E="0.0" SE="1.4043885393846234" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="54" TOTAL_2="109" VAR="1.972307169554876" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-015.04" MODIFIED="2011-06-30 13:53:36 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="4.51" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="421" TOTAL_2="864" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Weight change (kg)</NAME>
<GROUP_LABEL_1>Lixisenatide</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lixisenatide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-015.04.01" MODIFIED="2011-06-19 17:45:27 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="108" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 5 &#956;g QD</NAME>
<CONT_DATA CI_END="0.9452437267039737" CI_START="-1.0652437267039738" EFFECT_SIZE="-0.06000000000000005" ESTIMABLE="YES" MEAN_1="-2.0" MEAN_2="-1.94" MODIFIED="2011-04-29 11:12:57 +0200" MODIFIED_BY="[Empty name]" ORDER="248" SD_1="2.97" SD_2="3.33" SE="0.5128888768534565" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="55" TOTAL_2="108" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-015.04.02" MODIFIED="2011-06-19 17:45:35 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="108" WEIGHT="0.0" Z="0.0">
<NAME>LIXi 10 &#956;g QD</NAME>
<CONT_DATA CI_END="0.5855318837120955" CI_START="-1.4855318837120959" EFFECT_SIZE="-0.4500000000000002" ESTIMABLE="YES" MEAN_1="-2.39" MEAN_2="-1.94" MODIFIED="2011-04-29 11:12:59 +0200" MODIFIED_BY="[Empty name]" ORDER="249" SD_1="3.0" SD_2="3.33" SE="0.528342302144447" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="51" TOTAL_2="108" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-015.04.03" MODIFIED="2011-06-19 17:45:45 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="108" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 20 &#956;g QD</NAME>
<CONT_DATA CI_END="-0.05113969067842894" CI_START="-2.0888603093215705" EFFECT_SIZE="-1.0699999999999998" ESTIMABLE="YES" MEAN_1="-3.01" MEAN_2="-1.94" MODIFIED="2011-04-29 11:13:01 +0200" MODIFIED_BY="[Empty name]" ORDER="250" SD_1="2.98" SD_2="3.33" SE="0.5198362405422808" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="53" TOTAL_2="108" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-015.04.04" MODIFIED="2011-06-19 17:45:51 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="108" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 30 &#956;g QD</NAME>
<CONT_DATA CI_END="-0.5093736991344515" CI_START="-2.5506263008655488" EFFECT_SIZE="-1.5300000000000002" ESTIMABLE="YES" MEAN_1="-3.47" MEAN_2="-1.94" MODIFIED="2011-04-29 11:13:03 +0200" MODIFIED_BY="[Empty name]" ORDER="251" SD_1="2.96" SD_2="3.33" SE="0.5207372731928335" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="52" TOTAL_2="108" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-015.04.05" MODIFIED="2011-06-19 17:45:55 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="108" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 5 &#956;g BID</NAME>
<CONT_DATA CI_END="0.8603233900547167" CI_START="-1.180323390054717" EFFECT_SIZE="-0.16000000000000014" ESTIMABLE="YES" MEAN_1="-2.1" MEAN_2="-1.94" MODIFIED="2011-04-29 11:13:05 +0200" MODIFIED_BY="[Empty name]" ORDER="252" SD_1="2.93" SD_2="3.33" SE="0.5205827240208991" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="51" TOTAL_2="108" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-015.04.06" MODIFIED="2011-06-19 17:46:00 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="54" TOTAL_2="108" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 10 &#956;g BID</NAME>
<CONT_DATA CI_END="0.7492842207099566" CI_START="-1.2892842207099566" EFFECT_SIZE="-0.27" ESTIMABLE="YES" MEAN_1="-2.21" MEAN_2="-1.94" MODIFIED="2011-04-29 11:13:07 +0200" MODIFIED_BY="[Empty name]" ORDER="253" SD_1="3.01" SD_2="3.33" SE="0.5200525258371789" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="54" TOTAL_2="108" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-015.04.07" MODIFIED="2011-06-19 17:46:06 +0200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="108" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 20 &#956;g BID</NAME>
<CONT_DATA CI_END="0.3506263008655488" CI_START="-1.6906263008655487" EFFECT_SIZE="-0.6699999999999999" ESTIMABLE="YES" MEAN_1="-2.61" MEAN_2="-1.94" MODIFIED="2011-04-29 11:13:09 +0200" MODIFIED_BY="[Empty name]" ORDER="254" SD_1="2.96" SD_2="3.33" SE="0.5207372731928335" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="52" TOTAL_2="108" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-015.04.08" MODIFIED="2011-06-19 17:46:10 +0200" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="108" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 30 &#956;g BID</NAME>
<CONT_DATA CI_END="-0.9311396906784293" CI_START="-2.9688603093215713" EFFECT_SIZE="-1.9500000000000002" ESTIMABLE="YES" MEAN_1="-3.89" MEAN_2="-1.94" MODIFIED="2011-04-29 11:13:12 +0200" MODIFIED_BY="[Empty name]" ORDER="255" SD_1="2.98" SD_2="3.33" SE="0.5198362405422808" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="53" TOTAL_2="108" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="10" ID="CMP-015.05" MODIFIED="2011-06-30 13:53:49 +0200" MODIFIED_BY="[Empty name]" NO="5" ROWS_PER_STUDY="10" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Adverse events</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>LIXI 5 &#956;g QD</P>
</TH>
<TH>
<P>LIXI 10 &#956;g QD</P>
</TH>
<TH>
<P>LIXI 20 &#956;g QD</P>
</TH>
<TH>
<P>LIXI 30 &#956;g QD</P>
</TH>
<TH>
<P>LIXI 5 &#956;g BID</P>
</TH>
<TH>
<P>LIXI 10 &#956;g BID</P>
</TH>
<TH>
<P>LIXI 20 &#956;g BID</P>
</TH>
<TH>
<P>LIXI 30 &#956;g BID</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-06-30 10:24:32 +0200" MODIFIED_BY="[Empty name]" ORDER="1392" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010">
<TR>
<TD>
<P>Withdrawals due to adverse events</P>
</TD>
<TD>
<P>1 (1.8%)</P>
</TD>
<TD>
<P>2 (3.8%)</P>
</TD>
<TD>
<P>3 (5.5%)</P>
</TD>
<TD>
<P>6 (11.1%)</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>2 (3.6%)</P>
</TD>
<TD>
<P>8 (14.8%)</P>
</TD>
<TD>
<P>5 (9.3%)</P>
</TD>
<TD>
<P>2 (1.8%)</P>
</TD>
</TR>
<TR>
<TD>
<P>Any treatment-emergent adverse events</P>
</TD>
<TD>
<P>31 (56.4%)</P>
</TD>
<TD>
<P>26 (50.0%)</P>
</TD>
<TD>
<P>37 (67.3%)</P>
</TD>
<TD>
<P>42 (77.8%)</P>
</TD>
<TD>
<P>30 (56.6%)</P>
</TD>
<TD>
<P>32 (57.1%)</P>
</TD>
<TD>
<P>38 (70.4%)</P>
</TD>
<TD>
<P>40 (74.1%)</P>
</TD>
<TD>
<P>65 (59.6%)</P>
</TD>
</TR>
<TR>
<TD>
<P>Nausea</P>
</TD>
<TD>
<P>4 (7.3%)</P>
</TD>
<TD>
<P>6 (11.5%)</P>
</TD>
<TD>
<P>14 (25.5%)</P>
</TD>
<TD>
<P>19 (35.2%)</P>
</TD>
<TD>
<P>4 (7.5%)</P>
</TD>
<TD>
<P>8 (14.3%)</P>
</TD>
<TD>
<P>12 (22.2%)</P>
</TD>
<TD>
<P>18 (33.3%)</P>
</TD>
<TD>
<P>5 (4.6%)</P>
</TD>
</TR>
<TR>
<TD>
<P>Vomiting</P>
</TD>
<TD>
<P>2 (3.6%)</P>
</TD>
<TD>
<P>3 (5.8%)</P>
</TD>
<TD>
<P>3 (5.5%)</P>
</TD>
<TD>
<P>10 (18.5%)</P>
</TD>
<TD>
<P>3 (5.7%)</P>
</TD>
<TD>
<P>4 (7.1%)</P>
</TD>
<TD>
<P>5 (9.3%)</P>
</TD>
<TD>
<P>2 (3.7%)</P>
</TD>
<TD>
<P>1 (0.9%)</P>
</TD>
</TR>
<TR>
<TD>
<P>Diarrhoea</P>
</TD>
<TD>
<P>3 (5.5%)</P>
</TD>
<TD>
<P>4 (7.7%)</P>
</TD>
<TD>
<P>5 (9.1%)</P>
</TD>
<TD>
<P>4 (7.4%)</P>
</TD>
<TD>
<P>3 (5.7%)</P>
</TD>
<TD>
<P>4 (7.1%)</P>
</TD>
<TD>
<P>6 (11.1%)</P>
</TD>
<TD>
<P>14 (25.9%)</P>
</TD>
<TD>
<P>8 (7.3%)</P>
</TD>
</TR>
<TR>
<TD>
<P>Headache</P>
</TD>
<TD>
<P>7 (12.7%)</P>
</TD>
<TD>
<P>3 (5.8%)</P>
</TD>
<TD>
<P>7 (12.7%)</P>
</TD>
<TD>
<P>7 (13.0%)</P>
</TD>
<TD>
<P>7 (13.2%)</P>
</TD>
<TD>
<P>5 (8.9%)</P>
</TD>
<TD>
<P>6 (11.1%)</P>
</TD>
<TD>
<P>4 (7.4%)</P>
</TD>
<TD>
<P>11 (10.1%)</P>
</TD>
</TR>
<TR>
<TD>
<P>Dizziness</P>
</TD>
<TD>
<P>1 (1.8%)</P>
</TD>
<TD>
<P>4 (7.7%)</P>
</TD>
<TD>
<P>4 (7.3%)</P>
</TD>
<TD>
<P>6 (11.1%)</P>
</TD>
<TD>
<P>3 (5.7%)</P>
</TD>
<TD>
<P>5 (8.9%)</P>
</TD>
<TD>
<P>2 (3.7%)</P>
</TD>
<TD>
<P>5 (9.3%)</P>
</TD>
<TD>
<P>7 (6.4%)</P>
</TD>
</TR>
<TR>
<TD>
<P>Any serious treatment-emergent adverse events</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>1 (1.9%)</P>
</TD>
<TD>
<P>1 (1.8%)</P>
</TD>
<TD>
<P>3 (5.6%)</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>1 (1.8%)</P>
</TD>
<TD>
<P>2 (3.7%)</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>3 (2.8%)</P>
</TD>
</TR>
<TR>
<TD>
<P>Pancreatitis</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>Severe hypoglycaemia</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-015.06" MODIFIED="2011-06-30 13:54:09 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.87" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="421" TOTAL_2="864" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Fasting plasma glucose (mmol/L)</NAME>
<GROUP_LABEL_1>Lixisenatide</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lixisenatide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-015.06.01" MODIFIED="2011-06-19 17:47:04 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="108" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 5 &#956;g QD</NAME>
<CONT_DATA CI_END="0.18944636386494573" CI_START="-1.0094463638649458" EFFECT_SIZE="-0.41000000000000003" ESTIMABLE="YES" MEAN_1="-0.62" MEAN_2="-0.21" MODIFIED="2011-04-29 11:20:27 +0200" MODIFIED_BY="[Empty name]" ORDER="256" SD_1="1.78" SD_2="1.97" SE="0.3058456015484479" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="55" TOTAL_2="108" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-015.06.02" MODIFIED="2011-06-19 17:47:10 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="108" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 10 &#956;g QD</NAME>
<CONT_DATA CI_END="0.28593953491779434" CI_START="-0.9459395349177945" EFFECT_SIZE="-0.33000000000000007" ESTIMABLE="YES" MEAN_1="-0.54" MEAN_2="-0.21" MODIFIED="2011-04-29 11:20:35 +0200" MODIFIED_BY="[Empty name]" ORDER="257" SD_1="1.79" SD_2="1.97" SE="0.31426063936697146" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="51" TOTAL_2="108" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-015.06.03" MODIFIED="2011-06-19 17:47:15 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="108" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 20 &#956;g QD</NAME>
<CONT_DATA CI_END="0.02491780381971631" CI_START="-1.2049178038197166" EFFECT_SIZE="-0.5900000000000001" ESTIMABLE="YES" MEAN_1="-0.8" MEAN_2="-0.21" MODIFIED="2011-04-29 11:20:44 +0200" MODIFIED_BY="[Empty name]" ORDER="258" SD_1="1.82" SD_2="1.97" SE="0.31373933841137364" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="53" TOTAL_2="108" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-015.06.04" MODIFIED="2011-06-19 17:47:19 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="108" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 30 &#956;g QD</NAME>
<CONT_DATA CI_END="-0.19567727422056802" CI_START="-1.4243227257794322" EFFECT_SIZE="-0.81" ESTIMABLE="YES" MEAN_1="-1.02" MEAN_2="-0.21" MODIFIED="2011-04-29 11:20:52 +0200" MODIFIED_BY="[Empty name]" ORDER="259" SD_1="1.8" SD_2="1.97" SE="0.3134357215873002" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="52" TOTAL_2="108" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-015.06.05" MODIFIED="2011-06-19 17:47:24 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="108" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 5 &#956;g BID</NAME>
<CONT_DATA CI_END="0.6185742631636599" CI_START="-0.5785742631636599" EFFECT_SIZE="0.01999999999999999" ESTIMABLE="YES" MEAN_1="-0.19" MEAN_2="-0.21" MODIFIED="2011-04-29 11:21:00 +0200" MODIFIED_BY="[Empty name]" ORDER="260" SD_1="1.71" SD_2="1.97" SE="0.30540064403485845" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="51" TOTAL_2="108" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-015.06.06" MODIFIED="2011-06-19 17:47:28 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="54" TOTAL_2="108" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 10 &#956;g BID</NAME>
<CONT_DATA CI_END="-0.17133695850519082" CI_START="-1.368663041494809" EFFECT_SIZE="-0.77" ESTIMABLE="YES" MEAN_1="-0.98" MEAN_2="-0.21" MODIFIED="2011-04-29 11:21:09 +0200" MODIFIED_BY="[Empty name]" ORDER="261" SD_1="1.76" SD_2="1.97" SE="0.30544593993409414" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="54" TOTAL_2="108" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-015.06.07" MODIFIED="2011-06-19 17:47:33 +0200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="108" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 20 &#956;g BID</NAME>
<CONT_DATA CI_END="-0.3056772742205679" CI_START="-1.534322725779432" EFFECT_SIZE="-0.9199999999999999" ESTIMABLE="YES" MEAN_1="-1.13" MEAN_2="-0.21" MODIFIED="2011-04-29 11:21:16 +0200" MODIFIED_BY="[Empty name]" ORDER="262" SD_1="1.8" SD_2="1.97" SE="0.3134357215873002" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="52" TOTAL_2="108" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-015.06.08" MODIFIED="2011-06-19 17:47:37 +0200" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="108" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 30 &#956;g BID</NAME>
<CONT_DATA CI_END="-0.5950821961802836" CI_START="-1.8249178038197162" EFFECT_SIZE="-1.21" ESTIMABLE="YES" MEAN_1="-1.42" MEAN_2="-0.21" MODIFIED="2011-04-29 11:21:24 +0200" MODIFIED_BY="[Empty name]" ORDER="263" SD_1="1.82" SD_2="1.97" SE="0.31373933841137364" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="53" TOTAL_2="108" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-015.07" MODIFIED="2011-06-30 13:54:24 +0200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="6.91" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="421" TOTAL_2="864" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Post-prandial glucose (mmol/L)</NAME>
<GROUP_LABEL_1>Lixisenatide</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lixisenatide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-015.07.01" MODIFIED="2011-04-29 12:01:43 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="108" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 5&#956;g QD</NAME>
<CONT_DATA CI_END="-0.11691391417881603" CI_START="-3.3030860858211843" EFFECT_SIZE="-1.7100000000000002" ESTIMABLE="YES" MEAN_1="-2.12" MEAN_2="-0.41" MODIFIED="2011-04-29 12:01:43 +0200" MODIFIED_BY="[Empty name]" ORDER="265" SD_1="4.97" SD_2="4.78" SE="0.8128139590253922" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="55" TOTAL_2="108" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-015.07.02" MODIFIED="2011-04-29 12:01:53 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="108" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 10&#956;g QD</NAME>
<CONT_DATA CI_END="-1.646429034020441" CI_START="-4.673570965979558" EFFECT_SIZE="-3.1599999999999997" ESTIMABLE="YES" MEAN_1="-3.57" MEAN_2="-0.41" MODIFIED="2011-04-29 12:01:53 +0200" MODIFIED_BY="[Empty name]" ORDER="266" SD_1="4.43" SD_2="4.78" SE="0.7722442748532183" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="51" TOTAL_2="108" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-015.07.03" MODIFIED="2011-04-29 12:02:01 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="108" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 20&#956;g QD</NAME>
<CONT_DATA CI_END="-1.631073002401614" CI_START="-4.848926997598386" EFFECT_SIZE="-3.2399999999999998" ESTIMABLE="YES" MEAN_1="-3.65" MEAN_2="-0.41" MODIFIED="2011-04-29 12:02:01 +0200" MODIFIED_BY="[Empty name]" ORDER="267" SD_1="4.95" SD_2="4.78" SE="0.8208962053840767" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="53" TOTAL_2="108" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-015.07.04" MODIFIED="2011-04-29 12:02:09 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="108" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 30&#956;g QD</NAME>
<CONT_DATA CI_END="-2.261909464732817" CI_START="-5.578090535267183" EFFECT_SIZE="-3.92" ESTIMABLE="YES" MEAN_1="-4.33" MEAN_2="-0.41" MODIFIED="2011-04-29 12:02:09 +0200" MODIFIED_BY="[Empty name]" ORDER="268" SD_1="5.12" SD_2="4.78" SE="0.8459801038927193" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="52" TOTAL_2="108" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-015.07.05" MODIFIED="2011-04-29 12:02:17 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="108" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 5&#956;g BID</NAME>
<CONT_DATA CI_END="-0.10181743494811357" CI_START="-3.098182565051886" EFFECT_SIZE="-1.5999999999999999" ESTIMABLE="YES" MEAN_1="-2.01" MEAN_2="-0.41" MODIFIED="2011-04-29 12:02:17 +0200" MODIFIED_BY="[Empty name]" ORDER="269" SD_1="4.36" SD_2="4.78" SE="0.7643929056193681" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="51" TOTAL_2="108" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-015.07.06" MODIFIED="2011-04-29 12:02:25 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="54" TOTAL_2="108" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 10&#956;g BID</NAME>
<CONT_DATA CI_END="-1.5860931581491056" CI_START="-4.613906841850894" EFFECT_SIZE="-3.0999999999999996" ESTIMABLE="YES" MEAN_1="-3.51" MEAN_2="-0.41" MODIFIED="2011-04-29 12:02:25 +0200" MODIFIED_BY="[Empty name]" ORDER="270" SD_1="4.56" SD_2="4.78" SE="0.77241564324263" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="54" TOTAL_2="108" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-015.07.07" MODIFIED="2011-04-29 12:02:33 +0200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="108" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 20&#956;g BID</NAME>
<CONT_DATA CI_END="-2.1017662113895197" CI_START="-5.31823378861048" EFFECT_SIZE="-3.71" ESTIMABLE="YES" MEAN_1="-4.12" MEAN_2="-0.41" MODIFIED="2011-04-29 12:02:33 +0200" MODIFIED_BY="[Empty name]" ORDER="271" SD_1="4.9" SD_2="4.78" SE="0.8205425208299864" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="52" TOTAL_2="108" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-015.07.08" MODIFIED="2011-04-29 12:02:40 +0200" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="108" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 30&#956;g BID</NAME>
<CONT_DATA CI_END="-2.5910730024016146" CI_START="-5.808926997598386" EFFECT_SIZE="-4.2" ESTIMABLE="YES" MEAN_1="-4.61" MEAN_2="-0.41" MODIFIED="2011-04-29 12:02:40 +0200" MODIFIED_BY="[Empty name]" ORDER="272" SD_1="4.95" SD_2="4.78" SE="0.8208962053840767" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="53" TOTAL_2="108" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-015.08" MODIFIED="2011-06-30 13:54:37 +0200" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.87" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="421" TOTAL_2="864" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Average self-monitored 7-point blood glucose (mmol/L)</NAME>
<GROUP_LABEL_1>Lixisenatide</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lixisenatide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-015.08.01" MODIFIED="2011-06-19 17:47:48 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="108" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 5 &#956;g QD</NAME>
<CONT_DATA CI_END="-0.11205661590630323" CI_START="-1.2879433840936967" EFFECT_SIZE="-0.7" ESTIMABLE="YES" MEAN_1="-1.23" MEAN_2="-0.53" MODIFIED="2011-04-29 12:07:10 +0200" MODIFIED_BY="[Empty name]" ORDER="280" SD_1="1.78" SD_2="1.87" SE="0.2999766264744246" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="55" TOTAL_2="108" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-015.08.02" MODIFIED="2011-06-19 17:47:53 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="108" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 10 &#956;g QD</NAME>
<CONT_DATA CI_END="-0.1529458046563661" CI_START="-1.327054195343634" EFFECT_SIZE="-0.74" ESTIMABLE="YES" MEAN_1="-1.27" MEAN_2="-0.53" MODIFIED="2011-04-29 12:07:20 +0200" MODIFIED_BY="[Empty name]" ORDER="279" SD_1="1.71" SD_2="1.87" SE="0.2995229504083965" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="51" TOTAL_2="108" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-015.08.03" MODIFIED="2011-06-19 17:47:58 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="108" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 20 &#956;g QD</NAME>
<CONT_DATA CI_END="-0.6214827577192338" CI_START="-1.798517242280766" EFFECT_SIZE="-1.21" ESTIMABLE="YES" MEAN_1="-1.74" MEAN_2="-0.53" MODIFIED="2011-04-29 12:07:27 +0200" MODIFIED_BY="[Empty name]" ORDER="278" SD_1="1.75" SD_2="1.87" SE="0.3002694166438338" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="53" TOTAL_2="108" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-015.08.04" MODIFIED="2011-06-19 17:48:02 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="108" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 30 &#956;g QD</NAME>
<CONT_DATA CI_END="-0.6368964507170312" CI_START="-1.8431035492829688" EFFECT_SIZE="-1.24" ESTIMABLE="YES" MEAN_1="-1.77" MEAN_2="-0.53" MODIFIED="2011-04-29 12:07:34 +0200" MODIFIED_BY="[Empty name]" ORDER="277" SD_1="1.8" SD_2="1.87" SE="0.3077115467631919" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="52" TOTAL_2="108" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-015.08.05" MODIFIED="2011-06-19 17:48:09 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="108" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 5 &#956;g BID</NAME>
<CONT_DATA CI_END="0.23705419534363392" CI_START="-0.9370541953436339" EFFECT_SIZE="-0.35" ESTIMABLE="YES" MEAN_1="-0.88" MEAN_2="-0.53" MODIFIED="2011-04-29 12:07:41 +0200" MODIFIED_BY="[Empty name]" ORDER="276" SD_1="1.71" SD_2="1.87" SE="0.2995229504083965" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="51" TOTAL_2="108" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-015.08.06" MODIFIED="2011-06-19 17:48:14 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="54" TOTAL_2="108" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 10 &#956;g BID</NAME>
<CONT_DATA CI_END="-0.4828552844481535" CI_START="-1.6571447155518466" EFFECT_SIZE="-1.07" ESTIMABLE="YES" MEAN_1="-1.6" MEAN_2="-0.53" MODIFIED="2011-04-29 12:07:49 +0200" MODIFIED_BY="[Empty name]" ORDER="275" SD_1="1.76" SD_2="1.87" SE="0.2995691350367502" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="54" TOTAL_2="108" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-015.08.07" MODIFIED="2011-06-19 17:48:18 +0200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="108" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 20 &#956;g BID</NAME>
<CONT_DATA CI_END="-0.712224894761093" CI_START="-1.8877751052389071" EFFECT_SIZE="-1.3" ESTIMABLE="YES" MEAN_1="-1.83" MEAN_2="-0.53" MODIFIED="2011-04-29 12:07:57 +0200" MODIFIED_BY="[Empty name]" ORDER="274" SD_1="1.73" SD_2="1.87" SE="0.299890768338195" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="52" TOTAL_2="108" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-015.08.08" MODIFIED="2011-06-19 17:48:24 +0200" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="108" WEIGHT="0.0" Z="0.0">
<NAME>LIXI 30 &#956;g BID</NAME>
<CONT_DATA CI_END="-0.9614827577192339" CI_START="-2.1385172422807663" EFFECT_SIZE="-1.55" ESTIMABLE="YES" MEAN_1="-2.08" MEAN_2="-0.53" MODIFIED="2011-04-29 12:08:06 +0200" MODIFIED_BY="[Empty name]" ORDER="273" SD_1="1.75" SD_2="1.87" SE="0.3002694166438338" STUDY_ID="STD-Lixi-_x002d_-Ratner-2010" TOTAL_1="53" TOTAL_2="108" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-016" MODIFIED="2011-08-30 14:57:23 +0200" MODIFIED_BY="Bernd Richter" NO="16">
<NAME>Liraglutide 1.2 mg versus SU</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.28764199114351513" CI_START="-0.2676419911435151" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.010000000000000009" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-016.01" MODIFIED="2011-08-30 14:56:45 +0200" MODIFIED_BY="Bernd Richter" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.9437215132489196" Q="0.0" RANDOM="YES" SCALE="1.1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="240" TOTAL_2="242" UNITS="" WEIGHT="0.0" Z="0.07059321165604725">
<NAME>HbA1c</NAME>
<GROUP_LABEL_1>Liraglutide 1.2 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Glimepiride 4 mg daily</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Glimepiride</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.28764199114351513" CI_START="-0.2676419911435151" EFFECT_SIZE="0.010000000000000009" ESTIMABLE="YES" MEAN_1="-0.97" MEAN_2="-0.98" MODIFIED="2011-02-08 12:11:52 +0100" MODIFIED_BY="[Empty name]" ORDER="529" SD_1="1.55" SD_2="1.56" SE="0.141656680088777" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009" TOTAL_1="240" TOTAL_2="242" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-016.02" MODIFIED="2011-06-30 14:23:37 +0200" MODIFIED_BY="[Empty name]" NO="2" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>HbA1c (%)</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.2 mg daily</P>
</TH>
<TH>
<P>Glimepiride 4 mg daily</P>
</TH>
<TH>
<P>Difference between groups</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-05-04 13:55:23 +0200" MODIFIED_BY="[Empty name]" ORDER="1418" STUDY_ID="STD-L-_x002d_-Yang-2010">
<TR>
<TD>
<P>Change in HbA1c</P>
</TD>
<TD>
<P>-1.36</P>
</TD>
<TD>
<P>-1.39</P>
</TD>
<TD>
<P>0.03, 95% CI -0.14 to 0.20</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.002339557487978361" CI_END="1.144459405873366" CI_START="0.8362499175398976" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9782914104648791" ESTIMABLE="YES" EVENTS_1="185" EVENTS_2="189" I2="0.0" I2_Q="0.0" ID="CMP-016.03" LOG_CI_END="0.05860039280098816" LOG_CI_START="-0.07766391204859785" LOG_EFFECT_SIZE="-0.009531759623804823" METHOD="IV" MODIFIED="2011-06-30 13:56:10 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9614222008843119" P_Q="1.0" P_Z="0.7839301459450871" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="473" TOTAL_2="473" WEIGHT="100.0" Z="0.274201018272135">
<NAME>HbA1c &lt; 7%</NAME>
<GROUP_LABEL_1>Liraglutide 1.2 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Glimepiride 4 mg daily</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glimepiride</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Liraglutide</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2365066936699796" CI_START="0.767157056185433" EFFECT_SIZE="0.9739583333333334" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="88" LOG_CI_END="0.09219647170100989" LOG_CI_START="-0.11511571603511117" LOG_EFFECT_SIZE="-0.011459622167050623" MODIFIED="2011-02-08 12:11:55 +0100" MODIFIED_BY="[Empty name]" ORDER="530" O_E="0.0" SE="0.12177620528807737" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009" TOTAL_1="240" TOTAL_2="242" VAR="0.014829444174363961" WEIGHT="43.20306321878119"/>
<DICH_DATA CI_END="1.2087572797543453" CI_START="0.7971320436171553" EFFECT_SIZE="0.9816003059533421" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="101" LOG_CI_END="0.08233910264234785" LOG_CI_START="-0.09846973247538236" LOG_EFFECT_SIZE="-0.008065314916517229" MODIFIED="2011-02-08 12:14:51 +0100" MODIFIED_BY="[Empty name]" ORDER="535" O_E="0.0" SE="0.10620800476632325" STUDY_ID="STD-L-_x002d_-Yang-2010" TOTAL_1="233" TOTAL_2="231" VAR="0.011280140276443341" WEIGHT="56.79693678121882"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.655998632295889" CI_END="1.7156088235180533" CI_START="0.0019860147586221663" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.058371435167633726" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="85" I2="82.31965626211478" I2_Q="0.0" ID="CMP-016.04" LOG_CI_END="0.23441827118521427" LOG_CI_START="-2.7020175284668455" LOG_EFFECT_SIZE="-1.2337996286408155" METHOD="MH" MODIFIED="2011-08-22 15:33:09 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.01739578931359287" P_Q="1.0" P_Z="0.09955133249208978" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="5.016790585441279" TOTALS="YES" TOTAL_1="473" TOTAL_2="473" WEIGHT="100.00000000000001" Z="1.6470326622236566">
<NAME>Hypoglycaemia</NAME>
<GROUP_LABEL_1>Liraglutide 1.2 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Glimepiride 4 mg daily</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Glimepiride</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.41080873326230544" CI_START="0.09422818838339202" EFFECT_SIZE="0.1967479674796748" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="41" LOG_CI_END="-0.38636033243767837" LOG_CI_START="-1.0258191584802552" LOG_EFFECT_SIZE="-0.7060897454589666" MODIFIED="2011-02-08 12:15:41 +0100" MODIFIED_BY="[Empty name]" ORDER="79" O_E="0.0" SE="0.3756212797896489" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009" TOTAL_1="240" TOTAL_2="242" VAR="0.14109134583081367" WEIGHT="57.68260002170852"/>
<DICH_DATA CI_END="0.17981884429582656" CI_START="6.901270330870307E-4" EFFECT_SIZE="0.011139921252280803" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="44" LOG_CI_END="-0.7451647978928123" LOG_CI_START="-3.1610709604354996" LOG_EFFECT_SIZE="-1.953117879164156" MODIFIED="2011-06-16 12:27:01 +0200" MODIFIED_BY="[Empty name]" ORDER="536" O_E="0.0" SE="1.4191152388059503" STUDY_ID="STD-L-_x002d_-Yang-2010" TOTAL_1="233" TOTAL_2="231" VAR="2.013888061011269" WEIGHT="42.3173999782915"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-3.0456072119470115" CI_START="-4.154392788052988" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.5999999999999996" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-016.05" MODIFIED="2011-08-30 14:57:01 +0200" MODIFIED_BY="Bernd Richter" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="4.1752241862673794E-37" Q="0.0" RANDOM="YES" SCALE="4.51" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="240" TOTAL_2="242" UNITS="" WEIGHT="0.0" Z="12.727204423283009">
<NAME>Weight change</NAME>
<GROUP_LABEL_1>Liraglutide 1.2 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Glimepiride 4 mg daily</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Glimepiride</GRAPH_LABEL_2>
<CONT_DATA CI_END="-3.0456072119470115" CI_START="-4.154392788052989" EFFECT_SIZE="-3.6" ESTIMABLE="YES" MEAN_1="-2.6" MEAN_2="1.0" MODIFIED="2011-02-08 12:12:07 +0100" MODIFIED_BY="[Empty name]" ORDER="531" SD_1="3.1" SD_2="3.11" SE="0.2828586608866122" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009" TOTAL_1="240" TOTAL_2="242" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-016.06" MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" NO="6" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Weight change (kg)</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.2 mg daily</P>
</TH>
<TH>
<P>Glimepiride 4 mg daily</P>
</TH>
<TH>
<P>p value</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" ORDER="1424" STUDY_ID="STD-L-_x002d_-Yang-2010">
<TR>
<TD>
<P>Change from baseline</P>
</TD>
<TD>
<P>-2.35 SD 2.4</P>
</TD>
<TD>
<P>0.08</P>
</TD>
<TD>
<P>LIR 1.2 vs. GLIM: P &lt; 0.0001</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-016.07" MODIFIED="2011-06-30 13:58:05 +0200" MODIFIED_BY="[Empty name]" NO="7" ROWS_PER_STUDY="10" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO">
<NAME>Adverse events</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.2 mg daily</P>
</TH>
<TH>
<P>Glimepiride 4 mg daily</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-06-30 13:58:05 +0200" MODIFIED_BY="[Empty name]" ORDER="1425" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009">
<TR>
<TD>
<P>withdrawal due to adverse events</P>
</TD>
<TD>
<P>10%</P>
</TD>
<TD>
<P>3%</P>
</TD>
</TR>
<TR>
<TD>
<P>withdrawal due to nausea/vomiting/diarrhoea</P>
</TD>
<TD>
<P>5%</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>no significant differences across groups for: physical examination findings, laboratory analyses, ECG, ophthalmoscopy</P>
</TD>
<TD/>
<TD/>
</TR>
<TR>
<TD>
<P>any GI event</P>
</TD>
<TD>
<P>40%</P>
</TD>
<TD>
<P>17%</P>
</TD>
</TR>
<TR>
<TD>
<P>nausea</P>
</TD>
<TD>
<P>16%</P>
</TD>
<TD>
<P>3 to 4%</P>
</TD>
</TR>
<TR>
<TD>
<P>vomiting</P>
</TD>
<TD>
<P>5 to7%</P>
</TD>
<TD>
<P>1%</P>
</TD>
</TR>
<TR>
<TD>
<P>diarrhoea</P>
</TD>
<TD>
<P>8%</P>
</TD>
<TD>
<P>4%</P>
</TD>
</TR>
<TR>
<TD>
<P>serious adverse events: 2 deaths unrelated to liraglutide treatment; 1 participant each in 1.2 mg liraglutide group and in glimepiride group withdrawn due to acute pancreatitis</P>
</TD>
<TD/>
<TD/>
</TR>
<TR>
<TD>
<P>injection site reactions</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>anti-liraglutide antibodies</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2011-06-30 13:58:02 +0200" MODIFIED_BY="[Empty name]" ORDER="1426" STUDY_ID="STD-L-_x002d_-Yang-2010">
<TR>
<TD>
<P>withdrawal due to adverse events</P>
</TD>
<TD>
<P>9.4%</P>
</TD>
<TD>
<P>1.3%</P>
</TD>
</TR>
<TR>
<TD>
<P>serious adverse events</P>
</TD>
<TD>
<P>1.7 to 3.4%</P>
</TD>
<TD>
<P>1.7 to 3.4%</P>
</TD>
</TR>
<TR>
<TD>
<P>pancreatitis</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>none</P>
</TD>
</TR>
<TR>
<TD>
<P>deaths</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>none</P>
</TD>
</TR>
<TR>
<TD>
<P>anti-liraglutide antibodies</P>
</TD>
<TD>
<P>n = 8 from all liraglutide groups</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.8405960848971916" CI_START="-5.579403915102809" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.2100000000000004" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-016.08" MODIFIED="2011-08-30 14:57:12 +0200" MODIFIED_BY="Bernd Richter" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.00792372926165137" Q="0.0" RANDOM="YES" SCALE="15.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="240" TOTAL_2="242" UNITS="" WEIGHT="0.0" Z="2.655302605972349">
<NAME>Systolic blood pressure</NAME>
<GROUP_LABEL_1>Liraglutide 1.2 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Glimepiride 4 mg daily</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Glimepiride</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.8405960848971912" CI_START="-5.579403915102809" EFFECT_SIZE="-3.21" ESTIMABLE="YES" MEAN_1="-2.81" MEAN_2="0.4" MODIFIED="2011-02-08 12:12:14 +0100" MODIFIED_BY="[Empty name]" ORDER="532" SD_1="13.32" SD_2="13.22" SE="1.2089017623754132" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009" TOTAL_1="240" TOTAL_2="242" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-016.09" MODIFIED="2011-08-30 13:58:16 +0200" MODIFIED_BY="Bernd Richter" NO="9" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO">
<NAME>Blood pressure (mm Hg)</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.2 mg daily</P>
</TH>
<TH>
<P>Glimepiride 4 mg daily</P>
</TH>
<TH>
<P>p values</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-06-30 13:58:45 +0200" MODIFIED_BY="[Empty name]" ORDER="1428" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009">
<TR>
<TD>
<P>Systolic blood pressure, change from baseline</P>
</TD>
<TD>
<P>-2.81 SD 13.32</P>
</TD>
<TD>
<P>0.4 SD 13.22</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Diastolic blood pressure, change from baseline</P>
</TD>
<TD>
<P>No change </P>
</TD>
<TD>
<P>No change</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2011-08-30 13:58:16 +0200" MODIFIED_BY="Bernd Richter" ORDER="1429" STUDY_ID="STD-L-_x002d_-Yang-2010">
<TR>
<TD>
<P>Systolic blood pressure, change from baseline</P>
</TD>
<TD>
<P>Reduction of more than 3 mm Hg</P>
</TD>
<TD>
<P>Reduction of 0.91 mm Hg</P>
</TD>
<TD>
<P>Reduction in the liraglutide 1.2 group was significantly higher than that in the glimepiride; p value = NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Diastolic blood pressure, change from baseline</P>
</TD>
<TD>
<P>A slight decrease in mean diastolic BP was observed</P>
</TD>
<TD>
<P>A slight decrease in mean diastolic BP was observed</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.14369236203212365" CI_START="-0.7436923620321237" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-016.10" MODIFIED="2011-08-30 14:57:23 +0200" MODIFIED_BY="Bernd Richter" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.18509878910427793" Q="0.0" RANDOM="YES" SCALE="2.27" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="240" TOTAL_2="242" UNITS="" WEIGHT="0.0" Z="1.325218204498741">
<NAME>Fasting plasma glucose (mmol/L)</NAME>
<GROUP_LABEL_1>Liraglutide 1.2 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Glimepiride 4 mg daily</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Glimepiride</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.14369236203212365" CI_START="-0.7436923620321237" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" MEAN_1="-1.6" MEAN_2="-1.3" MODIFIED="2011-02-08 12:12:23 +0100" MODIFIED_BY="[Empty name]" ORDER="533" SD_1="2.48" SD_2="2.49" SE="0.22637781384347488" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009" TOTAL_1="240" TOTAL_2="242" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-016.11" MODIFIED="2011-06-30 14:23:44 +0200" MODIFIED_BY="[Empty name]" NO="11" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Fasting plasma glucose (mmol/L)</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.2 mg daily</P>
</TH>
<TH>
<P>Glimepiride 4 mg daily</P>
</TH>
<TH>
<P>p values</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-05-04 14:08:14 +0200" MODIFIED_BY="[Empty name]" ORDER="1431" STUDY_ID="STD-L-_x002d_-Yang-2010">
<TR>
<TD>
<P>Change from baseline</P>
</TD>
<TD>
<P>-2.05</P>
</TD>
<TD>
<P>-2.18</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-016.12" MODIFIED="2011-08-30 10:27:51 +0200" MODIFIED_BY="Bernd Richter" NO="12" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO">
<NAME>Post-prandial glucose (mmol/L)</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.2 mg daily</P>
</TH>
<TH>
<P>Glimepiride 4 mg daily</P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-05-04 16:18:41 +0200" MODIFIED_BY="[Empty name]" ORDER="1432" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009">
<TR>
<TD>
<P>Self-monitored 7-point plasma glucose measurements</P>
</TD>
<TD>
<P>-2.3 mmol/L</P>
<P/>
</TD>
<TD>
<P>-2.5 mmol/L</P>
<P/>
</TD>
<TD>
<P>no significant difference between groups</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2011-08-30 10:27:51 +0200" MODIFIED_BY="Bernd Richter" ORDER="1433" STUDY_ID="STD-L-_x002d_-Yang-2010">
<TR>
<TD>
<P>Self-monitored 7-point plasma glucose measurements</P>
</TD>
<TD>
<P>-3.03 mmol/L</P>
</TD>
<TD>
<P>-2.6 mmol/L</P>
</TD>
<TD>
<P>LIR 1.2 vs. GLIM: P = NS</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-016.13" MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" NO="13" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO">
<NAME>Beta-cell function</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.2 mg daily</P>
</TH>
<TH>
<P>Glimepiride 4 mg daily</P>
</TH>
<TH>
<P>Difference between groups</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" ORDER="1434" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009">
<TR>
<TD>
<P>HOMA-B (%)</P>
</TD>
<TD>
<P>+23%</P>
</TD>
<TD>
<P>+25%</P>
</TD>
<TD>
<P>No significant difference between liraglutide and glimepiride groups</P>
</TD>
</TR>
<TR>
<TD>
<P>proinsulin-to-insulin ratio</P>
</TD>
<TD>
<P>-0.1, P &lt; 0.0001 versus placebo</P>
</TD>
<TD>
<P>similar to liraglutide groups but no value stated</P>
</TD>
<TD>
<P>No significant difference between liraglutide and glimepiride groups</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2011-05-04 14:15:40 +0200" MODIFIED_BY="[Empty name]" ORDER="1435" STUDY_ID="STD-L-_x002d_-Yang-2010">
<TR>
<TD>
<P>HOMA-B</P>
</TD>
<TD>
<P>Increases between 14 and 21% points observed in all treatment groups.</P>
</TD>
<TD>
<P>see previous column</P>
</TD>
<TD>
<P>No significant difference between liraglutide and glimepiride groups</P>
</TD>
</TR>
<TR>
<TD>
<P>Proinsulin-to-insulin ratio</P>
</TD>
<TD>
<P>A slight decrease between 0.06 and 0.11 observed in all treatment groups.</P>
</TD>
<TD>
<P>see previous column</P>
</TD>
<TD>
<P>No significant difference between liraglutide and glimepiride groups</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-017" MODIFIED="2011-08-30 14:58:34 +0200" MODIFIED_BY="Bernd Richter" NO="17">
<NAME>Liraglutide 1.8 mg daily versus SU</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-017.01" MODIFIED="2011-08-30 14:57:57 +0200" MODIFIED_BY="Bernd Richter" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.65" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="242" TOTAL_2="242" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>HbA1c (%)</NAME>
<GROUP_LABEL_1>Liraglutide 1.8 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Glimepiride 4 mg daily</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Glimepiride</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.2579585287165895" CI_START="-0.2979585287165895" EFFECT_SIZE="-0.020000000000000018" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="-0.98" MODIFIED="2011-02-08 11:40:10 +0100" MODIFIED_BY="[Empty name]" ORDER="523" SD_1="1.56" SD_2="1.56" SE="0.14181818181818182" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009" TOTAL_1="242" TOTAL_2="242" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-017.02" MODIFIED="2011-06-30 14:23:51 +0200" MODIFIED_BY="[Empty name]" NO="2" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>HbA1c (%)</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.8 mg daily</P>
</TH>
<TH>
<P>Glimepiride 4 mg daily</P>
</TH>
<TH>
<P>Difference between groups</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-06-30 14:00:49 +0200" MODIFIED_BY="[Empty name]" ORDER="1437" STUDY_ID="STD-L-_x002d_-Yang-2010">
<TR>
<TD>
<P>Change in HbA1c</P>
</TD>
<TD>
<P>-1.45</P>
</TD>
<TD>
<P>-1.39</P>
</TD>
<TD>
<P>-0.06, 95% CI -0.23 to 0.11</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.8399521563663224" CI_END="1.2646351448330644" CI_START="0.9359278152544236" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.087937134303987" ESTIMABLE="YES" EVENTS_1="207" EVENTS_2="189" I2="0.0" I2_Q="0.0" ID="CMP-017.03" LOG_CI_END="0.10196524690229775" LOG_CI_START="-0.02875764554136591" LOG_EFFECT_SIZE="0.0366038006804659" METHOD="MH" MODIFIED="2011-06-30 14:01:12 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.3594105280135008" P_Q="1.0" P_Z="0.2723698018744649" Q="0.0" RANDOM="NO" SCALE="4.85" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="476" TOTAL_2="473" WEIGHT="100.0" Z="1.0976215365172384">
<NAME>HbA1c &lt; 7%</NAME>
<GROUP_LABEL_1>Liraglutide 1.8 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Glimepiride 4 mg daily</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glimepiride</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Liraglutide</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4611229778293209" CI_START="0.937610224301898" EFFECT_SIZE="1.1704545454545454" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="88" LOG_CI_END="0.16468677058521822" LOG_CI_START="-0.027977665475211026" LOG_EFFECT_SIZE="0.06835455255500357" MODIFIED="2011-02-08 11:40:50 +0100" MODIFIED_BY="[Empty name]" ORDER="525" O_E="0.0" SE="0.11317204344623577" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009" TOTAL_1="242" TOTAL_2="242" VAR="0.012807911417796677" WEIGHT="46.400870866784594"/>
<DICH_DATA CI_END="1.2474772826225204" CI_START="0.8282921213731353" EFFECT_SIZE="1.0165016501650166" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="101" LOG_CI_END="0.09603264558078577" LOG_CI_START="-0.0818164695845072" LOG_EFFECT_SIZE="0.007108087998139288" MODIFIED="2011-05-04 14:21:12 +0200" MODIFIED_BY="[Empty name]" ORDER="341" O_E="0.0" SE="0.10446945061541156" STUDY_ID="STD-L-_x002d_-Yang-2010" TOTAL_1="234" TOTAL_2="231" VAR="0.010913866111885915" WEIGHT="53.599129133215406"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9946232641237676" CI_END="0.24860997738922885" CI_START="0.07231152314548478" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.13407970067903519" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="85" I2="0.0" I2_Q="0.0" ID="CMP-017.04" LOG_CI_END="-0.6044814459351837" LOG_CI_START="-1.1407924905375872" LOG_EFFECT_SIZE="-0.8726369682363855" METHOD="MH" MODIFIED="2011-08-22 15:33:25 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.3186152716624937" P_Q="1.0" P_Z="1.7923605696704175E-10" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="476" TOTAL_2="473" WEIGHT="100.0" Z="6.378153299414163">
<NAME>Hypoglycaemia</NAME>
<GROUP_LABEL_1>Liraglutide 1.8 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Glimepiride 4 mg daily</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Glimepiride</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.3730017801194675" CI_START="0.07814792699934728" EFFECT_SIZE="0.17073170731707318" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="41" LOG_CI_END="-0.42828909555266065" LOG_CI_START="-1.1070825378582967" LOG_EFFECT_SIZE="-0.7676858167054786" MODIFIED="2011-05-04 14:39:01 +0200" MODIFIED_BY="[Empty name]" ORDER="342" O_E="0.0" SE="0.3987266280920607" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009" TOTAL_1="242" TOTAL_2="242" VAR="0.1589829239496645" WEIGHT="62.42495033044686"/>
<DICH_DATA CI_END="0.24573218483743786" CI_START="0.03277516091509849" EFFECT_SIZE="0.08974358974358974" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="44" LOG_CI_END="-0.6095379579607251" LOG_CI_START="-1.484455167391722" LOG_EFFECT_SIZE="-1.0469965626762237" MODIFIED="2011-06-16 12:26:53 +0200" MODIFIED_BY="[Empty name]" ORDER="343" O_E="0.0" SE="0.5139306997298022" STUDY_ID="STD-L-_x002d_-Yang-2010" TOTAL_1="234" TOTAL_2="231" VAR="0.2641247641247641" WEIGHT="37.57504966955314"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-017.05" MODIFIED="2011-08-30 14:58:13 +0200" MODIFIED_BY="Bernd Richter" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.56" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="242" TOTAL_2="242" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Weight change (kg)</NAME>
<GROUP_LABEL_1>Liraglutide 1.8 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Glimepiride 4 mg daily</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Glimepiride</GRAPH_LABEL_2>
<CONT_DATA CI_END="-3.245864728007312" CI_START="-4.354135271992688" EFFECT_SIZE="-3.8" ESTIMABLE="YES" MEAN_1="-2.8" MEAN_2="1.0" MODIFIED="2011-02-08 11:41:50 +0100" MODIFIED_BY="[Empty name]" ORDER="526" SD_1="3.11" SD_2="3.11" SE="0.2827272727272727" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009" TOTAL_1="242" TOTAL_2="242" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-017.06" MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" NO="6" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Weight change (kg)</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.8 mg daily</P>
</TH>
<TH>
<P>Glimepiride 4 mg daily</P>
</TH>
<TH>
<P>p value</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" ORDER="1443" STUDY_ID="STD-L-_x002d_-Yang-2010">
<TR>
<TD>
<P>Change from baseline</P>
</TD>
<TD>
<P>-2.44 SD 2.6</P>
</TD>
<TD>
<P>0.08</P>
</TD>
<TD>
<P>LIR 1.8 vs. GLIM: P &lt; 0.0001</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-017.07" MODIFIED="2011-06-30 14:02:39 +0200" MODIFIED_BY="[Empty name]" NO="7" ROWS_PER_STUDY="10" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO">
<NAME>Adverse events</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.8 mg daily</P>
</TH>
<TH>
<P>Glimepiride 4 mg daily</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-06-30 14:02:35 +0200" MODIFIED_BY="[Empty name]" ORDER="1444" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009">
<TR>
<TD>
<P>withdrawal due to adverse events</P>
</TD>
<TD>
<P>12%</P>
</TD>
<TD>
<P>3%</P>
</TD>
</TR>
<TR>
<TD>
<P>withdrawal due to nausea/vomiting/diarrhoea</P>
</TD>
<TD>
<P>8%</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>no significant differences across groups for: physical examination findings, laboratory analyses, ECG, ophthalmoscopy</P>
</TD>
<TD/>
<TD/>
</TR>
<TR>
<TD>
<P>any GI event</P>
</TD>
<TD>
<P>44%</P>
</TD>
<TD>
<P>17%</P>
</TD>
</TR>
<TR>
<TD>
<P>nausea</P>
</TD>
<TD>
<P>19%</P>
</TD>
<TD>
<P>3 to 4%</P>
</TD>
</TR>
<TR>
<TD>
<P>vomiting</P>
</TD>
<TD>
<P>5 to 7%</P>
</TD>
<TD>
<P>1%</P>
</TD>
</TR>
<TR>
<TD>
<P>diarrhoea</P>
</TD>
<TD>
<P>15%</P>
</TD>
<TD>
<P>4%</P>
</TD>
</TR>
<TR>
<TD>
<P>serious adverse events: 2 deaths unrelated to liraglutide treatment; 1 participant each in 1.2 mg liraglutide group and in glimepiride group withdrawn due to acute pancreatitis</P>
</TD>
<TD/>
<TD/>
</TR>
<TR>
<TD>
<P>injection site reactions</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>anti-liraglutide antibodies</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2011-06-30 14:02:39 +0200" MODIFIED_BY="[Empty name]" ORDER="1445" STUDY_ID="STD-L-_x002d_-Yang-2010">
<TR>
<TD>
<P>withdrawal due to adverse events</P>
</TD>
<TD>
<P>12.9%</P>
</TD>
<TD>
<P>1.3%</P>
</TD>
</TR>
<TR>
<TD>
<P>serious adverse events</P>
</TD>
<TD>
<P>1.7 to 3.4%</P>
</TD>
<TD>
<P>1.7 to 3.4%</P>
</TD>
</TR>
<TR>
<TD>
<P>pancreatitis</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>none</P>
</TD>
</TR>
<TR>
<TD>
<P>deaths</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>none</P>
</TD>
</TR>
<TR>
<TD>
<P>anti-liraglutide antibodies</P>
</TD>
<TD>
<P>n = 8 from all liraglutide groups</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-017.08" MODIFIED="2011-08-30 14:58:24 +0200" MODIFIED_BY="Bernd Richter" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="21.56" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="242" TOTAL_2="242" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Systolic blood pressure (mm Hg)</NAME>
<GROUP_LABEL_1>Liraglutide 1.8 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Glimepiride 4 mg daily</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Glimepiride</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.3619335030584869" CI_START="-5.018066496941513" EFFECT_SIZE="-2.69" ESTIMABLE="YES" MEAN_1="-2.29" MEAN_2="0.4" MODIFIED="2011-02-08 11:42:40 +0100" MODIFIED_BY="[Empty name]" ORDER="527" SD_1="12.91" SD_2="13.22" SE="1.1878108553549986" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009" TOTAL_1="242" TOTAL_2="242" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-017.09" MODIFIED="2011-08-30 13:58:16 +0200" MODIFIED_BY="Bernd Richter" NO="9" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO">
<NAME>Blood pressure (mm Hg)</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.8 mg daily</P>
</TH>
<TH>
<P>Glimepiride 4 mg daily</P>
</TH>
<TH>
<P>p values</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-06-24 11:15:04 +0200" MODIFIED_BY="[Empty name]" ORDER="1447" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009">
<TR>
<TD>
<P>Systolic blood pressure, change from baseline</P>
</TD>
<TD>
<P>-2.29 SD 12.91</P>
</TD>
<TD>
<P>0.4 SD 13.22</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Diastolic blood pressure, change from baseline</P>
</TD>
<TD>
<P>No change</P>
</TD>
<TD>
<P>No change</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2011-08-30 13:58:16 +0200" MODIFIED_BY="Bernd Richter" ORDER="1448" STUDY_ID="STD-L-_x002d_-Yang-2010">
<TR>
<TD>
<P>Systolic blood pressure, change from baseline</P>
</TD>
<TD>
<P>Reduction of more than 3 mm Hg</P>
</TD>
<TD>
<P>Reduction of 0.91 mm Hg</P>
</TD>
<TD>
<P>Reduction in the liraglutide 1.2 group was significantly higher than that in the glimepiride; p value = NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Diastolic blood pressure, change from baseline</P>
</TD>
<TD>
<P>A slight decrease in mean diastolic BP was observed</P>
</TD>
<TD>
<P>A slight decrease in mean diastolic BP was observed</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-017.10" MODIFIED="2011-08-30 14:58:34 +0200" MODIFIED_BY="Bernd Richter" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="3.33" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="242" TOTAL_2="242" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Fasting plasma glucose (mmol/L)</NAME>
<GROUP_LABEL_1>Liraglutide 1.8 mg daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Glimepiride 4 mg daily</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Liraglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Glimepiride</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.029646811638879278" CI_START="-0.8296468116388791" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="-1.7" MEAN_2="-1.3" MODIFIED="2011-02-08 12:10:55 +0100" MODIFIED_BY="[Empty name]" ORDER="528" SD_1="2.33" SD_2="2.49" SE="0.21921158502292817" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009" TOTAL_1="242" TOTAL_2="242" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-017.11" MODIFIED="2011-06-30 14:23:58 +0200" MODIFIED_BY="[Empty name]" NO="11" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Fasting plasma glucose (mmol/L)</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.8 mg daily</P>
</TH>
<TH>
<P>Glimepiride 4 mg daily</P>
</TH>
<TH>
<P>p values</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-05-04 16:16:42 +0200" MODIFIED_BY="[Empty name]" ORDER="1450" STUDY_ID="STD-L-_x002d_-Yang-2010">
<TR>
<TD>
<P>Change from baseline</P>
</TD>
<TD>
<P>-2.12</P>
</TD>
<TD>
<P>-2.18</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-017.12" MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" NO="12" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO">
<NAME>Post-prandial glucose (mmol/L)</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.8 mg daily</P>
</TH>
<TH>
<P>Glimepiride 4 mg daily</P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-05-04 16:18:20 +0200" MODIFIED_BY="[Empty name]" ORDER="1451" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009">
<TR>
<TD>
<P>Self-monitored 7-point plasma glucose measurements</P>
</TD>
<TD>
<P>-2.6 mmol/L</P>
<P/>
</TD>
<TD>
<P>-2.5 mmol/L</P>
<P/>
</TD>
<TD>
<P>no significant difference between groups</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" ORDER="1452" STUDY_ID="STD-L-_x002d_-Yang-2010">
<TR>
<TD>
<P>Self-monitored 7-point plasma glucose measurements</P>
</TD>
<TD>
<P>-3.51 mmol/L</P>
</TD>
<TD>
<P>-2.6 mmol/L</P>
</TD>
<TD>
<P>LIR 1.8 vs. GLIM: P &lt; 0.0001</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-017.13" MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" NO="13" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO">
<NAME>Beta-cell function</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Liraglutide 1.8 mg daily</P>
</TH>
<TH>
<P>Glimepiride 4 mg daily</P>
</TH>
<TH>
<P>Difference between groups</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" ORDER="1453" STUDY_ID="STD-L-_x002d_-LEAD-2-Nauck-2009">
<TR>
<TD>
<P>HOMA-B (%)</P>
</TD>
<TD>
<P>+28%</P>
</TD>
<TD>
<P>+25%</P>
</TD>
<TD>
<P>No significant difference between liraglutide and glimepiride groups</P>
</TD>
</TR>
<TR>
<TD>
<P>Proinsulin-to-insulin ratio</P>
</TD>
<TD>
<P>-0.1, P &lt; 0.0001 versus placebo</P>
</TD>
<TD>
<P>similar to liraglutide groups but no value stated</P>
</TD>
<TD>
<P>No significant difference between liraglutide and glimepiride groups</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2011-06-30 14:04:30 +0200" MODIFIED_BY="[Empty name]" ORDER="1454" STUDY_ID="STD-L-_x002d_-Yang-2010">
<TR>
<TD>
<P>HOMA-B</P>
</TD>
<TD>
<P>Increases between 14% and 21% points observed in all treatment groups.</P>
</TD>
<TD>
<P>see previous column</P>
</TD>
<TD>
<P>No significant difference between liraglutide and glimepiride groups</P>
</TD>
</TR>
<TR>
<TD>
<P>Proinsulin-to-insulin ratio</P>
</TD>
<TD>
<P>A slight decrease between 0.06 and 0.11 observed in all treatment groups.</P>
</TD>
<TD>
<P>see previous column</P>
</TD>
<TD>
<P>No significant difference between liraglutide and glimepiride groups</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-018" MODIFIED="2011-08-30 14:59:15 +0200" MODIFIED_BY="Bernd Richter" NO="18">
<NAME>Taspoglutide versus placebo</NAME>
<CONT_OUTCOME CHI2="5.040780031109427" CI_END="-0.7699825312648961" CI_START="-1.0183221986107882" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8941523649378422" ESTIMABLE="YES" I2="40.48540143617953" I2_Q="3.818145910389928" ID="CMP-018.01" MODIFIED="2011-08-30 14:59:15 +0200" MODIFIED_BY="Bernd Richter" NO="1" P_CHI2="0.16883545890058704" P_Q="0.3535618990465199" P_Z="3.1234956033714826E-45" Q="2.0793943087608326" RANDOM="YES" SCALE="2.42" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.007808454210875676" TOTALS="SUB" TOTAL_1="180" TOTAL_2="179" UNITS="" WEIGHT="300.0" Z="14.11378577332603">
<NAME>HbA1c (%)</NAME>
<GROUP_LABEL_1>Taspoglutide</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Taspoglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.8059734645910451" CI_START="-1.194026535408955" DF="0" EFFECT_SIZE="-1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-018.01.01" MODIFIED="2011-06-21 11:42:21 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="5.4389471779679155E-24" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="49" WEIGHT="100.0" Z="10.101525445522109">
<NAME>Taspoglutide 10 mg once weekly verus placebo</NAME>
<CONT_DATA CI_END="-0.8059734645910451" CI_START="-1.194026535408955" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="-1.2" MEAN_2="-0.2" MODIFIED="2011-06-14 12:08:07 +0200" MODIFIED_BY="[Empty name]" ORDER="355" SD_1="0.49" SD_2="0.49" SE="0.09899494936611665" STUDY_ID="STD-T-_x002d_-Nauck-2009" TOTAL_1="49" TOTAL_2="49" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.9991752268126275" CI_END="-0.5757270085208622" CI_START="-1.1596204914791377" DF="1" EFFECT_SIZE="-0.86767375" ESTIMABLE="YES" I2="66.65750000000001" ID="CMP-018.01.02" MODIFIED="2011-06-21 11:42:26 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0833071117395826" P_Z="5.708972589577078E-9" STUDIES="2" TAU2="0.02999587500000001" TOTAL_1="82" TOTAL_2="81" WEIGHT="100.00000000000001" Z="5.825066899924057">
<NAME>Taspoglutide 20 mg once weekly versus placebo</NAME>
<CONT_DATA CI_END="-0.806946034802767" CI_START="-1.193053965197233" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="-1.2" MEAN_2="-0.2" MODIFIED="2011-06-14 12:10:44 +0200" MODIFIED_BY="[Empty name]" ORDER="356" SD_1="0.49" SD_2="0.49" SE="0.09849873095629201" STUDY_ID="STD-T-_x002d_-Nauck-2009" TOTAL_1="50" TOTAL_2="49" WEIGHT="55.89125000000001"/>
<CONT_DATA CI_END="-0.42070513220304223" CI_START="-0.9792948677969577" EFFECT_SIZE="-0.7" ESTIMABLE="YES" MEAN_1="-1.2" MEAN_2="-0.5" MODIFIED="2011-06-14 12:09:39 +0200" MODIFIED_BY="[Empty name]" ORDER="357" SD_1="0.57" SD_2="0.57" SE="0.1425" STUDY_ID="STD-T_x002d_-Ratner-2010" TOTAL_1="32" TOTAL_2="32" WEIGHT="44.10875000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.6059734645910452" CI_START="-0.9940265354089549" DF="0" EFFECT_SIZE="-0.8" ESTIMABLE="YES" I2="0.0" ID="CMP-018.01.03" MODIFIED="2011-06-21 11:42:33 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="6.41218239098373E-16" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="49" WEIGHT="100.0" Z="8.081220356417687">
<NAME>Taspoglutide 20 mg once every 2 weeks versus placebo</NAME>
<CONT_DATA CI_END="-0.6059734645910452" CI_START="-0.9940265354089549" EFFECT_SIZE="-0.8" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="-0.2" MODIFIED="2011-06-14 12:12:43 +0200" MODIFIED_BY="[Empty name]" ORDER="358" SD_1="0.49" SD_2="0.49" SE="0.09899494936611665" STUDY_ID="STD-T-_x002d_-Nauck-2009" TOTAL_1="49" TOTAL_2="49" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-018.02" MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" NO="2" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>HbA1c (%)</NAME>
<TR>
<TH>
<P>20/30 mg (n = 33)</P>
</TH>
<TH>
<P>20/40 mg (n = 32)</P>
</TH>
<TH>
<P>Placebo (n = 32)</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" ORDER="1459" STUDY_ID="STD-T_x002d_-Ratner-2010">
<TR>
<TD>
<P>-0.90 SD 0.57, P &lt; 0.0001 versus placebo</P>
</TD>
<TD>
<P>-1.20 SD 0.57, P &lt; 0.0001 versus placebo</P>
</TD>
<TD>
<P>-0.50 SD 0.57</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.4692911424196924" CI_END="6.150401826139734" CI_START="3.1273212618109847" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="4.385690641115478" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-018.03" LOG_CI_END="0.7889034906005159" LOG_CI_START="0.49517249750936376" LOG_EFFECT_SIZE="0.6420379940549398" METHOD="MH" MODIFIED="2011-06-30 14:05:51 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.925584355504812" P_Q="0.8895285569223145" P_Z="1.0512507856641735E-17" Q="0.2341273431216795" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="180" TOTAL_2="179" WEIGHT="300.0" Z="8.568189089011248">
<NAME>HbA1c &lt; 7%</NAME>
<GROUP_LABEL_1>Taspoglutide</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Taspoglutide</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.333858057215124" CI_START="2.5461738173347346" DF="0" EFFECT_SIZE="4.875" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="8" I2="0.0" ID="CMP-018.03.01" LOG_CI_END="0.970061192152636" LOG_CI_START="0.40588804791647537" LOG_EFFECT_SIZE="0.6879746200345557" MODIFIED="2011-06-21 11:42:48 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.7519735293761054E-6" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="49" WEIGHT="100.0" Z="4.780112245048376">
<NAME>Taspoglutide 10 mg once weekly versus placebo</NAME>
<DICH_DATA CI_END="9.333858057215124" CI_START="2.5461738173347346" EFFECT_SIZE="4.875" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="8" LOG_CI_END="0.970061192152636" LOG_CI_START="0.40588804791647537" LOG_EFFECT_SIZE="0.6879746200345557" MODIFIED="2011-06-14 14:32:58 +0200" MODIFIED_BY="[Empty name]" ORDER="361" O_E="0.0" SE="0.3313980976264248" STUDY_ID="STD-T-_x002d_-Nauck-2009" TOTAL_1="49" TOTAL_2="49" VAR="0.1098246991104134" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.23513398625267523" CI_END="7.2153254448963775" CI_START="2.699535147002199" DF="1" EFFECT_SIZE="4.413391511701295" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="14" I2="0.0" ID="CMP-018.03.02" LOG_CI_END="0.8582559245819855" LOG_CI_START="0.4312889862061289" LOG_EFFECT_SIZE="0.6447724553940571" MODIFIED="2011-06-21 11:42:52 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6277429351681869" P_Z="3.2278028697524113E-9" STUDIES="2" TAU2="0.0" TOTAL_1="82" TOTAL_2="81" WEIGHT="99.99999999999999" Z="5.91957211302087">
<NAME>Taspoglutide 20 mg once weekly versus placebo</NAME>
<DICH_DATA CI_END="9.375262533073066" CI_START="2.560994949773411" EFFECT_SIZE="4.9" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="8" LOG_CI_END="0.9719834380070679" LOG_CI_START="0.40840872204995937" LOG_EFFECT_SIZE="0.6901960800285137" MODIFIED="2011-06-14 14:33:35 +0200" MODIFIED_BY="[Empty name]" ORDER="362" O_E="0.0" SE="0.3310465778930419" STUDY_ID="STD-T-_x002d_-Nauck-2009" TOTAL_1="50" TOTAL_2="49" VAR="0.10959183673469389" WEIGHT="57.39651093602232"/>
<DICH_DATA CI_END="8.140429252787065" CI_START="1.8051191145004373" EFFECT_SIZE="3.8333333333333335" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="6" LOG_CI_END="0.9106473062653152" LOG_CI_START="0.25650586500258327" LOG_EFFECT_SIZE="0.5835765856339493" MODIFIED="2011-06-14 14:33:58 +0200" MODIFIED_BY="[Empty name]" ORDER="363" O_E="0.0" SE="0.3842459206500856" STUDY_ID="STD-T_x002d_-Ratner-2010" TOTAL_1="32" TOTAL_2="32" VAR="0.14764492753623187" WEIGHT="42.60348906397767"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.563659685644727" CI_START="1.9852327608682019" DF="0" EFFECT_SIZE="3.875" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="8" I2="0.0" ID="CMP-018.03.03" LOG_CI_END="0.8787319802508061" LOG_CI_START="0.297811433433852" LOG_EFFECT_SIZE="0.5882717068423291" MODIFIED="2011-06-21 11:42:59 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="7.201392662804852E-5" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="49" WEIGHT="100.0" Z="3.9695320293023584">
<NAME>Taspoglutide 20 mg once every two weeks versus placebo</NAME>
<DICH_DATA CI_END="7.563659685644727" CI_START="1.9852327608682019" EFFECT_SIZE="3.875" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="8" LOG_CI_END="0.8787319802508061" LOG_CI_START="0.297811433433852" LOG_EFFECT_SIZE="0.5882717068423291" MODIFIED="2011-06-14 14:34:42 +0200" MODIFIED_BY="[Empty name]" ORDER="364" O_E="0.0" SE="0.3412356048033628" STUDY_ID="STD-T-_x002d_-Nauck-2009" TOTAL_1="49" TOTAL_2="49" VAR="0.1164417379855168" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-018.04" MODIFIED="2011-06-30 14:06:03 +0200" MODIFIED_BY="[Empty name]" NO="4" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>HbA1c &lt; 7%</NAME>
<TR>
<TH>
<P>20/30 mg once weekly</P>
</TH>
<TH>
<P>20/40 mg once weekly</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-06-30 14:06:03 +0200" MODIFIED_BY="[Empty name]" ORDER="1464" STUDY_ID="STD-T_x002d_-Ratner-2010">
<TR>
<TD>
<P>53%</P>
</TD>
<TD>
<P>70%</P>
</TD>
<TD>
<P>19%</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.35707678025867196" CI_END="7.753312104273358" CI_START="0.48431556896460687" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9377950776956072" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-018.05" LOG_CI_END="0.8894872665485765" LOG_CI_START="-0.3148715697584625" LOG_EFFECT_SIZE="0.28730784839505696" METHOD="MH" MODIFIED="2011-08-22 15:33:46 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.8364919818373502" P_Q="0.836786120479992" P_Z="0.349723889330414" Q="0.3563736356917556" RANDOM="YES" SCALE="73.36" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="97" TOTAL_2="96" WEIGHT="300.0" Z="0.9351250115068627">
<NAME>Hypoglycaemia</NAME>
<GROUP_LABEL_1>Taspoglutide</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Taspoglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.304614839074713" CI_START="0.06533976911636269" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-018.05.01" LOG_CI_END="1.1848224044743985" LOG_CI_START="-1.1848224044743985" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-06-21 11:43:10 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="0.0">
<NAME>Taspoglutide 20/20 mg once weekly versus placebo</NAME>
<DICH_DATA CI_END="15.304614839074713" CI_START="0.06533976911636269" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1848224044743985" LOG_CI_START="-1.1848224044743985" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-06-14 14:54:45 +0200" MODIFIED_BY="[Empty name]" ORDER="371" O_E="0.0" SE="1.3919410907075054" STUDY_ID="STD-T_x002d_-Ratner-2010" TOTAL_1="32" TOTAL_2="32" VAR="1.9375" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="26.526797898162883" CI_START="0.3190287025914072" DF="0" EFFECT_SIZE="2.909090909090909" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-018.05.02" LOG_CI_END="1.4236848286069304" LOG_CI_START="-0.49617024228356843" LOG_EFFECT_SIZE="0.46375729316168096" MODIFIED="2011-06-21 11:43:15 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.34369388573511916" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="32" WEIGHT="100.0" Z="0.94689188360773">
<NAME>Taspoglutide 20/30 mg once weekly versus placebo</NAME>
<DICH_DATA CI_END="26.526797898162883" CI_START="0.3190287025914072" EFFECT_SIZE="2.909090909090909" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4236848286069304" LOG_CI_START="-0.49617024228356843" LOG_EFFECT_SIZE="0.46375729316168096" MODIFIED="2011-06-14 14:54:48 +0200" MODIFIED_BY="[Empty name]" ORDER="372" O_E="0.0" SE="1.1277323720769494" STUDY_ID="STD-T_x002d_-Ratner-2010" TOTAL_1="33" TOTAL_2="32" VAR="1.271780303030303" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="20.96934157435162" CI_START="0.19075467800536708" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-018.05.03" LOG_CI_END="1.321584794074541" LOG_CI_START="-0.7195248027465787" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2011-06-21 11:43:22 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.5631799263271209" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="0.5781247128390816">
<NAME>Taspoglutide 20/40 mg once weekly versus placebo</NAME>
<DICH_DATA CI_END="20.96934157435162" CI_START="0.19075467800536708" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.321584794074541" LOG_CI_START="-0.7195248027465787" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2011-06-14 14:54:49 +0200" MODIFIED_BY="[Empty name]" ORDER="373" O_E="0.0" SE="1.1989578808281798" STUDY_ID="STD-T_x002d_-Ratner-2010" TOTAL_1="32" TOTAL_2="32" VAR="1.4375" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-018.06" MODIFIED="2011-06-30 10:27:26 +0200" MODIFIED_BY="[Empty name]" NO="6" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Hypoglycaemia</NAME>
<TR>
<TH>
<P>Results</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2009-11-16 16:16:21 +0100" MODIFIED_BY="[Empty name]" ORDER="1468" STUDY_ID="STD-T-_x002d_-Nauck-2009">
<TR>
<TD>
<P>hypoglycaemia not defined; no data reported for the separate comparison groups; overall, there were 7 hypoglycaemic events in 6 patients, 2 of which were asymptomatic; </P>
<P>there were no cases of severe hypoglycaemia in the taspoglutide group</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="8.503233053593204" CI_END="-0.6277201883027166" CI_START="-1.748567376963127" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.1881437826329218" ESTIMABLE="YES" I2="64.71930169275683" I2_Q="0.0" ID="CMP-018.07" MODIFIED="2011-06-30 14:06:45 +0200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.036679573731707826" P_Q="0.9376663930127359" P_Z="3.2488417879438976E-5" Q="0.1287221206176444" RANDOM="YES" SCALE="7.87" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.3569836248853255" TOTALS="SUB" TOTAL_1="142" TOTAL_2="179" UNITS="" WEIGHT="300.0" Z="4.155283692505668">
<NAME>Weight change (kg)</NAME>
<GROUP_LABEL_1>Taspoglutide</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Taspoglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.4692339369251016" CI_START="-2.1307660630748986" DF="0" EFFECT_SIZE="-1.3" ESTIMABLE="YES" I2="0.0" ID="CMP-018.07.01" MODIFIED="2011-06-21 11:43:35 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.0021622437361211505" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="49" WEIGHT="100.0" Z="3.0669923738475555">
<NAME>Taspoglutide 10 mg once weekly versus placebo</NAME>
<CONT_DATA CI_END="-0.4692339369251016" CI_START="-2.1307660630748986" EFFECT_SIZE="-1.3" ESTIMABLE="YES" MEAN_1="-2.1" MEAN_2="-0.8" MODIFIED="2011-06-14 14:38:53 +0200" MODIFIED_BY="[Empty name]" ORDER="366" SD_1="1.87" SD_2="2.1" SE="0.423868024937129" STUDY_ID="STD-T-_x002d_-Nauck-2009" TOTAL_1="39" TOTAL_2="49" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="8.391933515429765" CI_END="0.7932834249672678" CI_START="-2.929954477598846" DF="1" EFFECT_SIZE="-1.0683355263157892" ESTIMABLE="YES" I2="88.0837950138504" ID="CMP-018.07.02" MODIFIED="2011-06-21 11:43:39 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.003768907743936456" P_Z="0.26068516079900317" STUDIES="2" TAU2="1.5899124999999987" TOTAL_1="72" TOTAL_2="81" WEIGHT="99.99999999999999" Z="1.1247732268413158">
<NAME>Taspoglutide 20 mg once weekly versus placebo</NAME>
<CONT_DATA CI_END="-1.1678804458311793" CI_START="-2.83211955416882" EFFECT_SIZE="-1.9999999999999998" ESTIMABLE="YES" MEAN_1="-2.8" MEAN_2="-0.8" MODIFIED="2011-06-14 14:40:07 +0200" MODIFIED_BY="[Empty name]" ORDER="367" SD_1="1.9" SD_2="2.1" SE="0.4245585943070756" STUDY_ID="STD-T-_x002d_-Nauck-2009" TOTAL_1="40" TOTAL_2="49" WEIGHT="50.965027700831016"/>
<CONT_DATA CI_END="0.879834983944735" CI_START="-1.0798349839447352" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="-2.1" MEAN_2="-2.0" MODIFIED="2011-06-14 14:40:09 +0200" MODIFIED_BY="[Empty name]" ORDER="368" SD_1="2.26" SD_2="1.7" SE="0.49992499437415605" STUDY_ID="STD-T_x002d_-Ratner-2010" TOTAL_1="32" TOTAL_2="32" WEIGHT="49.03497229916897"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.268539671484068" CI_START="-1.9314603285159317" DF="0" EFFECT_SIZE="-1.0999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-018.07.03" MODIFIED="2011-06-21 11:43:47 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.009514817701013539" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="49" WEIGHT="99.99999999999999" Z="2.592980457458769">
<NAME>Taspoglutide 20 mg once every two weeks versus placebo</NAME>
<CONT_DATA CI_END="-0.268539671484068" CI_START="-1.9314603285159317" EFFECT_SIZE="-1.0999999999999999" ESTIMABLE="YES" MEAN_1="-1.9" MEAN_2="-0.8" MODIFIED="2011-06-14 14:40:58 +0200" MODIFIED_BY="[Empty name]" ORDER="369" SD_1="1.67" SD_2="2.1" SE="0.424222248507822" STUDY_ID="STD-T-_x002d_-Nauck-2009" TOTAL_1="31" TOTAL_2="49" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-018.08" MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" NO="8" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Weight change</NAME>
<TR>
<TH>
<P>20/30 mg once weekly</P>
</TH>
<TH>
<P>20/40 mg once weekly</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" ORDER="1473" STUDY_ID="STD-T_x002d_-Ratner-2010">
<TR>
<TD>
<P>-3 SD 1.72, P = 0.03 versus placebo</P>
</TD>
<TD>
<P>-2.7 SD 2.26, P = 0.17 versus placebo</P>
</TD>
<TD>
<P>-2 SD 1.70</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-018.09" MODIFIED="2011-06-30 14:07:18 +0200" MODIFIED_BY="[Empty name]" NO="9" ROWS_PER_STUDY="10" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Adverse events</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>20/20 mg once weekly</P>
</TH>
<TH>
<P>20/30 mg once weekly</P>
</TH>
<TH>
<P>20/40 mg once weekly</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-06-30 14:07:18 +0200" MODIFIED_BY="[Empty name]" ORDER="1474" STUDY_ID="STD-T_x002d_-Ratner-2010">
<TR>
<TD>
<P>Withdrawal due to adverse events</P>
</TD>
<TD>
<P>n = 3</P>
</TD>
<TD>
<P>n = 6</P>
</TD>
<TD>
<P>n = 6</P>
</TD>
<TD>
<P>n = 1</P>
</TD>
</TR>
<TR>
<TD>
<P>Nausea</P>
</TD>
<TD>
<P>38%</P>
</TD>
<TD>
<P>52%</P>
</TD>
<TD>
<P>34%</P>
</TD>
<TD>
<P>13%</P>
</TD>
</TR>
<TR>
<TD>
<P>Headache</P>
</TD>
<TD>
<P>16%</P>
</TD>
<TD>
<P>6%</P>
</TD>
<TD>
<P>9%</P>
</TD>
<TD>
<P>13%</P>
</TD>
</TR>
<TR>
<TD>
<P>Diarrhoea</P>
</TD>
<TD>
<P>13%</P>
</TD>
<TD>
<P>21%</P>
</TD>
<TD>
<P>9%</P>
</TD>
<TD>
<P>9%</P>
</TD>
</TR>
<TR>
<TD>
<P>Vomiting</P>
</TD>
<TD>
<P>13%</P>
</TD>
<TD>
<P>27%</P>
</TD>
<TD>
<P>13%</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>Dyspepsia</P>
</TD>
<TD>
<P>19%</P>
</TD>
<TD>
<P>15%</P>
</TD>
<TD>
<P>16%</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>Abdominal distension</P>
</TD>
<TD>
<P>9%</P>
</TD>
<TD>
<P>12%</P>
</TD>
<TD>
<P>3%</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>Injection site reactions</P>
</TD>
<TD>
<P>69%</P>
</TD>
<TD>
<P>52%</P>
</TD>
<TD>
<P>59%</P>
</TD>
<TD>
<P>13%</P>
</TD>
</TR>
<TR>
<TD>
<P>serious adverse events</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>n = 1, unrelated to study drug</P>
</TD>
<TD>
<P>n = 1, unrelated to study drug</P>
</TD>
</TR>
<TR>
<TD>
<P>severe hypoglycaemia</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-018.10" MODIFIED="2011-06-30 14:08:08 +0200" MODIFIED_BY="[Empty name]" NO="10" ROWS_PER_STUDY="7" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Adverse events</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>10 mg weekly</P>
</TH>
<TH>
<P>20 mg weekly</P>
</TH>
<TH>
<P>20 mg every 2 weeks</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-06-30 14:08:08 +0200" MODIFIED_BY="[Empty name]" ORDER="1475" STUDY_ID="STD-T-_x002d_-Nauck-2009">
<TR>
<TD>
<P>withdrawal due to adverse event</P>
</TD>
<TD>
<P>n = 2</P>
</TD>
<TD>
<P>n = 3</P>
</TD>
<TD>
<P>n = 1</P>
</TD>
<TD>
<P>n = 0</P>
</TD>
</TR>
<TR>
<TD>
<P>adverse events similar across groups for: headache</P>
<P>no clinically relevant abnormalities in ECG, vital signs, laboratory parameters</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
<TR>
<TD>
<P>nausea</P>
</TD>
<TD>
<P>n = 12 (24%)</P>
</TD>
<TD>
<P>n = 26 (52%)</P>
</TD>
<TD>
<P>n = 20 (41%)</P>
</TD>
<TD>
<P>n = 3 (6%)</P>
</TD>
</TR>
<TR>
<TD>
<P>vomiting</P>
</TD>
<TD>
<P>n = 2 (4%)</P>
</TD>
<TD>
<P>n = 11 (22%)</P>
</TD>
<TD>
<P>n = 12 (24%)</P>
</TD>
<TD>
<P>n = 2 (4%)</P>
</TD>
</TR>
<TR>
<TD>
<P>diarrhoea</P>
</TD>
<TD>
<P>n = 5 (10%)</P>
</TD>
<TD>
<P>n = 5 (10%)</P>
</TD>
<TD>
<P>n = 9 (18%)</P>
</TD>
<TD>
<P>n = 4 (8%)</P>
</TD>
</TR>
<TR>
<TD>
<P>serious adverse events: 6 patients, 2 of which in placebo group</P>
<P>considered to be unrelated to study treatment</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
<TR>
<TD>
<P>mild and moderate injection site reactions which did not result in treatment discontinuation</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="1.5909130679200398" CI_END="-0.9521725613481355" CI_START="-1.913429480354853" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.4328010208514943" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-018.11" MODIFIED="2011-06-30 14:08:29 +0200" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.4513752920063727" P_Q="0.45137529200637283" P_Z="5.131624477442713E-9" Q="1.5909130679200392" RANDOM="YES" SCALE="6.23" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="97" TOTAL_2="96" UNITS="" WEIGHT="300.0" Z="5.842846677832916">
<NAME>Fasting plasma glucose (mmol/L)</NAME>
<GROUP_LABEL_1>Taspoglutide</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Taspoglutide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.729622509415266E-31" CI_END="-0.8670153065704764" CI_START="-2.5329846934295226" DF="0" EFFECT_SIZE="-1.6999999999999995" ESTIMABLE="YES" I2="100.0" ID="CMP-018.11.01" MODIFIED="2011-06-21 11:44:00 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="6.334248366713475E-5" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.00000000000001" Z="3.999999999999999">
<NAME>Taspoglutide 20/20 mg once weekly versus placebo</NAME>
<CONT_DATA CI_END="-0.8670153065704767" CI_START="-2.5329846934295226" EFFECT_SIZE="-1.6999999999999997" ESTIMABLE="YES" MEAN_1="-2.3" MEAN_2="-0.6" MODIFIED="2011-06-14 15:13:31 +0200" MODIFIED_BY="[Empty name]" ORDER="375" SD_1="1.7" SD_2="1.7" SE="0.425" STUDY_ID="STD-T_x002d_-Ratner-2010" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.16854782902020515" CI_START="-1.8314521709797948" DF="0" EFFECT_SIZE="-1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-018.11.02" MODIFIED="2011-06-21 11:44:04 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.018409454745420106" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="32" WEIGHT="99.99999999999999" Z="2.3572780888050424">
<NAME>Taspoglutide 20/30 mg once weekly versus placebo</NAME>
<CONT_DATA CI_END="-0.16854782902020515" CI_START="-1.8314521709797948" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="-1.6" MEAN_2="-0.6" MODIFIED="2011-06-14 15:14:07 +0200" MODIFIED_BY="[Empty name]" ORDER="376" SD_1="1.72" SD_2="1.7" SE="0.42421808642310954" STUDY_ID="STD-T_x002d_-Ratner-2010" TOTAL_1="33" TOTAL_2="32" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.767015306570477" CI_START="-2.432984693429523" DF="0" EFFECT_SIZE="-1.6" ESTIMABLE="YES" I2="0.0" ID="CMP-018.11.03" MODIFIED="2011-06-21 11:44:11 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="1.6674523327352348E-4" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.00000000000001" Z="3.7647058823529416">
<NAME>Taspoglutide 20/40 mg once weekly versus placebo</NAME>
<CONT_DATA CI_END="-0.767015306570477" CI_START="-2.432984693429523" EFFECT_SIZE="-1.6" ESTIMABLE="YES" MEAN_1="-2.2" MEAN_2="-0.6" MODIFIED="2011-06-14 15:14:08 +0200" MODIFIED_BY="[Empty name]" ORDER="377" SD_1="1.7" SD_2="1.7" SE="0.425" STUDY_ID="STD-T_x002d_-Ratner-2010" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-018.12" MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" NO="12" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Fasting plasma glucose</NAME>
<TR>
<TH>
<P>10 mg once weekly</P>
</TH>
<TH>
<P>20 mg once weekly</P>
</TH>
<TH>
<P>20 mg every 2 weeks</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
<TH>
<P>FPG fluctuations</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" ORDER="1479" STUDY_ID="STD-T-_x002d_-Nauck-2009">
<TR>
<TD>
<P>-2.5 mmol/L, P &lt; 0.0001</P>
</TD>
<TD>
<P>-2.5 mmol/L, P &lt; 0.0001</P>
</TD>
<TD>
<P>-1.4 mmol/L, P = 0.02</P>
</TD>
<TD>
<P>-0.78 mmol/L</P>
</TD>
<TD>
<P>the fluctuation in FPG was less for the weekly regimens than for the dosing once every 2 weeks:</P>
<P>0.6 mmol/L amplitude between week 2 and week 8 for both 10 mg and 20 mg per week versus 1.3 mmol/L amplitude between week 2 and week 8 for 20 mg every 2 weeks</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-018.13" MODIFIED="2011-06-30 14:24:11 +0200" MODIFIED_BY="[Empty name]" NO="13" ROWS_PER_STUDY="3" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Postprandial glucose and insulin</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>10 mg once weekly</P>
</TH>
<TH>
<P>20 mg once weekly</P>
</TH>
<TH>
<P>20 mg every 2 weeks</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-06-30 14:09:02 +0200" MODIFIED_BY="[Empty name]" ORDER="1480" STUDY_ID="STD-T-_x002d_-Nauck-2009">
<TR>
<TD>
<P>plasma glucose 120 min after a mixed meal (% change from baseline)</P>
</TD>
<TD>
<P>-22.0%</P>
</TD>
<TD>
<P>-18.0%</P>
</TD>
<TD>
<P>-5.5%</P>
</TD>
<TD>
<P>-10.5%</P>
</TD>
</TR>
<TR>
<TD>
<P>glucose AUC (% change from baseline)</P>
</TD>
<TD>
<P>-27.5% (SE 3.2)</P>
</TD>
<TD>
<P>-22.2% (SE 3.3)</P>
</TD>
<TD>
<P>-9.2% (SE 5.0)</P>
</TD>
<TD>
<P>-7.2% (SE3 .5)</P>
</TD>
</TR>
<TR>
<TD>
<P>mean % change in plasma insulin at 120 min</P>
</TD>
<TD>
<P>+28.5%</P>
</TD>
<TD>
<P>+44.9%</P>
</TD>
<TD>
<P>-13%</P>
</TD>
<TD>
<P>-15.3%</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-018.14" MODIFIED="2011-06-30 14:24:15 +0200" MODIFIED_BY="[Empty name]" NO="14" ROWS_PER_STUDY="4" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Lipid profiles</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>10 mg once weekly</P>
</TH>
<TH>
<P>20 mg once weekly</P>
</TH>
<TH>
<P>20 mg every 2 weeks</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-06-30 14:09:15 +0200" MODIFIED_BY="[Empty name]" ORDER="1481" STUDY_ID="STD-T-_x002d_-Nauck-2009">
<TR>
<TD>
<P>Triglycerides (mmol/L)</P>
</TD>
<TD>
<P>-0.29 mmol/L</P>
</TD>
<TD>
<P>-0.54 mmol/L</P>
</TD>
<TD>
<P>-0.30 mmol/L</P>
</TD>
<TD>
<P>+0.10 mmol/L</P>
</TD>
</TR>
<TR>
<TD>
<P>Total cholesterol (mmol/L)</P>
</TD>
<TD>
<P>-0.31 mmol/L</P>
</TD>
<TD>
<P>-0.23 mmol/L</P>
</TD>
<TD>
<P>-0.31 mmol/L</P>
</TD>
<TD>
<P>+0.18 mmol/L</P>
</TD>
</TR>
<TR>
<TD>
<P>HDL (mmol/L)</P>
</TD>
<TD>
<P>-0.05 mmol/L</P>
</TD>
<TD>
<P>-0.03 mmol/L</P>
</TD>
<TD>
<P>+0 mmol/L</P>
</TD>
<TD>
<P>+0 mmol/L</P>
</TD>
</TR>
<TR>
<TD>
<P>LDL (mmol/L)</P>
</TD>
<TD>
<P>-0.21 mmol/L</P>
</TD>
<TD>
<P>+0.03 mmol/L</P>
</TD>
<TD>
<P>-0.16 mmol/L</P>
</TD>
<TD>
<P>+0.13 mmol/L</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-018.15" MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" NO="15" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Beta-cell function</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>10 mg once weekly</P>
</TH>
<TH>
<P>20 mg once weekly</P>
</TH>
<TH>
<P>20 mg every 2 weeks</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" ORDER="1482" STUDY_ID="STD-T-_x002d_-Nauck-2009">
<TR>
<TD>
<P>proinsulin-to-insulin ratio</P>
</TD>
<TD>
<P>-0.12, P = 0.0076</P>
</TD>
<TD>
<P>-0.166, P = 0.0003</P>
</TD>
<TD>
<P>-0.055, P = NS</P>
</TD>
<TD>
<P>0.002</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-018.16" MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" NO="16" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Subgroup</NAME>
<TR>
<TH>
<P>10 mg once weekly</P>
</TH>
<TH>
<P>20 mg once weekly</P>
</TH>
<TH>
<P>20 mg every 2 weeks</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-018.16.01" MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" NO="1" STUDIES="1">
<NAME>Participants with HbA1c &#8805;8%</NAME>
<OTHER_DATA MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" ORDER="1483" STUDY_ID="STD-T-_x002d_-Nauck-2009">
<TR>
<TD>
<P>-1.5%, P &lt; 0.0001 versus placebo</P>
</TD>
<TD>
<P>-1.4%, P &lt; 0.0001 versus placebo</P>
</TD>
<TD>
<P>-1.3%, P &lt; 0.0001 versus placebo</P>
</TD>
<TD>
<P>-0.3%</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-019" MODIFIED="2011-08-30 13:58:16 +0200" MODIFIED_BY="Bernd Richter" NO="19">
<NAME>LY2189265 versus placebo</NAME>
<OTHER_OUTCOME COLS="6" ID="CMP-019.01" MODIFIED="2011-08-30 10:28:57 +0200" MODIFIED_BY="Bernd Richter" NO="1" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>HbA1c</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>LY 0.5/1.0 QW</P>
</TH>
<TH>
<P>LY 1.0/1.0 QW</P>
</TH>
<TH>
<P>LY 1.0/2.0 QW</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
<TH>
<P>p values</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:28:57 +0200" MODIFIED_BY="Bernd Richter" ORDER="1484" STUDY_ID="STD-LY2189265-_x002d_Umpierrez-2011">
<TR>
<TD>
<P>Change in HbA1c</P>
</TD>
<TD>
<P>-1.38 SE 0.12</P>
</TD>
<TD>
<P>-1.32 SE 0.12</P>
</TD>
<TD>
<P>-1.59 SE 0.12</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>All LY groups vs. placebo: P &lt; 0.001;</P>
<P>Between LY groups: P &gt; 0.05</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-019.02" MODIFIED="2011-06-30 14:09:57 +0200" MODIFIED_BY="[Empty name]" NO="2" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>HbA1c &lt; 7%</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Result</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-06-30 14:09:57 +0200" MODIFIED_BY="[Empty name]" ORDER="1485" STUDY_ID="STD-LY2189265-_x002d_Umpierrez-2011">
<TR>
<TD>
<P>HbA1c &lt; 7%</P>
</TD>
<TD>
<P>49 to 54% of participants achieved a target HbA1c level of &lt; 7% at 16 weeks</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-019.03" MODIFIED="2011-06-30 14:10:26 +0200" MODIFIED_BY="[Empty name]" NO="3" ROWS_PER_STUDY="5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Hypoglycaemia</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>LY 0.5/1.0</P>
</TH>
<TH>
<P>LY 1.0/1.0</P>
</TH>
<TH>
<P>LY 1.0/2.0</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-019.03.01" MODIFIED="2011-06-30 14:10:26 +0200" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>LY 0.5/1.0 QW</NAME>
<OTHER_DATA MODIFIED="2011-06-30 14:10:26 +0200" MODIFIED_BY="[Empty name]" ORDER="1486" STUDY_ID="STD-LY2189265-_x002d_Umpierrez-2011">
<TR>
<TD>
<P>Oveall hypoglycaemic episodes</P>
</TD>
<TD>
<P>n = 183</P>
</TD>
<TD>
<P>n = 237</P>
</TD>
<TD>
<P>n = 164</P>
</TD>
<TD>
<P>n = 84</P>
</TD>
</TR>
<TR>
<TD>
<P>number of hypoglycaemic episodes at 4 weeks</P>
</TD>
<TD>
<P>n = 68</P>
</TD>
<TD>
<P>n = 85</P>
</TD>
<TD>
<P>n = 56</P>
</TD>
<TD>
<P>n = 16</P>
</TD>
</TR>
<TR>
<TD>
<P>number of hypoglycaemic episodes at 8 weeks</P>
</TD>
<TD>
<P>n = 59</P>
</TD>
<TD>
<P>n = 55</P>
</TD>
<TD>
<P>n = 47</P>
</TD>
<TD>
<P>n = 18</P>
</TD>
</TR>
<TR>
<TD>
<P>number of hypoglycaemic episodes at 16 weeks</P>
</TD>
<TD>
<P>n = 19</P>
</TD>
<TD>
<P>n = 35</P>
</TD>
<TD>
<P>n = 23</P>
</TD>
<TD>
<P>n = 16</P>
</TD>
</TR>
<TR>
<TD>
<P>severe hypoglycaemia</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="2.9217941414783275" CI_END="-1.0243489291975654" CI_START="-2.2767312483367075" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.6505400887671364" ESTIMABLE="YES" I2="31.548907857414324" I2_Q="31.548907857414314" ID="CMP-019.04" MODIFIED="2011-06-30 14:10:55 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.2320280872942002" P_Q="0.23202808729420044" P_Z="2.389616325166004E-7" Q="2.921794141478327" RANDOM="YES" SCALE="4.51" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.1411467410145975" TOTALS="SUB" TOTAL_1="191" TOTAL_2="195" UNITS="" WEIGHT="300.0" Z="5.16615266693767">
<NAME>Weight change (kg)</NAME>
<GROUP_LABEL_1>LY2189265</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours LY2189265</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.6251914010002232E-31" CI_END="-0.2404666622382856" CI_START="-2.3995333377617145" DF="0" EFFECT_SIZE="-1.32" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-019.04.01" MODIFIED="2011-04-27 16:33:56 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.016550367529302216" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="65" WEIGHT="100.0" Z="2.3965470718644304">
<NAME>LY 0.5/1.0 QW</NAME>
<CONT_DATA CI_END="-0.2404666622382854" CI_START="-2.3995333377617145" EFFECT_SIZE="-1.3199999999999998" ESTIMABLE="YES" MEAN_1="-1.44" MEAN_2="-0.12" MODIFIED="2011-04-27 16:33:56 +0200" MODIFIED_BY="[Empty name]" ORDER="363" SD_1="3.14" SD_2="3.14" SE="0.5507924361248143" STUDY_ID="STD-LY2189265-_x002d_Umpierrez-2011" TOTAL_1="65" TOTAL_2="65" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.13894911189740045" CI_START="-2.3010508881026" DF="0" EFFECT_SIZE="-1.2200000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-019.04.02" MODIFIED="2011-04-27 16:34:21 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.02697487934014785" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="65" WEIGHT="100.0" Z="2.211881131086891">
<NAME>LY 1.0/1.0 QW</NAME>
<CONT_DATA CI_END="-0.13894911189740045" CI_START="-2.3010508881026" EFFECT_SIZE="-1.2200000000000002" ESTIMABLE="YES" MEAN_1="-1.34" MEAN_2="-0.12" MODIFIED="2011-04-27 16:34:21 +0200" MODIFIED_BY="[Empty name]" ORDER="364" SD_1="3.1" SD_2="3.14" SE="0.5515667107302946" STUDY_ID="STD-LY2189265-_x002d_Umpierrez-2011" TOTAL_1="63" TOTAL_2="65" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.3366413279326301" CI_START="-3.5233586720673693" DF="0" EFFECT_SIZE="-2.4299999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-019.04.03" MODIFIED="2011-04-27 16:34:48 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="1.3243748501758641E-5" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="65" WEIGHT="100.0" Z="4.356038511522289">
<NAME>LY 1.0/2.0 QW</NAME>
<CONT_DATA CI_END="-1.3366413279326301" CI_START="-3.5233586720673693" EFFECT_SIZE="-2.4299999999999997" ESTIMABLE="YES" MEAN_1="-2.55" MEAN_2="-0.12" MODIFIED="2011-04-27 16:34:48 +0200" MODIFIED_BY="[Empty name]" ORDER="365" SD_1="3.17" SD_2="3.14" SE="0.5578463077340416" STUDY_ID="STD-LY2189265-_x002d_Umpierrez-2011" TOTAL_1="63" TOTAL_2="65" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="6" ID="CMP-019.05" MODIFIED="2011-06-30 14:11:18 +0200" MODIFIED_BY="[Empty name]" NO="5" ROWS_PER_STUDY="9" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Adverse events</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>LY 0.5/1.0 QW</P>
</TH>
<TH>
<P>LY 1.0/1.0 QW</P>
</TH>
<TH>
<P>LY 1.0/2.0 QW</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
<TH>
<P>comments</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-06-30 14:11:18 +0200" MODIFIED_BY="[Empty name]" ORDER="1490" STUDY_ID="STD-LY2189265-_x002d_Umpierrez-2011">
<TR>
<TD>
<P>withdrawal due to adverse events</P>
</TD>
<TD>
<P>3 (4.5%)</P>
</TD>
<TD>
<P>4 (6.2%)</P>
</TD>
<TD>
<P>4 (6.2%)</P>
</TD>
<TD>
<P>1 (1.5%)</P>
</TD>
<TD/>
</TR>
<TR>
<TD>
<P>nausea</P>
</TD>
<TD>
<P>9 (13.6%)</P>
</TD>
<TD>
<P>11 (16.9%)</P>
</TD>
<TD>
<P>9 (13.8%)</P>
</TD>
<TD>
<P>5 (7.6%)</P>
</TD>
<TD>
<P>Nausea occurred more commonly in participants receiving LY.</P>
</TD>
</TR>
<TR>
<TD>
<P>diarrhoea</P>
</TD>
<TD>
<P>5 (7.6)</P>
</TD>
<TD>
<P>4 (6.2%)</P>
</TD>
<TD>
<P>9 (13.8%)</P>
</TD>
<TD>
<P>5 (7.6%)</P>
</TD>
<TD>
<P>Higher LY dosage was generally associated with a higher prevalence of adverse events.</P>
</TD>
</TR>
<TR>
<TD>
<P>abdominal distention</P>
</TD>
<TD>
<P>3 (4.5%)</P>
</TD>
<TD>
<P>5 (7.7%)</P>
</TD>
<TD>
<P>9 (13.8%)</P>
</TD>
<TD>
<P>4 (6.1%)</P>
</TD>
<TD>
<P>Higher LY dosage was generally associated with a higher prevalence of adverse events.</P>
</TD>
</TR>
<TR>
<TD>
<P>vomiting</P>
</TD>
<TD>
<P>3 (4.5%)</P>
</TD>
<TD>
<P>1 (1.5%)</P>
</TD>
<TD>
<P>7 (10.8%)</P>
</TD>
<TD>
<P>2 (3.0%)</P>
</TD>
<TD>
<P>Higher LY dosage was generally associated with a higher prevalence of adverse events.</P>
</TD>
</TR>
<TR>
<TD>
<P>Pancreatitis</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD>
<P>Both cases related to study drug. One participant approximately 5 months after last dose of LY 0.5/1.0, later this was regarded as serious. Second participant after the 11th weekly dose of LY 0.5/1.0 had approximately 1.5- and 2.5-fold increase in amylase and lipase levels respectively with no obvious symptom or abnormality in the pancreas during abodominal CT scan.</P>
</TD>
</TR>
<TR>
<TD>
<P>possibly LY related adverse events</P>
</TD>
<TD>
<P>22 (33.3%)</P>
</TD>
<TD>
<P>20 (30.8%)</P>
</TD>
<TD>
<P>27 (41.5%)</P>
</TD>
<TD>
<P>15 (22.7%)</P>
</TD>
<TD/>
</TR>
<TR>
<TD>
<P>serious adverse events</P>
</TD>
<TD>
<P>3 (4.5%)</P>
</TD>
<TD>
<P>2 (3.1%)</P>
</TD>
<TD>
<P>1 (1.5%)</P>
</TD>
<TD>
<P>1 (1.5%)</P>
</TD>
<TD>
<P>three serious adverse events related to study drug and included hallucination, cryptogenic organizing pneumonia and pancreatitis</P>
</TD>
</TR>
<TR>
<TD>
<P>deaths</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-019.06" MODIFIED="2011-08-30 13:58:16 +0200" MODIFIED_BY="Bernd Richter" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.55" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="196" TOTAL_2="198" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Systolic blood pressure (mm Hg)</NAME>
<GROUP_LABEL_1>LY2189265</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours LY2189265</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-019.06.01" MODIFIED="2011-04-28 15:27:04 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="66" TOTAL_2="66" WEIGHT="0.0" Z="0.0">
<NAME>LY 0.5/1.0 QW</NAME>
<CONT_DATA CI_END="7.88813838704403" CI_START="-2.088138387044031" EFFECT_SIZE="2.9" ESTIMABLE="YES" MEAN_1="-0.6" MEAN_2="-3.5" MODIFIED="2011-04-28 15:27:04 +0200" MODIFIED_BY="[Empty name]" ORDER="372" SD_1="14.62" SD_2="14.62" SE="2.545015330072302" STUDY_ID="STD-LY2189265-_x002d_Umpierrez-2011" TOTAL_1="66" TOTAL_2="66" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-019.06.02" MODIFIED="2011-04-28 15:27:17 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="66" WEIGHT="0.0" Z="0.0">
<NAME>LY 1.0/1.0 QW</NAME>
<CONT_DATA CI_END="7.5883412885595956" CI_START="-2.388341288559595" EFFECT_SIZE="2.6" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-3.5" MODIFIED="2011-04-28 15:27:17 +0200" MODIFIED_BY="[Empty name]" ORDER="373" SD_1="14.51" SD_2="14.62" SE="2.5451188531559734" STUDY_ID="STD-LY2189265-_x002d_Umpierrez-2011" TOTAL_1="65" TOTAL_2="66" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-019.06.03" MODIFIED="2011-04-28 15:27:34 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="66" WEIGHT="0.0" Z="0.0">
<NAME>LY 1.0/2.0 QW</NAME>
<CONT_DATA CI_END="5.488341288559595" CI_START="-4.488341288559595" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="-3.0" MEAN_2="-3.5" MODIFIED="2011-04-28 15:27:34 +0200" MODIFIED_BY="[Empty name]" ORDER="374" SD_1="14.51" SD_2="14.62" SE="2.5451188531559734" STUDY_ID="STD-LY2189265-_x002d_Umpierrez-2011" TOTAL_1="65" TOTAL_2="66" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-019.07" MODIFIED="2011-08-30 13:58:16 +0200" MODIFIED_BY="Bernd Richter" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="6.91" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="196" TOTAL_2="198" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Diastolic blood pressure (mm Hg)</NAME>
<GROUP_LABEL_1>LY2189265</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours LY2189265</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-019.07.01" MODIFIED="2011-04-28 15:37:29 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="66" TOTAL_2="66" WEIGHT="0.0" Z="0.0">
<NAME>LY 0.5/1.0 QW</NAME>
<CONT_DATA CI_END="6.626562877816642" CI_START="-0.02656287781664224" EFFECT_SIZE="3.3" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="-2.3" MODIFIED="2011-04-28 15:37:29 +0200" MODIFIED_BY="[Empty name]" ORDER="375" SD_1="9.75" SD_2="9.75" SE="1.697257145568054" STUDY_ID="STD-LY2189265-_x002d_Umpierrez-2011" TOTAL_1="66" TOTAL_2="66" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-019.07.02" MODIFIED="2011-04-28 15:38:27 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="66" WEIGHT="0.0" Z="0.0">
<NAME>LY 1.0/1.0 QW</NAME>
<CONT_DATA CI_END="6.825556651080807" CI_START="0.17444334891919322" EFFECT_SIZE="3.5" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="-2.3" MODIFIED="2011-04-28 15:38:27 +0200" MODIFIED_BY="[Empty name]" ORDER="376" SD_1="9.67" SD_2="9.75" SE="1.6967437551467135" STUDY_ID="STD-LY2189265-_x002d_Umpierrez-2011" TOTAL_1="65" TOTAL_2="66" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-019.07.03" MODIFIED="2011-04-28 15:38:44 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="66" WEIGHT="0.0" Z="0.0">
<NAME>LY 1.0/2.0 QW</NAME>
<CONT_DATA CI_END="6.825556651080807" CI_START="0.17444334891919322" EFFECT_SIZE="3.5" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="-2.3" MODIFIED="2011-04-28 15:38:44 +0200" MODIFIED_BY="[Empty name]" ORDER="377" SD_1="9.67" SD_2="9.75" SE="1.6967437551467135" STUDY_ID="STD-LY2189265-_x002d_Umpierrez-2011" TOTAL_1="65" TOTAL_2="66" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="6" ID="CMP-019.08" MODIFIED="2011-08-30 10:28:57 +0200" MODIFIED_BY="Bernd Richter" NO="8" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Fasting plasma glucose (mmol/L)</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>LY 0.5/1.0 QW</P>
</TH>
<TH>
<P>LY 1.0/1.0 QW</P>
</TH>
<TH>
<P>LY 1.0/2.0 QW</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
<TH>
<P>p values</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:28:57 +0200" MODIFIED_BY="Bernd Richter" ORDER="1497" STUDY_ID="STD-LY2189265-_x002d_Umpierrez-2011">
<TR>
<TD>
<P>Change in FPG</P>
</TD>
<TD>
<P>-2.10</P>
</TD>
<TD>
<P>-2.05</P>
</TD>
<TD>
<P>-2.65</P>
</TD>
<TD>
<P>-0.49</P>
</TD>
<TD>
<P>All LY groups vs. placebo: P &lt; 0.001;</P>
<P>Between LY groups: P &gt; 0.05</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="6" ID="CMP-019.09" MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" NO="9" ROWS_PER_STUDY="3" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Beta-cell function</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>LY 0.5/1.0 QW</P>
</TH>
<TH>
<P>LY 1.0/1.0 QW</P>
</TH>
<TH>
<P>LY 1.0/2.0 QW</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
<TH>
<P>p values</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" ORDER="1498" STUDY_ID="STD-LY2189265-_x002d_Umpierrez-2011">
<TR>
<TD>
<P>&#946;-cell function (HOMA2-%B)</P>
</TD>
<TD>
<P>39.2 SE 45.6%</P>
</TD>
<TD>
<P>44.3 SE 93.9%</P>
</TD>
<TD>
<P>45.6 SE 55.2%</P>
</TD>
<TD>
<P>1.0 SE 41.1%</P>
</TD>
<TD>
<P>All LY groups vs. placebo: P &lt; 0.01</P>
</TD>
</TR>
<TR>
<TD>
<P>Insulin sensitivity (HOMA2-%S)</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>No statistically significant change in all LY groups</P>
</TD>
</TR>
<TR>
<TD>
<P>Insulin resistance (HOMA2-%IR)</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>No statistically significant change in all LY groups</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-020" MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" NO="20">
<NAME>GLP-1 agonist versus GLP-1 agonist</NAME>
<CONT_OUTCOME CHI2="4.35594452493822" CI_END="0.5870239772784607" CI_START="0.23268043722512138" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.409852207251791" ESTIMABLE="YES" I2="54.085732989715574" I2_Q="26.918653782104847" ID="CMP-020.01" MODIFIED="2011-06-30 14:16:24 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.11327106375182427" P_Q="0.24209778476767285" P_Z="5.7878947764679965E-6" Q="1.3683382309604113" RANDOM="YES" SCALE="1.02" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.020400070914598924" TOTALS="SUB" TOTAL_1="501" TOTAL_2="510" UNITS="" WEIGHT="200.0" Z="4.533993000560058">
<NAME>HbA1c</NAME>
<GROUP_LABEL_1>Exenatide 10 µg BID</GROUP_LABEL_1>
<GROUP_LABEL_2>Other GLP1-agonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours exenatide 10 µg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Other GLP1</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5520153291326758" CI_START="0.10798467086732433" DF="0" EFFECT_SIZE="0.33000000000000007" ESTIMABLE="YES" I2="0.0" ID="CMP-020.01.01" MODIFIED="2009-11-27 20:37:50 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.003576780159917427" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="233" WEIGHT="100.0" Z="2.9132588160689536">
<NAME>versus Liraglutide</NAME>
<CONT_DATA CI_END="0.5520153291326758" CI_START="0.10798467086732433" EFFECT_SIZE="0.33000000000000007" ESTIMABLE="YES" MEAN_1="-0.79" MEAN_2="-1.12" MODIFIED="2009-11-27 20:36:54 +0100" MODIFIED_BY="[Empty name]" ORDER="71" SD_1="1.22" SD_2="1.22" SE="0.11327520856704731" STUDY_ID="STD-L-_x002d_-LEAD-6-Buse-2009" TOTAL_1="231" TOTAL_2="233" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.243935065505757" CI_END="0.8438697108284463" CI_START="0.2558807189280607" DF="1" EFFECT_SIZE="0.5498752148782535" ESTIMABLE="YES" I2="55.43543058031353" ID="CMP-020.01.02" MODIFIED="2011-06-28 15:24:49 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.1341393300378595" P_Z="2.465318527332578E-4" STUDIES="2" TAU2="0.024945943761141114" TOTAL_1="270" TOTAL_2="277" WEIGHT="99.99999999999999" Z="3.665836034342579">
<NAME>versus Exenatide 2 mg once weekly</NAME>
<CONT_DATA CI_END="0.9778140354651796" CI_START="0.42218596453482055" EFFECT_SIZE="0.7000000000000001" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-1.6" MODIFIED="2011-06-28 15:24:49 +0200" MODIFIED_BY="[Empty name]" ORDER="346" SD_1="1.11" SD_2="1.14" SE="0.14174445941687763" STUDY_ID="STD-E-_x002d_-Blevins-2011" TOTAL_1="123" TOTAL_2="129" WEIGHT="49.958404959417834"/>
<CONT_DATA CI_END="0.6772959144262196" CI_START="0.12270408557378015" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" MEAN_1="-1.5" MEAN_2="-1.9" MODIFIED="2011-06-27 12:57:11 +0200" MODIFIED_BY="[Empty name]" ORDER="150" SD_1="1.21" SD_2="1.22" SE="0.14148010709048459" STUDY_ID="STD-E-_x002d_-Drucker-2008" TOTAL_1="147" TOTAL_2="148" WEIGHT="50.04159504058215"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="6.560834339936239" CI_END="0.9149186113035147" CI_START="0.6453488480602061" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7684020249020475" ESTIMABLE="YES" EVENTS_1="215" EVENTS_2="300" I2="69.51607224974626" I2_Q="0.0" ID="CMP-020.02" LOG_CI_END="-0.03861753788316722" LOG_CI_START="-0.19020546081865847" LOG_EFFECT_SIZE="-0.11441149935091281" METHOD="MH" MODIFIED="2011-06-30 14:16:37 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.03761263879684473" P_Q="0.423080399911792" P_Z="0.003090610728423286" Q="0.6417435147771327" RANDOM="YES" SCALE="2.74" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.02647553428858974" TOTALS="SUB" TOTAL_1="484" TOTAL_2="491" WEIGHT="200.0" Z="2.9585789395695334">
<NAME>HbA1c &lt; 7%</NAME>
<GROUP_LABEL_1>Exenatide 10 µg BID</GROUP_LABEL_1>
<GROUP_LABEL_2>Other GLP1-agonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Other GLP1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Exenatide 10 µg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9585367732792652" CI_START="0.6552520712614904" DF="0" EFFECT_SIZE="0.7925170068027211" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="126" I2="0.0" ID="CMP-020.02.01" LOG_CI_END="-0.01839122120436634" LOG_CI_START="-0.18359159756791035" LOG_EFFECT_SIZE="-0.10099140938613832" MODIFIED="2009-11-27 20:40:31 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.01655896107665331" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="233" WEIGHT="100.0" Z="2.3963568304370084">
<NAME>versus Liraglutide</NAME>
<DICH_DATA CI_END="0.9585367732792652" CI_START="0.6552520712614904" EFFECT_SIZE="0.7925170068027211" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="126" LOG_CI_END="-0.01839122120436634" LOG_CI_START="-0.18359159756791035" LOG_EFFECT_SIZE="-0.10099140938613832" MODIFIED="2009-11-27 20:40:31 +0100" MODIFIED_BY="[Empty name]" ORDER="72" O_E="0.0" SE="0.0970395188309973" STUDY_ID="STD-L-_x002d_-LEAD-6-Buse-2009" TOTAL_1="231" TOTAL_2="233" VAR="0.00941666821495148" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.358961446896315" CI_END="1.0109998335523922" CI_START="0.42014757555612636" DF="1" EFFECT_SIZE="0.6517431464577781" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="174" I2="84.27416161662562" ID="CMP-020.02.02" LOG_CI_END="0.004751084090226045" LOG_CI_START="-0.3765981381915203" LOG_EFFECT_SIZE="-0.18592352705064719" MODIFIED="2011-06-27 16:32:49 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.01167900919202125" P_Z="0.055988249135432065" STUDIES="2" TAU2="0.08518962383840932" TOTAL_1="253" TOTAL_2="258" WEIGHT="100.0" Z="1.9111271013879263">
<NAME>versus Exenatide 2 mg once weekly</NAME>
<DICH_DATA CI_END="0.7030727576983982" CI_START="0.3807587116266216" EFFECT_SIZE="0.5173983739837399" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="75" LOG_CI_END="-0.1529997295578492" LOG_CI_START="-0.4193501513718587" LOG_EFFECT_SIZE="-0.286174940464854" MODIFIED="2011-04-25 12:58:54 +0200" MODIFIED_BY="[Empty name]" ORDER="347" O_E="0.0" SE="0.1564555562294009" STUDY_ID="STD-E-_x002d_-Blevins-2011" TOTAL_1="123" TOTAL_2="129" VAR="0.02447834107505123" WEIGHT="45.75527286741936"/>
<DICH_DATA CI_END="0.9363529623828267" CI_START="0.6696331120757495" EFFECT_SIZE="0.7918414918414919" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="99" LOG_CI_END="-0.028560411176476466" LOG_CI_START="-0.17416307945291606" LOG_EFFECT_SIZE="-0.10136174531469627" MODIFIED="2011-06-27 16:32:49 +0200" MODIFIED_BY="[Empty name]" ORDER="151" O_E="0.0" SE="0.08552772809041259" STUDY_ID="STD-E-_x002d_-Drucker-2008" TOTAL_1="130" TOTAL_2="129" VAR="0.007314992272307551" WEIGHT="54.24472713258064"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.09392680485713523" CI_END="1.704561454524821" CI_START="0.9912648316931658" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.29987377207566" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="68" I2="0.0" I2_Q="0.0" ID="CMP-020.03" LOG_CI_END="0.23161266345865975" LOG_CI_START="-0.003810301541366104" LOG_EFFECT_SIZE="0.1139011809586468" METHOD="MH" MODIFIED="2011-08-22 15:35:10 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.759243181119466" P_Q="0.7601291901749426" P_Z="0.05789128235778738" Q="0.09321490889163353" RANDOM="YES" SCALE="26.73" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="379" TOTAL_2="383" WEIGHT="200.0" Z="1.8965202691717238">
<NAME>Hypoglycaemia</NAME>
<GROUP_LABEL_1>Exenatide 10 µg BID</GROUP_LABEL_1>
<GROUP_LABEL_2>Other GLP1-agonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Exenatide 10 µg BID</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Other GLP1</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.748410207900227" CI_START="0.9917520936504947" DF="0" EFFECT_SIZE="1.3168103448275863" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="60" I2="0.0" ID="CMP-020.03.01" LOG_CI_END="0.24264333340546612" LOG_CI_START="-0.003596874030119296" LOG_EFFECT_SIZE="0.1195232296876734" MODIFIED="2009-11-27 20:55:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.05707906129220648" STUDIES="1" TAU2="0.0" TOTAL_1="232" TOTAL_2="235" WEIGHT="99.99999999999999" Z="1.9027049070776096">
<NAME>versus Liraglutide</NAME>
<DICH_DATA CI_END="1.748410207900227" CI_START="0.9917520936504947" EFFECT_SIZE="1.3168103448275863" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="60" LOG_CI_END="0.24264333340546612" LOG_CI_START="-0.003596874030119296" LOG_EFFECT_SIZE="0.1195232296876734" MODIFIED="2009-11-27 20:55:25 +0100" MODIFIED_BY="[Empty name]" ORDER="83" O_E="0.0" SE="0.144642716756348" STUDY_ID="STD-L-_x002d_-LEAD-6-Buse-2009" TOTAL_1="232" TOTAL_2="235" VAR="0.02092151551065711" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.855317798833855" CI_START="0.44930303646941167" DF="0" EFFECT_SIZE="1.1326530612244898" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" I2="0.0" ID="CMP-020.03.02" LOG_CI_END="0.4556544525464374" LOG_CI_START="-0.34746064635811225" LOG_EFFECT_SIZE="0.05409690309416259" MODIFIED="2009-12-01 15:42:36 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7917477029840345" STUDIES="1" TAU2="0.0" TOTAL_1="147" TOTAL_2="148" WEIGHT="100.00000000000001" Z="0.2640418089121583">
<NAME>versus Exenatide 2 mg once weekly</NAME>
<DICH_DATA CI_END="2.8553177988338554" CI_START="0.4493030364694116" EFFECT_SIZE="1.1326530612244898" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.45565445254643744" LOG_CI_START="-0.3474606463581123" LOG_EFFECT_SIZE="0.05409690309416259" MODIFIED="2009-12-01 15:42:36 +0100" MODIFIED_BY="[Empty name]" ORDER="152" O_E="0.0" SE="0.47175378458038786" STUDY_ID="STD-E-_x002d_-Drucker-2008" TOTAL_1="147" TOTAL_2="148" VAR="0.22255163326591898" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-020.04" MODIFIED="2011-06-30 14:22:33 +0200" MODIFIED_BY="[Empty name]" NO="4" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Hypoglycaemia</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Exenatide 10 µg BID</P>
</TH>
<TH>
<P>Exenatide 2 mg QW</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-06-30 14:15:58 +0200" MODIFIED_BY="[Empty name]" ORDER="1507" STUDY_ID="STD-E-_x002d_-Blevins-2011">
<TR>
<TD>
<P>Minor hypoglycaemia occured only among participants using a concomitant SU (n = 74)</P>
</TD>
<TD>
<P>n = 4</P>
</TD>
<TD>
<P>n = 5</P>
</TD>
</TR>
<TR>
<TD>
<P>Major hypoglycaemia</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>None</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.10087723706035173" CI_END="1.053352158105906" CI_START="-0.476334192061757" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.2885089830220745" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-020.05" MODIFIED="2011-06-30 14:16:13 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.7507794708584081" P_Q="0.7507794708584081" P_Z="0.45971004657990877" Q="0.10087723706035173" RANDOM="YES" SCALE="4.3" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="378" TOTAL_2="381" UNITS="" WEIGHT="200.0" Z="0.7393243927130099">
<NAME>Weight change</NAME>
<GROUP_LABEL_1>Exenatide 10 µg BID</GROUP_LABEL_1>
<GROUP_LABEL_2>Other GLP1-agonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Exenatide 10 µg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Other GLP1</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.2853522481956166" CI_START="-0.5453522481956163" DF="0" EFFECT_SIZE="0.3700000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-020.05.01" MODIFIED="2010-01-05 18:40:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.42821565540131656" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="233" WEIGHT="100.0" Z="0.7922487498220941">
<NAME>versus Liraglutide</NAME>
<CONT_DATA CI_END="1.2853522481956166" CI_START="-0.5453522481956163" EFFECT_SIZE="0.3700000000000001" ESTIMABLE="YES" MEAN_1="-2.87" MEAN_2="-3.24" MODIFIED="2010-01-05 18:40:25 +0100" MODIFIED_BY="[Empty name]" ORDER="92" SD_1="5.02" SD_2="5.04" SE="0.46702503485563923" STUDY_ID="STD-L-_x002d_-LEAD-6-Buse-2009" TOTAL_1="231" TOTAL_2="233" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.4921928819282708" CI_START="-1.2921928819282706" DF="0" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" I2="0.0" ID="CMP-020.05.02" MODIFIED="2009-12-01 15:48:01 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.8880417660753032" STUDIES="1" TAU2="0.0" TOTAL_1="147" TOTAL_2="148" WEIGHT="100.0" Z="0.14078250291190889">
<NAME>versus Exenatide 2 mg once weekly</NAME>
<CONT_DATA CI_END="1.4921928819282708" CI_START="-1.2921928819282706" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="-3.6" MEAN_2="-3.7" MODIFIED="2009-12-01 15:48:01 +0100" MODIFIED_BY="[Empty name]" ORDER="153" SD_1="6.1" SD_2="6.1" SE="0.7103155429945195" STUDY_ID="STD-E-_x002d_-Drucker-2008" TOTAL_1="147" TOTAL_2="148" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-020.06" MODIFIED="2011-07-01 14:48:32 +0200" MODIFIED_BY="[Empty name]" NO="6" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Weight change</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Exenatide 10 µg BID</P>
</TH>
<TH>
<P>Exenatide 2 mg QW</P>
</TH>
<TH>
<P>Difference between groups</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-07-01 14:48:32 +0200" MODIFIED_BY="[Empty name]" ORDER="1510" STUDY_ID="STD-E-_x002d_-Blevins-2011">
<TR>
<TD>
<P>Change in weight (kg)</P>
</TD>
<TD>
<P>-1.4</P>
</TD>
<TD>
<P>-2.3</P>
</TD>
<TD>
<P>-0.95 (95% CI -1.9 to 0.01)</P>
</TD>
</TR>
<TR>
<TD>
<P>Proportion of participants experiencing weight loss by end of study, n (%)</P>
</TD>
<TD>
<P>77 (63)</P>
</TD>
<TD>
<P>99 (77)</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-020.07" MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" NO="7" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES">
<NAME>Treatment satisfaction</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Exenatide 10 µg BID</P>
</TH>
<TH>
<P>Other GLP1 agonist</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-020.07.01" MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" NO="1" STUDIES="1">
<NAME>versus Liraglutide</NAME>
<OTHER_DATA MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" ORDER="1511" STUDY_ID="STD-L-_x002d_-LEAD-6-Buse-2009">
<TR>
<TD>
<P>Diabetes Treatment Satisfaction Questionnaire (6 of 8 items)</P>
</TD>
<TD>
<P>13.3 SD6.94</P>
</TD>
<TD>
<P>15.18 SD 7.36, P = 0.0004 versus exenatide 10 µg BID</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-020.07.02" MODIFIED="2011-08-30 10:27:51 +0200" MODIFIED_BY="Bernd Richter" NO="2" STUDIES="1">
<NAME>versus Exenatide 2 mg once weekly</NAME>
<OTHER_DATA MODIFIED="2011-08-30 10:27:51 +0200" MODIFIED_BY="Bernd Richter" ORDER="1512" STUDY_ID="STD-E-_x002d_-Drucker-2008">
<TR>
<TD>
<P>Diabetes Treatment Satisfaction Questionnaire (8 of 8 items)</P>
</TD>
<TD>
<P>29.97</P>
</TD>
<TD>
<P>31.17, P = NS versus exenatide 10 µg BID</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-020.08" MODIFIED="2011-06-30 14:18:02 +0200" MODIFIED_BY="[Empty name]" NO="8" ROWS_PER_STUDY="10" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES">
<NAME>Adverse events</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Exenatide 10 µg BID</P>
</TH>
<TH>
<P>Other GLP1 agonist</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-020.08.01" MODIFIED="2009-12-01 16:02:56 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>versus Liraglutide</NAME>
<OTHER_DATA MODIFIED="2009-11-30 13:33:30 +0100" MODIFIED_BY="[Empty name]" ORDER="1513" STUDY_ID="STD-L-_x002d_-LEAD-6-Buse-2009">
<TR>
<TD>
<P>withdrawal due to adverse events</P>
</TD>
<TD>
<P>13%</P>
</TD>
<TD>
<P>10%</P>
</TD>
</TR>
<TR>
<TD>
<P>overall rate of adverse events</P>
</TD>
<TD>
<P>78.9%</P>
</TD>
<TD>
<P>74.9%</P>
</TD>
</TR>
<TR>
<TD>
<P>no significant differences across groups for: infections, headache, back pain, metabolism an nutrition disorders, general disorders and administration-site conditions; 1 episode of mild pancreatitis in liraglutide group (considered to be chronic and unrelated to treatment</P>
</TD>
<TD/>
<TD/>
</TR>
<TR>
<TD>
<P>nausea</P>
</TD>
<TD>
<P>28.0%</P>
</TD>
<TD>
<P>25.5%</P>
</TD>
</TR>
<TR>
<TD>
<P>diarrhoea</P>
</TD>
<TD>
<P>12.1%</P>
</TD>
<TD>
<P>12.3%</P>
</TD>
</TR>
<TR>
<TD>
<P>dyspepsia</P>
</TD>
<TD>
<P>4.7%</P>
</TD>
<TD>
<P>8.9%</P>
</TD>
</TR>
<TR>
<TD>
<P>vomiting</P>
</TD>
<TD>
<P>9.9%</P>
</TD>
<TD>
<P>6.0%</P>
</TD>
</TR>
<TR>
<TD>
<P>constipation</P>
</TD>
<TD>
<P>2.6%</P>
</TD>
<TD>
<P>5.1%</P>
</TD>
</TR>
<TR>
<TD>
<P>serious adverse events (only on event considered to be related to study medication (exenatide, severe hypoglycaemia))</P>
</TD>
<TD>
<P>2.6%</P>
</TD>
<TD>
<P>5.1%</P>
</TD>
</TR>
<TR>
<TD>
<P>severe adverse events</P>
</TD>
<TD>
<P>4.7%</P>
</TD>
<TD>
<P>7.2%</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-020.08.02" MODIFIED="2011-06-30 14:18:02 +0200" MODIFIED_BY="[Empty name]" NO="2" STUDIES="2">
<NAME>versus Exenatide 2 mg once weekly</NAME>
<OTHER_DATA MODIFIED="2011-06-30 14:18:02 +0200" MODIFIED_BY="[Empty name]" ORDER="1514" STUDY_ID="STD-E-_x002d_-Blevins-2011">
<TR>
<TD>
<P>withdrawal due to adverse events</P>
</TD>
<TD>
<P>5%</P>
</TD>
<TD>
<P>5%</P>
</TD>
</TR>
<TR>
<TD>
<P>nausea</P>
</TD>
<TD>
<P>35%; events: n = 51</P>
</TD>
<TD>
<P>14%; events: n = 21</P>
</TD>
</TR>
<TR>
<TD>
<P>vomiting</P>
</TD>
<TD>
<P>8.9%</P>
</TD>
<TD>
<P>4.7%</P>
</TD>
</TR>
<TR>
<TD>
<P>diarrhoea</P>
</TD>
<TD>
<P>4.1%</P>
</TD>
<TD>
<P>9.3%</P>
</TD>
</TR>
<TR>
<TD>
<P>headache</P>
</TD>
<TD>
<P>8.1%</P>
</TD>
<TD>
<P>4.7%</P>
</TD>
</TR>
<TR>
<TD>
<P>dizziness</P>
</TD>
<TD>
<P>6.5%</P>
</TD>
<TD>
<P>2.3%</P>
</TD>
</TR>
<TR>
<TD>
<P>upper respiratory tract infection</P>
</TD>
<TD>
<P>4.1%</P>
</TD>
<TD>
<P>7.0%</P>
</TD>
</TR>
<TR>
<TD>
<P>injection site erythema</P>
</TD>
<TD>
<P>2.4%</P>
</TD>
<TD>
<P>5.4%</P>
</TD>
</TR>
<TR>
<TD>
<P>serious adverse events</P>
</TD>
<TD>
<P>4%; one fatal myocardial infarction </P>
</TD>
<TD>
<P>2%, one participant with a history of dyslipidemia was hospitalised and withdrew due to a diagnosis of pancreatitis.</P>
</TD>
</TR>
<TR>
<TD>
<P>anti-exenatide antibody levels</P>
</TD>
<TD>
<P>51% participants positive for treatment-emergent antibodies to exenatide</P>
</TD>
<TD>
<P>73% participants positive for treatment-emergent antibodies to exenatide </P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2009-12-01 16:24:19 +0100" MODIFIED_BY="[Empty name]" ORDER="1515" STUDY_ID="STD-E-_x002d_-Drucker-2008">
<TR>
<TD>
<P>withdrawal due to adverse events</P>
</TD>
<TD>
<P>5.4%</P>
</TD>
<TD>
<P>6.1%</P>
</TD>
</TR>
<TR>
<TD>
<P>no clinically significant abnormalities in vital signs, ECG reports, haematological, chemistry or urinalysis values; no major hypoglycaemia</P>
</TD>
<TD/>
<TD/>
</TR>
<TR>
<TD>
<P>nausea </P>
<P>(modestly greater weight loss in people with nausea, but participants without nausea also lost weight)</P>
</TD>
<TD>
<P>34.5%</P>
</TD>
<TD>
<P>26.4%</P>
</TD>
</TR>
<TR>
<TD>
<P>diarrhoea</P>
</TD>
<TD>
<P>13.1%</P>
</TD>
<TD>
<P>13.5%</P>
</TD>
</TR>
<TR>
<TD>
<P>vomiting</P>
</TD>
<TD>
<P>18.6%</P>
</TD>
<TD>
<P>10.8%</P>
</TD>
</TR>
<TR>
<TD>
<P>constipation</P>
</TD>
<TD>
<P>6.2%</P>
</TD>
<TD>
<P>10.8%</P>
</TD>
</TR>
<TR>
<TD>
<P>injection site pruritus</P>
</TD>
<TD>
<P>1.4%</P>
</TD>
<TD>
<P>17.6%</P>
</TD>
</TR>
<TR>
<TD>
<P>injection site bruising</P>
</TD>
<TD>
<P>10.3%</P>
</TD>
<TD>
<P>4.7%</P>
</TD>
</TR>
<TR>
<TD>
<P>serious adverse events (none considered to be related to study treatment)</P>
</TD>
<TD>
<P>3.4%</P>
</TD>
<TD>
<P>5.4%</P>
</TD>
</TR>
<TR>
<TD>
<P>anti-exenatide antibody levels</P>
</TD>
<TD/>
<TD>
<P>significantly more anti-exenatide antibodies with exenatide once weekly, but mostly not detectable or low titre</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.2734367423546007" CI_END="2.999132884900119" CI_START="-0.6408408204278067" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="1.179146032236156" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-020.09" MODIFIED="2011-06-30 14:18:24 +0200" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.8722158407322289" P_Q="0.6228697648996553" P_Z="0.2041432889098722" Q="0.24185471889680443" RANDOM="YES" SCALE="14.47" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="501" TOTAL_2="510" UNITS="" WEIGHT="200.0" Z="1.2698354124445337">
<NAME>Systolic blood pressure</NAME>
<GROUP_LABEL_1>Exenatide 10 µg BID</GROUP_LABEL_1>
<GROUP_LABEL_2>Other GLP1-agonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Exenatide 10 µg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Other GLP1</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.7386554389974993" CI_START="-2.7186554389974997" DF="0" EFFECT_SIZE="0.5099999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-020.09.01" MODIFIED="2009-11-30 15:37:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7568675339849142" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="233" WEIGHT="100.0" Z="0.30959687430313043">
<NAME>versus Liraglutide</NAME>
<CONT_DATA CI_END="3.7386554389974993" CI_START="-2.7186554389974997" EFFECT_SIZE="0.5099999999999998" ESTIMABLE="YES" MEAN_1="-2.0" MEAN_2="-2.51" MODIFIED="2009-11-30 15:30:10 +0100" MODIFIED_BY="[Empty name]" ORDER="104" SD_1="17.93" SD_2="17.55" SE="1.6473034527495003" STUDY_ID="STD-L-_x002d_-LEAD-6-Buse-2009" TOTAL_1="231" TOTAL_2="233" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.03158202345779629" CI_END="3.6942257546427086" CI_START="-0.7126238639976954" DF="1" EFFECT_SIZE="1.4908009453225066" ESTIMABLE="YES" I2="0.0" ID="CMP-020.09.02" MODIFIED="2011-04-27 12:13:22 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8589481673706538" P_Z="0.18481341201771756" STUDIES="2" TAU2="0.0" TOTAL_1="270" TOTAL_2="277" WEIGHT="100.0" Z="1.3260793599995118">
<NAME>versus Exenatide 2 mg once weekly</NAME>
<CONT_DATA CI_END="4.890347350636503" CI_START="-1.490347350636503" EFFECT_SIZE="1.7" ESTIMABLE="YES" MEAN_1="-1.2" MEAN_2="-2.9" MODIFIED="2011-04-27 12:13:22 +0200" MODIFIED_BY="[Empty name]" ORDER="350" SD_1="13.31" SD_2="12.49" SE="1.6277581505586611" STUDY_ID="STD-E-_x002d_-Blevins-2011" TOTAL_1="123" TOTAL_2="129" WEIGHT="47.70023633062663"/>
<CONT_DATA CI_END="4.346831043227193" CI_START="-1.7468310432271927" EFFECT_SIZE="1.3000000000000003" ESTIMABLE="YES" MEAN_1="-3.4" MEAN_2="-4.7" MODIFIED="2011-04-27 12:12:46 +0200" MODIFIED_BY="[Empty name]" ORDER="160" SD_1="13.3" SD_2="13.4" SE="1.5545341992302957" STUDY_ID="STD-E-_x002d_-Drucker-2008" TOTAL_1="147" TOTAL_2="148" WEIGHT="52.29976366937336"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.5506281642399615" CI_END="1.3141007911807543" CI_START="1.017429134431678" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="1.165764962806216" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-020.10" MODIFIED="2011-06-30 14:18:49 +0200" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.46055924408705207" P_Q="0.5674467163502713" P_Z="1.5558923743761106E-53" Q="0.3269736442745442" RANDOM="YES" SCALE="2.137617235374669" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="501" TOTAL_2="510" UNITS="" WEIGHT="200.0" Z="15.403273548786503">
<NAME>Fasting plasma glucose (mmol/L)</NAME>
<GROUP_LABEL_1>Exenatide 10 µg BID</GROUP_LABEL_1>
<GROUP_LABEL_2>Other GLP1-agonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Exenatide 10 µg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Other GLP1</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.5641252489981559" CI_START="0.4558747510018446" DF="0" EFFECT_SIZE="1.0100000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-020.10.01" MODIFIED="2009-11-30 15:50:54 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="3.537085166319558E-4" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="233" WEIGHT="100.0" Z="3.5724118833503002">
<NAME>versus Liraglutide</NAME>
<CONT_DATA CI_END="1.5641252489981559" CI_START="0.4558747510018446" EFFECT_SIZE="1.0100000000000002" ESTIMABLE="YES" MEAN_1="-0.6" MEAN_2="-1.61" MODIFIED="2009-11-30 15:50:54 +0100" MODIFIED_BY="[Empty name]" ORDER="114" SD_1="3.04" SD_2="3.05" SE="0.2827221588605836" STUDY_ID="STD-L-_x002d_-LEAD-6-Buse-2009" TOTAL_1="231" TOTAL_2="233" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.131620345041312" CI_END="1.331743227043401" CI_START="1.0238341417986947" DF="1" EFFECT_SIZE="1.177788684421048" ESTIMABLE="YES" I2="11.631139862239483" ID="CMP-020.10.02" MODIFIED="2011-04-27 12:20:01 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2874300201140503" P_Z="8.013637097647533E-51" STUDIES="2" TAU2="0.00523401293800777" TOTAL_1="270" TOTAL_2="277" WEIGHT="100.0" Z="14.994188307431584">
<NAME>versus Exenatide 2 mg once weekly</NAME>
<CONT_DATA CI_END="1.2741006820255971" CI_START="1.1258993179744028" EFFECT_SIZE="1.2" ESTIMABLE="YES" MEAN_1="-0.7" MEAN_2="-1.9" MODIFIED="2011-04-27 12:20:01 +0200" MODIFIED_BY="[Empty name]" ORDER="355" SD_1="0.3" SD_2="0.3" SE="0.03780716513675446" STUDY_ID="STD-E-_x002d_-Blevins-2011" TOTAL_1="123" TOTAL_2="129" WEIGHT="92.59622814034934"/>
<CONT_DATA CI_END="1.4477480191193197" CI_START="0.3522519808806802" EFFECT_SIZE="0.8999999999999999" ESTIMABLE="YES" MEAN_1="-1.4" MEAN_2="-2.3" MODIFIED="2009-12-01 16:26:19 +0100" MODIFIED_BY="[Empty name]" ORDER="161" SD_1="2.4" SD_2="2.4" SE="0.2794684103584995" STUDY_ID="STD-E-_x002d_-Drucker-2008" TOTAL_1="147" TOTAL_2="148" WEIGHT="7.4037718596506545"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-020.11" MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" NO="11" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES">
<NAME>Post-prandial glucose (mmol/L)</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Exenatide 10 µg BID</P>
</TH>
<TH>
<P>Other GLP1 agonist</P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-020.11.01" MODIFIED="2011-06-30 14:19:15 +0200" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>versus Liraglutide</NAME>
<OTHER_DATA MODIFIED="2011-06-30 14:19:15 +0200" MODIFIED_BY="[Empty name]" ORDER="1522" STUDY_ID="STD-L-_x002d_-LEAD-6-Buse-2009">
<TR>
<TD>
<P>from self-monitored 7-point plasma glucose measurements</P>
</TD>
<TD>
<P>after breakfast: 8.9 SE 0.4 mmol/L</P>
<P>after dinner: 7.8 SE 0.4 mmol/L</P>
</TD>
<TD>
<P>after breakfast: 9.7 SE 0.5 mmol/L</P>
<P>after dinner: 8.2 SE 0.3 mmol/L</P>
</TD>
<TD>
<P>Exenatide reduced post-prandial plasma glucose increment more than did liraglutide after breakfast and dinner; treatment difference after lunch was not significant.</P>
</TD>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-020.11.02" MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" NO="2" STUDIES="1">
<NAME>versus Exenatide 2 mg once weekly</NAME>
<OTHER_DATA MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" ORDER="1523" STUDY_ID="STD-E-_x002d_-Drucker-2008">
<TR>
<TD>
<P>from self-monitored 7-point plasma glucose measurements</P>
</TD>
<TD>
<P>both treatments reduced post-prandial values compared to baseline</P>
</TD>
<TD/>
<TD/>
</TR>
<TR>
<TD>
<P>2 h post-prandial glucose, meal tolerance test (n = 51)</P>
</TD>
<TD>
<P>-6.9 mmol/L SE 0.5</P>
</TD>
<TD>
<P>-5.3 mmol/L SE 0.5</P>
</TD>
<TD>
<P>P = 0.0124</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="2.880842922693422" CI_END="0.0643080409164343" CI_START="-0.03565253969045041" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.014327750612991949" ESTIMABLE="YES" I2="30.575874712040346" I2_Q="30.27815691735454" ID="CMP-020.12" MODIFIED="2011-06-30 14:19:42 +0200" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.23682829673640127" P_Q="0.2310689748893595" P_Z="0.5742121028031667" Q="1.4342707475685064" RANDOM="YES" SCALE="0.53" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0020098667724037897" TOTALS="SUB" TOTAL_1="502" TOTAL_2="509" UNITS="" WEIGHT="200.0" Z="0.561858985020777">
<NAME>Triglycerides (mmol/L)</NAME>
<GROUP_LABEL_1>Exenatide 10 µg BID</GROUP_LABEL_1>
<GROUP_LABEL_2>Other GLP1-agonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Exenatide 10 µg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Other GLP1</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.45570111104645983" CI_START="-0.09570111104645987" DF="0" EFFECT_SIZE="0.17999999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-020.12.01" MODIFIED="2009-12-01 16:34:07 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.20067773875497563" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="233" WEIGHT="100.0" Z="1.2796231247604897">
<NAME>versus Liraglutide</NAME>
<CONT_DATA CI_END="0.45570111104645983" CI_START="-0.09570111104645987" EFFECT_SIZE="0.17999999999999997" ESTIMABLE="YES" MEAN_1="-0.23" MEAN_2="-0.41" MODIFIED="2009-11-30 17:44:10 +0100" MODIFIED_BY="[Empty name]" ORDER="129" SD_1="1.5" SD_2="1.53" SE="0.14066641694498216" STUDY_ID="STD-L-_x002d_-LEAD-6-Buse-2009" TOTAL_1="231" TOTAL_2="233" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.2479831834618391" CI_END="0.059520463444243644" CI_START="-0.042124297048369626" DF="1" EFFECT_SIZE="0.00869808319793701" ESTIMABLE="YES" I2="19.870715146493154" ID="CMP-020.12.02" MODIFIED="2011-04-27 12:14:30 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.26393811541103185" P_Z="0.7372921515920032" STUDIES="2" TAU2="7.34819046117305E-4" TOTAL_1="271" TOTAL_2="276" WEIGHT="100.0" Z="0.33544138861399403">
<NAME>versus Exenatide 2 mg once weekly</NAME>
<CONT_DATA CI_END="0.007125246531133026" CI_START="-0.007125246531133026" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.01" MEAN_2="0.01" MODIFIED="2011-04-27 12:14:30 +0200" MODIFIED_BY="[Empty name]" ORDER="351" SD_1="0.01" SD_2="0.04" SE="0.0036353966640897796" STUDY_ID="STD-E-_x002d_-Blevins-2011" TOTAL_1="123" TOTAL_2="129" WEIGHT="89.88594976984068"/>
<CONT_DATA CI_END="0.2367153147065071" CI_START="-0.06471531470650718" EFFECT_SIZE="0.08599999999999997" ESTIMABLE="YES" MEAN_1="-0.196" MEAN_2="-0.282" MODIFIED="2009-12-01 16:54:46 +0100" MODIFIED_BY="[Empty name]" ORDER="163" SD_1="0.64" SD_2="0.68" SE="0.07689698172789414" STUDY_ID="STD-E-_x002d_-Drucker-2008" TOTAL_1="148" TOTAL_2="147" WEIGHT="10.114050230159318"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.055162431679598" CI_END="0.34775809282197295" CI_START="0.06303476936342484" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.2053964310926989" ESTIMABLE="YES" I2="60.436483950220136" I2_Q="46.42029533548905" ID="CMP-020.13" MODIFIED="2011-06-30 14:20:08 +0200" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.07985201093875538" P_Q="0.17189064759353778" P_Z="0.004686979704901809" Q="1.866378335344502" RANDOM="YES" SCALE="0.89" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.013745934214348766" TOTALS="SUB" TOTAL_1="501" TOTAL_2="510" UNITS="" WEIGHT="200.0" Z="2.8277950861539556">
<NAME>Total cholesterol (mmol/L)</NAME>
<GROUP_LABEL_1>Exenatide 10 µg BID</GROUP_LABEL_1>
<GROUP_LABEL_2>Other GLP1-agonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Exenatide 10 µg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Other GLP1</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.30747869153442514" CI_START="-0.08747869153442511" DF="0" EFFECT_SIZE="0.11000000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-020.13.01" MODIFIED="2009-12-01 16:34:17 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2749459644285105" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="233" WEIGHT="100.00000000000001" Z="1.091743299614797">
<NAME>versus Liraglutide</NAME>
<CONT_DATA CI_END="0.30747869153442514" CI_START="-0.08747869153442511" EFFECT_SIZE="0.11000000000000001" ESTIMABLE="YES" MEAN_1="-0.09" MEAN_2="-0.2" MODIFIED="2009-11-30 17:43:40 +0100" MODIFIED_BY="[Empty name]" ORDER="130" SD_1="1.1" SD_2="1.07" SE="0.10075628587673643" STUDY_ID="STD-L-_x002d_-LEAD-6-Buse-2009" TOTAL_1="231" TOTAL_2="233" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.5739158119845804" CI_END="0.5140302735050893" CI_START="0.10319955492448565" DF="1" EFFECT_SIZE="0.3086149142147875" ESTIMABLE="YES" I2="61.14869043719947" ID="CMP-020.13.02" MODIFIED="2011-04-27 12:16:15 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.10863888131824184" P_Z="0.003233314771368218" STUDIES="2" TAU2="0.01348328624140249" TOTAL_1="270" TOTAL_2="277" WEIGHT="99.99999999999999" Z="2.9446391888255437">
<NAME>versus Exenatide 2 mg once weekly</NAME>
<CONT_DATA CI_END="0.6150886142129515" CI_START="0.2249113857870486" EFFECT_SIZE="0.42000000000000004" ESTIMABLE="YES" MEAN_1="0.02" MEAN_2="-0.4" MODIFIED="2011-04-27 12:16:15 +0200" MODIFIED_BY="[Empty name]" ORDER="352" SD_1="0.78" SD_2="0.8" SE="0.09953683626423011" STUDY_ID="STD-E-_x002d_-Blevins-2011" TOTAL_1="123" TOTAL_2="129" WEIGHT="46.959482959422594"/>
<CONT_DATA CI_END="0.37660668914879303" CI_START="0.04339331085120693" EFFECT_SIZE="0.21" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="-0.31" MODIFIED="2009-12-01 16:49:03 +0100" MODIFIED_BY="[Empty name]" ORDER="164" SD_1="0.73" SD_2="0.73" SE="0.08500497481737693" STUDY_ID="STD-E-_x002d_-Drucker-2008" TOTAL_1="147" TOTAL_2="148" WEIGHT="53.04051704057739"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.6656219532724965" CI_END="0.029043325154375008" CI_START="-0.03166522944700405" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.0013109521463145193" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-020.14" MODIFIED="2011-06-30 14:20:46 +0200" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.4348255348135732" P_Q="0.7140229469431543" P_Z="0.9325414960839482" Q="0.13429195261058052" RANDOM="YES" SCALE="0.16" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="501" TOTAL_2="510" UNITS="" WEIGHT="200.0" Z="0.08464767475039094">
<NAME>HDL-cholesterol (mmol/L)</NAME>
<GROUP_LABEL_1>Exenatide 10 µg BID</GROUP_LABEL_1>
<GROUP_LABEL_2>Other GLP1-agonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Exenatide 10 µg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Other GLP1</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.045507368380176605" CI_START="-0.06550736838017661" DF="0" EFFECT_SIZE="-0.010000000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-020.14.01" MODIFIED="2009-12-01 16:34:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7240136346745799" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="233" WEIGHT="100.0" Z="0.35309978508006845">
<NAME>versus Liraglutide</NAME>
<CONT_DATA CI_END="0.045507368380176605" CI_START="-0.06550736838017661" EFFECT_SIZE="-0.010000000000000002" ESTIMABLE="YES" MEAN_1="-0.05" MEAN_2="-0.04" MODIFIED="2009-11-30 17:43:16 +0100" MODIFIED_BY="[Empty name]" ORDER="131" SD_1="0.3" SD_2="0.31" SE="0.028320606306040132" STUDY_ID="STD-L-_x002d_-LEAD-6-Buse-2009" TOTAL_1="231" TOTAL_2="233" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.6018742965522763" CI_END="0.0386516505688724" CI_START="-0.0338595749030831" DF="1" EFFECT_SIZE="0.0023960378328946492" ESTIMABLE="YES" I2="37.573129043127416" ID="CMP-020.14.02" MODIFIED="2011-04-27 12:17:02 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.20563784975139732" P_Z="0.8969391975115801" STUDIES="2" TAU2="3.005850323450192E-4" TOTAL_1="270" TOTAL_2="277" WEIGHT="100.00000000000001" Z="0.12952885094695302">
<NAME>versus Exenatide 2 mg once weekly</NAME>
<CONT_DATA CI_END="0.08555982662182224" CI_START="-0.025559826621822247" EFFECT_SIZE="0.03" ESTIMABLE="YES" MEAN_1="0.03" MEAN_2="0.0" MODIFIED="2011-04-27 12:17:02 +0200" MODIFIED_BY="[Empty name]" ORDER="353" SD_1="0.22" SD_2="0.23" SE="0.028347371206854342" STUDY_ID="STD-E-_x002d_-Blevins-2011" TOTAL_1="123" TOTAL_2="129" WEIGHT="30.990094582236623"/>
<CONT_DATA CI_END="0.017387400955965984" CI_START="-0.03738740095596598" EFFECT_SIZE="-0.009999999999999998" ESTIMABLE="YES" MEAN_1="-0.03" MEAN_2="-0.02" MODIFIED="2009-12-01 16:49:53 +0100" MODIFIED_BY="[Empty name]" ORDER="165" SD_1="0.12" SD_2="0.12" SE="0.013973420517924976" STUDY_ID="STD-E-_x002d_-Drucker-2008" TOTAL_1="147" TOTAL_2="148" WEIGHT="69.00990541776339"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.025184193342926" CI_END="0.2399457699218375" CI_START="0.06471002540602114" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.15232789766392932" ESTIMABLE="YES" I2="33.88832308455454" I2_Q="59.257720021661555" ID="CMP-020.15" MODIFIED="2011-06-30 14:21:00 +0200" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.22033817402234512" P_Q="0.11719224470278211" P_Z="6.55628455365186E-4" Q="2.454452722163985" RANDOM="YES" SCALE="0.65" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0031051720917064725" TOTALS="SUB" TOTAL_1="501" TOTAL_2="510" UNITS="" WEIGHT="200.0" Z="3.407491937069466">
<NAME>LDL-cholesterol (mmol/L)</NAME>
<GROUP_LABEL_1>Exenatide 10 µg BID</GROUP_LABEL_1>
<GROUP_LABEL_2>Other GLP1-agonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Exenatide 10 µg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Other GLP1</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2056037528785507" CI_START="-0.12560375287855075" DF="0" EFFECT_SIZE="0.03999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-020.15.01" MODIFIED="2009-12-01 16:34:40 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.635920324844514" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="233" WEIGHT="100.0" Z="0.47341052372827264">
<NAME>versus Liraglutide</NAME>
<CONT_DATA CI_END="0.2056037528785507" CI_START="-0.12560375287855075" EFFECT_SIZE="0.03999999999999998" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-0.44" MODIFIED="2009-11-30 17:42:17 +0100" MODIFIED_BY="[Empty name]" ORDER="132" SD_1="0.9" SD_2="0.92" SE="0.08449326323586147" STUDY_ID="STD-L-_x002d_-LEAD-6-Buse-2009" TOTAL_1="231" TOTAL_2="233" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.5707314711789422" CI_END="0.29924862072952485" CI_START="0.09274175919506719" DF="1" EFFECT_SIZE="0.195995189962296" ESTIMABLE="YES" I2="0.0" ID="CMP-020.15.02" MODIFIED="2011-04-27 12:17:49 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4499685160160978" P_Z="1.9891168882487037E-4" STUDIES="2" TAU2="0.0" TOTAL_1="270" TOTAL_2="277" WEIGHT="100.0" Z="3.72039466984092">
<NAME>versus Exenatide 2 mg once weekly</NAME>
<CONT_DATA CI_END="0.3939314106345999" CI_START="0.0860685893654001" EFFECT_SIZE="0.24000000000000002" ESTIMABLE="YES" MEAN_1="0.07" MEAN_2="-0.17" MODIFIED="2011-04-27 12:17:49 +0200" MODIFIED_BY="[Empty name]" ORDER="354" SD_1="0.67" SD_2="0.57" SE="0.07853787714916766" STUDY_ID="STD-E-_x002d_-Blevins-2011" TOTAL_1="123" TOTAL_2="129" WEIGHT="44.993987452869945"/>
<CONT_DATA CI_END="0.29921928819282706" CI_START="0.02078071180717292" EFFECT_SIZE="0.16" ESTIMABLE="YES" MEAN_1="0.03" MEAN_2="-0.13" MODIFIED="2009-12-01 16:50:52 +0100" MODIFIED_BY="[Empty name]" ORDER="166" SD_1="0.61" SD_2="0.61" SE="0.07103155429945196" STUDY_ID="STD-E-_x002d_-Drucker-2008" TOTAL_1="147" TOTAL_2="148" WEIGHT="55.00601254713005"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-020.16" MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" NO="16" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Beta-cell function</NAME>
<TR>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Exenatide 10 µg BID</P>
</TH>
<TH>
<P>Liraglutide 1.8 mg daily</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-08-30 10:28:26 +0200" MODIFIED_BY="Bernd Richter" ORDER="1536" STUDY_ID="STD-L-_x002d_-LEAD-6-Buse-2009">
<TR>
<TD>
<P>HOMA-B (%)</P>
</TD>
<TD>
<P>+2.74% SD 103</P>
</TD>
<TD>
<P>+32.12% SD 103, P &lt; 0.0001 versus exenatide 10 µg BID</P>
</TD>
</TR>
<TR>
<TD>
<P>proinsulin-to-insulin ratio</P>
</TD>
<TD>
<P>-0.02 SD 0.46</P>
</TD>
<TD>
<P>0.00 SD 0.46, P = NS</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2011-09-01 15:32:51 +0200" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2011-09-01 15:32:51 +0200" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvIAAANMCAYAAAA+LEn9AACAAElEQVR42uy9D8QWyxv//yVJkkSS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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2011-08-30 10:14:05 +0200" MODIFIED_BY="Bernd Richter" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADOCAMAAADbsfL2AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2011-08-30 10:14:14 +0200" MODIFIED_BY="Bernd Richter" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAU0AAAMYCAIAAADATiL+AAApM0lEQVR42u3dv24US/rG8ZGQEIED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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2013-07-23 15:50:12 +0200" MODIFIED_BY="[Empty name]">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2013-07-23 15:50:12 +0200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-07-23 15:18:59 +0200" MODIFIED_BY="[Empty name]">Comments and Criticisms</TITLE>
<DATE_SUBMITTED>
<DATE DAY="8" MONTH="6" YEAR="2013"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2013-07-23 15:38:47 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Shyangdan et al. (2011) concludes in the abstract of their review that GLP-1 analogues are effective in improving glycemic control<SUP>1</SUP>. Although this statement is technically correct, we believe this one-line conclusion is a misleading representation of the known clinical benefits and safety of these new agents. The authors also suggest the utilization of GLP-1 analogues provides a &#8220;useful improvement in glucose control&#8221; despite acknowledging there is no morbidity and mortality data available. They recognize studies of longer duration are needed to find an effect in these outcomes; however, this message is obfuscated in the abstract as well as the author&#8217;s implications for practice.</LI>
<LI>This is important to address as discordance between the abstract and full text has been frequently recognized in the literature and has been suggested to mislead readers in the interpretation of the results<SUP>2-4</SUP>.</LI>
<LI>Additionally, there remains a lack of convincing, hard outcome data for GLP-1 analogues. In fact, a recent meta-analysis has been unable to find a statistically significant difference in cardiovascular (CV) disease reduction<SUP>5</SUP>. </LI>
<LI>Focusing predominantly on improvements in surrogate markers such as HbA1c could lead to unintentional, increased CV harm or in this instance, pancreatitis and pancreatic cancer. Rosiglitazone, for example, was effective for decreasing HbA1c but there are concerns regarding increased risk of myocardial infarction<SUP>6</SUP>. Thus, we feel the lack of outcome data should be emphasized and should be at the fore-front of the reader&#8217;s take home messages.</LI>
<LI>In this same analysis, there were also two issues which caught our attention. The first is found in the risk of bias assessment (figure 3) which suggested all the included trials were at low risk of attrition bias. Conversely, the authors specified that a range of studies had substantial losses to follow-up with more withdrawals occurring in the GLP-1 groups. We recognize these trials reported reasons for dropouts and utilized LOCF; however, the assessment for this risk of bias goes beyond how the study authors checked for and handled missing data. The disproportionate loss between the different arms could imbalance the groups and if the dropouts occur early in the study period, LOCF could lead to an underestimation of the potential harms of GLP-1 analogues. These dropouts seemed likely to occur early as the review authors themselves recognize nausea, vomiting and diarrhea were &#8220;strongest at the beginning and then subsided&#8221;.</LI>
<LI>Second, the author included one trial of 0.6 to 0.9 mg of liraglutide in Japanese patients and excluded other trials with doses less than 1.2 mg per day on the basis of these doses being standard in Japan. We acknowledge the exclusion of the few studies based on this criteria did not impact the results in any significant fashion; however, the rationale and justification of such an exclusion is lacking. In order to appropriately gauge the safety and efficacy of liraglutide across multiple doses, all collected information for a particular dosage should be included in the analysis.</LI>
</OL>
<P>References:</P>
<P>1. Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, Issue 10. Art. No.: CD006423/ DOI: 10.1002/14651858.CD006423.pub2.</P>
<P>2. Altwairgi AK, Booth CM, Hopamn WM, Baetz TD. Discordance between conclusions stated in the abstract and conclusions in the article: analysis of published randomized controlled trials of systemic therapy in lung cancer. J Clin Oncol 2012;30(28):3552-7.</P>
<P>3. Bernal-Delgado E, Fisher ES. Abstracts in high profile journals often fail to report harm. BMC Med Res Methodol 2008; 8:14. doi: 10.1186/1471-2288-8-14.</P>
<P>4. Boutron I, Dutton S, Ravaud P, Altman DG. Reporting and interpretation of randomized controlled trials with statistically nonsignifcant results for primary outcomes. JAMA 2010;303(20):2058-64.</P>
<P>5. Sun F, Yu K, Wu S, Zhang Y, Yang Z et al. Cardiovascular safety and glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus: A pairwise and network meta-analysis. Diabetes Res Clin Pract 2012;98(3):386-95.</P>
<P>6. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010;170(14):1191-201.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2013-07-23 15:49:23 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Disagree. As the commentators admit, we have noted the lack of long-term outcomes.</LI>
<LI>Disagree, this is an unjustified assertion.</LI>
<LI>Agreed, as we said. Note that it is not surprising that a meta-analysis showed no difference. This is to be expected given the duration of use. Note the time it took for UKPDS to show a significant reduction in CVD.</LI>
<LI>Disagree. The evidence on pancreatitis has emerged since we produced this review, and it will be mentioned when it is updated. This criticism is unjustified. There is no evidence for CV harm. Indeed, the evidence for pancreatitis (mainly Singh et al 2013) is not entirely convincing. The suggestion that the incretin drugs increase the risk of pancreatic cancer is unproven. If there is a risk, it will take years to prove it because it is probably very small.</LI>
<LI>Disagree. This paragraph is confused. Early drop-outs, will not be exposed to any long-term harm &#8211; they stop taking the drugs. Though we agree that LOCF is unsatisfactory and have said so on various occasions in other HTAs.</LI>
<LI>Disagree. As explained, that dose was included only for Japanese patients in whom it appears to be standard. It is not a standard dose in other ethnic groups so information should not be included. As stated, the review aimed to be relevant to clinical practice. It therefore focused on clinically relevant dosage. To do as the commentators suggest, would mean including lots of data from early dose-ranging studies. These are clinically irrelevant.</LI>
</OL>
<P>The letter submitted reads more like an attempt to pick fault with the published review, rather than constructive criticism. Some of the language used is intemperate and inappropriate - &#8220;obfuscation&#8221;, &#8220;to mislead readers&#8221;.</P>
<P>
<B>Note from the Coordinating Editor</B>
</P>
<UL>
<LI>Numbering introduced by the Feedback Editor for better readability.</LI>
<LI>The Cochrane Metabolic and Endocrine Disorders Review Group now has a policy that a set of patient-important outcomes whether investigated or not have to be specified in major sections of the Cochrane review like the abstract and plain language summary. However, this policy was not in place when Cochrane review authors published this review.</LI>
</UL>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2013-07-23 15:50:12 +0200" MODIFIED_BY="[Empty name]">
<P>I certify that I have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter of my criticisms.</P>
<P>
<I>Nichoe Huan, Bsc(Pharm)</I> (<A HREF="mailto:lawrence.huan@vch.ca">lawrence.huan@vch.ca</A> )</P>
<P>
<I>Krystin Boyce, Bsc, Bsc(Pharm)</I>
</P>
<P>
<I>Lora Wang, Bsc(Pharm)</I>
</P>
<P>
<I>Aaron M Tejani, Bsc(Pharm), PharmD</I>
</P>
<P>
<B>Reply</B> by <I>the review authors</I>
</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter">
<APPENDIX ID="APP-01" MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter" NO="1">
<TITLE MODIFIED="2011-08-30 09:29:41 +0200" MODIFIED_BY="Bernd Richter">Search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2011-08-30 10:28:45 +0200" MODIFIED_BY="Bernd Richter">
<TABLE COLS="1" ROWS="2">
<TR>
<TH>
<P>Search terms</P>
</TH>
</TR>
<TR>
<TD>
<P>Unless otherwise stated, search terms are free text terms; MeSH = Medical subject heading (MEDLINE medical index term); exP = exploded MeSH; the dollar sign ($) stands for any character(s); the question mark (?) substitutes one or no characters; tw = text word; pt = publication type; sh = MeSH; adj = adjacent (i.e. number of words within range of search term).</P>
<P/>
<P>
<B>MEDLINE</B>
</P>
<P>1. exp Glucagon-Like Peptides/</P>
<P>2. (glucagon like peptide* or GLP-1).tw.</P>
<P>3. (exenatide or liraglutide or albiglutide or taspoglutide or lixisenatide).tw.</P>
<P>4. randomized controlled trial.pt.</P>
<P>5. random*.tw.</P>
<P>6. 1 or 3 or 2</P>
<P>7. 4 or 5</P>
<P>8. 6 and 7</P>
<P> </P>
<P>
<B>Embase</B>
</P>
<P>1. exp Glucagon-Like Peptide 1/</P>
<P>2. (Glucagon-Like Peptide 1 or GLP-1).tw.</P>
<P>3. (exenatide or liraglutide or albiglutide or taspoglutide or lixisenatide).tw.</P>
<P>4. randomized controlled trial/</P>
<P>5. (randomised or randomized).tw.</P>
<P>6. 1 or 3 or 2</P>
<P>7. 4 or 5</P>
<P>8. 6 and 7</P>
<P>
<B> </B>
</P>
<P>
<B>
<I>The Cochrane Library</I>
</B>
</P>
<P>(exenatide or liraglutide or albiglutide or taspoglutide or lixisenatide or glucagon like peptide or GLP-1):ti</P>
<P>
<B> </B>
</P>
<P>
<B>Web of Science databases - Science Citation Index Expanded; Social Sciences Citation Index (SSCI); Conference Proceedings Citation Index- Science</B> <B> </B>
</P>
<P>Title=(glucagon like peptide* or GLP-1 or exenatide or liraglutide or albiglutide or taspoglutide)</P>
<P>Refined by: Document Type=( MEETING ABSTRACT )</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2011-08-30 09:56:25 +0200" MODIFIED_BY="Bernd Richter" NO="2">
<TITLE MODIFIED="2011-08-30 09:44:53 +0200" MODIFIED_BY="Bernd Richter">Overview of results</TITLE>
<APPENDIX_BODY MODIFIED="2011-08-30 09:56:25 +0200" MODIFIED_BY="Bernd Richter">
<TABLE COLS="15" ROWS="17">
<TR>
<TH>
<P>Study ID &#9658;</P>
<P>Characteristic &#9660;</P>
</TH>
<TH>
<P>
<B>Albiglutide versus placebo</B>
</P>
</TH>
<TH>
<P>
<B>Exenatide QW versus pioglitazone</B>
</P>
</TH>
<TH>
<P>
<B>Exenatide QW versus insulin glargine</B>
</P>
</TH>
<TH>
<P>
<B>Exenatide QW versus sitagliptin</B>
</P>
</TH>
<TH>
<P>
<B>Exenatide BID versus exenatide QW</B>
</P>
</TH>
<TH>
<P>
<B>Liraglutide versus placebo</B>
</P>
</TH>
<TH>
<P>
<B>Exenatide versus Liraglutide</B>
</P>
</TH>
<TH>
<P>
<B>Liraglutide versus insulin</B>
</P>
</TH>
<TH>
<P>
<B>Liraglutide versus glimepiride</B>
</P>
</TH>
<TH>
<P>
<B>Liraglutide versus TZD</B>
</P>
</TH>
<TH>
<P>
<B>Liraglutide versus DPP-4 inhibitors</B>
</P>
</TH>
<TH>
<P>
<B>Lixisenatide versus placebo</B>
</P>
</TH>
<TH>
<P>
<B>LY2189265 versus placebo</B>
</P>
</TH>
<TH>
<P>
<B>Taspoglutide versus placebo</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>n studies</B>
</P>
</TD>
<TD ALIGN="RIGHT">
<P>1</P>
</TD>
<TD ALIGN="RIGHT">
<P>1</P>
</TD>
<TD ALIGN="RIGHT">
<P>1</P>
</TD>
<TD ALIGN="RIGHT">
<P>1</P>
</TD>
<TD ALIGN="RIGHT">
<P>1</P>
</TD>
<TD>
<P>0.6 mg: 1; 0.9 mg: 1; 1.2 mg: 3; 1.8 mg: 4</P>
</TD>
<TD ALIGN="RIGHT">
<P>1</P>
</TD>
<TD ALIGN="RIGHT">
<P>1</P>
</TD>
<TD ALIGN="RIGHT">
<P>2</P>
</TD>
<TD ALIGN="RIGHT">
<P>1</P>
</TD>
<TD ALIGN="RIGHT">
<P>1</P>
</TD>
<TD ALIGN="RIGHT">
<P>1</P>
</TD>
<TD ALIGN="RIGHT">
<P>1</P>
</TD>
<TD ALIGN="RIGHT">
<P>2</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>HbA1c </B>
</P>
</TD>
<TD>
<P>versus placebo -0.62% to -0.7%</P>
</TD>
<TD>
<P>-0.3% versus pioglitazone</P>
</TD>
<TD>
<P>-0.2% versus glargine</P>
</TD>
<TD>
<P>-0.6% versus sitagliptin</P>
</TD>
<TD>
<P>favours exenatide QW<BR/>0.55% (95% CI 0.26 to 0.84, P = 0.0002)</P>
</TD>
<TD>
<P>-1.06 to -1.16% more with 0.6 and 0.9 mg dose versus placebo;<BR/>-1. to -1.23% with 1.2 and 1.8 mg dose versus placebo<BR/>
</P>
</TD>
<TD>
<P>favours liraglutide 0.33% (95% CI 0.11 to 0.55, P &lt; 0.0001)</P>
</TD>
<TD>
<P>favours liraglutide -0.24% (95% CI -0.39 to -0.08, P = 0.0015)</P>
</TD>
<TD>
<P>no significant difference</P>
</TD>
<TD>
<P>favours liraglutide -0.64% to -0.69%</P>
</TD>
<TD>
<P>favours liraglutide -0.34% to -0.60%</P>
</TD>
<TD>
<P>versus placebo -0.29% to -0.69%</P>
</TD>
<TD>
<P>-1.32% to -1.59%; no data for placebo</P>
</TD>
<TD>
<P>significant reduction with taspoglutide; titration of taspoglutide dose did not lead to increased reduction.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>HbA1c </B>&#8804; <B>7%</B>
</P>
</TD>
<TD>
<P>30% to 32% more than placebo</P>
</TD>
<TD>
<P>5% more than pioglitazone</P>
</TD>
<TD>
<P>28% more than glargine</P>
</TD>
<TD>
<P>25% more than sitagliptin</P>
</TD>
<TD>
<P>16% to 28% more with exenatide QW</P>
</TD>
<TD>
<P>31.7% to 56.5% more with 0.6 and 0.9 mg dose versus placebo; 26% to 34% more than placebo with 1.2 and 1.8 mg</P>
</TD>
<TD>
<P>11% more with liraglutide</P>
</TD>
<TD>
<P>7% more with liraglutide</P>
</TD>
<TD>
<P>no significant difference</P>
</TD>
<TD>
<P>13% to 20% more with liraglutide</P>
</TD>
<TD>
<P>22% to 34% more than sitagliptin</P>
</TD>
<TD>
<P>15% to 45% more than placebo</P>
</TD>
<TD>
<P>49% to 54% across all groups</P>
</TD>
<TD>
<P>34% to 64% more with taspoglutide; titration of taspoglutide dose did not lead to increment</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Hypoglycaemia </B>
</P>
</TD>
<TD>
<P>no difference versus placebo</P>
</TD>
<TD>
<P>no difference versus pioglitazone</P>
</TD>
<TD>
<P>minor hypoglycaemia and symptoms only hypoglycaemia 18% less than glargine. 2 major hypoglycaemia in glargine and 1 in exenatide QW</P>
</TD>
<TD>
<P>hypoglycaemia more with sitagliptin. No cases of severe hypoglycaemia</P>
</TD>
<TD>
<P>no significant difference; more hypoglycaemia in participants receiving concomitant sulphonylurea treatment</P>
</TD>
<TD>
<P>rate of hypoglycaemia more with 0.6 and 0.9 mg dose; no significant difference with 1.2 mg liraglutide, 0 to 11% more patients with hypoglycaemia in 1.8 mg liraglutide than placebo group (RR 1.66)</P>
</TD>
<TD>
<P>8% more patients with hypoglycaemia in exenatide than liraglutide group (RR 1.32)</P>
</TD>
<TD>
<P>no significant difference</P>
</TD>
<TD>
<P>15% to 17% more patients with hypoglycaemia in glimepiride group than liraglutide</P>
</TD>
<TD>
<P>4% more patients with hypoglycaemia in liraglutide group than rosiglitazone (RR 2.01)</P>
</TD>
<TD>
<P>no difference</P>
</TD>
<TD>
<P>dose-dependent relation (1 to 3 events of hypoglycaemia per group)</P>
</TD>
<TD>
<P>significantly higher in all LY groups</P>
</TD>
<TD>
<P>unclear in one study; other study says that the incidence was similar between the groups.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Weight </B>
</P>
</TD>
<TD>
<P>versus placebo -0.7 kg to -0.9 kg</P>
</TD>
<TD>
<P>-5.1 kg versus pioglitazone</P>
</TD>
<TD>
<P>-4 kg versus glargine</P>
</TD>
<TD>
<P>-1.5 kg versus sitagliptin</P>
</TD>
<TD>
<P>no significant difference</P>
</TD>
<TD>
<P>no difference between 0.6/0.9 mg verus placebo; versus placebo -0.75 to -1.3 kg with 1.2 and 1.8 mg dose</P>
</TD>
<TD>
<P>no significant difference</P>
</TD>
<TD>
<P>favours liraglutide -3.43 kg (95% CI -4.00 to -2.86, P &lt; 0.0001)</P>
</TD>
<TD>
<P>versus glimepiride -2.68 to -3.8 kg</P>
</TD>
<TD>
<P>favours liraglutide -1.8 to -2.3 kg </P>
</TD>
<TD>
<P>favours liraglutide -1.9 to -2.42 kg</P>
</TD>
<TD>
<P>versus placebo 0 to -1.95 kg </P>
</TD>
<TD>
<P>versus placebo -1.32 to -2.43 kg</P>
</TD>
<TD>
<P>significant reduction in weight when the 20 mg once weekly dose was titrated to 30 mg weekly but not when titrated to 40 mg once weekly</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>QoL</B>
</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>significant improvement with exenatide; not with pioglitazone</P>
</TD>
<TD>
<P>significant improvement with exenatide for one of IWQOL-Lite and one EQ-5D dimensions; no difference for others</P>
</TD>
<TD>
<P>significant improvement with exenatide QW</P>
</TD>
<TD>
<P>no significant difference in treatment satisfaction</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>greater treatment satisfaction with liraglutide</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>
<B>Adverse events</B>
</P>
</TH>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Nausea</B>
</P>
</TD>
<TD>
<P>25% to 26%</P>
</TD>
<TD>
<P>19% more with exenatide24%</P>
</TD>
<TD>
<P>12% more with exenatide</P>
</TD>
<TD>
<P>14% more with exenatide</P>
</TD>
<TD>
<P>8.1% to 21% more with the twice daily dose</P>
</TD>
<TD>
<P>10.5% to 40%</P>
</TD>
<TD>
<P>nausea less persistent with liraglutide</P>
</TD>
<TD>
<P>see before</P>
</TD>
<TD>
<P>see before</P>
</TD>
<TD>
<P>see before</P>
</TD>
<TD>
<P>see before</P>
</TD>
<TD>
<P>dose-dependent; 2.7% to 30.6% more than placebo</P>
</TD>
<TD>
<P>more common with LY; 6% to 9.3% more than placebo</P>
</TD>
<TD>
<P>24% to 52%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Vomiting</B>
</P>
</TD>
<TD>
<P>9% to 13%</P>
</TD>
<TD>
<P>811% more with exenatide</P>
</TD>
<TD>
<P>5% more with exenatide</P>
</TD>
<TD>
<P>8% more with exenatide</P>
</TD>
<TD>
<P>4.2% to 7.8% more with the twice daily dose</P>
</TD>
<TD>
<P>4.5% to 17%</P>
</TD>
<TD>
<P>no obvious difference</P>
</TD>
<TD>
<P>see before</P>
</TD>
<TD>
<P>see before</P>
</TD>
<TD>
<P>see before</P>
</TD>
<TD>
<P>see before</P>
</TD>
<TD>
<P>2.7% to 17.6% more than placebo</P>
</TD>
<TD>
<P>more common in higher dose of LY </P>
</TD>
<TD>
<P>9% to 21%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Diarrhoea</B>
</P>
</TD>
<TD>
<P>16% to 22%</P>
</TD>
<TD>
<P>118% more with exenatide</P>
</TD>
<TD>
<P>3% more with exenatide</P>
</TD>
<TD>
<P>9% more with exenatide</P>
</TD>
<TD>
<P>0.4% to 5.2% more with exenatide QW</P>
</TD>
<TD>
<P>8% to 15%</P>
</TD>
<TD>
<P>no obvious difference</P>
</TD>
<TD>
<P>see before</P>
</TD>
<TD>
<P>see before</P>
</TD>
<TD>
<P>see before</P>
</TD>
<TD>
<P>see before</P>
</TD>
<TD>
<P>more common with lixisenatide</P>
</TD>
<TD>
<P>more common in higher dose of LY </P>
</TD>
<TD>
<P>10% to 27%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Systolic blood pressure</B>
</P>
</TD>
<TD>
<P>no difference</P>
</TD>
<TD>
<P>no difference</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-4 mm Hg versus sitagliptin</P>
</TD>
<TD>
<P>no significant difference</P>
</TD>
<TD>
<P>no significant difference</P>
</TD>
<TD>
<P>no significant difference</P>
</TD>
<TD>
<P>favours liraglutide -2.53 mm Hg (95% CI -6.82 to -2.20, P = 0.0001)</P>
</TD>
<TD>
<P>versus glimepiride -2.7 to -3.2 mm Hg</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>no difference</P>
</TD>
<TD>
<P>versus placebo +1 to -6 mm Hg</P>
</TD>
<TD>
<P>dose dependent reduction (-0.6 to -3 mm Hg)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>FPG</B>
</P>
</TD>
<TD>
<P>versus placebo -1.3 to -1.5 mmol/L</P>
</TD>
<TD>
<P>versus pioglitazone -0.3 mmol/L </P>
</TD>
<TD>
<P>favour glargine; 0.70 mmol/L (95% CI 0.14 to 1.26, P = 0.01)</P>
</TD>
<TD>
<P>favour exenatide QW: -0.90 mmol/L (95% CI -1.50 to -0.30, P = 0.0038)</P>
</TD>
<TD>
<P>favours exenatide QW compared to exenatide BID 1.18 mmol/L (95% CI 1.02 to 1.33, P &lt; 0.00001)</P>
</TD>
<TD>
<P>with 0.6 and 0.9 mg versus placebo -1.64 to -1.66 mmol/L; with 1.2 and 1.8 mg versus placebo -2.0 to -2.2 mmol/L</P>
</TD>
<TD>
<P>favours liraglutide 1.01 mmol/L (95% CI 0.46 to 1.56, P &lt; 0.0001)</P>
</TD>
<TD>
<P>no significant difference</P>
</TD>
<TD>
<P>no significant difference</P>
</TD>
<TD>
<P>favours liraglutide -0.7 mmol/L</P>
</TD>
<TD>
<P>favours liraglutide -1.04 to -1.31 mmol/L</P>
</TD>
<TD>
<P>dose-dependent reduction; versus placebo +0.02 to -1.21 mmol/L</P>
</TD>
<TD>
<P>versus placebo -1.56 to -2.16 mmol/L</P>
</TD>
<TD>
<P>significant reduction with taspoglutide</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>PPG</B>
</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>no difference</P>
</TD>
<TD>
<P>exenatide QW led to lower glucose concentration after dinner and also post-prandial glucose excursion after morning and evening meals was lower with exenatide QW.</P>
</TD>
<TD>
<P>significant reduction at all time points with exenatide QW</P>
</TD>
<TD>
<P>meal test (n = 51), 2 h PPG significantly more reduced with exenatide twice daily than once weekly;</P>
</TD>
<TD>
<P>versus placebo -1.8 to -2.3 mmol/L</P>
</TD>
<TD>
<P>post-prandial plasma glucose increment reduced more by exenatide than liraglutide after breakfast and dinner</P>
</TD>
<TD>
<P>no significant difference</P>
</TD>
<TD>
<P>no significant difference</P>
</TD>
<TD>
<P>favours liraglutide -0.7 to -0.9 mmol/L</P>
</TD>
<TD>
<P>recorded values during the study were highly variable therefore not post-prandial in most cases. Not reported</P>
</TD>
<TD>
<P>dose-dependent reduction</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>more improvement with taspoglutide versus placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Lipid profiles </B>
</P>
</TD>
<TD>
<P>no difference versus placebo</P>
</TD>
<TD>
<P>pioglitazone decreased triglycerides significantly; no difference for other parameters.</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>exenatide QW reduced total cholesterol and LDL; all led to improvement in HDL levels</P>
</TD>
<TD>
<P>significantly greater reductions in total cholesterol and LDL with exenatide QW than exenatide BID</P>
</TD>
<TD>
<P>one study, triglycerides and LDL reduced with 1.2 but not 1.8 mg liraglutide</P>
</TD>
<TD>
<P>triglycerides and free fatty acids more reduced with liraglutide than exenatide</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>dose-related decline in triglycerides, P not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Beta-cell function</B>
</P>
</TD>
<TD>
<P>improved, HOMA-B ratio 1.2 to 1.4</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>improved with liraglutide</P>
</TD>
<TD>
<P>more improvement in HOMA-B with liraglutide</P>
</TD>
<TD>
<P>more improvement in proinsulin-to-insulin ratio with liraglutide</P>
</TD>
<TD>
<P>no significant difference</P>
</TD>
<TD>
<P>more improvement with liraglutide</P>
</TD>
<TD>
<P>significant improvement in HOMA-B, C-peptide concentration and proinsulin-to-insulin ratio with liraglutide</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>significant improvement in HOMA2-%B; 31.9 to 44.6% more than placebo</P>
</TD>
<TD>
<P>improved in weekly taspoglutide regimens</P>
</TD>
</TR>
<TR>
<TD COLSPAN="15">
<P>
<I>Footnotes</I>
</P>
<P>
<SUP>"-" denotes not reported</SUP>
</P>
<P>
<SUP>BID: twice daily; CI: confidence interval; DPP-4: dipeptidyl peptidase-4 inhibitor; FPG: fasting plasma glucose; HbA1c: glycosylated haemoglobin A1c; HDL: high density lipoprotein; HOMA-B: homeostatic model assessment-beta-cell function; IWQOL: impact of weight on quality of life questionnaire; LDL: low density lipoprotein; LY: LY2189265; n: number; PPG: post-prandial glucose; QoL: quality of life; QW: once weekly; RR: relative risk;TZD: thiazolidinedione.</SUP>
</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;17 studies included in systematic review&lt;/p&gt;" WIDTH="181">
<FLOWCHARTBOX TEXT="&lt;p&gt;37 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="180">
<FLOWCHARTBOX TEXT="&lt;p&gt;486 records screened&lt;/p&gt;" WIDTH="200">
<FLOWCHARTBOX TEXT="&lt;p&gt;890 of records identified through database searching&lt;/p&gt;" WIDTH="227">
<OUT TEXT="&lt;p&gt;404 records excluded as duplicates&lt;/p&gt;" WIDTH="234"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;449 articles excluded on basis of title/abstract&lt;/p&gt;" WIDTH="251"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;20 articles excluded as not meeting inclusion criteria&lt;/p&gt;&lt;ul&gt;&lt;li&gt;Participants without type 2 diabetes mellitus: 1&lt;/li&gt;&lt;/ul&gt;&lt;ul&gt;&lt;li&gt;Less than 70% of participants were on metformin: 2&lt;/li&gt;&lt;/ul&gt;&lt;ul&gt;&lt;li&gt;Combined analysis of more than one trial, therefore participants not randomised: 5&lt;/li&gt;&lt;/ul&gt;&lt;ul&gt;&lt;li&gt;Monotherapy: 5&lt;/li&gt;&lt;/ul&gt;&lt;ul&gt;&lt;li&gt;All participants received exenatide: 1&lt;/li&gt;&lt;/ul&gt;&lt;ul&gt;&lt;li&gt;Liraglutide dose not clinically relevant: 3&lt;/li&gt;&lt;/ul&gt;&lt;ul&gt;&lt;li&gt;Follow-up less than 8 weeks: 1&lt;/li&gt;&lt;/ul&gt;&lt;ul&gt;&lt;li&gt;Participants aged &amp;lt;18 years of age: 1&lt;/li&gt;&lt;/ul&gt;&lt;ul&gt;&lt;li&gt;Published as abstract only: 1&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="469"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;ul&gt;&lt;li&gt;Albiglutide: 1&lt;/li&gt;&lt;/ul&gt;&lt;ul&gt;&lt;li&gt;Exenatide: 4&lt;/li&gt;&lt;/ul&gt;&lt;ul&gt;&lt;li&gt;Liraglutide: 8&lt;/li&gt;&lt;/ul&gt;&lt;ul&gt;&lt;li&gt;Lixisenatide: 1&lt;/li&gt;&lt;/ul&gt;&lt;ul&gt;&lt;li&gt;LY2189265: 1&lt;/li&gt;&lt;/ul&gt;&lt;ul&gt;&lt;li&gt;Taspoglutide: 2&lt;/li&gt;&lt;/ul&gt;" WIDTH="190"/>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>